GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: May 10, 2005, 07:14:40 ; Search time 1 Seconds
(without alignments)
4.816 Million cell updates/sec

Title: US-10-605-498-91
Perfect score: 764
Sequence: 1 ggcacgaggagcagagtcag.....aagttcaaagcaaccacctg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 159 seqs, 3152 residues

Total number of hits satisfying chosen parameters: 318

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 160 summaries

Database : rge91.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	52.2	6.8	65	1	CQ533030	ACCESSION:CQ533030
c	2	25	3.3	25	1	AR091050	ACCESSION:AR091050
c	3	25	3.3	25	1	AR198085	ACCESSION:AR198085
c	4	25	3.3	25	1	AR260239	ACCESSION:AR260239
	5	24	3.1	24	1	AR091049	ACCESSION:AR091049
	6	24	3.1	24	1	AR198084	ACCESSION:AR198084
	7	24	3.1	24	1	AR260238	ACCESSION:AR260238
	8	21.4	2.8	23	1	AX454996	ACCESSION:AX454996
c	9	21	2.7	21	1	CQ799903	ACCESSION:CQ799903
c	10	21	2.7	21	1	CQ799904	ACCESSION:CQ799904
c	11	21	2.7	21	1	CQ799905	ACCESSION:CQ799905
c	12	21	2.7	21	1	CQ799906	ACCESSION:CQ799906
c	13	21	2.7	21	1	CQ799907	ACCESSION:CQ799907
c	14	21	2.7	21	1	CQ799908	ACCESSION:CQ799908
c	15	21	2.7	21	1	CQ799909	ACCESSION:CQ799909
c	16	21	2.7	21	1	CQ799910	ACCESSION:CQ799910
c	17	21	2.7	21	1	CQ799911	ACCESSION:CQ799911
c	18	21	2.7	21	1	CQ799912	ACCESSION:CQ799912
c	19	21	2.7	21	1	CQ799913	ACCESSION:CQ799913
c	20	21	2.7	21	1	CQ799914	ACCESSION:CQ799914
c	21	21	2.7	21	1	CQ799915	ACCESSION:CQ799915
c	22	21	2.7	21	1	CQ799916	ACCESSION:CQ799916
c	23	21	2.7	21	1	CQ799917	ACCESSION:CQ799917
c	24	21	2.7	21	1	CQ799918	ACCESSION:CQ799918
c	25	21	2.7	21	1	CQ799919	ACCESSION:CQ799919
c	26	21	2.7	21	1	CQ799920	ACCESSION:CQ799920
c	27	21	2.7	21	1	CQ799921	ACCESSION:CQ799921
c	28	21	2.7	21	1	CQ799922	ACCESSION:CQ799922
c	29	21	2.7	21	1	CQ799923	ACCESSION:CQ799923
c	30	21	2.7	21	1	CQ799924	ACCESSION:CQ799924
c	31	21	2.7	21	1	CQ799925	ACCESSION:CQ799925
c	32	21	2.7	21	1	CQ799926	ACCESSION:CQ799926
c	33	21	2.7	21	1	CQ799927	ACCESSION:CQ799927
c	34	21	2.7	21	1	CQ799928	ACCESSION:CQ799928
c	35	21	2.7	21	1	CQ799929	ACCESSION:CQ799929
c	36	21	2.7	21	1	CQ799930	ACCESSION:CQ799930
c	37	21	2.7	21	1	CQ799931	ACCESSION:CQ799931
c	38	21	2.7	21	1	CQ799932	ACCESSION:CQ799932
c	39	21	2.7	21	1	CQ799933	ACCESSION:CQ799933
c	40	21	2.7	21	1	CQ799934	ACCESSION:CQ799934
c	41	21	2.7	21	1	CQ799935	ACCESSION:CQ799935
c	42	21	2.7	21	1	CQ799936	ACCESSION:CQ799936
c	43	21	2.7	21	1	CQ799937	ACCESSION:CQ799937
c	44	21	2.7	21	1	CQ799938	ACCESSION:CQ799938
c	45	21	2.7	21	1	CQ799939	ACCESSION:CQ799939
c	46	21	2.7	21	1	CQ799940	ACCESSION:CQ799940
c	47	21	2.7	21	1	CQ799941	ACCESSION:CQ799941
c	48	21	2.7	21	1	CQ799942	ACCESSION:CQ799942
c	49	21	2.7	21	1	CQ799943	ACCESSION:CQ799943
c	50	21	2.7	21	1	CQ799944	ACCESSION:CQ799944
c	51	21	2.7	21	1	CQ799945	ACCESSION:CQ799945
c	52	21	2.7	21	1	CQ799946	ACCESSION:CQ799946
c	53	21	2.7	21	1	CQ799947	ACCESSION:CQ799947
c	54	21	2.7	21	1	CQ799948	ACCESSION:CQ799948
c	55	21	2.7	21	1	CQ799949	ACCESSION:CQ799949
c	56	21	2.7	21	1	CQ799950	ACCESSION:CQ799950
c	57	21	2.7	21	1	CQ799951	ACCESSION:CQ799951
c	58	21	2.7	21	1	CQ799952	ACCESSION:CQ799952
c	59	21	2.7	21	1	CQ799953	ACCESSION:CQ799953
c	60	21	2.7	21	1	CQ799954	ACCESSION:CQ799954
c	61	21	2.7	21	1	CQ799955	ACCESSION:CQ799955
c	62	21	2.7	21	1	CQ799956	ACCESSION:CQ799956
c	63	21	2.7	21	1	CQ799957	ACCESSION:CQ799957
c	64	21	2.7	21	1	CQ799958	ACCESSION:CQ799958
c	65	21	2.7	21	1	CQ799959	ACCESSION:CQ799959
c	66	21	2.7	21	1	CQ799960	ACCESSION:CQ799960
c	67	21	2.7	21	1	CQ799961	ACCESSION:CQ799961
c	68	21	2.7	21	1	CQ799962	ACCESSION:CQ799962
c	69	21	2.7	21	1	CQ799963	ACCESSION:CQ799963
c	70	21	2.7	21	1	CQ799964	ACCESSION:CQ799964
c	71	21	2.7	21	1	CQ799965	ACCESSION:CQ799965
c	72	21	2.7	21	1	CQ799966	ACCESSION:CQ799966
c	73	21	2.7	21	1	CQ799967	ACCESSION:CQ799967
c	74	21	2.7	21	1	CQ799968	ACCESSION:CQ799968
c	75	21	2.7	21	1	CQ799969	ACCESSION:CQ799969
c	76	21	2.7	21	1	CQ799970	ACCESSION:CQ799970
c	77	21	2.7	21	1	CQ799971	ACCESSION:CQ799971
c	78	21	2.7	21	1	CQ799972	ACCESSION:CQ799972
c	79	21	2.7	21	1	CQ799973	ACCESSION:CQ799973
c	80	21	2.7	21	1	CQ799974	ACCESSION:CQ799974
c	81	21	2.7	21	1	CQ799975	ACCESSION:CQ799975
c	82	21	2.7	21	1	CQ799976	ACCESSION:CQ799976
c	83	21	2.7	21	1	CQ799977	ACCESSION:CQ799977
c	84	21	2.7	21	1	CQ799978	ACCESSION:CQ799978
c	85	21	2.7	21	1	CQ799980	ACCESSION:CQ799980
c	86	21	2.7	21	1	CQ799981	ACCESSION:CQ799981
c	87	21	2.7	21	1	CQ799982	ACCESSION:CQ799982
c	88	21	2.7	21	1	CQ799983	ACCESSION:CQ799983
c	89	20	2.6	20	1	CQ799984	ACCESSION:CQ799984
	90	19	2.5	19	1	CQ799989	ACCESSION:CQ799989
	91	19	2.5	19	1	CQ799992	ACCESSION:CQ799992
	92	18.4	2.4	21	1	BD178972	ACCESSION:BD178972
c	93	18	2.4	18	1	CQ799979	ACCESSION:CQ799979
	94	17.8	2.3	21	1	CQ799991	ACCESSION:CQ799991
c	95	17.8	2.3	22	1	BD178973	ACCESSION:BD178973
	96	17.4	2.3	20	1	BD230260	ACCESSION:BD230260
	97	17	2.2	17	1	AX671859	ACCESSION:AX671859
	98	17	2.2	17	1	AX728678	ACCESSION:AX728678
	99	17	2.2	17	1	AX738957	ACCESSION:AX738957
	100	17	2.2	17	1	AX762937	ACCESSION:AX762937
	101	15.8	2.1	19	1	CQ799985	ACCESSION:CQ799985
	102	15.8	2.1	21	1	CQ799909	ACCESSION:CQ799909
	103	15.4	2.0	17	1	CQ625927	ACCESSION:CQ625927
	104	15.4	2.0	17	1	AR466990	ACCESSION:AR466990
	105	15.4	2.0	17	1	AX735327	ACCESSION:AX735327
	106	15.4	2.0	17	1	AX762926	ACCESSION:AX762926

	107	15	2.0	15	1	AR180537 ACCESSION:AR180537
c	108	14.8	1.9	18	1	AR072210 ACCESSION:AR072210
	109	14.8	1.9	18	1	CQ786325 ACCESSION:CQ786325
c	110	14.8	1.9	18	1	I26321 ACCESSION:I26321
c	111	14.8	1.9	18	1	AR392122 ACCESSION:AR392122
c	112	14.8	1.9	18	1	AX480662 ACCESSION:AX480662
c	113	14.4	1.9	16	1	I69196 ACCESSION:I69196
c	114	14.4	1.9	16	1	AR253794 ACCESSION:AR253794
c	115	14.4	1.9	16	1	AX696849 ACCESSION:AX696849
	116	14.4	1.9	17	1	CQ625926 ACCESSION:CQ625926
	117	14.4	1.9	17	1	CQ625928 ACCESSION:CQ625928
	118	14.4	1.9	17	1	AR466989 ACCESSION:AR466989
	119	14.4	1.9	17	1	AR466991 ACCESSION:AR466991
c	120	14.4	1.9	17	1	AX615411 ACCESSION:AX615411
c	121	14.4	1.9	17	1	AX615412 ACCESSION:AX615412
	122	14.4	1.9	17	1	AX783872 ACCESSION:AX783872
	123	14.4	1.9	17	1	AX783873 ACCESSION:AX783873
	124	14.4	1.9	18	1	AR096356 ACCESSION:AR096356
	125	14.4	1.9	18	1	AR109825 ACCESSION:AR109825
	126	14.4	1.9	18	1	BD217404 ACCESSION:BD217404
c	127	14.4	1.9	18	1	AR294360 ACCESSION:AR294360
	128	14	1.8	17	1	AX215323 ACCESSION:AX215323
	129	14	1.8	17	1	AX216349 ACCESSION:AX216349
c	130	14	1.8	17	1	AX266839 ACCESSION:AX266839
	131	14	1.8	17	1	AX266840 ACCESSION:AX266840
c	132	13.8	1.8	17	1	AR164573 ACCESSION:AR164573
	133	13.8	1.8	17	1	BD197647 ACCESSION:BD197647
c	134	13.8	1.8	17	1	BD241652 ACCESSION:BD241652
c	135	13.8	1.8	17	1	CQ617589 ACCESSION:CQ617589
c	136	13.8	1.8	17	1	CQ617590 ACCESSION:CQ617590
c	137	13.8	1.8	17	1	CQ617591 ACCESSION:CQ617591
	138	13.8	1.8	17	1	CQ625929 ACCESSION:CQ625929
	139	13.8	1.8	17	1	CQ625930 ACCESSION:CQ625930
	140	13.8	1.8	17	1	AR286401 ACCESSION:AR286401
	141	13.8	1.8	17	1	AR398391 ACCESSION:AR398391
c	142	13.8	1.8	17	1	AR458652 ACCESSION:AR458652
c	143	13.8	1.8	17	1	AR458653 ACCESSION:AR458653
c	144	13.8	1.8	17	1	AR458654 ACCESSION:AR458654
	145	13.8	1.8	17	1	AR466992 ACCESSION:AR466992
	146	13.8	1.8	17	1	AR466993 ACCESSION:AR466993
c	147	13.8	1.8	17	1	AR483153 ACCESSION:AR483153
	148	13.8	1.8	17	1	AX216972 ACCESSION:AX216972
c	149	13.8	1.8	17	1	AX498863 ACCESSION:AX498863
	150	13.8	1.8	17	1	AX531714 ACCESSION:AX531714
	151	13.8	1.8	17	1	AX579468 ACCESSION:AX579468
c	152	13.8	1.8	17	1	AX580066 ACCESSION:AX580066
c	153	13.8	1.8	17	1	AX580067 ACCESSION:AX580067
c	154	13.8	1.8	17	1	AX725108 ACCESSION:AX725108
	155	13.8	1.8	17	1	AX725434 ACCESSION:AX725434
c	156	13.8	1.8	17	1	AX735751 ACCESSION:AX735751
	157	13.8	1.8	17	1	AX736224 ACCESSION:AX736224
	158	13.8	1.8	17	1	AX753978 ACCESSION:AX753978
c	159	13.8	1.8	17	1	AX783428 ACCESSION:AX783428
c	160	13.8	1.8	17	1	AX783429 ACCESSION:AX783429

ALIGNMENTS

RESULT 1
CQ533030
LOCUS CQ533030 65 bp DNA linear PAT 30-JAN-2004
DEFINITION Sequence 2665 from Patent WO0210449.
ACCESSION CQ533030
VERSION CQ533030.1 GI:41499294
KEYWORDS .
SOURCE Rattus norvegicus (Norway rat)
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
REFERENCE 1
AUTHORS Shoshan,A., Wasserman,A., Mintz,E., Mintz,L. and Faigler,S.
TITLE Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
JOURNAL Patent: WO 0210449-A 2665 07-FEB-2002; Compugen Inc. (US)
FEATURES Location/Qualifiers
source 1. .65
/organism="Rattus norvegicus"
/mol_type="unassigned DNA"
/db_xref="taxon:10116"

Query Match 6.8%; Score 52.2; DB 1; Length 65;
Best Local Similarity 87.7%; Pred. No. 0.05;
Matches 57; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

```
Qy        314 GTGTCCCTGGATGTCAACCACTTCGCCCCGGACGAGCTGACGGTCAAGACCAAGGATGGC 373
              ||||||||||| ||||||||||||||| || || ||||| || || ||||||||||| |||
Db          1 GTGTCCCTGGACGTCAACCACTTCGCTCCTGAGGAGCTCACAGTTAAGACCAAGGAAGGC 60

Qy        374 GTGGT 378
              |||||
Db         61 GTGGT 65
```

RESULT 2
AR091050/c
LOCUS AR091050 25 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 1170 from patent US 5994076.
ACCESSION AR091050
VERSION AR091050.1 GI:10017805
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 25)
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 5994076-A 1170 30-NOV-1999;
FEATURES Location/Qualifiers
source 1. .25
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 3.3%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1
```

RESULT 3
AR198085/c
LOCUS AR198085 25 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1170 from patent US 6352829.
ACCESSION AR198085
VERSION AR198085.1 GI:20247934
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 25)
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6352829-A 1170 05-MAR-2002;
FEATURES Location/Qualifiers
source 1. .25
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 3.3%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 4
AR260239/c
LOCUS       AR260239                  25 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 1170 from patent US 6489455.
ACCESSION   AR260239
VERSION     AR260239.1  GI:27310750
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 6489455-A 1170 03-DEC-2002;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           3.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 5
AR091049
LOCUS       AR091049                  24 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 1169 from patent US 5994076.
ACCESSION   AR091049
VERSION     AR091049.1  GI:10017804
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 5994076-A 1169 30-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match           3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 6
AR198084
LOCUS       AR198084                  24 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 1169 from patent US 6352829.
ACCESSION   AR198084
VERSION     AR198084.1  GI:20247933
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 6352829-A 1169 05-MAR-2002;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match           3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 7
AR260238
LOCUS       AR260238                  24 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 1169 from patent US 6489455.
ACCESSION   AR260238
VERSION     AR260238.1  GI:27310749
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
  TITLE     Methods of assaying differential expression
  JOURNAL   Patent: US 6489455-A 1169 03-DEC-2002;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match           3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 8
AX454996
LOCUS       AX454996                  23 bp    DNA     linear   PAT 06-JUL-2002
DEFINITION  Sequence 63 from Patent WO0208453.
ACCESSION   AX454996
VERSION     AX454996.1  GI:21714181
KEYWORDS    .
SOURCE      Canis familiaris (dog)
  ORGANISM  Canis familiaris
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE   1
  AUTHORS   Farr,S.B., Pickett,G.G., Neft,R.E. and Dunn,R.T.
  TITLE     Canine toxicity genes
  JOURNAL   Patent: WO 0208453-A 63 31-JAN-2002;
            Phase-1 Molecular Toxicology (US)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Canis familiaris"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9615"

  Query Match           2.8%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 22;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         73 GGACCCCTTCCGCGACTGGTACC 95
              |||||| ||||||||||||||||
```

```
Db          1 GGACCCTTTCCGCGACTGGTACC 23


RESULT 9
CQ799903/c
LOCUS       CQ799903                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 1 from Patent WO2004030660.
ACCESSION   CQ799903
VERSION     CQ799903.1  GI:46848850
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 1 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 GGCACGAGGAGCAGAGTCAGC 21
              |||||||||||||||||||||
Db         21 GGCACGAGGAGCAGAGTCAGC 1


RESULT 10
CQ799904/c
LOCUS       CQ799904                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 2 from Patent WO2004030660.
ACCESSION   CQ799904
VERSION     CQ799904.1  GI:46848851
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 2 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         11 GCAGAGTCAGCCAGCATGACC 31
              |||||||||||||||||||||
Db         21 GCAGAGTCAGCCAGCATGACC 1


RESULT 11
CQ799905/c
LOCUS       CQ799905                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 3 from Patent WO2004030660.
ACCESSION   CQ799905
VERSION     CQ799905.1  GI:46848852
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 3 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          21 CCAGCATGACCGAGCGCCGCG 41
               |||||||||||||||||||||
Db          21 CCAGCATGACCGAGCGCCGCG 1


RESULT 12
CQ799906/c
LOCUS       CQ799906                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 4 from Patent WO2004030660.
ACCESSION   CQ799906
VERSION     CQ799906.1  GI:46848853
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 4 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          31 CGAGCGCCGCGTCCCCTTCTC 51
               |||||||||||||||||||||
Db          21 CGAGCGCCGCGTCCCCTTCTC 1


RESULT 13
CQ799907/c
LOCUS       CQ799907                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 5 from Patent WO2004030660.
ACCESSION   CQ799907
VERSION     CQ799907.1  GI:46848854
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 5 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
```

```
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         41 GTCCCCTTCTCGCTCCTGCGG 61
              |||||||||||||||||||||
Db         21 GTCCCCTTCTCGCTCCTGCGG 1


RESULT 14
CQ799908/c
LOCUS       CQ799908                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 6 from Patent WO2004030660.
ACCESSION   CQ799908
VERSION     CQ799908.1  GI:46848855
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 6 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 CGCTCCTGCGGGGCCCCAGCT 71
              |||||||||||||||||||||
Db         21 CGCTCCTGCGGGGCCCCAGCT 1


RESULT 15
CQ799909/c
LOCUS       CQ799909                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 7 from Patent WO2004030660.
ACCESSION   CQ799909
VERSION     CQ799909.1  GI:46848856
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 7 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         61 GGGCCCCAGCTGGGACCCCTT 81
              |||||||||||||||||||||
Db         21 GGGCCCCAGCTGGGACCCCTT 1


RESULT 16
CQ799910/c
LOCUS       CQ799910                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 8 from Patent WO2004030660.
ACCESSION   CQ799910
VERSION     CQ799910.1  GI:46848857
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 8 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         71 TGGGACCCCTTCCGCGACTGG 91
              |||||||||||||||||||||
Db         21 TGGGACCCCTTCCGCGACTGG 1


RESULT 17
CQ799911/c
LOCUS       CQ799911                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 9 from Patent WO2004030660.
ACCESSION   CQ799911
VERSION     CQ799911.1  GI:46848858
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 9 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         81 TCCGCGACTGGTACCCGCATA 101
              |||||||||||||||||||||
Db         21 TCCGCGACTGGTACCCGCATA 1


RESULT 18
CQ799912/c
LOCUS       CQ799912                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 10 from Patent WO2004030660.
ACCESSION   CQ799912
VERSION     CQ799912.1  GI:46848859
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 10 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          91 GTACCCGCATAGCCGCCTCTT 111
               |||||||||||||||||||||
Db          21 GTACCCGCATAGCCGCCTCTT 1


RESULT 19
CQ799913/c
LOCUS       CQ799913                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 11 from Patent WO2004030660.
ACCESSION   CQ799913
VERSION     CQ799913.1  GI:46848860
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 11 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         101 AGCCGCCTCTTCGACCAGGCC 121
               |||||||||||||||||||||
Db          21 AGCCGCCTCTTCGACCAGGCC 1


RESULT 20
CQ799914/c
LOCUS       CQ799914                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 12 from Patent WO2004030660.
ACCESSION   CQ799914
VERSION     CQ799914.1  GI:46848861
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 12 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         111 TCGACCAGGCCTTCGGGCTGC 131
               |||||||||||||||||||||
Db          21 TCGACCAGGCCTTCGGGCTGC 1


RESULT 21
CQ799915/c
LOCUS       CQ799915                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 13 from Patent WO2004030660.
ACCESSION   CQ799915
VERSION     CQ799915.1  GI:46848862
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 13 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         121 CTTCGGGCTGCCCCGGCTGCC 141
               |||||||||||||||||||||
Db          21 CTTCGGGCTGCCCCGGCTGCC 1


RESULT 22
CQ799916/c
LOCUS       CQ799916                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 14 from Patent WO2004030660.
ACCESSION   CQ799916
VERSION     CQ799916.1  GI:46848863
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 14 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         131 CCCCGGCTGCCGGAGGAGTGG 151
               |||||||||||||||||||||
Db          21 CCCCGGCTGCCGGAGGAGTGG 1


RESULT 23
```

```
CQ799917/c
LOCUS       CQ799917                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 15 from Patent WO2004030660.
ACCESSION   CQ799917
VERSION     CQ799917.1  GI:46848864
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 15 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        141 CGGAGGAGTGGTCGCAGTGGT 161
              |||||||||||||||||||||
Db         21 CGGAGGAGTGGTCGCAGTGGT 1


RESULT 24
CQ799918/c
LOCUS       CQ799918                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 16 from Patent WO2004030660.
ACCESSION   CQ799918
VERSION     CQ799918.1  GI:46848865
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 16 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        151 GTCGCAGTGGTTAGGCGGCAG 171
              |||||||||||||||||||||
Db         21 GTCGCAGTGGTTAGGCGGCAG 1


RESULT 25
CQ799919/c
LOCUS       CQ799919                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 17 from Patent WO2004030660.
ACCESSION   CQ799919
VERSION     CQ799919.1  GI:46848866
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 17 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        161 TTAGGCGGCAGCAGCTGGCCA 181
              |||||||||||||||||||||
Db         21 TTAGGCGGCAGCAGCTGGCCA 1


RESULT 26
CQ799920/c
LOCUS       CQ799920                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 18 from Patent WO2004030660.
ACCESSION   CQ799920
VERSION     CQ799920.1  GI:46848867
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 18 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        171 GCAGCTGGCCAGGCTACGTGC 191
              |||||||||||||||||||||
Db         21 GCAGCTGGCCAGGCTACGTGC 1


RESULT 27
CQ799921/c
LOCUS       CQ799921                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 19 from Patent WO2004030660.
ACCESSION   CQ799921
VERSION     CQ799921.1  GI:46848868
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 19 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
```

```
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        181 AGGCTACGTGCGCCCCCTGCC 201
              |||||||||||||||||||||
Db         21 AGGCTACGTGCGCCCCCTGCC 1


RESULT 28
CQ799922/c
LOCUS       CQ799922                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 20 from Patent WO2004030660.
ACCESSION   CQ799922
VERSION     CQ799922.1  GI:46848869
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 20 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        191 CGCCCCCTGCCCCCCGCCGCC 211
              |||||||||||||||||||||
Db         21 CGCCCCCTGCCCCCCGCCGCC 1


RESULT 29
CQ799923/c
LOCUS       CQ799923                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 21 from Patent WO2004030660.
ACCESSION   CQ799923
VERSION     CQ799923.1  GI:46848870
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 21 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        201 CCCCCGCCGCCATCGAGAGCC 221
              |||||||||||||||||||||
Db         21 CCCCCGCCGCCATCGAGAGCC 1


RESULT 30
CQ799924/c
LOCUS       CQ799924                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 22 from Patent WO2004030660.
ACCESSION   CQ799924
VERSION     CQ799924.1  GI:46848871
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 22 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        211 CATCGAGAGCCCCGCAGTGGC 231
              |||||||||||||||||||||
Db         21 CATCGAGAGCCCCGCAGTGGC 1


RESULT 31
CQ799925/c
LOCUS       CQ799925                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 23 from Patent WO2004030660.
ACCESSION   CQ799925
VERSION     CQ799925.1  GI:46848872
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 23 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        221 CCCGCAGTGGCCGCGCCCGCC 241
              |||||||||||||||||||||
Db         21 CCCGCAGTGGCCGCGCCCGCC 1


RESULT 32
CQ799926/c
LOCUS       CQ799926                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 24 from Patent WO2004030660.
ACCESSION   CQ799926
VERSION     CQ799926.1  GI:46848873
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
```

```
  JOURNAL   Patent: WO 2004030660-A 24 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        231 CCGCGCCCGCCTACAGCCGCG 251
              |||||||||||||||||||||
Db         21 CCGCGCCCGCCTACAGCCGCG 1


RESULT 33
CQ799927/c
LOCUS       CQ799927                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 25 from Patent WO2004030660.
ACCESSION   CQ799927
VERSION     CQ799927.1  GI:46848874
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 25 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        241 CTACAGCCGCGCGCTCAGCCG 261
              |||||||||||||||||||||
Db         21 CTACAGCCGCGCGCTCAGCCG 1


RESULT 34
CQ799928/c
LOCUS       CQ799928                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 26 from Patent WO2004030660.
ACCESSION   CQ799928
VERSION     CQ799928.1  GI:46848875
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 26 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        251 GCGCTCAGCCGGCAACTCAGC 271
              |||||||||||||||||||||
Db         21 GCGCTCAGCCGGCAACTCAGC 1


RESULT 35
CQ799929/c
LOCUS       CQ799929                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 27 from Patent WO2004030660.
ACCESSION   CQ799929
VERSION     CQ799929.1  GI:46848876
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 27 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        261 GGCAACTCAGCAGCGGGGTCT 281
              |||||||||||||||||||||
Db         21 GGCAACTCAGCAGCGGGGTCT 1


RESULT 36
CQ799930/c
LOCUS       CQ799930                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 28 from Patent WO2004030660.
ACCESSION   CQ799930
VERSION     CQ799930.1  GI:46848877
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 28 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        271 CAGCGGGGTCTCGGAGATCCG 291
              |||||||||||||||||||||
Db         21 CAGCGGGGTCTCGGAGATCCG 1


RESULT 37
CQ799931/c
LOCUS       CQ799931                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 29 from Patent WO2004030660.
ACCESSION   CQ799931
```

```
VERSION     CQ799931.1  GI:46848878
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 29 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        281 TCGGAGATCCGGCACACTGCG 301
              |||||||||||||||||||||
Db         21 TCGGAGATCCGGCACACTGCG 1


RESULT 38
CQ799932/c
LOCUS       CQ799932                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 30 from Patent WO2004030660.
ACCESSION   CQ799932
VERSION     CQ799932.1  GI:46848879
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 30 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        291 GGCACACTGCGGACCGCTGGC 311
              |||||||||||||||||||||
Db         21 GGCACACTGCGGACCGCTGGC 1


RESULT 39
CQ799933/c
LOCUS       CQ799933                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 31 from Patent WO2004030660.
ACCESSION   CQ799933
VERSION     CQ799933.1  GI:46848880
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 31 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        301 GGACCGCTGGCGCGTGTCCCT 321
              |||||||||||||||||||||
Db         21 GGACCGCTGGCGCGTGTCCCT 1


RESULT 40
CQ799934/c
LOCUS       CQ799934                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 32 from Patent WO2004030660.
ACCESSION   CQ799934
VERSION     CQ799934.1  GI:46848881
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 32 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        311 CGCGTGTCCCTGGATGTCAAC 331
              |||||||||||||||||||||
Db         21 CGCGTGTCCCTGGATGTCAAC 1


RESULT 41
CQ799935/c
LOCUS       CQ799935                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 33 from Patent WO2004030660.
ACCESSION   CQ799935
VERSION     CQ799935.1  GI:46848882
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 33 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        321 TGGATGTCAACCACTTCGCCC 341
```

```
                    ||||||||||||||||||||
Db         21 TGGATGTCAACCACTTCGCCC 1


RESULT 42
CQ799936/c
LOCUS       CQ799936                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 34 from Patent WO2004030660.
ACCESSION   CQ799936
VERSION     CQ799936.1  GI:46848883
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 34 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        331 CCACTTCGCCCCGGACGAGCT 351
              ||||||||||||||||||||
Db         21 CCACTTCGCCCCGGACGAGCT 1


RESULT 43
CQ799937/c
LOCUS       CQ799937                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 35 from Patent WO2004030660.
ACCESSION   CQ799937
VERSION     CQ799937.1  GI:46848884
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 35 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        341 CCGGACGAGCTGACGGTCAAG 361
              ||||||||||||||||||||
Db         21 CCGGACGAGCTGACGGTCAAG 1


RESULT 44
CQ799938/c
LOCUS       CQ799938                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 36 from Patent WO2004030660.
ACCESSION   CQ799938
VERSION     CQ799938.1  GI:46848885
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 36 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        351 TGACGGTCAAGACCAAGGATG 371
              ||||||||||||||||||||
Db         21 TGACGGTCAAGACCAAGGATG 1


RESULT 45
CQ799939/c
LOCUS       CQ799939                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 37 from Patent WO2004030660.
ACCESSION   CQ799939
VERSION     CQ799939.1  GI:46848886
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 37 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        361 GACCAAGGATGGCGTGGTGGA 381
              ||||||||||||||||||||
Db         21 GACCAAGGATGGCGTGGTGGA 1


RESULT 46
CQ799940/c
LOCUS       CQ799940                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 38 from Patent WO2004030660.
ACCESSION   CQ799940
VERSION     CQ799940.1  GI:46848887
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 38 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
```

```
                 /organism="Homo sapiens"
                 /mol_type="unassigned DNA"
                 /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        371 GGCGTGGTGGAGATCACCGGC 391
              |||||||||||||||||||||
Db         21 GGCGTGGTGGAGATCACCGGC 1


RESULT 47
CQ799941/c
LOCUS       CQ799941                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 39 from Patent WO2004030660.
ACCESSION   CQ799941
VERSION     CQ799941.1  GI:46848888
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 39 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        381 AGATCACCGGCAAGCACGAGG 401
              |||||||||||||||||||||
Db         21 AGATCACCGGCAAGCACGAGG 1


RESULT 48
CQ799942/c
LOCUS       CQ799942                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 40 from Patent WO2004030660.
ACCESSION   CQ799942
VERSION     CQ799942.1  GI:46848889
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 40 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        391 CAAGCACGAGGAGCGGCAGGA 411
              |||||||||||||||||||||
Db         21 CAAGCACGAGGAGCGGCAGGA 1


RESULT 49
CQ799943/c
LOCUS       CQ799943                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 41 from Patent WO2004030660.
ACCESSION   CQ799943
VERSION     CQ799943.1  GI:46848890
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 41 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        401 GAGCGGCAGGACGAGCATGGC 421
              |||||||||||||||||||||
Db         21 GAGCGGCAGGACGAGCATGGC 1


RESULT 50
CQ799944/c
LOCUS       CQ799944                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 42 from Patent WO2004030660.
ACCESSION   CQ799944
VERSION     CQ799944.1  GI:46848891
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 42 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        411 ACGAGCATGGCTACATCTCCC 431
              |||||||||||||||||||||
Db         21 ACGAGCATGGCTACATCTCCC 1


RESULT 51
CQ799945/c
LOCUS       CQ799945                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 43 from Patent WO2004030660.
ACCESSION   CQ799945
VERSION     CQ799945.1  GI:46848892
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
```

```
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 43 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        421 CTACATCTCCCGGTGCTTCAC 441
              |||||||||||||||||||||
Db         21 CTACATCTCCCGGTGCTTCAC 1


RESULT 52
CQ799946/c
LOCUS       CQ799946                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 44 from Patent WO2004030660.
ACCESSION   CQ799946
VERSION     CQ799946.1  GI:46848893
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 44 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        431 CGGTGCTTCACGCGGAAATAC 451
              |||||||||||||||||||||
Db         21 CGGTGCTTCACGCGGAAATAC 1


RESULT 53
CQ799947/c
LOCUS       CQ799947                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 45 from Patent WO2004030660.
ACCESSION   CQ799947
VERSION     CQ799947.1  GI:46848894
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 45 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        441 CGCGGAAATACACGCTGCCCC 461
              |||||||||||||||||||||
Db         21 CGCGGAAATACACGCTGCCCC 1


RESULT 54
CQ799948/c
LOCUS       CQ799948                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 46 from Patent WO2004030660.
ACCESSION   CQ799948
VERSION     CQ799948.1  GI:46848895
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 46 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        451 CACGCTGCCCCCCGGTGTGGA 471
              |||||||||||||||||||||
Db         21 CACGCTGCCCCCCGGTGTGGA 1


RESULT 55
CQ799949/c
LOCUS       CQ799949                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 47 from Patent WO2004030660.
ACCESSION   CQ799949
VERSION     CQ799949.1  GI:46848896
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 47 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        461 CCCGGTGTGGACCCCACCCAA 481
              |||||||||||||||||||||
Db         21 CCCGGTGTGGACCCCACCCAA 1
```

```
RESULT 56
CQ799950/c
LOCUS       CQ799950                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 48 from Patent WO2004030660.
ACCESSION   CQ799950
VERSION     CQ799950.1  GI:46848897
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 48 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        471 ACCCCACCCAAGTTTCCTCCT 491
              |||||||||||||||||||||
Db         21 ACCCCACCCAAGTTTCCTCCT 1


RESULT 57
CQ799951/c
LOCUS       CQ799951                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 49 from Patent WO2004030660.
ACCESSION   CQ799951
VERSION     CQ799951.1  GI:46848898
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 49 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        481 AGTTTCCTCCTCCCTGTCCCC 501
              |||||||||||||||||||||
Db         21 AGTTTCCTCCTCCCTGTCCCC 1


RESULT 58
CQ799952/c
LOCUS       CQ799952                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 50 from Patent WO2004030660.
ACCESSION   CQ799952
VERSION     CQ799952.1  GI:46848899
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 50 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        491 TCCCTGTCCCCTGAGGGCACA 511
              |||||||||||||||||||||
Db         21 TCCCTGTCCCCTGAGGGCACA 1


RESULT 59
CQ799953/c
LOCUS       CQ799953                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 51 from Patent WO2004030660.
ACCESSION   CQ799953
VERSION     CQ799953.1  GI:46848900
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 51 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        501 CTGAGGGCACACTGACCGTGG 521
              |||||||||||||||||||||
Db         21 CTGAGGGCACACTGACCGTGG 1


RESULT 60
CQ799954/c
LOCUS       CQ799954                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 52 from Patent WO2004030660.
ACCESSION   CQ799954
VERSION     CQ799954.1  GI:46848901
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 52 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
```

```
  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        511 ACTGACCGTGGAGGCCCCCAT 531
              |||||||||||||||||||||
Db         21 ACTGACCGTGGAGGCCCCCAT 1


RESULT 61
CQ799955/c
LOCUS       CQ799955                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 53 from Patent WO2004030660.
ACCESSION   CQ799955
VERSION     CQ799955.1  GI:46848902
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 53 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        521 GAGGCCCCCATGCCCAAGCTA 541
              |||||||||||||||||||||
Db         21 GAGGCCCCCATGCCCAAGCTA 1


RESULT 62
CQ799956/c
LOCUS       CQ799956                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 54 from Patent WO2004030660.
ACCESSION   CQ799956
VERSION     CQ799956.1  GI:46848903
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 54 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        531 TGCCCAAGCTAGCCACGCAGT 551
              |||||||||||||||||||||
Db         21 TGCCCAAGCTAGCCACGCAGT 1


RESULT 63
CQ799957/c
LOCUS       CQ799957                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 55 from Patent WO2004030660.
ACCESSION   CQ799957
VERSION     CQ799957.1  GI:46848904
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 55 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCAACGAGAT 561
              |||||||||||||||||||||
Db         21 AGCCACGCAGTCCAACGAGAT 1


RESULT 64
CQ799958/c
LOCUS       CQ799958                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 56 from Patent WO2004030660.
ACCESSION   CQ799958
VERSION     CQ799958.1  GI:46848905
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 56 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCATCCCA 571
              |||||||||||||||||||||
Db         21 TCCAACGAGATCACCATCCCA 1


RESULT 65
CQ799959/c
LOCUS       CQ799959                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 57 from Patent WO2004030660.
ACCESSION   CQ799959
VERSION     CQ799959.1  GI:46848906
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
```

```
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 57 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        561 TCACCATCCCAGTCACCTTCG 581
              |||||||||||||||||||||
Db         21 TCACCATCCCAGTCACCTTCG 1


RESULT 66
CQ799960/c
LOCUS       CQ799960                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 58 from Patent WO2004030660.
ACCESSION   CQ799960
VERSION     CQ799960.1  GI:46848907
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 58 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        571 AGTCACCTTCGAGTCGCGGGC 591
              |||||||||||||||||||||
Db.        21 AGTCACCTTCGAGTCGCGGGC 1


RESULT 67
CQ799961/c
LOCUS       CQ799961                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 59 from Patent WO2004030660.
ACCESSION   CQ799961
VERSION     CQ799961.1  GI:46848908
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 59 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        581 GAGTCGCGGGCCCAGCTTGGG 601
              |||||||||||||||||||||
Db         21 GAGTCGCGGGCCCAGCTTGGG 1


RESULT 68
CQ799962/c
LOCUS       CQ799962                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 60 from Patent WO2004030660.
ACCESSION   CQ799962
VERSION     CQ799962.1  GI:46848909
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 60 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        591 CCCAGCTTGGGGGCCCAGAAG 611
              |||||||||||||||||||||
Db         21 CCCAGCTTGGGGGCCCAGAAG 1


RESULT 69
CQ799963/c
LOCUS       CQ799963                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 61 from Patent WO2004030660.
ACCESSION   CQ799963
VERSION     CQ799963.1  GI:46848910
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 61 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        601 GGGCCCAGAAGCTGCAAAATC 621
              |||||||||||||||||||||
Db         21 GGGCCCAGAAGCTGCAAAATC 1


RESULT 70
CQ799964/c
LOCUS       CQ799964                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 62 from Patent WO2004030660.
```

```
ACCESSION   CQ799964
VERSION     CQ799964.1  GI:46848911
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 62 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        611 GCTGCAAAATCCGATGAGACT 631
              |||||||||||||||||||||
Db         21 GCTGCAAAATCCGATGAGACT 1


RESULT 71
CQ799965/c
LOCUS       CQ799965                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 63 from Patent WO2004030660.
ACCESSION   CQ799965
VERSION     CQ799965.1  GI:46848912
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 63 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        621 CCGATGAGACTGCCGCCAAGT 641
              |||||||||||||||||||||
Db         21 CCGATGAGACTGCCGCCAAGT 1


RESULT 72
CQ799966/c
LOCUS       CQ799966                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 64 from Patent WO2004030660.
ACCESSION   CQ799966
VERSION     CQ799966.1  GI:46848913
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 64 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAG 651
              |||||||||||||||||||||
Db         21 TGCCGCCAAGTAAAGCCTTAG 1


RESULT 73
CQ799967/c
LOCUS       CQ799967                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 65 from Patent WO2004030660.
ACCESSION   CQ799967
VERSION     CQ799967.1  GI:46848914
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 65 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        641 TAAAGCCTTAGCCCGGATGCC 661
              |||||||||||||||||||||
Db         21 TAAAGCCTTAGCCCGGATGCC 1


RESULT 74
CQ799968/c
LOCUS       CQ799968                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 66 from Patent WO2004030660.
ACCESSION   CQ799968
VERSION     CQ799968.1  GI:46848915
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 66 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        651 GCCCGGATGCCCACCCCTGCT 671
              |||||||||||||||||||||
Db         21 GCCCGGATGCCCACCCCTGCT 1


RESULT 75
CQ799969/c
LOCUS       CQ799969                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 67 from Patent WO2004030660.
ACCESSION   CQ799969
VERSION     CQ799969.1  GI:46848916
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 67 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        661 CCACCCCTGCTGCCGCCACTG 681
              |||||||||||||||||||||
Db         21 CCACCCCTGCTGCCGCCACTG 1


RESULT 76
CQ799970/c
LOCUS       CQ799970                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 68 from Patent WO2004030660.
ACCESSION   CQ799970
VERSION     CQ799970.1  GI:46848917
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 68 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        671 TGCCGCCACTGGCTGTGCCTC 691
              |||||||||||||||||||||
Db         21 TGCCGCCACTGGCTGTGCCTC 1


RESULT 77
CQ799971/c
LOCUS       CQ799971                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 69 from Patent WO2004030660.
ACCESSION   CQ799971
VERSION     CQ799971.1  GI:46848918
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 69 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        681 GGCTGTGCCTCCCCCGCCACC 701
              |||||||||||||||||||||
Db         21 GGCTGTGCCTCCCCCGCCACC 1


RESULT 78
CQ799972/c
LOCUS       CQ799972                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 70 from Patent WO2004030660.
ACCESSION   CQ799972
VERSION     CQ799972.1  GI:46848919
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 70 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        691 CCCCCGCCACCTGTGTGTTCT 711
              |||||||||||||||||||||
Db         21 CCCCCGCCACCTGTGTGTTCT 1


RESULT 79
CQ799973/c
LOCUS       CQ799973                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 71 from Patent WO2004030660.
ACCESSION   CQ799973
VERSION     CQ799973.1  GI:46848920
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 71 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
```

```
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGATACAT 721
              |||||||||||||||||||||
Db         21 CTGTGTGTTCTTTTGATACAT 1


RESULT 80
CQ799974/c
LOCUS       CQ799974                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 72 from Patent WO2004030660.
ACCESSION   CQ799974
VERSION     CQ799974.1  GI:46848921
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 72 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        711 TTTTGATACATTTATCTTCTG 731
              |||||||||||||||||||||
Db         21 TTTTGATACATTTATCTTCTG 1


RESULT 81
CQ799975/c
LOCUS       CQ799975                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 73 from Patent WO2004030660.
ACCESSION   CQ799975
VERSION     CQ799975.1  GI:46848922
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 73 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        721 TTTATCTTCTGTTTTTCTCAA 741
              |||||||||||||||||||||
Db         21 TTTATCTTCTGTTTTTCTCAA 1


RESULT 82
CQ799976/c
LOCUS       CQ799976                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 74 from Patent WO2004030660.
ACCESSION   CQ799976
VERSION     CQ799976.1  GI:46848923
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 74 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        731 GTTTTTCTCAAATAAAGTTCA 751
              |||||||||||||||||||||
Db         21 GTTTTTCTCAAATAAAGTTCA 1


RESULT 83
CQ799977/c
LOCUS       CQ799977                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 75 from Patent WO2004030660.
ACCESSION   CQ799977
VERSION     CQ799977.1  GI:46848924
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 75 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        741 AATAAAGTTCAAAGCAACCAC 761
              |||||||||||||||||||||
Db         21 AATAAAGTTCAAAGCAACCAC 1


RESULT 84
CQ799978/c
LOCUS       CQ799978                21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 76 from Patent WO2004030660.
ACCESSION   CQ799978
VERSION     CQ799978.1  GI:46848925
KEYWORDS    .
SOURCE      Homo sapiens (human)
```

```
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 76 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        744 AAAGTTCAAAGCAACCACCTG 764
              |||||||||||||||||||||
Db         21 AAAGTTCAAAGCAACCACCTG 1


RESULT 85
CQ799980/c
LOCUS       CQ799980                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 78 from Patent WO2004030660.
ACCESSION   CQ799980
VERSION     CQ799980.1  GI:46848927
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 78 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        365 AAGGATGGCGTGGTGGAGATC 385
              |||||||||||||||||||||
Db         21 AAGGATGGCGTGGTGGAGATC 1


RESULT 86
CQ799981/c
LOCUS       CQ799981                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 79 from Patent WO2004030660.
ACCESSION   CQ799981
VERSION     CQ799981.1  GI:46848928
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 79 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        265 ACTCAGCAGCGGGGTCTCGGA 285
              |||||||||||||||||||||
Db         21 ACTCAGCAGCGGGGTCTCGGA 1


RESULT 87
CQ799982/c
LOCUS       CQ799982                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 80 from Patent WO2004030660.
ACCESSION   CQ799982
VERSION     CQ799982.1  GI:46848929
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 80 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        264 AACTCAGCAGCGGGGTCTCGG 284
              |||||||||||||||||||||
Db         21 AACTCAGCAGCGGGGTCTCGG 1


RESULT 88
CQ799983/c
LOCUS       CQ799983                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 81 from Patent WO2004030660.
ACCESSION   CQ799983
VERSION     CQ799983.1  GI:46848930
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 81 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 20;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCCCC 46
              |||||||||||||||||||||
Db         21 ATGACCGAGCGCCGCGTCCCC 1
```

```
RESULT 89
CQ799984/c
LOCUS       CQ799984                  20 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 82 from Patent WO2004030660.
ACCESSION   CQ799984
VERSION     CQ799984.1  GI:46848931
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 82 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCCC 45
              ||||||||||||||||||||
Db         20 ATGACCGAGCGCCGCGTCCC 1


RESULT 90
CQ799989
LOCUS       CQ799989                  19 bp    RNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 87 from Patent WO2004030660.
ACCESSION   CQ799989
VERSION     CQ799989.1  GI:46848936
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 87 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 28;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        556 CGAGATCACCATCCCAGTC 574
              |||||||||||||||||||
Db          1 CGAGATCACCATCCCAGTC 19


RESULT 91
CQ799992
LOCUS       CQ799992                  19 bp    RNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 90 from Patent WO2004030660.
ACCESSION   CQ799992
VERSION     CQ799992.1  GI:46848939
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 90 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 28;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCC 44
              |||||||||||||||||||
Db          1 ATGACCGAGCGCCGCGTCC 19


RESULT 92
BD178972
LOCUS       BD178972                  21 bp    DNA     linear   PAT 16-APR-2003
DEFINITION  HSP inducing agent.
ACCESSION   BD178972
VERSION     BD178972.1  GI:30016240
KEYWORDS    WO 02078705-A/1.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Terashita,Z., Naruo,K., Uchikawa,O. and Nakanishi,A.
  TITLE     HSP inducing agent
  JOURNAL   Patent: WO 02078705-A 1 10-OCT-2002;
            TAKEDA CHEMICAL INDUSTRIES LTD,ZENICHI TERASHITA,KENICHI NARUO,
            OSAMU UCHIKAWA,ATSUSHI NAKANISHI
COMMENT     OS   Artificial Sequence
            PN   WO 02078705-A/1
            PD   10-OCT-2002
            PF   27-MAR-2002 WO 2002JP002946
            PR   28-MAR-2001 JP 01P   092704
            PI   ZENICHI TERASHITA,KENICHI NARUO,OSAMU UCHIKAWA,ATSUSHI  PI
            NAKANISHI
            PC   A61K31/437,A61K45/00,A61K45/06,C07D471/04,A61P1/00,A61P1/04,
            PC   A61P1/08,
            PC
            A61P1/16,A61P3/04,A61P3/06,A61P3/10,A61P5/00,A61P7/02,A61P7/06, PC
             A61P9/04,
            PC
            A61P9/06,A61P9/08,A61P9/10,A61P9/12,A61P11/00,A61P11/04,A61P11/ PC
             06,
            PC   A61P13/08,A61P13/12,A61P19/02,A61P19/06,A61P19/10,A61P23/00,
            PC   A61P25/16,
            PC   A61P25/18,A61P25/22,A61P25/24,A61P25/28,A61P27/02,A61P29/00,
            PC   A61P31/00,
            PC   A61P35/00,A61P37/08,A61P43/00
            CC   PCR primer for amplifying HSP27 gene
            FH   Key             Location/Qualifiers
            FT   source          1. .21
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 40;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        359 AAGACCAAGGATGGCGTGGT 378
              |||||||||| ||||||||
```

```
Db          2 AAGACCAAGGAAGGCGTGGT 21


RESULT 93
CQ799979/c
LOCUS       CQ799979                  18 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 77 from Patent WO2004030660.
ACCESSION   CQ799979
VERSION     CQ799979.1  GI:46848926
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 77 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        226 AGTGGCCGCGCCCGCCTA 243
              ||||||||||||||||||
Db         18 AGTGGCCGCGCCCGCCTA 1


RESULT 94
CQ799991
LOCUS       CQ799991                  21 bp    RNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 89 from Patent WO2004030660.
ACCESSION   CQ799991
VERSION     CQ799991.1  GI:46848938
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 89 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   90.5%;  Pred. No. 47;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        576 CCTTCGAGTCGCGGGCCCAGC 596
              |||||| |||||||||| ||
Db          1 CCTTCGTGTCGCGGGCCCTGC 21


RESULT 95
BD178973/c
LOCUS       BD178973                  22 bp    DNA     linear   PAT 16-APR-2003
DEFINITION  HSP inducing agent.
ACCESSION   BD178973
VERSION     BD178973.1  GI:30016241
KEYWORDS    WO 02078705-A/2.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Terashita,Z., Naruo,K., Uchikawa,O. and Nakanishi,A.
  TITLE     HSP inducing agent
  JOURNAL   Patent: WO 02078705-A 2 10-OCT-2002;
            TAKEDA CHEMICAL INDUSTRIES LTD,ZENICHI TERASHITA,KENICHI NARUO,
            OSAMU UCHIKAWA,ATSUSHI NAKANISHI
COMMENT     OS   Artificial Sequence
            PN   WO 02078705-A/2
            PD   10-OCT-2002
            PF   27-MAR-2002 WO 2002JP002946
            PR   28-MAR-2001 JP 01P   092704
            PI   ZENICHI TERASHITA,KENICHI NARUO,OSAMU UCHIKAWA,ATSUSHI  PI
            NAKANISHI
            PC   A61K31/437,A61K45/00,A61K45/06,C07D471/04,A61P1/00,A61P1/04,
            PC   A61P1/08,
            PC
            A61P1/16,A61P3/04,A61P3/06,A61P3/10,A61P5/00,A61P7/02,A61P7/06, PC
             A61P9/04,
            PC
            A61P9/06,A61P9/08,A61P9/10,A61P9/12,A61P11/00,A61P11/04,A61P11/ PC
             06,
            PC   A61P13/08,A61P13/12,A61P19/02,A61P19/06,A61P19/10,A61P23/00,
            PC   A61P25/16,
            PC   A61P25/18,A61P25/22,A61P25/24,A61P25/28,A61P27/02,A61P29/00,
            PC   A61P31/00,
            PC   A61P35/00,A61P37/08,A61P43/00
            CC   PCR primer for amplifying HSP27 gene
            FH   Key             Location/Qualifiers
            FT   source          1. .22
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 51;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        413 GAGCATGGCTACATCTCCCGG 433
              || |||||||||||||| |||
Db         21 GAACATGGCTACATCTCTCGG 1


RESULT 96
BD230260
LOCUS       BD230260                  20 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Total genome radiation hybrid map of canine genome and its use for
            identification of interesting genes.
ACCESSION   BD230260
VERSION     BD230260.1  GI:33040030
KEYWORDS    JP 2002530091-A/129.
SOURCE      Canis familiaris (dog)
  ORGANISM  Canis familiaris
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Galibert,F. and Andre,C.
  TITLE     Total genome radiation hybrid map of canine genome and its use for
            identification of interesting genes
  JOURNAL   Patent: JP 2002530091-A 129 17-SEP-2002;
            CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
COMMENT     OS   Canis familiaris (dog)
            PN   JP 2002530091-A/129
            PD   17-SEP-2002
            PF   15-NOV-1999 JP 2000582596
            PR   13-NOV-1998 US    60/108193
            PI   FRANCIS GALIBERT,CATHERINE ANDRE
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC   A0086R
```

```
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Canis familiaris (dog)'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Canis familiaris"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9615"

  Query Match             2.3%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 47;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        495 TGTCCCCTGAGGGCACACT 513
              ||||||||||||||||| ||
Db          1 TGTCCCCTGAGGGCACTCT 19


RESULT 97
AX671859
LOCUS       AX671859                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 304 from Patent WO03004526.
ACCESSION   AX671859
VERSION     AX671859.1  GI:29330207
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 304 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 98
AX728678
LOCUS       AX728678                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 312 from Patent WO03025175.
ACCESSION   AX728678
VERSION     AX728678.1  GI:30508021
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 312 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 99
AX738957
LOCUS       AX738957                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4547 from Patent WO03025177.
ACCESSION   AX738957
VERSION     AX738957.1  GI:30518247
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 4547 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 100
AX762937
LOCUS       AX762937                 17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 6258 from Patent WO03040369.
ACCESSION   AX762937
VERSION     AX762937.1  GI:32257553
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 6258 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
```

```
              ||||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 101
CQ799985    .
LOCUS       CQ799985                  19 bp    RNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 83 from Patent WO2004030660.
ACCESSION   CQ799985
VERSION     CQ799985.1  GI:46848932
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 83 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 63;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        266 CTCAGCAGCGGGGTCTCGG 284
              ||| || ||||||||||||
Db          1 CTCTGCTGCGGGGTCTCGG 19


RESULT 102
CQ799909
LOCUS       CQ799909                  21 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 7 from Patent WO2004030660.
ACCESSION   CQ799909
VERSION     CQ799909.1  GI:46848856
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gleave,M.E., Rocchi,P. and Signaevsky,M.
  TITLE     Compositions for treatment of prostate and other cancers
  JOURNAL   Patent: WO 2004030660-A 7 15-APR-2004;
            The University of British Columbia (CA)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 77;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         60 GGGGCCCCAGCTGGGACCC 78
              |||| |||||||||| |||
Db          3 GGGGTCCCAGCTGGGGCCC 21


RESULT 103
CQ625927
LOCUS       CQ625927                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10667 from Patent WO0192524.
ACCESSION   CQ625927
VERSION     CQ625927.1  GI:41676145
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10667 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 56;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17


RESULT 104
AR466990
LOCUS       AR466990                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10667 from patent US 6686188.
ACCESSION   AR466990
VERSION     AR466990.1  GI:42702047
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10667 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 56;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17


RESULT 105
AX735327
LOCUS       AX735327                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 917 from Patent WO03025177.
ACCESSION   AX735327
VERSION     AX735327.1  GI:30514604
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 917 27-MAR-2003;
            Molecular Engines Laboratories (FR)
```

```
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 56;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||||||||| ||
Db          1 GATCACCATCCCAGCCA 17


RESULT 106
AX762926
LOCUS       AX762926                 17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 6247 from Patent WO03040369.
ACCESSION   AX762926
VERSION     AX762926.1  GI:32257542
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 6247 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 56;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||||||||| ||
Db          1 GATCACCATCCCAGCCA 17


RESULT 107
AR180537
LOCUS       AR180537                 15 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 605 from patent US 6333152.
ACCESSION   AR180537
VERSION     AR180537.1  GI:20222570
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
  TITLE     Gene expression profiles in normal and cancer cells
  JOURNAL   Patent: US 6333152-A 605 25-DEC-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 48;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        529 CATGCCCAAGCTAGC 543
              |||||||||||||||
Db          1 CATGCCCAAGCTAGC 15


RESULT 108
AR072210/c
LOCUS       AR072210                 18 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 13 from patent US 5948611.
ACCESSION   AR072210
VERSION     AR072210.1  GI:9998974
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Prockop,D.J., Ala-Kokko,L., Williams,C.J., Ritvaniemi,P.,
            Baldwin,C., Hopkinson,I. and Ahmad,N.Nina.
  TITLE     Primers and methods for detecting mutations in the procollagen II
            gene (COL2A1) that indicate a genetic predisposition for a
            COL2A1-associated disease
  JOURNAL   Patent: US 5948611-A 13 07-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 73;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        129 TGCCCCGGCTGCCGGAGG 146
              ||||| |||||| |||||
Db         18 TGCCCTGGCTGCAGGAGG 1


RESULT 109
CQ786325
LOCUS       CQ786325                 18 bp    DNA     linear   PAT 24-MAR-2004
DEFINITION  Sequence 133 from Patent WO2004020668.
ACCESSION   CQ786325
VERSION     CQ786325.1  GI:45721427
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Nakamura,Y. and Katagiri,T.
  TITLE     Method for treating synovial sarcoma
  JOURNAL   Patent: WO 2004020668-A 133 11-MAR-2004;
            Oncotherapy Science, Inc. (JP); The University of Tokyo (JP)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: synthetic
                     oligonucleotide"

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 73;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        100 TAGCCGCCTCTTCGACCA 117
              || | ||||||||||||||
Db          1 TAACTGCCTCTTCGACCA 18


RESULT 110
I26321/c
LOCUS       I26321                   18 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 13 from patent US 5558988.
ACCESSION   I26321
VERSION     I26321.1  GI:1606191
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Prockop,D.J., Ala-Kokko,L. and Ritvaniemi,P.
  TITLE     Primers and methods for detecting mutations in the procollagen II
            gene that indicate a genetic predisposition for osteoarthritis
  JOURNAL   Patent: US 5558988-A 13 24-SEP-1996;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 73;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        129 TGCCCCGGCTGCCGGAGG 146
              ||||| |||||| |||||
Db         18 TGCCCTGGCTGCAGGAGG 1


RESULT 111
AR392122/c
LOCUS       AR392122                  18 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 37 from patent US 6613567.
ACCESSION   AR392122
VERSION     AR392122.1  GI:40116012
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Bennett,C.F. and Cowsert,L.M.
  TITLE     Antisense inhibition of Her-2 expression
  JOURNAL   Patent: US 6613567-A 37 02-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 73;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTGC 140
              |||||||| | |||||||
Db         18 TCGGGCTGGCTCGGCTGC 1


RESULT 112
AX480662/c
LOCUS       AX480662                  18 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 50 from Patent WO0248189.
ACCESSION   AX480662
VERSION     AX480662.1  GI:22217411
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Etzerodt,M., Holtet,T.L., Graversen,N.J. and th Gersen,H.C.
  TITLE     Combinatorial libraries of proteins having the scaffold structure
            of c-type lectin-like domains
  JOURNAL   Patent: WO 0248189-A 50 20-JUN-2002;
            Borean Pharma A/S (DK)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="oligonucleotide"

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 73;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         86 GACTGGTACCCGCATAGC 103
              ||| |||||||||| ||
Db         18 GACCGGTACCCGCATCGC 1


RESULT 113
I69196/c
LOCUS       I69196                    16 bp    DNA     linear   PAT 04-FEB-1998
DEFINITION  Sequence 466 from patent US 5677149.
ACCESSION   I69196
VERSION     I69196.1  GI:2831318
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Bauer,S.Christopher., Abrams,M.Allen., Braford-Goldberg,S.Ruth.,
            Caparon,M.Helena., Easton,A.Michael., Klein,B.Kure.,
            McKearn,J.Patrick., Olins,P., Paik,K., Polazzi,J. and
            Thomas,J.Warren.
  TITLE     Interleukin-3 (IL-3) mutant polypeptides and their recombinant
            production
  JOURNAL   Patent: US 5677149-A 466 14-OCT-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 114
AR253794/c
LOCUS       AR253794                  16 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 466 from patent US 6479261.
ACCESSION   AR253794
VERSION     AR253794.1  GI:27302222
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Bauer,S.C., Abrams,M.A., Braford-Goldberg,S.R., Caparon,M.H.,
            Easton,A.M., Klein,B.K., McKearn,J.P., Olins,P., Paik,K.,
            Polazzi,J. and Thomas,J.W.
  TITLE     Methods of using interleukin-3 (IL-3) mutant polypeptides for
            ex-vivo expansion of hematopoietic stem cells
  JOURNAL   Patent: US 6479261-A 466 12-NOV-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 115
```

```
AX696849/c
LOCUS       AX696849                16 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 466 from Patent EP1283264.
ACCESSION   AX696849
VERSION     AX696849.1  GI:29419961
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Bauer,S.C., Abrams,M.A., Braford-Goldberg,S.R., Caparon,M.H.,
            Easton,A.M., Klein,B.K., Mckearn,J.P., Olins,P.O., Paik,K.,
            Polazzi,J.O. and Thomas,J.W.
  TITLE     Interleukin-3 (il-3) mutant polypeptides
  JOURNAL   Patent: EP 1283264-A 466 12-FEB-2003;
            G.D. SEARLE & CO. (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 64;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 116
CQ625926
LOCUS       CQ625926                17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10666 from Patent WO0192524.
ACCESSION   CQ625926
VERSION     CQ625926.1  GI:41676144
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10666 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 117
CQ625928
LOCUS       CQ625928                17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10668 from Patent WO0192524.
ACCESSION   CQ625928
VERSION     CQ625928.1  GI:41676146
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10668 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 118
AR466989
LOCUS       AR466989                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10666 from patent US 6686188.
ACCESSION   AR466989
VERSION     AR466989.1  GI:42702046
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10666 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 119
AR466991
LOCUS       AR466991                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10668 from patent US 6686188.
ACCESSION   AR466991
VERSION     AR466991.1  GI:42702048
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10668 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"
```

```
  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 120
AX615411/c
LOCUS       AX615411                  17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 218 from Patent EP1262488.
ACCESSION   AX615411
VERSION     AX615411.1  GI:28446457
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 218 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         11 GCAGAGTCAGCCAGCA 26
              |||||||||||| |||
Db         17 GCAGAGTCAGCCTGCA 2


RESULT 121
AX615412/c
LOCUS       AX615412                  17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 219 from Patent EP1262488.
ACCESSION   AX615412
VERSION     AX615412.1  GI:28446458
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 219 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         11 GCAGAGTCAGCCAGCA 26
              |||||||||||| |||
Db         16 GCAGAGTCAGCCTGCA 1


RESULT 122
AX783872
LOCUS       AX783872                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 2203 from Patent WO03050284.
ACCESSION   AX783872
VERSION     AX783872.1  GI:32951721
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 2203 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              ||| ||||||||||||
Db          2 CTGAGGGGCCCCAGCT 17


RESULT 123
AX783873
LOCUS       AX783873                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 2204 from Patent WO03050284.
ACCESSION   AX783873
VERSION     AX783873.1  GI:32951722
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 2204 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 72;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              ||| ||||||||||||
Db          1 CTGAGGGGCCCCAGCT 16


RESULT 124
AR096356
LOCUS       AR096356                  18 bp    DNA     linear   PAT 08-SEP-2000
DEFINITION  Sequence 27 from patent US 6007995.
ACCESSION   AR096356
VERSION     AR096356.1  GI:10025093
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Baker,B.F. and Cowsert,L.M.
  TITLE     Antisense inhibition of TNFR1 expression
```

```
  JOURNAL   Patent: US 6007995-A 27 28-DEC-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 80;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || |||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 125
AR109825
LOCUS       AR109825                 18 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 249 from patent US 6114139.
ACCESSION   AR109825
VERSION     AR109825.1  GI:12826101
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Hinuma,S., Hosoya,M., Fujii,R., Ohtaki,T., Fukusumi,S. and Ohgi,K.
  TITLE     G-protein coupled receptor protein and a DNA encoding the receptor
  JOURNAL   Patent: US 6114139-A 249 05-SEP-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 80;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        218 AGCCCCGCAGTGGCCG 233
              |||| ||||||||||
Db          1 AGCCTCGCAGTGGCCG 16


RESULT 126
BD217404
LOCUS       BD217404                 18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Antisense modulation of TNFR1 expression.
ACCESSION   BD217404
VERSION     BD217404.1  GI:33027174
KEYWORDS    JP 2002519015-A/27.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Baker,B.F. and Cowsert,L.M.
  TITLE     Antisense modulation of TNFR1 expression
  JOURNAL   Patent: JP 2002519015-A 27 02-JUL-2002;
            ISIS PHARMACEUTICALS INC
COMMENT     OS   Unidentified
            PN   JP 2002519015-A/27
            PD   02-JUL-2002
            PF   17-JUN-1999 JP 2000557265
            PR   26-JUN-1998 US    09/106038
            PI   BRENDA F BAKER,LEX M COWSERT
            PC
            C12N15/09,A61K31/7105,A61K31/711,A61K48/00,A61P29/00,A61P43/00, PC
             C12Q1/68,
            PC   C12N15/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Antisense modulation of TNFR1 expression
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 80;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || |||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 127
AR294360/c  .
LOCUS       AR294360                 18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 6095 from patent US 6537751.
ACCESSION   AR294360
VERSION     AR294360.1  GI:31681644
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 6095 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 80;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGA 716
              |||||||||||| |||
Db         18 CTGTGTGTTCTTCTGA 3


RESULT 128
AX215323
LOCUS       AX215323                 17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 765 from Patent WO0159103.
ACCESSION   AX215323
VERSION     AX215323.1  GI:15525366
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 765 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        164 GGCGGCAGCAGCTG 177
              ||||||||||||||
Db          3 GGCGGCAGCAGCTG 16


RESULT 129
AX216349
LOCUS       AX216349                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1791 from Patent WO0159103.
ACCESSION   AX216349
VERSION     AX216349.1  GI:15526410
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1791 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        164 GGCGGCAGCAGCTG 177
              ||||||||||||||
Db          2 GGCGGCAGCAGCTG 15


RESULT 130
AX266839/c
LOCUS       AX266839                  17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 4230 from Patent WO0173002.
ACCESSION   AX266839
VERSION     AX266839.1  GI:16515640
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 4230 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         15 AGCCACGCAGTCCA 2


RESULT 131
AX266840
LOCUS       AX266840                  17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 4231 from Patent WO0173002.
ACCESSION   AX266840
VERSION     AX266840.1  GI:16515641
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 4231 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          3 AGCCACGCAGTCCA 16


RESULT 132
AR164573/c
LOCUS       AR164573                  17 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 6 from patent US 6274310.
ACCESSION   AR164573
VERSION     AR164573.1  GI:16237643
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Habener,J.F. and Stoffers,D.A.
  TITLE     Compositions and methods for detecting pancreatic disease
  JOURNAL   Patent: US 6274310-A 6 14-AUG-2001;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         38 CGCGTCCCCTTCTCGCT 54
              ||| |||||| ||||||
Db         17 CGCCTCCCCTGCTCGCT 1


RESULT 133
BD197647
LOCUS       BD197647                  17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD197647
VERSION     BD197647.1  GI:33007417
KEYWORDS    JP 2002509721-A/673.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
```

```
  JOURNAL   Patent: JP 2002509721-A 673 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/673
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="genomic RNA"
                      /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         64 CCCCAGCTGGGACCCCT 80
              ||||| || ||||||||
Db          1 CCCCAACTTGGACCCCT 17


RESULT 134
BD241652/c
LOCUS       BD241652                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Methods and products related to genotyping and DNA analysis.
ACCESSION   BD241652
VERSION     BD241652.1  GI:33051422
KEYWORDS    JP 2002525127-A/599.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: JP 2002525127-A 599 13-AUG-2002;
            MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002525127-A/599
            PD   13-AUG-2002
            PF   24-SEP-1999 JP 2000572407
            PR   25-SEP-1998 US    60/101757
            PI   JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
              C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
            G01N37/00,
            PC   C12N15/00
            CC   Methods and products related to genotyping and DNA analysis FH
              Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 AGTTCAAAGCAACCACC 762
              ||| |||||||| ||||
Db         17 AGTACAAAGCAAACACC 1


RESULT 135
CQ617589/c
LOCUS       CQ617589                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 2329 from Patent WO0192524.
ACCESSION   CQ617589
VERSION     CQ617589.1  GI:41667807
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 2329 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
              |||| ||| ||||||||
Db         17 TCCAGCGACATCACCAT 1


RESULT 136
CQ617590/c
LOCUS       CQ617590                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 2330 from Patent WO0192524.
ACCESSION   CQ617590
VERSION     CQ617590.1  GI:41667808
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 2330 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 137
CQ617591/c
LOCUS       CQ617591                  17 bp    DNA     linear   PAT 02-FEB-2004
```

```
DEFINITION  Sequence 2331 from Patent WO0192524.
ACCESSION   CQ617591
VERSION     CQ617591.1  GI:41667809
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 2331 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              ||||||  |||  ||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 138
CQ625929
LOCUS       CQ625929                 17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10669 from Patent WO0192524.
ACCESSION   CQ625929
VERSION     CQ625929.1  GI:41676147
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10669 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              |||  ||||||||||| |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 139
CQ625930
LOCUS       CQ625930                 17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10670 from Patent WO0192524.
ACCESSION   CQ625930
VERSION     CQ625930.1  GI:41676148
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10670 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||| ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 140
AR286401
LOCUS       AR286401                 17 bp    RNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 773 from patent US 6528640.
ACCESSION   AR286401
VERSION     AR286401.1  GI:29723997
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Synthetic ribonucleic acids with RNAse activity
  JOURNAL   Patent: US 6528640-A 773 04-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              |||||||| | ||||||
Db          1 TCGGGCTGGCTCGGCTG 17


RESULT 141
AR398391
LOCUS       AR398391                 17 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 772 from patent US 6617438.
ACCESSION   AR398391
VERSION     AR398391.1  GI:40136165
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
            Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
  TITLE     Oligoribonucleotides with enzymatic activity
  JOURNAL   Patent: US 6617438-A 772 09-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy        123 TCGGGCTGCCCCGGCTG 139
              ||||||||| | ||||||
Db          1 TCGGGCTGGCTCGGCTG 17


RESULT 142
AR458652/c
LOCUS       AR458652                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 2329 from patent US 6686188.
ACCESSION   AR458652
VERSION     AR458652.1  GI:42693709
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 2329 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
              |||| ||| ||||||||
Db         17 TCCAGCGACATCACCAT 1


RESULT 143
AR458653/c
LOCUS       AR458653                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 2330 from patent US 6686188.
ACCESSION   AR458653
VERSION     AR458653.1  GI:42693710
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 2330 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||-| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 144
AR458654/c
LOCUS       AR458654                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 2331 from patent US 6686188.
ACCESSION   AR458654
VERSION     AR458654.1  GI:42693711
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 2331 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              |||||| ||| ||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 145
AR466992
LOCUS       AR466992                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10669 from patent US 6686188.
ACCESSION   AR466992
VERSION     AR466992.1  GI:42702049
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10669 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              ||| ||||||||||| |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 146
AR466993
LOCUS       AR466993                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10670 from patent US 6686188.
ACCESSION   AR466993
VERSION     AR466993.1  GI:42702050
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10670 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"
```

```
  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||| ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 147
AR483153/c
LOCUS       AR483153                 17 bp    DNA     linear   PAT 14-MAY-2004
DEFINITION  Sequence 599 from patent US 6703228.
ACCESSION   AR483153
VERSION     AR483153.1  GI:47245676
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: US 6703228-A 599 09-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 AGTTCAAAGCAACCACC 762
              ||| |||||||| ||||
Db         17 AGTACAAAGCAAACACC 1


RESULT 148
AX216972
LOCUS       AX216972                 17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2414 from Patent WO0159103.
ACCESSION   AX216972
VERSION     AX216972.1  GI:15527033
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2414 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        462 CCGGTGTGGACCCCACC 478
              || |||||||||| ||
Db          1 CCCGTGTGGACCCCGCC 17


RESULT 149
AX498863/c
LOCUS       AX498863                 17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 170 from Patent EP1229046.
ACCESSION   AX498863
VERSION     AX498863.1  GI:23381156
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 170 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        295 CACTGCGGACCGCTGGC 311
              |||||||| ||| ||||
Db         17 CACTGCGGCCCGGTGGC 1


RESULT 150
AX531714
LOCUS       AX531714                 17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 1223 from Patent EP1239051.
ACCESSION   AX531714
VERSION     AX531714.1  GI:25255211
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 1223 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        557 GAGATCACCATCCCAGT 573
              ||||||| || ||||||
Db          1 GAGATCAGCACCCCAGT 17


RESULT 151
AX579468
LOCUS       AX579468                 17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1306 from Patent WO0211674.
ACCESSION   AX579468
VERSION     AX579468.1  GI:27648670
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
```

```
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1306 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
    source           1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        506 GGCACACTGACCGTGGA 522
              |||||| ||| ||||||
Db          1 GGCACAGTGATCGTGGA 17


RESULT 152
AX580066/c
LOCUS       AX580066                 17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1904 from Patent WO0211674.
ACCESSION   AX580066
VERSION     AX580066.1  GI:27649268
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1904 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
    source           1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        423 ACATCTCCCGGTGCTTC 439
              ||||||||| ||| |||
Db         17 ACATCTCCCTGTGATTC 1


RESULT 153
AX580067/c
LOCUS       AX580067                 17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1905 from Patent WO0211674.
ACCESSION   AX580067
VERSION     AX580067.1  GI:27649269
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1905 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
    source           1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        422 TACATCTCCCGGTGCTT 438
              ||||||||| ||| ||
Db         17 TACATCTCCCTGTGATT 1


RESULT 154
AX725108/c
LOCUS       AX725108                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2795 from Patent WO03025176.
ACCESSION   AX725108
VERSION     AX725108.1  GI:30504451
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2795 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
    source           1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        273 GCGGGGTCTCGGAGATC 289
              || ||||||| ||||||
Db         17 GCTGGGTCTCAGAGATC 1


RESULT 155
AX725434
LOCUS       AX725434                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3121 from Patent WO03025176.
ACCESSION   AX725434
VERSION     AX725434.1  GI:30504777
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 3121 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
    source           1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
```

```
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||  |||||||
Db          1 GATCACCAAACCAGTCA 17


RESULT 156
AX735751/c
LOCUS       AX735751                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1341 from Patent WO03025177.
ACCESSION   AX735751
VERSION     AX735751.1  GI:30515028
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 1341 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        734 TTTCTCAAATAAAGTTC 750
              ||||||||||||  | ||
Db         17 TTTCTCAAATAATGATC 1


RESULT 157
AX736224
LOCUS       AX736224                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1814 from Patent WO03025177.
ACCESSION   AX736224
VERSION     AX736224.1  GI:30515501
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 1814 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||  |||||||
Db          1 GATCACCAAACCAGTCA 17


RESULT 158
AX753978
LOCUS       AX753978                  17 bp    DNA     linear   PAT 23-JUN-2003
DEFINITION  Sequence 325 from Patent WO03037931.
ACCESSION   AX753978
VERSION     AX753978.1  GI:32166675
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M. and Phan,T.
  TITLE     Human angiomotin-like protein 1
  JOURNAL   Patent: WO 03037931-A 325 08-MAY-2003;
            Amersham Biosciences SV Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        243 ACAGCCGCGCGCTCAGC 259
              ||| |||| ||||||||
Db          1 ACATCCGCTCGCTCAGC 17


RESULT 159
AX783428/c
LOCUS       AX783428                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 1759 from Patent WO03050284.
ACCESSION   AX783428
VERSION     AX783428.1  GI:32951277
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 1759 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        520 GGAGGCCCCCATGCCCA 536
              |||||| |||| |||||
Db         17 GGAGGCACCCAGGCCCA 1


RESULT 160
AX783429/c
LOCUS       AX783429                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 1760 from Patent WO03050284.
ACCESSION   AX783429
VERSION     AX783429.1  GI:32951278
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 1760 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 84;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        519 TGGAGGCCCCCATGCCC 535
              ||||||| |||| ||||
Db         17 TGGAGGCACCCAGGCCC 1


Search completed: May 10, 2005, 07:14:42
Job time : 2 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: May 10, 2005, 07:16:05 ; Search time 1 Seconds
(without alignments)
5.678 Million cell updates/sec

Title: US-10-605-498-91
Perfect score: 764
Sequence: 1 ggcacgaggagcagagtcag.....aagttcaaagcaaccacctg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 190 seqs, 3716 residues

Total number of hits satisfying chosen parameters: 380

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 192 summaries

Database : rng91.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	52.2	6.8	65	1	ABN29917	Rat spliced transc
	2	50	6.5	50	1	ABZ03868	Human leukocyte ge
	3	33.6	4.4	40	1	ADC52133	Human heat shock p
c	4	25	3.3	25	1	ABK67082	Human gene specifi
	5	24	3.1	24	1	ABK67081	Human gene specifi
	6	21.4	2.8	23	1	ABL99424	Left PCR primer us
c	7	21	2.7	21	1	ADM94658	Human heat shock p
c	8	21	2.7	21	1	ADM94663	Human heat shock p
c	9	21	2.7	21	1	ADM94670	Human heat shock p
c	10	21	2.7	21	1	ADM94703	Human heat shock p
c	11	21	2.7	21	1	ADM94709	Human heat shock p
c	12	21	2.7	21	1	ADM94717	Human heat shock p
c	13	21	2.7	21	1	ADM94721	Human heat shock p
c	14	21	2.7	21	1	ADM94731	Human heat shock p
c	15	21	2.7	21	1	ADM94685	Human heat shock p
c	16	21	2.7	21	1	ADM94725	Human heat shock p
c	17	21	2.7	21	1	ADM94653	Human heat shock p
c	18	21	2.7	21	1	ADM94667	Human heat shock p
c	19	21	2.7	21	1	ADM94688	Human heat shock p
c	20	21	2.7	21	1	ADM94691	Human heat shock p
c	21	21	2.7	21	1	ADM94692	Human heat shock p
c	22	21	2.7	21	1	ADM94697	Human heat shock p
c	23	21	2.7	21	1	ADM94704	Human heat shock p
c	24	21	2.7	21	1	ADM94712	Human heat shock p
c	25	21	2.7	21	1	ADM94714	Human heat shock p
c	26	21	2.7	21	1	ADM94672	Human heat shock p
c	27	21	2.7	21	1	ADM94705	Human heat shock p
c	28	21	2.7	21	1	ADM94654	Human heat shock p
c	29	21	2.7	21	1	ADM94657	Human heat shock p
c	30	21	2.7	21	1	ADM94687	Human heat shock p
c	31	21	2.7	21	1	ADM94689	Human heat shock p
c	32	21	2.7	21	1	ADM94702	Human heat shock p
c	33	21	2.7	21	1	ADM94713	Human heat shock p
c	34	21	2.7	21	1	ADM94716	Human heat shock p
c	35	21	2.7	21	1	ADM94724	Human heat shock p
c	36	21	2.7	21	1	ADM94651	Human heat shock p
c	37	21	2.7	21	1	ADM94668	Human heat shock p
c	38	21	2.7	21	1	ADM94686	Human heat shock p
c	39	21	2.7	21	1	ADM94700	Human heat shock p
c	40	21	2.7	21	1	ADM94701	Human heat shock p
c	41	21	2.7	21	1	ADM94706	Human heat shock p
c	42	21	2.7	21	1	ADM94711	Human heat shock p
c	43	21	2.7	21	1	ADM94729	Human heat shock p
c	44	21	2.7	21	1	ADM94660	Human heat shock p
c	45	21	2.7	21	1	ADM94661	Human heat shock p
c	46	21	2.7	21	1	ADM94669	Human heat shock p
c	47	21	2.7	21	1	ADM94680	Human heat shock p
c	48	21	2.7	21	1	ADM94652	Human heat shock p
c	49	21	2.7	21	1	ADM94676	Human heat shock p
c	50	21	2.7	21	1	ADM94684	Human heat shock p
c	51	21	2.7	21	1	ADM94690	Human heat shock p
c	52	21	2.7	21	1	ADM94662	Human heat shock p
c	53	21	2.7	21	1	ADM94665	Human heat shock p
c	54	21	2.7	21	1	ADM94698	Human heat shock p
c	55	21	2.7	21	1	ADM94718	Human heat shock p
c	56	21	2.7	21	1	ADM94728	Human heat shock p
c	57	21	2.7	21	1	ADM94674	Human heat shock p
c	58	21	2.7	21	1	ADM94678	Human heat shock p
c	59	21	2.7	21	1	ADM94715	Human heat shock p
c	60	21	2.7	21	1	ADM94726	Human heat shock p
c	61	21	2.7	21	1	ADM94677	Human heat shock p
c	62	21	2.7	21	1	ADM94699	Human heat shock p
c	63	21	2.7	21	1	ADM94719	Human heat shock p
c	64	21	2.7	21	1	ADM94671	Human heat shock p
c	65	21	2.7	21	1	ADM94679	Human heat shock p
c	66	21	2.7	21	1	ADM94683	Human heat shock p
c	67	21	2.7	21	1	ADM94693	Human heat shock p
c	68	21	2.7	21	1	ADM94694	Human heat shock p
c	69	21	2.7	21	1	ADM94722	Human heat shock p
c	70	21	2.7	21	1	ADM94723	Human heat shock p
c	71	21	2.7	21	1	ADM94682	Human heat shock p
c	72	21	2.7	21	1	ADM94655	Human heat shock p
c	73	21	2.7	21	1	ADM94656	Human heat shock p
c	74	21	2.7	21	1	ADM94664	Human heat shock p
c	75	21	2.7	21	1	ADM94666	Human heat shock p
c	76	21	2.7	21	1	ADM94673	Human heat shock p
c	77	21	2.7	21	1	ADM94659	Human heat shock p
c	78	21	2.7	21	1	ADM94681	Human heat shock p
c	79	21	2.7	21	1	ADM94696	Human heat shock p
c	80	21	2.7	21	1	ADM94707	Human heat shock p
c	81	21	2.7	21	1	ADM94675	Human heat shock p
c	82	21	2.7	21	1	ADM94695	Human heat shock p
c	83	21	2.7	21	1	ADM94708	Human heat shock p
c	84	21	2.7	21	1	ADM94710	Human heat shock p
c	85	21	2.7	21	1	ADM94720	Human heat shock p
c	86	21	2.7	21	1	ADM94730	Human heat shock p
c	87	20	2.6	20	1	ADM94732	Human heat shock p
	88	20	2.6	20	1	ADO55958	Probe HSP27 for de
	89	19	2.5	19	1	ADM94740	Human heat shock p
	90	19	2.5	19	1	ADM94737	Human heat shock p
	91	18.4	2.4	21	1	ABA00784	HSP27 forward prim
c	92	18	2.4	18	1	ADM94727	Human heat shock p
	93	17.8	2.3	21	1	ADM94739	Human heat shock p
c	94	17.8	2.3	22	1	ABA00785	HSP27 reverse prim
	95	17.4	2.3	20	1	AAA66267	Dog genomic marker
	96	17	2.2	17	1	ABT34675	Tumour suppression
	97	17	2.2	17	1	ADB45935	Tumour suppression
	98	17	2.2	17	1	ADE30781	Cholesterol homeos
	99	17	2.2	17	1	ADI52044	Human tumour suppr
	100	17	2.2	17	1	ACC51537	Human tumour suppr
c	101	16.4	2.1	18	1	ADR30706	Skunk cabbage S. f
	102	15.8	2.1	19	1	ADI00879	RT-PCR 32P end-lab
	103	15.8	2.1	19	1	ADM94733	Human heat shock p
	104	15.8	2.1	21	1	ADM94657	Human heat shock p
c	105	15.8	2.1	40	1	ADC52133	Human heat shock p
	106	15.4	2.0	17	1	ABN10675	Human GDMLP-1 17-m

	107	15.4	2.0	17	1	ADB45924	Tumour suppression
	108	15.4	2.0	17	1	ADI48414	Human tumour suppr
c	109	15.4	2.0	17	1	ADG71955	Human NOVX related
c	110	15.4	2.0	17	1	ADJ87293	Human G protein-co
	111	15.4	2.0	17	1	ACN73765	Human GDMLP-1 prob
	112	15.4	2.0	19	1	ADE29797	Mitogen activated
c	113	15.4	2.0	19	1	ADE29902	Mitogen activated
	114	15.4	2.0	19	1	ADO14933	Human PDGFr-target
c	115	15.4	2.0	19	1	ADO14622	Human PDGFr-target
	116	15	2.0	15	1	AAX31550	Tag sequence of a
	117	15	2.0	15	1	AAF46290	IGFBP2 oligonucleo
	118	15	2.0	15	1	ABK32504	Human pancreatic c
c	119	14.8	1.9	18	1	AAQ65740	Type II procollage
	120	14.8	1.9	18	1	AAF77820	PCR primer BAR2.
c	121	14.8	1.9	18	1	AAD38938	Human Her-2 antise
	122	14.8	1.9	18	1	ABK98126	Triple helix formi
c	123	14.8	1.9	18	1	ABS66626	TN-KpnI-fo PCR pri
	124	14.8	1.9	18	1	ABZ98168	Human CD23 + A1261
	125	14.8	1.9	18	1	ABD31199	Human CD23-derived
	126	14.8	1.9	18	1	ADJ60033	Oligonucleotide as
	127	14.8	1.9	18	1	ADL91732	Collagen type IX a
	128	14.8	1.9	18	1	ADO45523	Human oligonucleot
c	129	14.4	1.9	16	1	ADC03006	Ex vivo stem-cell
c	130	14.4	1.9	16	1	ADI58681	Human interleukin
	131	14.4	1.9	17	1	AAV92679	Human A-Raf substr
	132	14.4	1.9	17	1	ABN10674	Human GDMLP-1 17-m
	133	14.4	1.9	17	1	ABN10676	Human GDMLP-1 17-m
c	134	14.4	1.9	17	1	ABZ61415	Human H-Ras DNAzym
	135	14.4	1.9	17	1	ADF64299	Human PCCP1 DNA fr
	136	14.4	1.9	17	1	ADF64300	Human PCCP1 DNA fr
	137	14.4	1.9	17	1	ADL47964	Human IKK-gamma su
	138	14.4	1.9	17	1	ACN73764	Human GDMLP-1 prob
	139	14.4	1.9	17	1	ACN73766	Human GDMLP-1 prob
	140	14.4	1.9	18	1	AAZ48501	Human TNFR1 mRNA i
c	141	14.4	1.9	18	1	AAZ71739	Human biallelic ma
	142	14.4	1.9	18	1	AAA87651	Rat hepatocyte car
	143	14.4	1.9	18	1	ABT04997	TNFR1 expression m
	144	14.4	1.9	18	1	ADR06029	Human TNFR1 antise
	145	14	1.8	15	1	AAF46289	IGFBP2 oligonucleo
	146	14	1.8	15	1	AAF46291	IGFBP2 oligonucleo
c	147	14	1.8	15	1	ADF32131	Probe #55 used to
c	148	14	1.8	17	1	AAQ78888	Humicola grisea gl
	149	14	1.8	17	1	ABK01791	Human NOGO Zinzyme
	150	14	1.8	17	1	ABK00765	Human NOGO Inozyme
	151	14	1.8	17	1	ABA81385	PSEN1 mutation cor
c	152	14	1.8	17	1	ABA81384	PSEN1 mutation cor
	153	14	1.8	17	1	ADF92264	Human cytokeratin
	154	13.8	1.8	17	1	AAA17447	Aryl hydrocarbon n
	155	13.8	1.8	17	1	AAV93490	Human B-raf substr
c	156	13.8	1.8	17	1	AAX01065	IPF1 gene exon 1 a
c	157	13.8	1.8	17	1	AAA36540	Human genomic SNP
	158	13.8	1.8	17	1	ABK02414	Human NOGO Amberzy
c	159	13.8	1.8	17	1	AAH24028	Yeast GAL3 gene up
c	160	13.8	1.8	17	1	ABN02338	Human GDMLP-1 17-m
c	161	13.8	1.8	17	1	ABN02339	Human GDMLP-1 17-m
c	162	13.8	1.8	17	1	ABN02337	Human GDMLP-1 17-m
	163	13.8	1.8	17	1	ABN10677	Human GDMLP-1 17-m
	164	13.8	1.8	17	1	ABN10678	Human GDMLP-1 17-m
c	165	13.8	1.8	17	1	ABV78924	Human HTPL scannin
	166	13.8	1.8	17	1	ABV90510	Human POSHL1 scann
	167	13.8	1.8	17	1	ABK56935	Human CLCA1 gene e
c	168	13.8	1.8	17	1	ABK57534	Human CLCA1 gene e
c	169	13.8	1.8	17	1	ABK57533	Human CLCA1 gene e
c	170	13.8	1.8	17	1	ACN00114	WNV Hammerhead Rib
	171	13.8	1.8	17	1	ACN09334	WNV minus strand H
	172	13.8	1.8	17	1	ACN09335	WNV minus strand H
c	173	13.8	1.8	17	1	ACA07606	NFKB sub-unit modu
	174	13.8	1.8	17	1	ABZ65193	Human HER2 DNAzyme
	175	13.8	1.8	17	1	ABZ60372	Human K-Ras DNAzym
	176	13.8	1.8	17	1	ACD65526	HCV minus strand D
	177	13.8	1.8	17	1	ACC65874	Murine oligonucleo
c	178	13.8	1.8	17	1	ACC65548	Murine oligonucleo
	179	13.8	1.8	17	1	ADC37976	Human AMLP1a scann
c	180	13.8	1.8	17	1	ADC24273	Human NOV9 forward
c	181	13.8	1.8	17	1	ADF63855	Human PCCP1 DNA fr
c	182	13.8	1.8	17	1	ADF63856	Human PCCP1 DNA fr
	183	13.8	1.8	17	1	ADI49311	Human tumour suppr
c	184	13.8	1.8	17	1	ADI48838	Human tumour suppr
c	185	13.8	1.8	17	1	ABZ76956	Bovine DGAT BAC-DN
	186	13.8	1.8	17	1	ADL47965	Human IKK-gamma su
	187	13.8	1.8	17	1	ADI87132	HCV DNAzyme substr
c	188	13.8	1.8	17	1	ACN65429	Human GDMLP-1 prob
	189	13.8	1.8	17	1	ACN73767	Human GDMLP-1 prob
c	190	13.8	1.8	17	1	ACN65427	Human GDMLP-1 prob
	191	13.8	1.8	17	1	ACN73768	Human GDMLP-1 prob
c	192	13.8	1.8	17	1	ACN65428	Human GDMLP-1 prob

ALIGNMENTS

RESULT 1
ABN29917
ID ABN29917 standard; DNA; 65 BP.
XX
AC ABN29917;
XX
DT 15-JUL-2002 (first entry)
XX
DE Rat spliced transcript detection oligonucleotide SEQ ID NO:2665.
XX
KW Human; mouse; rat; splice transcript; detection; RNA transcript;
KW splice variant; transcriptome; oligonucleotide library; ss.
XX
OS Rattus norvegicus.
XX
PN WO200210449-A2.
XX
PD 07-FEB-2002.
XX
PF 20-JUL-2001; 2001WO-IB001903.
XX
PR 28-JUL-2000; 2000US-0221607P.
PR 02-MAY-2001; 2001US-0287724P.
XX
PA (COMP-) COMPUGEN INC.
XX
PI Shoshan A, Wasserman A, Mintz E, Mintz L, Faigler S;
XX
DR WPI; 2002-257383/30.
XX
PT New oligonucleotide libraries comprising oligonucleotides which
PT selectively hybridize to mRNAs transcribed from a transcription unit of a
PT genome, useful for detecting tissue-, pathology-, and developmental-
PT specific genes.
XX
PS Example 1; SEQ ID NO 2665; 47pp; English.
XX
CC The present invention describes oligonucleotide libraries for detecting
CC messenger RNAs that populate a (sub-)transcriptome, where the (sub-
CC)transcriptome comprises messenger RNAs transcribed from multiple
CC transcription units that populate a genome. The library comprises several
CC oligonucleotides, each capable of hybridising selectively to a set of
CC messenger RNAs transcribed from a given transcription unit of the genome,
CC which encodes one or more messenger RNA splice variants. The
CC oligonucleotide libraries are useful for detecting mRNAs from a
CC biological sample, in expression profiling studies, in qualitatively or
CC quantitatively characterising the corresponding transcriptome, and in
CC detecting RNA transcripts and splice variants of human or animal
CC transcriptomes. The libraries may also be used as specialised mini
CC libraries to detect transcripts of a sub-transcriptome under a particular
CC biological or pathological state, and so allowing the detection of tissue
CC - and pathology-specific genes such as those genes only expressed in
CC specific tissue under a specific pathological condition; to detect
CC developmental specific genes; and to detect RNA transcripts and splice
CC variants of a transcriptome of a patient suffering from a particular

```
CC   disorder. ABN27253 to ABN59589 represent oligonucleotide sequences from
CC   rats, humans and mice, which are used in the exemplification of the
CC   present invention. N.B. The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 65 BP; 15 A; 18 C; 19 G; 13 T; 0 U; 0 Other;

  Query Match             6.8%;  Score 52.2;  DB 1;  Length 65;
  Best Local Similarity   87.7%;  Pred. No. 0.017;
  Matches   57;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy        314 GTGTCCCTGGATGTCAACCACTTCGCCCCGGACGAGCTGACGGTCAAGACCAAGGATGGC 373
              |||||||||||| |||||||||||||| || || ||||| || || |||||||||||| |||
Db          1 GTGTCCCTGGACGTCAACCACTTCGCTCCTGAGGAGCTCACAGTTAAGACCAAGGAAGGC 60

Qy        374 GTGGT 378
              |||||
Db         61 GTGGT 65


RESULT 2
ABZ03868
ID   ABZ03868 standard; DNA; 50 BP.
XX
AC   ABZ03868;
XX
DT   09-JAN-2003  (first entry)
XX
DE   Human leukocyte gene expression profiling probe SEQ ID NO 3859.
XX
KW   T7; leukocyte; gene expression profiling; allograft rejection;
KW   atherosclerosis; congestive heart failure; systemic lupus erythematosus;
KW   rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO200257414-A2.
XX
PD   25-JUL-2002.
XX
PF   22-OCT-2001; 2001WO-US047856.
XX
PR   20-OCT-2000; 2000US-0241994P.
PR   08-JUN-2001; 2001US-0296764P.
XX
PA   (BIOC-) BIOCARDIA INC.
XX
PI   Wohlgemuth J,  Fry K,  Matcuk G,  Altman P,  Prentice J,  Phillips J;
PI   Ly N,  Woodward R,  Quertermous T,  Johnson F;
XX
DR   WPI; 2002-636525/68.
XX
PT   New system for leukocyte expression profiling, diagnosing a disease, or
PT   monitoring (the rate of) progression of a disease, e.g. atherosclerosis
PT   or congestive heart failure, comprises diagnostic oligonucleotides.
XX
PS   Claim 1; Page 450; 0pp; English.
XX
CC   The invention relates to a system for detecting gene expression, which
CC   comprises one or two isolated DNA molecules that detect expression of a
CC   gene, where the gene corresponds to any of 8143 oligonucleotides
CC   (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful
CC   for leukocyte expression profiling. It is particularly useful for
CC   diagnosing a disease, monitoring (rate of) progression of a disease,
CC   predicting therapeutic outcome, determining prognosis for a patient,
CC   predicting disease complications in an individual or monitoring response
CC   to treatment in an individual. The diseases include cardiac allograft
CC   rejection, kidney allograft rejection, liver allograft rejection,
CC   atherosclerosis, congestive heart failure, systemic lupus erythematosus,
CC   rheumatoid arthritis, osteoarthritis or cytomegalovirus infection
XX
SQ   Sequence 50 BP; 5 A; 16 C; 8 G; 21 T; 0 U; 0 Other;

  Query Match             6.5%;  Score 50;  DB 1;  Length 50;
  Best Local Similarity   100.0%;  Pred. No. 0.024;
  Matches   50;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        683 CTGTGCCTCCCCCGCCACCTGTGTGTTCTTTTGATACATTTATCTTCTGT 732
              ||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CTGTGCCTCCCCCGCCACCTGTGTGTTCTTTTGATACATTTATCTTCTGT 50


RESULT 3
ADC52133
ID   ADC52133 standard; DNA; 40 BP.
XX
AC   ADC52133;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human heat shock protein 27 mutating PCR primer SEQ ID NO 2.
XX
KW   mitogen activated protein kinase-activated protein kinase; Cytostatic;
KW   cancer; cell dedifferentiation; MAPKAP; HSP27; heat shock protein 27;
KW   primer; ss; Human.
XX
OS   Homo sapiens.
XX
PN   JP2003061698-A.
XX
PD   04-MAR-2003.
XX
PF   24-AUG-2001; 2001JP-00254731.
XX
PR   24-AUG-2001; 2001JP-00254731.
XX
PA   (SANY ) SANKYO CO LTD.
XX
DR   WPI; 2003-648869/62.
XX
PT   Identifying inhibitor of cancer cell dedifferentiation for use in
PT   treating cancer, by measuring mitogen activated protein kinase-activated
PT   protein kinase substrate phosphorylation activity in presence of test
PT   compound.
XX
PS   Example 3; SEQ ID NO 2; 15pp; Japanese.
XX
CC   The invention relates to identifying an inhibitor of cancer cell
CC   dedifferentiation, comprising reacting mitogen activated protein kinase-
CC   activated protein kinase (MAPKAP), a substrate and ATP in the presence
CC   and absence of a test material and measuring the rate of decrease in
CC   substrate protein phosphorylation activity of the MAPKAP kinase in
CC   presence of test material with respect to the activity of the MAPKAP
CC   kinase in the absence of the test material. DNA coding for Mitogen
CC   activated protein kinase- activated protein kinase (MAPKAP) (GenBank
CC   Accession No. NM004635) was amplified by reverse transcription-polymerase
CC   chain reaction and inserted into pMIKNeo vector, by standard methods.
CC   This vector was transfected into Chinese Hamster Ovary (CHO) cells. The
CC   cells were cultured and MAPKAP was collected and purified from the cells.
CC   The MAPKAP obtained was cultured with wild type heat-shock protein (HSP)
CC   27, at 37 degrees C for 30 minutes, in the presence or absence of the
CC   test compound. The immune precipitation of wild type HSP27 and
CC   phosphorylation of HSP27 was measured, using anti-HSP27 antibody. The
CC   enzyme inhibition rate by the test compound was determined. The test
CC   material was identified as positive if the inhibition rate was 50 % or
CC   more. The present sequence is that of a PCR primer used to mutate human
CC   heat shock protein 27 (HSP27, GenBank Accession No. XM050410), to change
CC   three serine residues in the amino terminus at position 15, 78 and 82 in
CC   regions that are phosphorylated, to aspartic acid residues. The mutated
CC   protein is used in methods of the invention.
XX
SQ   Sequence 40 BP; 6 A; 16 C; 14 G; 4 T; 0 U; 0 Other;

  Query Match             4.4%;  Score 33.6;  DB 1;  Length 40;
```

```
  Best Local Similarity   90.0%;  Pred. No. 1.5;
  Matches   36;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy        244 CAGCCGCGCGCTCAGCCGGCAACTCAGCAGCGGGGTCTCG 283
              ||||||||||||  ||||||||||  ||||||||||||
Db          1 CAGCCGCGCGCTCGACCGGCAACTCGACAGCGGGGTCTCG 40


RESULT 4
ABK67082/c
ID   ABK67082 standard; DNA; 25 BP.
XX
AC   ABK67082;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human gene specific PCR primer #1170.
XX
KW   Primer; ss; DNA microarray; differential expression analysis; human.
XX
OS   Homo sapiens.
XX
PN   US6352829-B1.
XX
PD   05-MAR-2002.
XX
PF   05-JAN-1999;   99US-00225928.
XX
PR   21-MAY-1997;   97US-00859998.
XX
PA   (CLON-) CLONTECH LAB INC.
XX
PI   Chenchik A,  Jokhadze G,  Bibilashvilli R;
XX
DR   WPI; 2002-314699/35.
XX
PT   Producing sub-population of labeled nucleic acids, useful for analyzing
PT   differences in RNA profiles between several different physiological
PT   sources, using set of distinct gene specific primers.
XX
PS   Example 3; SEQ ID NO 1170; 11pp; English.
XX
CC   The invention relates to producing a sub-population of labeled nucleic
CC   acids (NAs) comprising contacting a NA sample from a physiological
CC   source, with a pool of 50 distinct gene specific primers under suitable
CC   conditions to enzymatically generate sub-population of NAs, where each
CC   gene specific primer has a sequence complementary to a distinct mRNA, and
CC   each labeled NA is generated using a single gene specific primer. The
CC   method is useful for producing a sub-population of labeled NAs which is
CC   useful for analysing the differences in the RNA profiles between several
CC   different physiological sources, where the method comprises producing
CC   subpopulation of labeled NAs for the different physiological sources,
CC   comprising the populations for each physiological source to identify
CC   differences in the population, where the comparison is preferably
CC   performed by hybridising the labeled NAs for each of the distinct
CC   physiological sources to an array of probe NAs stably associated with the
CC   surface of a substrate to produce a hybridisation pattern for each of the
CC   sources, and comparing the patterns for each of the sources, where
CC   differential gene expression assays are utilised in differential
CC   expression analysis of diseased a normal tissue e.g. neoplastic a normal
CC   tissue, or different tissue or subtissue types. The present sequence is a
CC   human gene specific PCR primer used in the method of the invention. Note:
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from USPTO
CC   at http.wipo.seqdata.uspto.gov/sequence.html?DocID=6352829B1
XX
SQ   Sequence 25 BP; 4 A; 6 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             3.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 9;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 5
ABK67081
ID   ABK67081 standard; DNA; 24 BP.
XX
AC   ABK67081;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human gene specific PCR primer #1169.
XX
KW   Primer; ss; DNA microarray; differential expression analysis; human.
XX
OS   Homo sapiens.
XX
PN   US6352829-B1.
XX
PD   05-MAR-2002.
XX
PF   05-JAN-1999;   99US-00225928.
XX
PR   21-MAY-1997;   97US-00859998.
XX
PA   (CLON-) CLONTECH LAB INC.
XX
PI   Chenchik A,  Jokhadze G,  Bibilashvilli R;
XX
DR   WPI; 2002-314699/35.
XX
PT   Producing sub-population of labeled nucleic acids, useful for analyzing
PT   differences in RNA profiles between several different physiological
PT   sources, using set of distinct gene specific primers.
XX
PS   Example 3; SEQ ID NO 1169; 11pp; English.
XX
CC   The invention relates to producing a sub-population of labeled nucleic
CC   acids (NAs) comprising contacting a NA sample from a physiological
CC   source, with a pool of 50 distinct gene specific primers under suitable
CC   conditions to enzymatically generate sub-population of NAs, where each
CC   gene specific primer has a sequence complementary to a distinct mRNA, and
CC   each labeled NA is generated using a single gene specific primer. The
CC   method is useful for producing a sub-population of labeled NAs which is
CC   useful for analysing the differences in the RNA profiles between several
CC   different physiological sources, where the method comprises producing
CC   subpopulation of labeled NAs for the different physiological sources,
CC   comprising the populations for each physiological source to identify
CC   differences in the population, where the comparison is preferably
CC   performed by hybridising the labeled NAs for each of the distinct
CC   physiological sources to an array of probe NAs stably associated with the
CC   surface of a substrate to produce a hybridisation pattern for each of the
CC   sources, and comparing the patterns for each of the sources, where
CC   differential gene expression assays are utilised in differential
CC   expression analysis of diseased a normal tissue e.g. neoplastic a normal
CC   tissue, or different tissue or subtissue types. The present sequence is a
CC   human gene specific PCR primer used in the method of the invention. Note:
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from USPTO
CC   at http.wipo.seqdata.uspto.gov/sequence.html?DocID=6352829B1
XX
SQ   Sequence 24 BP; 7 A; 5 C; 11 G; 1 T; 0 U; 0 Other;

  Query Match             3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24
```

```
RESULT 6
ABL99424
ID   ABL99424 standard; DNA; 23 BP.
XX
AC   ABL99424;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Left PCR primer used to target HSP27 canine gene.
XX
KW   Canine gene array; toxicological response; ss.
XX
OS   Canis sp.
XX
PN   WO200208453-A2.
XX
PD   31-JAN-2002.
XX
PF   23-JUL-2001; 2001WO-US023311.
XX
PR   21-JUL-2000; 2000US-0220057P.
XX
PA   (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY.
XX
PI   Farr SB,  Pickett GG,  Neft RE,  Dunn RT;
XX
DR   WPI; 2002-217063/27.
XX
PT   Identifying toxicologically relevant canine gene to determine
PT   toxicological responses of agents, by obtaining and comparing gene
PT   expression profiles of untreated canine cells and canine cells treated
PT   with an agent.
XX
PS   Example 5; Page 51; 140pp; English.
XX
CC   This invention relates to identifying a toxicologically relevant canine
CC   gene and the generation of an array of toxicologically relevant canine
CC   genes. The gene array is useful for obtaining a gene expression profile,
CC   by exposing a population of cells to an agent, obtaining cDNA from the
CC   population of cells, labeling the cDNA, and contacting the cDNA with the
CC   gene array. The relevant gene is useful for making and using arrays to
CC   determine toxicological responses to various agents, and also useful for
CC   identifying novel gene sequences and novel canine genes. The method for
CC   analysing toxicological responses using the canine gene array is rapid
CC   and efficient. The present sequence is related to the canine gene array
XX
SQ   Sequence 23 BP; 3 A; 9 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.8%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 21;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         73 GGACCCCTTCCGCGACTGGTACC 95
              |||||| ||||||||||||||||
Db          1 GGACCCTTTCCGCGACTGGTACC 23


RESULT 7
ADM94658/c
ID   ADM94658 standard; DNA; 21 BP.
XX
AC   ADM94658;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:8.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 8; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 7 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         71 TGGGACCCCTTCCGCGACTGG 91
              |||||||||||||||||||||
Db         21 TGGGACCCCTTCCGCGACTGG 1


RESULT 8
ADM94663/c
ID   ADM94663 standard; DNA; 21 BP.
XX
AC   ADM94663;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:13.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
```

```
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 13; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 7 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        121 CTTCGGGCTGCCCCGGCTGCC 141
              |||||||||||||||||||||
Db         21 CTTCGGGCTGCCCCGGCTGCC 1


RESULT 9
ADM94670/c
ID   ADM94670 standard; DNA; 21 BP.
XX
AC   ADM94670;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:20.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 20; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 4 C; 16 G; 0 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        191 CGCCCCCTGCCCCCCGCCGCC 211
              |||||||||||||||||||||
Db         21 CGCCCCCTGCCCCCCGCCGCC 1


RESULT 10
ADM94703/c
ID   ADM94703 standard; DNA; 21 BP.
XX
AC   ADM94703;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:53.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 53; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 5 C; 9 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        521 GAGGCCCCCATGCCCAAGCTA 541
              ||||||||||||||||||||
Db         21 GAGGCCCCCATGCCCAAGCTA 1
```

RESULT 11
ADM94709/c
ID ADM94709 standard; DNA; 21 BP.
XX
AC ADM94709;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:59.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 59; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 10 C; 6 G; 2 T; 0 U; 0 Other;

```
  Query Match              2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        581 GAGTCGCGGGCCCAGCTTGGG 601
              |||||||||||||||||||||
Db         21 GAGTCGCGGGCCCAGCTTGGG 1
```

RESULT 12
ADM94717/c
ID ADM94717 standard; DNA; 21 BP.
XX
AC ADM94717;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:67.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 67; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 4 C; 12 G; 2 T; 0 U; 0 Other;

```
  Query Match              2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        661 CCACCCCTGCTGCCGCCACTG 681
              |||||||||||||||||||||
Db         21 CCACCCCTGCTGCCGCCACTG 1
```

RESULT 13
ADM94721/c
ID ADM94721 standard; DNA; 21 BP.
XX
AC ADM94721;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:71.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX

```
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 71; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 11 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGATACAT 721
              |||||||||||||||||||||
Db         21 CTGTGTGTTCTTTTGATACAT 1


RESULT 14
ADM94731/c
ID   ADM94731 standard; DNA; 21 BP.
XX
AC   ADM94731;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:81.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 81; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 6 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCCCC 46
              |||||||||||||||||||||
Db         21 ATGACCGAGCGCCGCGTCCCC 1


RESULT 15
ADM94685/c
ID   ADM94685 standard; DNA; 21 BP.
XX
AC   ADM94685;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:35.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 35; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
```

```
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 8 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        341 CCGGACGAGCTGACGGTCAAG 361
              |||||||||||||||||||||
Db         21 CCGGACGAGCTGACGGTCAAG 1


RESULT 16
ADM94725/c
ID   ADM94725 standard; DNA; 21 BP.
XX
AC   ADM94725;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:75.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 75; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 2 C; 5 G; 11 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        741 AATAAAGTTCAAAGCAACCAC 761
              |||||||||||||||||||||
Db         21 AATAAAGTTCAAAGCAACCAC 1


RESULT 17
ADM94653/c
ID   ADM94653 standard; DNA; 21 BP.
XX
AC   ADM94653;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:3.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 3; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 7 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         21 CCAGCATGACCGAGCGCCGCG 41
              |||||||||||||||||||||
Db         21 CCAGCATGACCGAGCGCCGCG 1


RESULT 18
ADM94667/c
ID   ADM94667 standard; DNA; 21 BP.
XX
AC   ADM94667;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:17.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
```

XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 17; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 161 TTAGGCGGCAGCAGCTGGCCA 181
||||||||||||||||||||
Db 21 TTAGGCGGCAGCAGCTGGCCA 1

RESULT 19
ADM94688/c
ID ADM94688 standard; DNA; 21 BP.
XX
AC ADM94688;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:38.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 38; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 10 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 371 GGCGTGGTGGAGATCACCGGC 391
||||||||||||||||||||
Db 21 GGCGTGGTGGAGATCACCGGC 1

RESULT 20
ADM94691/c
ID ADM94691 standard; DNA; 21 BP.
XX
AC ADM94691;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:41.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 41; 38pp; English.
XX

CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 10 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 401 GAGCGGCAGGACGAGCATGGC 421
||||||||||||||||||||
Db 21 GAGCGGCAGGACGAGCATGGC 1

RESULT 21
ADM94692/c
ID ADM94692 standard; DNA; 21 BP.
XX
AC ADM94692;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:42.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 42; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 411 ACGAGCATGGCTACATCTCCC 431
||||||||||||||||||||
Db 21 ACGAGCATGGCTACATCTCCC 1

RESULT 22
ADM94697/c
ID ADM94697 standard; DNA; 21 BP.
XX
AC ADM94697;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:47.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 47; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 5 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 461 CCCGGTGTGGACCCCACCCAA 481
||||||||||||||||||||
Db 21 CCCGGTGTGGACCCCACCCAA 1

RESULT 23
ADM94704/c
ID ADM94704 standard; DNA; 21 BP.
XX
AC ADM94704;

XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:54.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 54; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 5 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 531 TGCCCAAGCTAGCCACGCAGT 551
||||||||||||||||||||
Db 21 TGCCCAAGCTAGCCACGCAGT 1

RESULT 24
ADM94712/c
ID ADM94712 standard; DNA; 21 BP.
XX
AC ADM94712;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:62.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 62; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 611 GCTGCAAAATCCGATGAGACT 631
||||||||||||||||||||
Db 21 GCTGCAAAATCCGATGAGACT 1

RESULT 25
ADM94714/c
ID ADM94714 standard; DNA; 21 BP.
XX
AC ADM94714;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:64.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.

XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 64; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 631 TGCCGCCAAGTAAAGCCTTAG 651
||||||||||||||||||||
Db 21 TGCCGCCAAGTAAAGCCTTAG 1

RESULT 26
ADM94672/c
ID ADM94672 standard; DNA; 21 BP.
XX
AC ADM94672;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:22.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 22; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 7 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 211 CATCGAGAGCCCCGCAGTGGC 231
||||||||||||||||||||
Db 21 CATCGAGAGCCCCGCAGTGGC 1

RESULT 27
ADM94705/c
ID ADM94705 standard; DNA; 21 BP.
XX
AC ADM94705;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:55.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 55; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 5 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCAGTCCAACGAGAT 561
||||||||||||||||||||

```
Db         21 AGCCACGCAGTCCAACGAGAT 1


RESULT 28
ADM94654/c
ID   ADM94654 standard; DNA; 21 BP.
XX
AC   ADM94654;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:4.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 4; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 11 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         31 CGAGCGCCGCGTCCCCTTCTC 51
              |||||||||||||||||||||
Db         21 CGAGCGCCGCGTCCCCTTCTC 1


RESULT 29
ADM94657/c
ID   ADM94657 standard; DNA; 21 BP.
XX
AC   ADM94657;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:7.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 7; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         61 GGGCCCCAGCTGGGACCCCTT 81
              |||||||||||||||||||||
Db         21 GGGCCCCAGCTGGGACCCCTT 1


RESULT 30
ADM94687/c
ID   ADM94687 standard; DNA; 21 BP.
XX
AC   ADM94687;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:37.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
```

PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 37; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 10 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 361 GACCAAGGATGGCGTGGTGGA 381
||||||||||||||||||||
Db 21 GACCAAGGATGGCGTGGTGGA 1

RESULT 31
ADM94689/c
ID ADM94689 standard; DNA; 21 BP.
XX
AC ADM94689;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:39.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 39; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 7 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 381 AGATCACCGGCAAGCACGAGG 401
||||||||||||||||||||
Db 21 AGATCACCGGCAAGCACGAGG 1

RESULT 32
ADM94702/c
ID ADM94702 standard; DNA; 21 BP.
XX
AC ADM94702;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:52.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 52; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX

```
SQ   Sequence 21 BP; 3 A; 6 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        511 ACTGACCGTGGAGGCCCCCAT 531
              |||||||||||||||||||||
Db         21 ACTGACCGTGGAGGCCCCCAT 1


RESULT 33
ADM94713/c
ID   ADM94713 standard; DNA; 21 BP.
XX
AC   ADM94713;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:63.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 63; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 6 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        621 CCGATGAGACTGCCGCCAAGT 641
              |||||||||||||||||||||
Db         21 CCGATGAGACTGCCGCCAAGT 1


RESULT 34
ADM94716/c
ID   ADM94716 standard; DNA; 21 BP.
XX
AC   ADM94716;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:66.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 66; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        651 GCCCGGATGCCCACCCCTGCT 671
              |||||||||||||||||||||
Db         21 GCCCGGATGCCCACCCCTGCT 1


RESULT 35
ADM94724/c
ID   ADM94724 standard; DNA; 21 BP.
XX
AC   ADM94724;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:74.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
```

OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 74; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 9 A; 2 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 731 GTTTTTCTCAAATAAAGTTCA 751
||||||||||||||||||||
Db 21 GTTTTTCTCAAATAAAGTTCA 1

RESULT 36
ADM94651/c
ID ADM94651 standard; DNA; 21 BP.
XX
AC ADM94651;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:1.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 1; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 9 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGCACGAGGAGCAGAGTCAGC 21
||||||||||||||||||||
Db 21 GGCACGAGGAGCAGAGTCAGC 1

RESULT 37
ADM94668/c
ID ADM94668 standard; DNA; 21 BP.
XX
AC ADM94668;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:18.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 18; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27

```
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        171 GCAGCTGGCCAGGCTACGTGC 191
              |||||||||||||||||||||
Db         21 GCAGCTGGCCAGGCTACGTGC 1


RESULT 38
ADM94686/c
ID   ADM94686 standard; DNA; 21 BP.
XX
AC   ADM94686;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:36.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 36; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        351 TGACGGTCAAGACCAAGGATG 371
              |||||||||||||||||||||
Db         21 TGACGGTCAAGACCAAGGATG 1


RESULT 39
ADM94700/c
ID   ADM94700 standard; DNA; 21 BP.
XX
AC   ADM94700;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:50.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 50; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        491 TCCCTGTCCCCTGAGGGCACA 511
              |||||||||||||||||||||
Db         21 TCCCTGTCCCCTGAGGGCACA 1


RESULT 40
ADM94701/c
ID   ADM94701 standard; DNA; 21 BP.
XX
AC   ADM94701;
XX
DT   01-JUL-2004  (first entry)
```

XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:51.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 51; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 501 CTGAGGGCACACTGACCGTGG 521
||||||||||||||||||||
Db 21 CTGAGGGCACACTGACCGTGG 1

RESULT 41
ADM94706/c
ID ADM94706 standard; DNA; 21 BP.
XX
AC ADM94706;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:56.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 56; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 2 C; 9 G; 7 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 551 TCCAACGAGATCACCATCCCA 571
||||||||||||||||||||
Db 21 TCCAACGAGATCACCATCCCA 1

RESULT 42
ADM94711/c
ID ADM94711 standard; DNA; 21 BP.
XX
AC ADM94711;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:61.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of

```
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 61; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 6 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        601 GGGCCCAGAAGCTGCAAAATC 621
              |||||||||||||||||||||
Db         21 GGGCCCAGAAGCTGCAAAATC 1


RESULT 43
ADM94729/c
ID   ADM94729 standard; DNA; 21 BP.
XX
AC   ADM94729;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:79.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 79; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        265 ACTCAGCAGCGGGGTCTCGGA 285
              |||||||||||||||||||||
Db         21 ACTCAGCAGCGGGGTCTCGGA 1


RESULT 44
ADM94660/c
ID   ADM94660 standard; DNA; 21 BP.
XX
AC   ADM94660;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:10.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 10; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         91 GTACCCGCATAGCCGCCTCTT 111
              |||||||||||||||||||||
Db         21 GTACCCGCATAGCCGCCTCTT 1
```

```
RESULT 45
ADM94661/c
ID   ADM94661 standard; DNA; 21 BP.
XX
AC   ADM94661;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:11.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 11; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        101 AGCCGCCTCTTCGACCAGGCC 121
              |||||||||||||||||||||
Db         21 AGCCGCCTCTTCGACCAGGCC 1


RESULT 46
ADM94669/c
ID   ADM94669 standard; DNA; 21 BP.
XX
AC   ADM94669;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:19.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 19; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 6 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        181 AGGCTACGTGCGCCCCCTGCC 201
              |||||||||||||||||||||
Db         21 AGGCTACGTGCGCCCCCTGCC 1


RESULT 47
ADM94680/c
ID   ADM94680 standard; DNA; 21 BP.
XX
AC   ADM94680;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:30.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
```

XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 30; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 8 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 291 GGCACACTGCGGACCGCTGGC 311
||||||||||||||||||||
Db 21 GGCACACTGCGGACCGCTGGC 1

RESULT 48
ADM94652/c
ID ADM94652 standard; DNA; 21 BP.
XX
AC ADM94652;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:2.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 2; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 GCAGAGTCAGCCAGCATGACC 31
||||||||||||||||||||
Db 21 GCAGAGTCAGCCAGCATGACC 1

RESULT 49
ADM94676/c
ID ADM94676 standard; DNA; 21 BP.
XX
AC ADM94676;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:26.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 26; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 6 C; 9 G; 4 T; 0 U; 0 Other;

```
  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        251 GCGCTCAGCCGGCAACTCAGC 271
              |||||||||||||||||||||
Db         21 GCGCTCAGCCGGCAACTCAGC 1


RESULT 50
ADM94684/c
ID   ADM94684 standard; DNA; 21 BP.
XX
AC   ADM94684;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:34.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 34; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        331 CCACTTCGCCCCGGACGAGCT 351
              |||||||||||||||||||||
Db         21 CCACTTCGCCCCGGACGAGCT 1


RESULT 51
ADM94690/c
ID   ADM94690 standard; DNA; 21 BP.
XX
AC   ADM94690;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:40.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 40; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 0 A; 9 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        391 CAAGCACGAGGAGCGGCAGGA 411
              |||||||||||||||||||||
Db         21 CAAGCACGAGGAGCGGCAGGA 1


RESULT 52
ADM94662/c
ID   ADM94662 standard; DNA; 21 BP.
XX
AC   ADM94662;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:12.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
```

PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 12; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 7 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 111 TCGACCAGGCCTTCGGGCTGC 131
||||||||||||||||||||||
Db 21 TCGACCAGGCCTTCGGGCTGC 1

RESULT 53
ADM94665/c
ID ADM94665 standard; DNA; 21 BP.
XX
AC ADM94665;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:15.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 15; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 11 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 141 CGGAGGAGTGGTCGCAGTGGT 161
|||||||||||||||||||||
Db 21 CGGAGGAGTGGTCGCAGTGGT 1

RESULT 54
ADM94698/c
ID ADM94698 standard; DNA; 21 BP.
XX
AC ADM94698;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:48.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 48; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The

```
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 5 A; 1 C; 11 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        471 ACCCCACCCAAGTTTCCTCCT 491
              |||||||||||||||||||||
Db         21 ACCCCACCCAAGTTTCCTCCT 1


RESULT 55
ADM94718/c
ID   ADM94718 standard; DNA; 21 BP.
XX
AC   ADM94718;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:68.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 68; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 5 A; 6 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        671 TGCCGCCACTGGCTGTGCCTC 691
              |||||||||||||||||||||
Db         21 TGCCGCCACTGGCTGTGCCTC 1


RESULT 56
ADM94728/c
ID   ADM94728 standard; DNA; 21 BP.
XX
AC   ADM94728;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:78.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 78; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 10 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        365 AAGGATGGCGTGGTGGAGATC 385
              |||||||||||||||||||||
Db         21 AAGGATGGCGTGGTGGAGATC 1


RESULT 57
ADM94674/c
ID   ADM94674 standard; DNA; 21 BP.
XX
AC   ADM94674;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:24.
```

XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 24; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 6 C; 12 G; 2 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 231 CCGCGCCCGCCTACAGCCGCG 251
||||||||||||||||||||
Db 21 CCGCGCCCGCCTACAGCCGCG 1

RESULT 58
ADM94678/c
ID ADM94678 standard; DNA; 21 BP.
XX
AC ADM94678;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:28.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 28; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 9 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 271 CAGCGGGGTCTCGGAGATCCG 291
||||||||||||||||||||
Db 21 CAGCGGGGTCTCGGAGATCCG 1

RESULT 59
ADM94715/c
ID ADM94715 standard; DNA; 21 BP.
XX
AC ADM94715;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:65.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous

```
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 65; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        641 TAAAGCCTTAGCCCGGATGCC 661
              |||||||||||||||||||||
Db         21 TAAAGCCTTAGCCCGGATGCC 1


RESULT 60
ADM94726/c
ID   ADM94726 standard; DNA; 21 BP.
XX
AC   ADM94726;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:76.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 76; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 3 C; 6 G; 9 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        744 AAAGTTCAAAGCAACCACCTG 764
              |||||||||||||||||||||
Db         21 AAAGTTCAAAGCAACCACCTG 1


RESULT 61
ADM94677/c
ID   ADM94677 standard; DNA; 21 BP.
XX
AC   ADM94677;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:27.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 27; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        261 GGCAACTCAGCAGCGGGGTCT 281
              |||||||||||||||||||||
Db         21 GGCAACTCAGCAGCGGGGTCT 1


RESULT 62
```

```
ADM94699/c
ID   ADM94699 standard; DNA; 21 BP.
XX
AC   ADM94699;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:49.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 49; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 7 A; 2 C; 11 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        481 AGTTTCCTCCTCCCTGTCCCC 501
              |||||||||||||||||||||
Db         21 AGTTTCCTCCTCCCTGTCCCC 1


RESULT 63
ADM94719/c
ID   ADM94719 standard; DNA; 21 BP.
XX
AC   ADM94719;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:69.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 69; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 12 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        681 GGCTGTGCCTCCCCCGCCACC 701
              |||||||||||||||||||||
Db         21 GGCTGTGCCTCCCCCGCCACC 1


RESULT 64
ADM94671/c
ID   ADM94671 standard; DNA; 21 BP.
XX
AC   ADM94671;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:21.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
```

```
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 21; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 5 C; 12 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        201 CCCCCGCCGCCATCGAGAGCC 221
              |||||||||||||||||||||
Db         21 CCCCCGCCGCCATCGAGAGCC 1


RESULT 65
ADM94679/c
ID   ADM94679 standard; DNA; 21 BP.
XX
AC   ADM94679;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:29.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 29; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        281 TCGGAGATCCGGCACACTGCG 301
              |||||||||||||||||||||
Db         21 TCGGAGATCCGGCACACTGCG 1


RESULT 66
ADM94683/c
ID   ADM94683 standard; DNA; 21 BP.
XX
AC   ADM94683;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:33.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 33; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
```

```
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        321 TGGATGTCAACCACTTCGCCC 341
              |||||||||||||||||||||
Db         21 TGGATGTCAACCACTTCGCCC 1


RESULT 67
ADM94693/c
ID   ADM94693 standard; DNA; 21 BP.
XX
AC   ADM94693;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:43.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 43; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 6 A; 3 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        421 CTACATCTCCCGGTGCTTCAC 441
              |||||||||||||||||||||
Db         21 CTACATCTCCCGGTGCTTCAC 1


RESULT 68
ADM94694/c
ID   ADM94694 standard; DNA; 21 BP.
XX
AC   ADM94694;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:44.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 44; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        431 CGGTGCTTCACGCGGAAATAC 451
              |||||||||||||||||||||
Db         21 CGGTGCTTCACGCGGAAATAC 1


RESULT 69
ADM94722/c
ID   ADM94722 standard; DNA; 21 BP.
XX
AC   ADM94722;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:72.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
```

```
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 72; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 12 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        711 TTTTGATACATTTATCTTCTG 731
              |||||||||||||||||||||
Db         21 TTTTGATACATTTATCTTCTG 1


RESULT 70
ADM94723/c
ID   ADM94723 standard; DNA; 21 BP.
XX
AC   ADM94723;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:73.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 73; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 13 A; 1 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        721 TTTATCTTCTGTTTTTCTCAA 741
              |||||||||||||||||||||
Db         21 TTTATCTTCTGTTTTTCTCAA 1


RESULT 71
ADM94682/c
ID   ADM94682 standard; DNA; 21 BP.
XX
AC   ADM94682;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:32.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 32; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
```

```
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 5 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        311 CGCGTGTCCCTGGATGTCAAC 331
              |||||||||||||||||||||
Db         21 CGCGTGTCCCTGGATGTCAAC 1


RESULT 72
ADM94655/c
ID   ADM94655 standard; DNA; 21 BP.
XX
AC   ADM94655;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:5.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 5; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 6 A; 5 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         41 GTCCCCTTCTCGCTCCTGCGG 61
              |||||||||||||||||||||
Db         21 GTCCCCTTCTCGCTCCTGCGG 1


RESULT 73
ADM94656/c
ID   ADM94656 standard; DNA; 21 BP.
XX
AC   ADM94656;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:6.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 6; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 CGCTCCTGCGGGGCCCCAGCT 71
              |||||||||||||||||||||
Db         21 CGCTCCTGCGGGGCCCCAGCT 1


RESULT 74
ADM94664/c
ID   ADM94664 standard; DNA; 21 BP.
XX
AC   ADM94664;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:14.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
```

KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 14; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 10 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 131 CCCCGGCTGCCGGAGGAGTGG 151
||||||||||||||||||||
Db 21 CCCCGGCTGCCGGAGGAGTGG 1

RESULT 75
ADM94666/c
ID ADM94666 standard; DNA; 21 BP.
XX
AC ADM94666;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:16.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 16; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 151 GTCGCAGTGGTTAGGCGGCAG 171
||||||||||||||||||||
Db 21 GTCGCAGTGGTTAGGCGGCAG 1

RESULT 76
ADM94673/c
ID ADM94673 standard; DNA; 21 BP.
XX
AC ADM94673;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:23.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX

```
PS   Claim 5; SEQ ID NO 23; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 1 A; 7 C; 12 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        221 CCCGCAGTGGCCGCGCCCGCC 241
              |||||||||||||||||||||
Db         21 CCCGCAGTGGCCGCGCCCGCC 1


RESULT 77
ADM94659/c
ID   ADM94659 standard; DNA; 21 BP.
XX
AC   ADM94659;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:9.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 9; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 5 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         81 TCCGCGACTGGTACCCGCATA 101
              |||||||||||||||||||||
Db         21 TCCGCGACTGGTACCCGCATA 1


RESULT 78
ADM94681/c
ID   ADM94681 standard; DNA; 21 BP.
XX
AC   ADM94681;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:31.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 31; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 4 A; 8 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        301 GGACCGCTGGCGCGTGTCCCT 321
              |||||||||||||||||||||
Db         21 GGACCGCTGGCGCGTGTCCCT 1


RESULT 79
ADM94696/c
ID   ADM94696 standard; DNA; 21 BP.
```

```
XX
AC   ADM94696;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:46.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 46; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        451 CACGCTGCCCCCCGGTGTGGA 471
              |||||||||||||||||||||
Db         21 CACGCTGCCCCCCGGTGTGGA 1


RESULT 80
ADM94707/c
ID   ADM94707 standard; DNA; 21 BP.
XX
AC   ADM94707;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:57.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 57; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 5 A; 2 C; 10 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        561 TCACCATCCCAGTCACCTTCG 581
              |||||||||||||||||||||
Db         21 TCACCATCCCAGTCACCTTCG 1


RESULT 81
ADM94675/c
ID   ADM94675 standard; DNA; 21 BP.
XX
AC   ADM94675;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:25.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
```

XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 25; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 6 C; 10 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 241 CTACAGCCGCGCGCTCAGCCG 261
||||||||||||||||||||
Db 21 CTACAGCCGCGCGCTCAGCCG 1

RESULT 82
ADM94695/c
ID ADM94695 standard; DNA; 21 BP.
XX
AC ADM94695;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:45.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 45; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 5 C; 9 G; 5 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 441 CGCGGAAATACACGCTGCCCC 461
||||||||||||||||||||
Db 21 CGCGGAAATACACGCTGCCCC 1

RESULT 83
ADM94708/c
ID ADM94708 standard; DNA; 21 BP.
XX
AC ADM94708;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:58.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 58; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        571 AGTCACCTTCGAGTCGCGGGC 591
              |||||||||||||||||||||
Db         21 AGTCACCTTCGAGTCGCGGGC 1


RESULT 84
ADM94710/c
ID   ADM94710 standard; DNA; 21 BP.
XX
AC   ADM94710;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:60.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 60; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 2 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        591 CCCAGCTTGGGGGCCCAGAAG 611
              |||||||||||||||||||||
Db         21 CCCAGCTTGGGGGCCCAGAAG 1


RESULT 85
ADM94720/c
ID   ADM94720 standard; DNA; 21 BP.
XX
AC   ADM94720;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:70.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 70; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 6 A; 4 C; 10 G; 1 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        691 CCCCCGCCACCTGTGTGTTCT 711
              |||||||||||||||||||||
Db         21 CCCCCGCCACCTGTGTGTTCT 1


RESULT 86
ADM94730/c
ID   ADM94730 standard; DNA; 21 BP.
XX
AC   ADM94730;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:80.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
```

```
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 80; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 22;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        264 AACTCAGCAGCGGGGTCTCGG 284
              |||||||||||||||||||||
Db         21 AACTCAGCAGCGGGGTCTCGG 1


RESULT 87
ADM94732/c
ID   ADM94732 standard; DNA; 20 BP.
XX
AC   ADM94732;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:82.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 6; SEQ ID NO 82; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 27;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCCC 45
              ||||||||||||||||||||
Db         20 ATGACCGAGCGCCGCGTCCC 1


RESULT 88
ADO55958
ID   ADO55958 standard; DNA; 20 BP.
XX
AC   ADO55958;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Probe HSP27 for detecting gene expression in metastatic melanoma cells.
XX
KW   ss; probe; detection; metastatic melanoma; GaINAcT; PAX3.
XX
OS   Homo sapiens.
XX
PN   WO2004045521-A2.
XX
PD   03-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-US036493.
XX
PR   14-NOV-2002; 2002US-0426216P.
XX
PA   (WAYN-) WAYNE CANCER INST JOHN.
XX
PI   Hoon DSB,  Takeuchi H;
XX
DR   WPI; 2004-420519/39.
XX
PT   Detecting metastatic melanoma cells in a patient by isolating nucleic
PT   acid from a biological sample obtained from the patient, amplifying
PT   nucleic acid targets, if present, from a panel of marker genes.
XX
PS   Example 4; SEQ ID NO 13; 43pp; English.
XX
CC   The invention relates to a method of detecting metastatic melanoma cells
CC   in a patient by: (a) isolating nucleic acid from a biological sample
CC   obtained from the patient; (b) amplifying nucleic acid targets, if
CC   present, from a panel of marker genes, where the panel comprises GaINAcT
CC   and/or PAX3; and (c) detecting the presence or absence of the nucleic
CC   acid targets. The method is useful in detecting metastatic melanoma
CC   cells. This sequence corresponds to a probe used in the method of the
CC   invention.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 27;
```

```
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        399 AGGAGCGGCAGGACGAGCAT 418
              ||||||||||||||||||||
Db          1 AGGAGCGGCAGGACGAGCAT 20


RESULT 89
ADM94740
ID   ADM94740 standard; DNA; 19 BP.
XX
AC   ADM94740;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:90.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 10; SEQ ID NO 90; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC   which is used in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 3 A; 8 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 33;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCC 44
              |:|||||||||||||:||
Db          1 AUGACCGAGCGCCGCGUCC 19


RESULT 90
ADM94737
ID   ADM94737 standard; DNA; 19 BP.
XX
AC   ADM94737;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:87.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 10; SEQ ID NO 87; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC   which is used in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 5 A; 8 C; 3 G; 0 T; 3 U; 0 Other;

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 33;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        556 CGAGATCACCATCCCAGTC 574
              |||||:|||||:|||||:|
Db          1 CGAGAUCACCAUCCCAGUC 19


RESULT 91
ABA00784
ID   ABA00784 standard; DNA; 21 BP.
XX
AC   ABA00784;
XX
DT   01-APR-2003  (first entry)
XX
DE   HSP27 forward primer.
XX
KW   Primer; PCR; amplify; heat shock protein; HSP; HSP27; inducer;
KW   digestive system; nephropathy; inflammation; arthritis;
KW   chronic rheumatism; arthritis deformans; asthma; allergy;
KW   arteriosclerosis; diabetic complication; diabetic neuropathy;
KW   chronic obstructive pulmonary disease; systemic lupus erythematosus;
KW   autoimmune haemolytic anaemia; psoriasis; neurodegeneration;
KW   Parkinson's disease; AIDS related dementia; CNS; cerebral haemorrhage;
KW   cerebral ischaemia; toxaemia; cachexia; cancer; Addison's disease;
KW   viral infection; pain; chronic inflammation; toothache; angina; ss.
```

XX
OS Synthetic.
XX
PN WO200278705-A1.
XX
PD 10-OCT-2002.
XX
PF 27-MAR-2002; 2002WO-JP002946.
XX
PR 28-MAR-2001; 2001JP-00092704.
XX
PA (TAKE) TAKEDA CHEM IND LTD.
XX
PI Terashita Z, Naruo K, Uchikawa O, Nakanishi A;
XX
DR WPI; 2003-111786/10.
XX
PT Heat shock protein (HSP) inducer comprises a fused bicyclic or tricyclic
PT compound.
XX
PS Example 4; Page 46; 66pp; Japanese.
XX
CC The sequences given in ABA00784-86 are primers and a probe which were
CC used in the amplification and isolation of the heat shock protein (HSP)
CC 27 coding sequence. These sequences may be used to monitor the
CC effectiveness of the heat shock protein inducer of the invention. The HSP
CC inducer of the invention may be used for treating and preventing
CC digestive system disorders, nephropathies, inflammatory diseases,
CC arthritis, chronic rheumatism and arthritis deformans. The inducer may
CC also be useful for treating and preventing asthma, allergic diseases,
CC arteriosclerosis, diabetic complications (e.g. diabetic neuropathy),
CC chronic obstructive pulmonary disease, systemic lupus erythematosus,
CC autoimmune haemolytic anaemia, psoriasis, neuro- degenerative disorders
CC (e.g. Parkinson's disease or AIDS related dementia), CNS disorders (e.g.
CC cerebral haemorrhage or cerebral ischaemia), toxaemia, cachexia, cancer,
CC Addison's disease, viral infections or pain (e.g. due to chronic
CC inflammatory diseases, toothache or angina)
XX
SQ Sequence 21 BP; 7 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 2.4%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 42;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 359 AAGACCAAGGATGGCGTGGT 378
||||||||||| ||||||||
Db 2 AAGACCAAGGAAGGCGTGGT 21

RESULT 92
ADM94727/c
ID ADM94727 standard; DNA; 18 BP.
XX
AC ADM94727;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:77.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 77; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 18 BP; 2 A; 6 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 2.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 226 AGTGGCCGCGCCCGCCTA 243
||||||||||||||||||
Db 18 AGTGGCCGCGCCCGCCTA 1

RESULT 93
ADM94739
ID ADM94739 standard; DNA; 21 BP.
XX
AC ADM94739;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:89.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX

```
PS   Claim 10; SEQ ID NO 89; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC   which is used in the exemplification of the present invention.
XX
SQ   Sequence 21 BP; 0 A; 9 C; 7 G; 0 T; 5 U; 0 Other;

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 48;
  Matches   16;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        576 CCTTCGAGTCGCGGGCCCAGC 596
              ||::|| |:|||||||||| ||
Db          1 CCUUCGUGUCGCGGGCCCUGC 21


RESULT 94
ABA00785/c
ID   ABA00785 standard; DNA; 22 BP.
XX
AC   ABA00785;
XX
DT   01-APR-2003  (first entry)
XX
DE   HSP27 reverse primer.
XX
KW   Primer; PCR; amplify; heat shock protein; HSP; HSP27; inducer;
KW   digestive system; nephropathy; inflammation; arthritis;
KW   chronic rheumatism; arthritis deformans; asthma; allergy;
KW   arteriosclerosis; diabetic complication; diabetic neuropathy;
KW   chronic obstructive pulmonary disease; systemic lupus erythematosus;
KW   autoimmune haemolytic anaemia; psoriasis; neurodegeneration;
KW   Parkinson's disease; AIDS related dementia; CNS; cerebral haemorrhage;
KW   cerebral ischaemia; toxaemia; cachexia; cancer; Addison's disease;
KW   viral infection; pain; chronic inflammation; toothache; angina; ss.
XX
OS   Synthetic.
XX
PN   WO200278705-A1.
XX
PD   10-OCT-2002.
XX
PF   27-MAR-2002; 2002WO-JP002946.
XX
PR   28-MAR-2001; 2001JP-00092704.
XX
PA   (TAKE ) TAKEDA CHEM IND LTD.
XX
PI   Terashita Z,  Naruo K,  Uchikawa O,  Nakanishi A;
XX
DR   WPI; 2003-111786/10.
XX
PT   Heat shock protein (HSP) inducer comprises a fused bicyclic or tricyclic
PT   compound.
XX
PS   Example 4; Page 46; 66pp; Japanese.
XX
CC   The sequences given in ABA00784-86 are primers and a probe which were
CC   used in the amplification and isolation of the heat shock protein (HSP)
CC   27 coding sequence. These sequences may be used to monitor the
CC   effectiveness of the heat shock protein inducer of the invention. The HSP
CC   inducer of the invention may be used for treating and preventing
CC   digestive system disorders, nephropathies, inflammatory diseases,
CC   arthritis, chronic rheumatism and arthritis deformans. The inducer may
CC   also be useful for treating and preventing asthma, allergic diseases,
CC   arteriosclerosis, diabetic complications (e.g. diabetic neuropathy),
CC   chronic obstructive pulmonary disease, systemic lupus erythematosus,
CC   autoimmune haemolytic anaemia, psoriasis, neuro- degenerative disorders
CC   (e.g. Parkinson's disease or AIDS related dementia), CNS disorders (e.g.
CC   cerebral haemorrhage or cerebral ischaemia), toxaemia, cachexia, cancer,
CC   Addison's disease, viral infections or pain (e.g. due to chronic
CC   inflammatory diseases, toothache or angina)
XX
SQ   Sequence 22 BP; 6 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 50;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        413 GAGCATGGCTACATCTCCCGG 433
              || |||||||||||||| |||
Db         21 GAACATGGCTACATCTCTCGG 1


RESULT 95
AAA66267
ID   AAA66267 standard; DNA; 20 BP.
XX
AC   AAA66267;
XX
DT   09-OCT-2000  (first entry)
XX
DE   Dog genomic marker oligonucleotide sequence SEQ ID NO:129.
XX
KW   Dog; genome; genomic marker; radiation hybrid map; identification;
KW   chromosome location; gene marker; polymorphic microsatellite marker;
KW   phenotype; behaviour; pedigree; ss.
XX
OS   Canis familiaris.
XX
PN   WO200029615-A2.
XX
PD   25-MAY-2000.
XX
PF   15-NOV-1999;   99WO-IB001907.
XX
PR   13-NOV-1998;   98US-0108193P.
XX
PA   (CNRS ) CNRS CENT NAT RECH SCI.
XX
PI   Galibert F,  Andre C;
XX
DR   WPI; 2000-387821/33.
XX
PT   New radiation hybrid map of the dog, Canine familiaris, genome, useful
PT   for e.g. identifying genes implicated in phenotypic and behavioral traits
PT   or in genetic diseases and for studying dog pedigrees.
XX
PS   Claim 1; Page 58; 87pp; English.
XX
CC   The present invention describes a radiation hybrid map of the dog (Canine
CC   familiaris) genome comprising the genome location of a marker selected
CC   from AAA66139 to AAA66942. The radiation hybrid map is useful for
CC   identifying and localising dog genes, since it covers approximately 80 %
CC   of the dog genome and provides a dense map integrating different types
CC   (i.e. Type I and Type II) of markers. The map and the dog genome markers
CC   (or complementary sequences) are especially useful to identify genes
CC   responsible for phenotypic and behavioural traits in dogs, to identify
CC   morbid genes, to analyse diseases and identify implicated genes in such
CC   diseases and their alleles, and to study dog pedigrees. They may also be
CC   useful for isolating corresponding human gene sequences e.g. genes
CC   involved in genetic diseases
XX
SQ   Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 17.4;  DB 1;  Length 20;
  Best Local Similarity   94.7%;  Pred. No. 51;
  Matches   18;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy        495 TGTCCCCTGAGGGCACACT 513
              ||||||||||||||||| ||
Db          1 TGTCCCCTGAGGGCACTCT 19


RESULT 96
ABT34675
ID   ABT34675 standard; DNA; 17 BP.
XX
AC   ABT34675;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 312.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 70; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 97
ADB45935
ID   ADB45935 standard; DNA; 17 BP.
XX
AC   ADB45935;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #6258.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 763; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 98
```

```
ADE30781
ID   ADE30781 standard; DNA; 17 BP.
XX
AC   ADE30781;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Cholesterol homeostasis/adipogenesis related DNA seq id 168.
XX
KW   expression vector; anorectic; antiarteriosclerotic; cardiant;
KW   antidiabetic; elevated cholesterol; elevated lipid; adipogenesis;
KW   obesity; athersclerosis; diabetes mellitus;
KW   coronary artery heart disease; cholesterol homeostasis; ss;
KW   differntial expression.
XX
OS   Homo sapiens.
XX
PN   US2003180764-A1.
XX
PD   25-SEP-2003.
XX
PF   08-JAN-2003; 2003US-00339793.
XX
PR   09-JAN-2002; 2002US-0347286P.
XX
PA   (LYNX-) LYNX THERAPEUTICS INC.
XX
PI   Shang J,  Bowen B;
XX
DR   WPI; 2003-830986/77.
XX
PT   Polynucleotides differentially regulated in response to cholesterol and
PT   adipogenesis are useful to detect and treat associated conditions such as
PT   obesity, athersclerosis, diabetes mellitus and coronary artery heart
PT   disease.
XX
PS   Claim 8; SEQ ID NO 168; 59pp; English.
XX
CC   The invention describes a composition comprising at least one expression
CC   vector comprising a polynucleotide of the invention. The composition has
CC   anorectic, antiarteriosclerotic, cardiant and antidiabetic properties.
CC   The invention is used to detect and treat conditions associated with
CC   elevated cholesterol and lipid or during adipogenesis, particularly
CC   obesity, athersclerosis, diabetes mellitus or coronary artery heart
CC   disease. This sequence represents a polynucleotide differentially
CC   expressed during cholesterol homeostasis and adipogenesis.
XX
SQ   Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 99
ADI52044
ID   ADI52044 standard; DNA; 17 BP.
XX
AC   ADI52044;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID4547.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 4547; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 100
ACC51537
ID   ACC51537 standard; DNA; 17 BP.
XX
AC   ACC51537;
XX
DT   27-JUN-2003  (first entry)
XX
DE   Human tumour suppressor sequence #304.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
```

```
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 110; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
CC   identity to them, and polypeptides encoded by the sequences or
CC   polypeptides having 80% identity to the polypeptide sequences. The
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 49;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 101
ADR30706/c
ID   ADR30706 standard; DNA; 18 BP.
XX
AC   ADR30706;
XX
DT   18-NOV-2004  (first entry)
XX
DE   Skunk cabbage S. foetidus alternative oxidase gene primer, RACE-R2-4.
XX
KW   skunk cabbage; Symplocarpus foetidus alternative oxidase; Sfaox;
KW   skunk cabbage origin cyanogen resistant respiratory enzyme; Sfpre-AOX;
KW   mitochondria transfer signal peptide; Sfmit1; low temperature; heat;
KW   plant; homeothermism; environmental purification; genetic engineering;
KW   crop breeding; diabetes; obesity; primer; ss.
XX
OS   Unidentified.
XX
PN   JP2004242643-A.
XX
PD   02-SEP-2004.
XX
PF   17-FEB-2003; 2003JP-00038874.
XX
PR   17-FEB-2003; 2003JP-00038874.
XX
PA   (IWAT-) UNIV IWATE.
XX
DR   WPI; 2004-629613/61.
XX
PT   Novel skunk cabbage Symplocarpus foetidus alternative oxidase gene
PT   encoding skunk cabbage origin cyanogen resistant respiratory enzyme Sfpre
PT   -AOX, useful in development of crops capable of growing at low
PT   temperature.
XX
PS   Example 1; SEQ ID NO 7; 26pp; Japanese.
XX
CC   The invention relates to a novel skunk cabbage Symplocarpus foetidus
CC   alternative oxidase (Sfaox) gene encoding a skunk cabbage origin cyanogen
CC   resistant respiratory enzyme, Sfpre-AOX, having a fully defined sequence
CC   of 349 amino acids as given in the specification. The invention further
CC   comprises: a polynucleotide purified from the genomic DNA, mRNA and cDNA
CC   or complementary sequence of the Sfaox gene; an oligonucleotide probe
CC   hybridising under stringent conditions with the purified polynucleotide
CC   from above; an oligonucleotide primer set carrying out PCR amplification
CC   of the purified polynucleotide; a recombinant vector containing the
CC   purified polynucleotide; transforming a somatic cell using the vector; an
CC   expression product of the Sfaox gene, comprising a skunk cabbage origin
CC   cyanogen resistant respiratory enzyme Sfpre-AOX having the 349 amino acid
CC   protein; a mitochondria transfer signal peptide Sfmit1, which is a
CC   portion of enzyme Sfpre-AOX; a protein SfmAOX having a fully defined
CC   sequence of 328 amino acids as given in the specification, and capable of
CC   being transferred to a mitochondrial inner membrane and functioning as a
CC   cyanogen resistant respiratory enzyme, where the protein is a portion of
CC   enzyme Sfpre-AOX; an oligonucleotide encoding the mitochondria transfer
CC   signal peptide; and a polynucleotide encoding the SfmAOX protein. The
CC   Sfaox gene is useful in the development of crops capable of growing at
CC   low temperature, as the cyanogen resistant respiratory enzyme encoded by
CC   the Sfaox gene is useful for generating heat in a plant, and for
CC   maintaining homeothermism. The Sfaox gene is useful in developing
CC   microorganisms involved in environmental purification. The expression
CC   product of the Sfaox gene is useful in genetic engineering for crop
CC   breeding and in the medicinal field for the development of drugs related
CC   to diabetes or obesity. This polynucleotide sequence represents a primer
CC   of the skunk cabbage Symplocarpus foetidus alternative oxidase (Sfaox)
CC   gene of the invention.
XX
SQ   Sequence 18 BP; 4 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             2.1%;  Score 16.4;  DB 1;  Length 18;
  Best Local Similarity   94.4%;  Pred. No. 60;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        326 GTCAACCACTTCGCCCCG 343
              ||||||||||||||| ||
Db         18 GTCAACCACTTCGCCTCG 1


RESULT 102
ADI00879
ID   ADI00879 standard; DNA; 19 BP.
XX
AC   ADI00879;
XX
DT   22-APR-2004  (first entry)
XX
DE   RT-PCR 32P end-labelled Pell primer used to amplify human MUC5B RNA.
XX
KW   MUC5B-b1; MUC5B-b2; mucin; MUC5B promoter; ss; PCR; primer; human;
KW   RT-PCR; Pell.
XX
OS   Homo sapiens.
XX
PN   US2003096219-A1.
XX
PD   22-MAY-2003.
XX
PF   21-NOV-2001; 2001US-00990613.
XX
PR   21-NOV-2001; 2001US-00990613.
XX
PA   (WURR/) WU R.
PA   (CHEN/) CHEN Y.
XX
PI   Wu R,  Chen Y;
XX
DR   WPI; 2004-088749/09.
XX
PT   Novel MUC5B gene useful for identifying a compound capable of modulating
PT   MUC5B gene promoter activity.
XX
PS   Example 5; SEQ ID NO 7; 52pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid molecule
```

```
CC   comprising a nucleotide sequence chosen from a fully defined sequence of
CC   MUC5B-b1 and MUC5B-b2. The method of the invention may be useful for
CC   identifying a compound capable of modulating mucin MUC5B gene promoter
CC   activity. The current sequence is that of the RT-PCR 32P end-labelled
CC   Pell primer of the invention which was used to amplify human MUC5B RNA.
XX
SQ   Sequence 19 BP; 4 A; 7 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 72;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        403 GCGGCAGGACGAGCATGGC 421
              ||||||  ||||||||||||
Db          1 GCGGCACCACGAGCATGGC 19


RESULT 103
ADM94733
ID   ADM94733 standard; DNA; 19 BP.
XX
AC   ADM94733;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:83.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 10; SEQ ID NO 83; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC   which is used in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 0 A; 6 C; 8 G; 0 T; 5 U; 0 Other;

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 72;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        266 CTCAGCAGCGGGGTCTCGG 284
              |:| || ||||||:|:|||
Db          1 CUCUGCUGCGGGGUCUCGG 19


RESULT 104
ADM94657
ID   ADM94657 standard; DNA; 21 BP.
XX
AC   ADM94657;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:7.
XX
KW   heat shock protein 27; hsp27; cytostatic; gene therapy;
KW   heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004030660-A2.
XX
PD   15-APR-2004.
XX
PF   02-OCT-2003; 2003WO-CA001588.
XX
PR   02-OCT-2002; 2002US-0415859P.
PR   18-APR-2003; 2003US-0463952P.
XX
PA   (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI   Gleave ME,  Rocchi P,  Signaevsky M;
XX
DR   WPI; 2004-316331/29.
XX
PT   New composition comprising a therapeutic agent that reduces the amount of
PT   active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT   useful in treating cancer, e.g., prostate cancer or a central nervous
PT   system malignancy.
XX
PS   Claim 5; SEQ ID NO 7; 38pp; English.
XX
CC   The present invention describes a composition which comprises a
CC   therapeutic agent that reduces the amount of active heat shock protein 27
CC   (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC   composition has cytostatic activity, and can be used in gene therapy. The
CC   composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC   breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC   cancer or a central nervous system malignancy. The present sequence
CC   represents a human hsp27 antisense oligonucleotide which is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 3 A; 7 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 78;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         60 GGGGCCCCAGCTGGGACCC 78
              |||| |||||||||| |||
Db          3 GGGGTCCCAGCTGGGGCCC 21


RESULT 105
ADC52133/c
ID   ADC52133 standard; DNA; 40 BP.
XX
AC   ADC52133;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human heat shock protein 27 mutating PCR primer SEQ ID NO 2.
```

```
XX
KW   mitogen activated protein kinase-activated protein kinase; Cytostatic;
KW   cancer; cell dedifferentiation; MAPKAP; HSP27; heat shock protein 27;
KW   primer; ss; Human.
XX
OS   Homo sapiens.
XX
PN   JP2003061698-A.
XX
PD   04-MAR-2003.
XX
PF   24-AUG-2001; 2001JP-00254731.
XX
PR   24-AUG-2001; 2001JP-00254731.
XX
PA   (SANY ) SANKYO CO LTD.
XX
DR   WPI; 2003-648869/62.
XX
PT   Identifying inhibitor of cancer cell dedifferentiation for use in
PT   treating cancer, by measuring mitogen activated protein kinase-activated
PT   protein kinase substrate phosphorylation activity in presence of test
PT   compound.
XX
PS   Example 3; SEQ ID NO 2; 15pp; Japanese.
XX
CC   The invention relates to identifying an inhibitor of cancer cell
CC   dedifferentiation, comprising reacting mitogen activated protein kinase-
CC   activated protein kinase (MAPKAP), a substrate and ATP in the presence
CC   and absence of a test material and measuring the rate of decrease in
CC   substrate protein phosphorylation activity of the MAPKAP kinase in
CC   presence of test material with respect to the activity of the MAPKAP
CC   kinase in the absence of the test material. DNA coding for Mitogen
CC   activated protein kinase- activated protein kinase (MAPKAP) (GenBank
CC   Accession No. NM004635) was amplified by reverse transcription-polymerase
CC   chain reaction and inserted into pMIKNeo vector, by standard methods.
CC   This vector was transfected into Chinese Hamster Ovary (CHO) cells. The
CC   cells were cultured and MAPKAP was collected and purified from the cells.
CC   The MAPKAP obtained was cultured with wild type heat-shock protein (HSP)
CC   27, at 37 degrees C for 30 minutes, in the presence or absence of the
CC   test compound. The immune precipitation of wild type HSP27 and
CC   phosphorylation of HSP27 was measured, using anti-HSP27 antibody. The
CC   enzyme inhibition rate by the test compound was determined. The test
CC   material was identified as positive if the inhibition rate was 50 % or
CC   more. The present sequence is that of a PCR primer used to mutate human
CC   heat shock protein 27 (HSP27, GenBank Accession No. XM050410), to change
CC   three serine residues in the amino terminus at position 15, 78 and 82 in
CC   regions that are phosphorylated, to aspartic acid residues. The mutated
CC   protein is used in methods of the invention.
XX
SQ   Sequence 40 BP; 6 A; 16 C; 14 G; 4 T; 0 U; 0 Other;

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 40;
  Best Local Similarity   65.7%;  Pred. No. 1.1e+02;
  Matches   23;  Conservative    0;  Mismatches   12;  Indels    0;  Gaps    0;

Qy        337 CGCCCCGGACGAGCTGACGGTCAAGACCAAGGATG 371
              | || | | |||| || ||||| ||  |  || ||
Db         35 CCCCGCTGTCGAGTTGCCGGTCGAGCGCGCGGCTG 1


RESULT 106
ABN10675
ID   ABN10675 standard; DNA; 17 BP.
XX
AC   ABN10675;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10667.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 10667; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 73;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17


RESULT 107
```

```
ADB45924
ID   ADB45924 standard; DNA; 17 BP.
XX
AC   ADB45924;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #6247.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 762; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 5 A; 8 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 73;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||||||||| ||
Db          1 GATCACCATCCCAGCCA 17


RESULT 108
ADI48414
ID   ADI48414 standard; DNA; 17 BP.
XX
AC   ADI48414;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID917.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 917; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 5 A; 8 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 73;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||||||||| ||
Db          1 GATCACCATCCCAGCCA 17


RESULT 109
ADG71955/c
ID   ADG71955 standard; DNA; 17 BP.
XX
AC   ADG71955;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human NOVX related primer #3.
XX
KW   human; NOVX-associated disorder; NOVX; cancer; infectious disease;
KW   anorexia; Alzheimer's disease; Parkinson's disease; immune disorder;
KW   haematopoietic disorder; dyslipidaemia; diabetes; obesity;
```

KW metabolic syndrome X; tissue typing; vaccine; ss; primer.
XX
OS Homo sapiens.
XX
PN US2003232347-A1.
XX
PD 18-DEC-2003.
XX
PF 01-AUG-2002; 2002US-00211689.
XX
PR 08-AUG-2001; 2001US-0310795P.
PR 08-AUG-2001; 2001US-0310802P.
PR 09-AUG-2001; 2001US-0311292P.
PR 10-AUG-2001; 2001US-0311571P.
PR 10-AUG-2001; 2001US-0311594P.
PR 10-AUG-2001; 2001US-0311751P.
PR 13-AUG-2001; 2001US-0311979P.
PR 16-AUG-2001; 2001US-0312892P.
PR 17-AUG-2001; 2001US-0313201P.
PR 21-AUG-2001; 2001US-0314031P.
PR 29-AUG-2001; 2001US-0315853P.
PR 17-SEP-2001; 2001US-0322716P.
PR 21-SEP-2001; 2001US-0323944P.
PR 21-FEB-2002; 2002US-0359294P.
PR 28-FEB-2002; 2002US-0360890P.
PR 28-FEB-2002; 2002US-0361159P.
PR 16-APR-2002; 2002US-0372998P.
PR 16-APR-2002; 2002US-0373050P.
PR 15-MAY-2002; 2002US-0380970P.
PR 15-MAY-2002; 2002US-0380971P.
PR 16-MAY-2002; 2002US-0381030P.
XX
PA (ANDE/) ANDERSON D W.
PA (ALSO/) ALSOBROOK J P.
PA (BOLD/) BOLDOG F L.
PA (BURG/) BURGESS C E.
PA (CASM/) CASMAN S J.
PA (EDIN/) EDINGER S R.
PA (GANG/) GANGOLLI E A.
PA (GORM/) GORMAN L.
PA (GUOX/) GUO X S.
PA (KHRA/) KHRAMTSOV N V.
PA (LEPL/) LEPLEY D M.
PA (MACD/) MACDOUGALL J R.
PA (PENA/) PENA C E A.
PA (PEYM/) PEYMAN J A.
PA (PATT/) PATTURAJAN M.
PA (RIEG/) RIEGER D K.
PA (SHIM/) SHIMKETS R A.
PA (SMIT/) SMITHSON G.
PA (SPYT/) SPYTEK K A.
PA (VERN/) VERNET C A M.
PA (VOSS/) VOSS E Z.
PA (ZHON/) ZHONG M.
XX
PI Anderson DW, Alsobrook JP, Boldog FL, Burgess CE, Casman SJ;
PI Edinger SR, Gangolli EA, Gorman L, Guo XS, Khramtsov NV, Lepley DM;
PI Macdougall JR, Pena CEA, Peyman JA, Patturajan M, Rieger DK;
PI Shimkets RA, Smithson G, Spytek KA, Vernet CAM, Voss EZ, Zhong M;
XX
DR WPI; 2004-061271/06.
XX
PT New NOVX polypeptides and nucleic acids, useful for diagnosing,
PT preventing or treating NOVX-associated disorders, e.g. cancer, diabetes
PT or immune diseases, and in chromosome mapping, tissue typing or
PT pharmacogenomics.
XX
PS Example; SEQ ID NO 82; 115pp; English.
XX
CC The invention relates to a new isolated polypeptide. The polypeptide is
CC useful in the manufacture of a medicament for treating a syndrome
CC associated with a human disease selected from a pathology associated with
CC the polypeptide. These are used in diagnosing, treating or preventing
CC NOVX-associated disorders such as cancer, infectious diseases, anorexia,
CC Alzheimer's disease, Parkinson's disease, immune disorders,
CC haematopoietic disorders, dyslipidaemias, diabetes, obesity or metabolic
CC syndrome X. The nucleic acids are further used as hybridisation probes,
CC in chromosome mapping, tissue typing, preventive medicine, and
CC pharmacogenomics. The polypeptides are also useful as vaccines. The
CC present sequence is used in the exemplification of the invention.
XX
SQ Sequence 17 BP; 0 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 73;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 399 AGGAGCGGCAGGACGAG 415
|||||| ||||||||||
Db 17 AGGAGCAGCAGGACGAG 1

RESULT 110
ADJ87293/c
ID ADJ87293 standard; DNA; 17 BP.
XX
AC ADJ87293;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human G protein-coupled receptor NOV4 forward PCR primer SEQ ID NO:82.
XX
KW human; NOVX; G protein-coupled receptor; GPCR; antiarteriosclerotic;
KW hypotensive; dermatological; anorectic; cytostatic; antidiabetic;
KW haemostatic; immunosuppressive; anti-HIV; antiasthmatic;
KW antiinflammatory; neuroprotective; antimicrobial; anabolic;
KW eating disorder; immunomodulator; nootropic; antiparkinsonian;
KW antilipaemic; gene therapy; vaccine; cardiomyopathy; atherosclerosis;
KW hypertension; scleroderma; obesity; cancer; diabetes; haemophilia;
KW graft-versus-host disease; AIDS; asthma; Crohn's disease;
KW multiple sclerosis; infection; anorexia; cancer-associated cachexia;
KW neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
KW haematopoietic disorder; dyslipidaemia; wasting disorder;
KW chromosome mapping; tissue typing; preventive medicine; pharmacogenomic;
KW PCR; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004015060-A2.
XX
PD 19-FEB-2004.
XX
PF 02-AUG-2002; 2002WO-US024492.
XX
PR 08-AUG-2001; 2001US-0310795P.
PR 08-AUG-2001; 2001US-0310802P.
PR 09-AUG-2001; 2001US-0311292P.
PR 10-AUG-2001; 2001US-0311571P.
PR 10-AUG-2001; 2001US-0311594P.
PR 10-AUG-2001; 2001US-0311751P.
PR 13-AUG-2001; 2001US-0311979P.
PR 16-AUG-2001; 2001US-0312892P.
PR 17-AUG-2001; 2001US-0313201P.
PR 21-AUG-2001; 2001US-0314031P.
PR 29-AUG-2001; 2001US-0315853P.
PR 17-SEP-2001; 2001US-0322716P.
PR 21-SEP-2001; 2001US-0323944P.
PR 21-FEB-2002; 2002US-0359294P.
PR 28-FEB-2002; 2002US-0360890P.
PR 28-FEB-2002; 2002US-0361159P.
PR 16-APR-2002; 2002US-0372998P.
PR 16-APR-2002; 2002US-0373050P.
PR 15-MAY-2002; 2002US-0380970P.
PR 15-MAY-2002; 2002US-0380971P.
PR 16-MAY-2002; 2002US-0381030P.

```
PR   01-AUG-2002; 2002US-00211689.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Anderson DW,  Boldog FL,  Casman SJ,  Edinger SR,  Gangolli EA;
PI   Gerlach VL,  Gorman L,  Guo X,  Khramtsov NV,  Li L,  Macdougall JR;
PI   Pena CEA,  Peyman JA,  Patturajan M,  Shimkets RA,  Smithson G;
PI   Spytek KA,  Vernet CAM,  Voss EZ,  Zhong M;
XX
DR   WPI; 2004-191740/18.
XX
PT   New NOVX polypeptides and nucleic acids, useful for preventing or
PT   treating NOVX-associated disorders, e.g. cancer, diabetes,
PT   atherosclerosis, asthma, and in chromosome mapping, tissue typing or
PT   pharmacogenomics.
XX
PS   Example C; SEQ ID NO 82; 210pp; English.
XX
CC   The present sequence represents a PCR primer for a human NOVX polypeptide
CC   (I), which is a G protein-coupled receptor (GPCR). Also described: (1) a
CC   composition comprising (I) and a carrier; (2) a kit comprising, in one or
CC   more containers, the composition of (1); (3) determining the presence or
CC   amount of the above polypeptide (I) in a sample; (4) determining the
CC   presence of or predisposition to a disease associated with altered levels
CC   of expression of (I) in a first mammalian subject; (5) identifying an
CC   agent that binds to the polypeptide (I); (6) identifying a potential
CC   therapeutic agent for use in the treatment of a pathology, where the
CC   pathology is related to aberrant expression or aberrant physiological
CC   interactions of polypeptide (I); (7) screening for a modulator of
CC   activity of or of latency or predisposition to a pathology associated
CC   with the polypeptide (I); (8) modulating the activity of the polypeptide
CC   (I); (9) treating or preventing a pathology associated with polypeptide
CC   (I), or treating a pathological state in a mammal; (10) an isolated
CC   nucleic acid molecule (II) encoding (I); (11) a vector (III) comprising
CC   (II); (12) a cell (IV) comprising (III); (13) an antibody that
CC   immunospecifically binds to (I); (14) determining the presence of or
CC   amount of (II) in a sample; (15) determining the presence of or
CC   predisposition to a disease associated with altered levels of expression
CC   of the nucleic acid molecule (II) in a first mammalian subject; and (16)
CC   producing the above polypeptide (I). (I) has antiarteriosclerotic,
CC   hypotensive, dermatological, anorectic, cytostatic, antidiabetic,
CC   haemostatic, immunosuppressive, anti-HIV, antiasthmatic,
CC   antiinflammatory, neuroprotective, antimicrobial, anabolic, eating
CC   disorder, immunomodulator, nootropic, antiparkinsonian and antilipaemic
CC   activities, and can be used in gene therapy, and in vaccines. The NOVX
CC   polypeptide (I) is useful in the manufacture of a medicament for treating
CC   a syndrome associated with a human disease, the disease selected from a
CC   pathology associated with the polypeptide. (I) may also be used in
CC   diagnosing, treating or preventing NOVX-associated disorders such as
CC   cardiomyopathy, atherosclerosis, hypertension, scleroderma, obesity,
CC   cancer, diabetes, haemophilia, graft-versus-host disease, AIDS, asthma,
CC   Crohn's disease, multiple sclerosis, infections, anorexia, cancer-
CC   associated cachexia, neurodegenerative disorders (e.g. Alzheimer's
CC   disease or Parkinson's disease), haematopoietic disorders, dyslipidaemias
CC   and other wasting disorders associated with chronic diseases. The nucleic
CC   acids (II) are also used as hybridisation probes, in chromosome mapping,
CC   tissue typing, preventive medicine, and pharmacogenomics.
XX
SQ   Sequence 17 BP; 0 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 73;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        399 AGGAGCGGCAGGACGAG 415
              ||||||  ||||||||||
Db         17 AGGAGCAGCAGGACGAG 1


RESULT 111
ACN73765
ID   ACN73765 standard; DNA; 17 BP.
XX
AC   ACN73765;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:10667.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 10667; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63103
XX
SQ   Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 73;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
```

```
            ||||| ||||||||||||
Db          1 CAGAGCCAGCCAGCATG 17
```

RESULT 112
ADE29797
ID ADE29797 standard; RNA; 19 BP.
XX
AC ADE29797;
XX
DT 29-JAN-2004 (first entry)
XX
DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:419.
XX
KW short interfering nucleic acid; siNA; downregulation; inhibition;
KW mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW cytostatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW psoriasis; inflammatory bowel disease; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN WO2003072590-A1.
XX
PD 04-SEP-2003.
XX
PF 28-JAN-2003; 2003WO-US002510.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Usman N, Haeberli P, Chowrira B;
XX
DR WPI; 2003-689980/65.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
PS Example 3; SEQ ID NO 419; 164pp; English.
XX
CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNAs
CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC siNAs can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siNA which is used
CC in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 3 A; 10 C; 1 G; 0 T; 5 U; 0 Other;

```
  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   76.5%;  Pred. No. 80;
  Matches   13;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        471 ACCCCACCCAAGTTTCC 487
              ||||||||| ||:::||
Db          1 ACCCCACCCUAGUUUCC 17
```

RESULT 113
ADE29902/c
ID ADE29902 standard; RNA; 19 BP.
XX
AC ADE29902;
XX
DT 29-JAN-2004 (first entry)
XX
DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:524.
XX
KW short interfering nucleic acid; siNA; downregulation; inhibition;
KW mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW cytostatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW psoriasis; inflammatory bowel disease; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
PN WO2003072590-A1.
XX
PD 04-SEP-2003.
XX
PF 28-JAN-2003; 2003WO-US002510.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L, Usman N, Haeberli P, Chowrira B;
XX
DR WPI; 2003-689980/65.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
PS Example 3; SEQ ID NO 524; 164pp; English.
XX
CC The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNAs
CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC siNAs can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide

```
CC  polymorphisms). The present sequence represents a MAPK siNA which is used
CC  in the exemplification of the present invention.
XX
SQ  Sequence 19 BP; 5 A; 1 C; 10 G; 0 T; 3 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 80;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        471 ACCCCACCCAAGTTTCC 487
              |||||||||  |||||||
Db         19 ACCCCACCCTAGTTTCC 3


RESULT 114
ADO14933
ID  ADO14933 standard; RNA; 19 BP.
XX
AC  ADO14933;
XX
DT  01-JUL-2004  (first entry)
XX
DE  Human PDGFr-targeted siNA lower strand SEQ ID NO:364.
XX
KW  cytostatic; vasotropic; nephrotropic; cerebroprotective;
KW  treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
KW  bronchiolitis; glomerulonephritis; stroke; RNA interference;
KW  short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW  double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW  expression modulation; gene therapy; drug screening; diagnosis;
KW  therapeutic target identification; pharmacogenomics;
KW  gene function analysis; gene mapping; human;
KW  platelet derived growth factor receptor; PDGFr; ss.
XX
OS  Homo sapiens.
XX
PN  WO2003072704-A2.
XX
PD  04-SEP-2003.
XX
PF  05-FEB-2003; 2003WO-US003473.
XX
PR  20-FEB-2002; 2002US-0358580P.
PR  11-MAR-2002; 2002US-0363124P.
PR  06-JUN-2002; 2002US-0386782P.
PR  29-AUG-2002; 2002US-0406784P.
PR  05-SEP-2002; 2002US-0408378P.
PR  09-SEP-2002; 2002US-0409293P.
PR  15-JAN-2003; 2003US-0440129P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
XX
PI  Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR  WPI; 2003-731605/69.
XX
PT  New short interfering nucleic acid, useful e.g. for treatment and
PT  diagnosis of tumors, downregulates expression of the platelet-derived
PT  growth factor receptor gene.
XX
PS  Example 3; SEQ ID NO 364; 148pp; English.
XX
CC  The invention relates to short interfering nucleic acids (siNA) which
CC  downregulate expression of the human platelet-derived growth factor
CC  receptor (PDGFr) gene by RNA interference. The siNAs may or may not
CC  comprise ribonucleotides and may be double or single stranded. They
CC  further comprise sense and antisense regions, or alternatively are
CC  assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC  Specifically, the siNAs include short interfering RNA (siRNA, double-
CC  stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC  can be unmodified or chemically modified, can contain
CC  deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC  vector or enzymatically synthesised. The invention also relates to kits
CC  for the in vitro or in vivo delivery of siRNA; conjugates and/or
CC  complexes of siRNA; and vectors that express siNA. The siNAs are used to
CC  modulate expression of the PDGFr gene in cells, tissue explants or
CC  organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC  for the treatment of a variety of conditions. They may be used for
CC  treating leukaemia and solid tumours, restenosis, polycystic kidney
CC  disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
CC  useful for drug screening, diagnosis, therapeutic target identification
CC  and validation, genetic engineering, pharmacogenomics, studying gene
CC  function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC  The present sequence represents the lower strand of a human PDGFr-
CC  targeted double-stranded siNA, which is identical to the PDGFr transcript
CC  target sequence.
XX
SQ  Sequence 19 BP; 3 A; 11 C; 1 G; 0 T; 4 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 80;
  Matches   12;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        485 TCCTCCTCCCTGTCCCC 501
              :|| ||:|||:|:||||
Db          3 UCCACCUCCCUGUCCCC 19


RESULT 115
ADO14622/c
ID  ADO14622 standard; RNA; 19 BP.
XX
AC  ADO14622;
XX
DT  01-JUL-2004  (first entry)
XX
DE  Human PDGFr-targeted siNA upper strand SEQ ID NO:53.
XX
KW  cytostatic; vasotropic; nephrotropic; cerebroprotective;
KW  treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
KW  bronchiolitis; glomerulonephritis; stroke; RNA interference;
KW  short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW  double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW  expression modulation; gene therapy; drug screening; diagnosis;
KW  therapeutic target identification; pharmacogenomics;
KW  gene function analysis; gene mapping; human;
KW  platelet derived growth factor receptor; PDGFr; ss.
XX
OS  Homo sapiens.
XX
PN  WO2003072704-A2.
XX
PD  04-SEP-2003.
XX
PF  05-FEB-2003; 2003WO-US003473.
XX
PR  20-FEB-2002; 2002US-0358580P.
PR  11-MAR-2002; 2002US-0363124P.
PR  06-JUN-2002; 2002US-0386782P.
PR  29-AUG-2002; 2002US-0406784P.
PR  05-SEP-2002; 2002US-0408378P.
PR  09-SEP-2002; 2002US-0409293P.
PR  15-JAN-2003; 2003US-0440129P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
XX
PI  Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR  WPI; 2003-731605/69.
XX
PT  New short interfering nucleic acid, useful e.g. for treatment and
PT  diagnosis of tumors, downregulates expression of the platelet-derived
PT  growth factor receptor gene.
XX
PS  Example 3; SEQ ID NO 53; 148pp; English.
XX
```

```
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human platelet-derived growth factor
CC   receptor (PDGFr) gene by RNA interference. The siNAs may or may not
CC   comprise ribonucleotides and may be double or single stranded. They
CC   further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA, double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siRNA; conjugates and/or
CC   complexes of siRNA; and vectors that express siNA. The siNAs are used to
CC   modulate expression of the PDGFr gene in cells, tissue explants or
CC   organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC   for the treatment of a variety of conditions. They may be used for
CC   treating leukaemia and solid tumours, restenosis, polycystic kidney
CC   disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
CC   useful for drug screening, diagnosis, therapeutic target identification
CC   and validation, genetic engineering, pharmacogenomics, studying gene
CC   function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC   The present sequence represents the upper strand of a human PDGFr-
CC   targeted double-stranded siNA, which is identical to the PDGFr transcript
CC   target sequence.
XX
SQ   Sequence 19 BP; 4 A; 1 C; 11 G; 0 T; 3 U; 0 Other;

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 80;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        485 TCCTCCTCCCTGTCCCC 501
              ||| ||||||||||||
Db         17 TCCACCTCCCTGTCCCC 1


RESULT 116
AAX31550
ID   AAX31550 standard; DNA; 15 BP.
XX
AC   AAX31550;
XX
DT   21-MAY-1999  (first entry)
XX
DE   Tag sequence of a transcript increased in pancreatic cancer.
XX
KW   Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
KW   diagnosis; prognosis; treatment; ss.
XX
OS   Homo sapiens.
XX
PN   WO9853319-A2.
XX
PD   26-NOV-1998.
XX
PF   20-MAY-1998;   98WO-US010277.
XX
PR   21-MAY-1997;   97US-0047352P.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Vogelstein B,  Kinzler KW;
XX
DR   WPI; 1999-070161/06.
XX
PT   Use of isolated gene transcripts - useful for developing products for the
PT   diagnosis, prognosis and treatment of cancers, particularly colon and
PT   pancreatic cancer.
XX
PS   Claim 13; Page 60; 120pp; English.
XX
CC   AAX30947-31815 represent tag sequences of transcripts that are
CC   differentially expressed in colorectal cancer, in pancreatic cancer, or
CC   in both. The tag sequences can be used to identify genes by matching the
CC   tag to a gen data base member, or by using the tag sequences as probes to
CC   isolate unidentified genes from cDNA libraries. The tag sequences can
CC   also be used in a method for diagnosing colon or pancreatic cancer in a
CC   sample suspected of being neoplastic. The method comprises comparing the
CC   level of at least one transcript in a first sample of a tissue to a
CC   second sample, where the first sample is a colonic tissue suspected of
CC   being neoplastic and the second sample is a normal human colonic tissue.
CC   The transcript is identified by a tag selected from AAX30947-31815. The
CC   methods of the invention can be used in the diagnosis, prognosis and
CC   treatment of cancer
XX
SQ   Sequence 15 BP; 4 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        529 CATGCCCAAGCTAGC 543
              |||||||||||||||
Db          1 CATGCCCAAGCTAGC 15


RESULT 117
AAF46290
ID   AAF46290 standard; DNA; 15 BP.
XX
AC   AAF46290;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1129.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 41; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
```

```
CC   P45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 12 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        194 CCCCTGCCCCCCGCC 208
              |||||||||||||||
Db          1 CCCCTGCCCCCCGCC 15


RESULT 118
ABK32504
ID   ABK32504 standard; DNA; 15 BP.
XX
AC   ABK32504;
XX
DT   23-APR-2002  (first entry)
XX
DE   Human pancreatic cancer SAGE tag #56.
XX
KW   Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
KW   serial analysis of gene expression; diagnostic; prognostic; probe;
KW   cancer marker; ss.
XX
OS   Homo sapiens.
XX
PN   US6333152-B1.
XX
PD   25-DEC-2001.
XX
PF   20-MAY-1998;   98US-00081646.
XX
PR   20-MAY-1998;   98US-00081646.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Vogelstein B,  Kinzler KW,  Zhang L,  Zhou W;
XX
DR   WPI; 2002-153821/20.
XX
PT   New human nucleic acid containing specific SAGE tags, useful as
PT   diagnostic markers for cancer, also derived probes.
XX
PS   Disclosure; Col 69; 161pp; English.
XX
CC   The invention relates to an isolated, purified human nucleic acid (I)
CC   that has the same sequence as a mRNA found in humans and is a SAGE
CC   (serial analysis of gene expression) tag comprising a single stranded
CC   probe containing at least 10 consecutive nucleotides. SAGE tags, are
CC   diagnostic and prognostic markers of cancer, especially of the colon and
CC   pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
CC   SAGE tags of the invention
XX
SQ   Sequence 15 BP; 4 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.0%;  Score 15;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 73;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        529 CATGCCCAAGCTAGC 543
              |||||||||||||||
Db          1 CATGCCCAAGCTAGC 15


RESULT 119
AAQ65740/c
ID   AAQ65740 standard; DNA; 18 BP.
XX
AC   AAQ65740;
XX
DT   25-MAR-2003  (revised)
DT   19-DEC-1994  (first entry)
XX
DE   Type II procollagen sequencing primer CW-14.
XX
KW   Type II procollagen; COL2A1; amplification; primer;
KW   polymerase chain reaction; PCR; osteoarthritis; cartilage; ss.
XX
OS   Synthetic.
XX
PN   WO9411532-A1.
XX
PD   26-MAY-1994.
XX
PF   12-NOV-1993;   93WO-US010964.
XX
PR   13-NOV-1992;   92US-00977284.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI   Prockop DJ,  Ala-Kokko L,  Williams CJ,  Ritvaniemi P,  Baldwin C;
PI   Hopkinson I,  Ahmad NN;
XX
DR   WPI; 1994-183530/22.
XX
PT   Detecting genetic pre-disposition to osteoarthritis - and other diseases
PT   involving mutation in cartilage protein genes, by amplification and
PT   analysis of DNA and comparison with standards.
XX
PS   Claim 18; Page 20; 112pp; English.
XX
CC   Claim 18 claims primers for use in detecting mutations in a mammalian
CC   gene for a structural protein of cartilage comprising a sequence
CC   identified in Table I (Page 18-31). Table I includes 179 primer sequences
CC   (see AAQ65728-Q65906). The following details are given for primer CW-14:
CC   Region/exon: 11 Direction: sense Primer position: 1640 (Updated on 25-MAR
CC   -2003 to correct PN field.)
XX
SQ   Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 88;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        129 TGCCCCGGCTGCCGGAGG 146
              ||||| |||||| |||||
Db         18 TGCCCTGGCTGCAGGAGG 1


RESULT 120
AAF77820
ID   AAF77820 standard; DNA; 18 BP.
XX
AC   AAF77820;
XX
DT   29-MAY-2001  (first entry)
XX
DE   PCR primer BAR2.
XX
KW   PCR primer; gene amplification; ss.
XX
OS   Unidentified.
XX
PN   JP2001008680-A.
XX
PD   16-JAN-2001.
XX
```

```
PF   30-JUN-1999;   99JP-00185279.
XX
PR   30-JUN-1999;   99JP-00185279.
XX
PA   (SHMA ) SHIMADZU CORP.
XX
DR   WPI; 2001-248255/26.
XX
PT   Amplification of viral, bacterial or fungal nucleic acids, by adding
PT   biological sample of a host infected with a microbe directly to
PT   amplification solution containing polyamine, sulfated polysaccharide,
PT   dithiothreitol.
XX
PS   Example 3; Page 5; 7pp; Japanese.
XX
CC   The present invention relates to a method for gene amplification. The
CC   method is useful for direct nucleic acid amplification of bacterial,
CC   fungal, protozoal genes, viral genes including DNA, RNA or retrovirus
CC   genes or a cell containing a malignant neoplasm without pre-processing.
CC   Nucleic acid amplification is carried out quickly and sensitively.
CC   Nucleic acid synthesis is not inhibited by the presence of impurities.
CC   The present sequence is a PCR primer used in the method of the present
CC   invention
XX
SQ   Sequence 18 BP; 5 A; 1 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 88;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        366 AGGATGGCGTGGTGGAGA 383
              ||||||||||| |||||
Db          1 AGGATGGCGTGAGGGAGA 18


RESULT 121
AAD38938/c
ID   AAD38938 standard; DNA; 18 BP.
XX
AC   AAD38938;
XX
DT   23-SEP-2002  (first entry)
XX
DE   Human Her-2 antisense oligonucleotide, ISIS #27965.
XX
KW   Human; Her-2; epidermal growth factor receptor 2; infection; cancer;
KW   hyperproliferative disorder; prophylaxis; inflammation; antisense;
KW   tumour; gene therapy; phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .18
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone"
FT   modified_base    1. .4
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    2
FT                    /*tag=  d
FT                    /mod_base= m5c
FT   modified_base    5
FT                    /*tag=  e
FT                    /mod_base= m5c
FT   modified_base    6
FT                    /*tag=  f
FT                    /mod_base= m5c
FT   modified_base    10
FT                    /*tag=  g
FT                    /mod_base= m5c
FT   modified_base    11
FT                    /*tag=  h
FT                    /mod_base= m5c
FT   modified_base    14
FT                    /*tag=  i
FT                    /mod_base= m5c
FT   modified_base    15. .18
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    15
FT                    /*tag=  j
FT                    /mod_base= m5c
FT   modified_base    16
FT                    /*tag=  k
FT                    /mod_base= m5c
XX
PN   WO200222636-A1.
XX
PD   21-MAR-2002.
XX
PF   12-SEP-2001; 2001WO-US028572.
XX
PR   15-SEP-2000; 2000US-00663834.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Cowsert LM;
XX
DR   WPI; 2002-471192/50.
XX
PT   Novel antisense oligonucleotide which modulates the expression of Human
PT   Epidermal Growth Factor receptor, Her2, is useful for treating tumors
PT   inflammation or to prevent infection in humans.
XX
PS   Claim 1; Page 89; 116pp; English.
XX
CC   The invention relates to antisense compounds targetted to a nucleic acid
CC   molecule encoding Her2 (human Epidermal Growth Factor receptor 2) that
CC   specifically hybridises with and inhibits the expression of Her2.
CC   Antisense compounds of the invention are used for treating diseases or
CC   conditions associated with Her2 such as hyperproliferative disorders e.g.
CC   lung, breast, gastric, oesophageal, colon, bladder, salivary, neural or
CC   cardiac cancer. They are also useful prophylactically e.g. to prevent or
CC   delay infection, inflammation and tumour formation. The invention is also
CC   used in gene therapy. The present sequence is an antisense
CC   oligonucleotide targetted to human Her-2
XX
SQ   Sequence 18 BP; 4 A; 8 C; 6 G; 0 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 88;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTGC 140
              |||||||| | |||||||
Db         18 TCGGGCTGGCTCGGCTGC 1


RESULT 122
ABK98126
ID   ABK98126 standard; DNA; 18 BP.
XX
AC   ABK98126;
XX
DT   07-OCT-2002  (first entry)
XX
DE   Triple helix forming associated oligonucleotide #15.
XX
KW   Triple-helix formation; purine-rich target sequence; double-helix DNA;
KW   gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW   pathogenic bacteria; virus; replication; virulence; cancer;
KW   oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
```

XX
OS Synthetic.
XX
PN US6403302-B1.
XX
PD 11-JUN-2002.
XX
PF 16-DEC-1993; 93US-00168920.
XX
PR 17-SEP-1992; 92US-00946976.
XX
PA (CALY) CALIFORNIA INST OF TECHNOLOGY.
XX
PI Dervan PB, Beal PA;
XX
DR WPI; 2002-536030/57.
XX
PT A triple-helix comprising a double helical nucleic acid (DHNA) and an
PT oligonucleotide which binds in parallel and antiparallel orientation,
PT respectively, for targetting sequences on alternate strands of DHNA to
PT control gene expression.
XX
PS Example 7; Col 41; 108pp; English.
XX
CC The present invention relates to methods and oligonucleotides for forming
CC a triple-helix comprising a double helical nucleic acid comprising first
CC and second substantially complementary strands, and an oligonucleotide
CC bound to a purine-rich target sequence within the double helical nucleic
CC acid, where the oligonucleotide binds in a parallel and antiparallel
CC orientation, respectively, to target sequences on alternate strands of
CC the double helical nucleic acid. The method has therapeutic applications,
CC where gene expression is controlled by selective triple-helix formation
CC within expression regulatory sequences of a target gene. The
CC oligonucleotides can be used to form triple-helices, and are useful to
CC detect the presence or absence of specific sequences within genomic DNA
CC for diagnostic and therapeutic purposes. The oligonucleotides can be
CC selected to specifically bind to pathogenic double-stranded DNA including
CC specific sequences required by pathogenic bacteria or viruses for
CC replication or virulence, reducing their pathogenicity. Alternatively,
CC the oligonucleotide can be chosen to target a unique sequence of the
CC pathogen which is not found in the genome of pathogen's host. The
CC oligonucleotides can be used in cancer treatment by way of triple-helix
CC suppression of specific oncogenes including those of endogenous or viral
CC origin. Such therapeutic oligonucleotides are capable of forming triple-
CC helices with such sequences in cancerous cells containing the activated
CC oncogene, so preferentially killing or repressing the cancer causing
CC cell. The present sequence represents an oligonucleotide used in the
CC methods of the present invention
XX
SQ Sequence 18 BP; 0 A; 2 C; 0 G; 14 T; 0 U; 2 Other;

```
  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 88;
  Matches   15;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        721 TTTATCTTCTGTTTTTCT 738
              |||:| ||||:|||||||
Db          1 TTTDTTTTCTDTTTTTCT 18
```

RESULT 123
ABS66626/c
ID ABS66626 standard; DNA; 18 BP.
XX
AC ABS66626;
XX
DT 29-NOV-2002 (first entry)
XX
DE TN-KpnI-fo PCR primer.
XX
KW Scaffold protein; C-type lectin-like domain; CTLD; alpha-helix;
KW beta-strand; connecting segment; 14loop region; tetranectin;
KW ligand-binding specificity; human; PCR; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200248189-A2.
XX
PD 20-JUN-2002.
XX
PF 13-DEC-2001; 2001WO-DK000825.
XX
PR 13-DEC-2000; 2000DK-00001872.
PR 28-FEB-2001; 2001US-0272098P.
XX
PA (BORE-) BOREAN PHARMA AS.
XX
PI Etzerodt M, Holtet TL, Graversen NJH, Thogersen HC;
XX
DR WPI; 2002-643278/69.
XX
PT Protein comprising a variant of model C-type lectin-like domains (CTLD),
PT in which alpha helices, beta-strands, connecting segments are conserved
PT to maintain CTLD scaffold structure, while the loop region is altered.
XX
PS Example 5; Page 157; 168pp; English.
XX
CC The present invention relates to a new protein with scaffold structure of
CC C-type lectin-like domains (CTLD). The invention comprises a variant of a
CC model CTLD where alpha-helices and beta-strands and connecting segments
CC are conserved such that scaffold structure of C-type lectin-like domains
CC (CTLD) is substantially maintained, while the 14loop region is altered by
CC amino acid substitution, deletion, insertion or their combination. The
CC invention is useful for preparing a library of nucleotide sequences
CC encoding related proteins by randomising part or all of the nucleic acid
CC sequence encoding the loop region of its CTLD. The artificial CTLD
CC protein products are preferable to antibody derivatives as each binding
CC site is a single structurally autonomous protein domain. When used as
CC components of compositions to be used for in vivo diagnostic or
CC therapeutic purposes, artificial CTLD protein products constructed on the
CC basis of human CTLDs are virtually identical to the corresponding natural
CC CTLD protein already present in the body and are therefore less
CC immunogenic to the patient. They also have a smaller size, and thus
CC provide tissue penetration and distribution, as well as shorter half life
CC in circulation. Since murine and human tetranectin are identical in
CC structure, straightforward swapping of polypeptide segments defining
CC ligand-binding specificity between murine and human tetranectin
CC derivatives may be achieved. The present nucleic acid sequence represents
CC an oligonucleotide used in the methods of the invention
XX
SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

```
  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 88;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         86 GACTGGTACCCGCATAGC 103
              ||| |||||||||||  ||
Db         18 GACCGGTACCCGCATCGC 1
```

RESULT 124
ABZ98168
ID ABZ98168 standard; DNA; 18 BP.
XX
AC ABZ98168;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human CD23 + A1261 oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13410; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 88;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3 CACGAGGAGCAGAGTCAG 20
|| ||| ||||||||||
Db 1 CAGGAGAAGCAGAGTCAG 18

RESULT 125
ABD31199
ID ABD31199 standard; DNA; 18 BP.
XX
AC ABD31199;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human CD23-derived oligonucleotide SEQ ID 13410.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 13410; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 88;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3 CACGAGGAGCAGAGTCAG 20
|| ||| ||||||||||
Db 1 CAGGAGAAGCAGAGTCAG 18

RESULT 126
ADJ60033

```
ID   ADJ60033 standard; DNA; 18 BP.
XX
AC   ADJ60033;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Oligonucleotide associated to CD23-X04772 #27.
XX
KW   interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW   airway inflammation; allergy; asthma; impeded respiration;
KW   cystic fibrosis; acute respiratory distress syndrome;
KW   pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO2004011613-A2.
XX
PD   05-FEB-2004.
XX
PF   25-JUL-2003; 2003WO-US023509.
XX
PR   29-JUL-2002; 2002US-0399076P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Tang L,  Sandrasagra A,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-203534/19.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
PS   Claim 2; SEQ ID NO 889; 85pp; English.
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g.
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 88;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          3 CACGAGGAGCAGAGTCAG 20
              || ||| ||||||||||
Db          1 CAGGAGAAGCAGAGTCAG 18


RESULT 127
ADL91732
ID   ADL91732 standard; DNA; 18 BP.
XX
AC   ADL91732;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Collagen type IX alpha 3 (SYX 4) control S-oligo, SEQ ID NO:133.
XX
KW   Synovial sarcoma; SYX; sarcoma-associated gene; drug screening;
KW   Frizzled homologue 10; FZD10-associated disease; colorectal cancer;
KW   gastric cancer; chronic myeloid leukaemia; acute myeloid leukaemia.;
KW   FZD10 antibody; diagnosis; prognosis; prevention; cytostatic;
KW   gene therapy; control oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004020668-A2.
XX
PD   11-MAR-2004.
XX
PF   21-AUG-2003; 2003WO-JP010591.
XX
PR   30-AUG-2002; 2002US-0407506P.
PR   11-JUL-2003; 2003US-0486195P.
XX
PA   (ONCO-) ONCOTHERAPY SCI INC.
PA   (UYTY ) UNIV TOKYO.
XX
PI   Nakamura Y,  Katagiri T;
XX
DR   WPI; 2004-239208/22.
XX
PT   Use of a compound or composition for diagnosing, treating or preventing
PT   synovial sarcoma or a disease associated with Frizzled homologue 10, e.g.
PT   colorectal cancer, gastric cancer, chronic myeloid leukemia or acute
PT   myeloid leukemia.
XX
PS   Example 4; SEQ ID NO 133; 143pp; English.
XX
CC   The invention relates to the use of a compound or composition for
CC   diagnosing, prognosing, treating or preventing synovial sarcoma or a
CC   Frizzled homologue 10 (FZD10)-associated disease in a patient. The
CC   invention encompasses the use of sarcoma-associated genes designated SYX
CC   1-26 or their encoded proteins in diagnosing of synovial sarcoma and in
CC   screening for compounds for treating or preventing this condition; and
CC   the use of antibodies specific for FZD10 (FZD10 is also referred to as
CC   SYX 1 in the specification) for diagnosing, treating or preventing FZD10-
CC   associated diseases. The compound, composition and methods of the
CC   invention are useful for diagnosing, treating or preventing synovial
CC   sarcoma or FZD10-associated diseases, such as colorectal cancer, gastric
CC   cancer, chronic myeloid leukaemia or acute myeloid leukaemia. Sequences
CC   ADL91688-ADL91751 represent antisense and control S-oligonucleotides used
CC   in a study of antisense-mediated inhibition of the expression of synovial
CC   sarcoma-associated genes.
XX
SQ   Sequence 18 BP; 4 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 88;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        100 TAGCCGCCTCTTCGACCA 117
              || | ||||||||||||||
Db          1 TAACTGCCTCTTCGACCA 18


RESULT 128
ADO45523
ID   ADO45523 standard; DNA; 18 BP.
XX
AC   ADO45523;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Human oligonucleotide #889.
XX
KW   Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW   CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
```

```
KW   tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW   lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW   asthma; lung allergy; inflammation; inflammatory disease;
KW   airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW   chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW   acute respiratory distress syndrome; pulmonary hypertension;
KW   lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS   Homo sapiens.
XX
PN   US2004049022-A1.
XX
PD   11-MAR-2004.
XX
PF   25-JUL-2003; 2003US-00627930.
XX
PR   23-APR-2002; 2002WO-US013135.
PR   23-APR-2002; 2002WO-US013143.
XX
PA   (NYCE/) NYCE J W.
PA   (SAND/) SANDRASAGRA A.
PA   (TANG/) TANG L.
PA   (AGUI/) AGUILAR D.
PA   (MILL/) MILLER S.
PA   (SHAH/) SHAHABUDDIN S.
PA   (LUHH/) LU H.
PA   (CONG/) CONG H.
XX
PI   Nyce JW,  Sandrasagra A,  Tang L,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-293804/27.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT   RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT   asthma.
XX
PS   Claim 2; SEQ ID NO 889; 174pp; English.
XX
CC   The invention relates to oligonucleotides anti-sense to an initiation
CC   codon, coding region, 5' or 3' intron-exon junction, intron or region
CC   with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC   chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC   -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC   tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC   also relates to a method of screening a candidate compound that binds to
CC   one or more nucleic acid target(s) or expressed product(s), for the
CC   prevention and/or treatment of a respiratory or lung disease. The
CC   oligonucleotides are useful for reducing or inhibiting expression of a
CC   gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC   CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC   tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC   useful for preventing or treating a respiratory or lung disease. The
CC   respiratory or lung disease is associated with hyper-responsiveness to
CC   and/or increased levels of, adenosine and/or levels of adenosine A
CC   receptor(s), and/or asthma and/or lung allergies associated with
CC   inflammation or an inflammatory disease. The respiratory or lung disease
CC   is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC   cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC   allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC   hypertension, lung inflammation, bronchitis, airway obstruction or
CC   bronchoconstriction. This sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 88;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          3 CACGAGGAGCAGAGTCAG 20
              || ||| ||||||||||
Db          1 CAGGAGAAGCAGAGTCAG 18


RESULT 129
ADC03006/c
ID   ADC03006 standard; DNA; 16 BP.
XX
AC   ADC03006;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Ex vivo stem-cell expansion related polynucleotide #441.
XX
KW   cytostatic; antianaemic; immunomodulator; immunostimulant;
KW   immunosuppressive; antiinflammatory; interleukin agonist 3;
KW   interleukin antagonist 3; gene therapy; ex vivo expansion of stem cell;
KW   modified human interleukin-3; cell proliferatiion;
KW   acute myelogenous leukaemia cell proliferation; TF-1 cell proliferation;
KW   methylcellulose assay; haematopoietic disorder; cancer;
KW   acute myelogenous leukaemia; B lymphoid cancer; leukopenia; neutropenia;
KW   aplastic anaemia; Chediak-Higashi's syndrome;
KW   systemic lupus erythematosus; myelodysplastic syndrome; myelofibrosis;
KW   bone marrow; blood cell activation; blood cell growth; ds.
XX
OS   Synthetic.
XX
PN   US6479261-B1.
XX
PD   12-NOV-2002.
XX
PF   15-NOV-1995;   95US-00559390.
XX
PR   24-NOV-1992;   92US-00981044.
PR   22-NOV-1993;   93WO-US011198.
PR   06-APR-1995;   95US-00411796.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Bauer SC,  Abrams MA,  Braford-Goldberg SR,  Caparon MH,  Easton AM;
PI   Klein BK,  Mckearn JP,  Olins P,  Paik K,  Polazzi J,  Thomas JW;
XX
DR   WPI; 2003-655574/62.
XX
PT   Selective ex vivo expansion of stem cells, useful for treating a patient
PT   having hematopoietic disorder, e.g. leukemia, neutropenia or aplastic
PT   anemia, comprises using recombinant human interleukin-3 variant or mutant
PT   proteins.
XX
PS   Example 66; SEQ ID NO 466; 288pp; English.
XX
CC   The invention describes selective ex vivo expansion of stem cells
CC   comprising separating stem cells from other cells, culturing the cells
CC   with modified human interleukin-3 polypeptide with at least 3 times
CC   greater cell proliferative activity than native human interleukin-3 in at
CC   least one assay selected from the group of acute myelogenous leukaemia
CC   cell proliferation, TF-1 cell proliferation, and methylcellulose assay,
CC   and harvesting the cultured cells. The method is useful for selective ex
CC   vivo expansion of stem cells. The recombinant human interleukin-3 variant
CC   or mutant proteins are useful for treating a patient having a
CC   haematopoietic disorder, such as cancer (e.g. acute myelogenous leukaemia
CC   or certain types of B lymphoid cancers), leukopenia, neutropenia,
CC   aplastic anaemia, Chediak-Higashi's syndrome, systemic lupus
CC   erythematosus, myelodysplastic syndrome, or myelofibrosis. The
CC   interleukin-3 muteins are also useful as antagonists for producing
CC   antibodies used in immunoassay and immunotherapy protocols, or for
CC   stimulating bone marrow and blood cell activation and growth before
CC   infusion into patients. This sequence represents an ex vivo stem cell
CC   expansion method associated polynucleotide.
XX
SQ   Sequence 16 BP; 5 A; 1 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 88;
```

```
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 130
ADI58681/c
ID   ADI58681 standard; DNA; 16 BP.
XX
AC   ADI58681;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human interleukin 3 expressing vector related DNA seq id 466.
XX
KW   immunostimulant; antianemic; immunomodulator; antiinflammatory;
KW   dermatological; immunosuppressive; cytostatic; neuroprotective;
KW   gene therapy; interleukin-agonist-3; cultured stem cell;
KW   ex-vivo cell expansion; interleukin-3 mutant; aplastic anaemia;
KW   cyclic neutropenia; idiopathic neutropenia; Chediak-Higashi syndrome;
KW   systemic lupus erythematosus; leukaemia; myelodysplastic syndrome;
KW   myelofibrosis; interleukin 3; IL-3; mutagenesis; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   US2004018618-A1.
XX
PD   29-JAN-2004.
XX
PF   19-JUN-2002; 2002US-00179940.
XX
PR   24-NOV-1992;   92US-00981044.
PR   22-NOV-1993;   93WO-US011198.
PR   06-APR-1995;   95US-00411796.
PR   15-NOV-1995;   95US-00559390.
XX
PA   (BAUE/) BAUER S C.
PA   (ABRA/) ABRAMS M A.
PA   (BRAF/) BRAFORD-GOLDBERG S R.
PA   (CAPA/) CAPARON M H.
PA   (EAST/) EASTON A M.
PA   (KLEI/) KLEIN B K.
PA   (MCKE/) MCKEARN J P.
PA   (OLIN/) OLINS P.
PA   (PAIK/) PAIK K.
PA   (POLA/) POLAZZI J.
PA   (THOM/) THOMAS J W.
XX
PI   Bauer SC,  Abrams MA,  Braford-Goldberg SR,  Caparon MH,  Easton AM;
PI   Klein BK,  Mckearn JP,  Olins P,  Paik K,  Polazzi J,  Thomas JW;
XX
DR   WPI; 2004-122043/12.
XX
PT   Culturing stem cells using a recombinant human interleukin-3 mutant
PT   polypeptide, useful for treating aplastic anemia, neutropenia, Chediak-
PT   Higashi syndrome, systemic lupus erythematosus, leukemia and
PT   myelodysplastic syndrome.
XX
PS   Example 65; SEQ ID NO 466; 328pp; English.
XX
CC   The invention describes cultured stem cells obtained by a method for
CC   selective ex-vivo expansion of stem cells comprising separating stem
CC   cells from other cells, culturing the separated stem cells with a
CC   selected media which comprises a human interleukin-3 mutant polypeptide
CC   comprising defined amino acid sequences SEQ ID NO 15 or 19 given in the
CC   specification, and harvesting the cultured cells. The methods and
CC   compositions of the present invention are useful for treating aplastic
CC   anaemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi
CC   syndrome, systemic lupus erythematosus, leukaemia, myelodysplastic
CC   syndrome and myelofibrosis. This sequence represents a DNA used in the
CC   construction of human interleukin 3 (IL-3) mutants.
XX
SQ   Sequence 16 BP; 5 A; 1 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 88;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 131
AAV92679
ID   AAV92679 standard; RNA; 17 BP.
XX
AC   AAV92679;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Human A-Raf substrate position 2408.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T,  Matulic-Adamic J,  Reynolds M,  Kisich K,  Bellon L;
PI   Parry T,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Burgin A;
PI   Thompson J,  Workman CT,  Beaudry A,  Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 177; Page 162; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
```

```
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 17 BP; 1 A; 8 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 93;
  Matches   12;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        684 TGTGCCTCCCCCGCCA 699
              :|:| |:||||||||||
Db          2 UGUGUCUCCCCCGCCA 17


RESULT 132
ABN10674
ID   ABN10674 standard; DNA; 17 BP.
XX
AC   ABN10674;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10666.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 10666; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 7 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 93;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 133
ABN10676
ID   ABN10676 standard; DNA; 17 BP.
XX
AC   ABN10676;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10668.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
```

XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 10668; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

```
  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 93;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||
Db          1 AGAGCCAGCCAGCATG 16
```

RESULT 134
ABZ61415/c
ID ABZ61415 standard; RNA; 17 BP.
XX
AC ABZ61415;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #206.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 115; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 2 A; 7 C; 8 G; 0 T; 0 U; 0 Other;

```
  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 93;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        227 GTGGCCGCGCCCGCCT 242
              ||||||||| ||||||
Db         16 GTGGCCGCGGCCGCCT 1
```

RESULT 135
ADF64299
ID ADF64299 standard; DNA; 17 BP.
XX
AC ADF64299;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2203.
XX
KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
OS Homo sapiens.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX
PR 10-DEC-2001; 2001US-0339764P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Guo J;
XX
DR WPI; 2003-532916/50.
XX
PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT composition for treating or preventing a disorder associated with
PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS Example 2; SEQ ID NO 2203; 164pp; English.
XX
CC The invention relates to a novel isolated nucleic acid that encodes a
CC protein with a chromatin organisation modifier (CHROMO) domain. The
CC polynucleotide of the invention demonstrates cytostatic activity and may
CC be useful for preparing a composition for treating or preventing a
CC disorder associated with decreased or increased expression or activity of
CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC during gene therapy and vaccine production procedures. The current

```
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 93;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              ||| ||||||||||||
Db          2 CTGAGGGGCCCCAGCT 17


RESULT 136
ADF64300
ID   ADF64300 standard; DNA; 17 BP.
XX
AC   ADF64300;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2204.
XX
KW   chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW   prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW   human; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO2003050284-A1.
XX
PD   19-JUN-2003.
XX
PF   22-NOV-2002; 2002WO-US037506.
XX
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 2204; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 2 A; 7 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 93;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              ||| ||||||||||||
Db          1 CTGAGGGGCCCCAGCT 16


RESULT 137
ADL47964
ID   ADL47964 standard; RNA; 17 BP.
XX
AC   ADL47964;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human IKK-gamma substrate sequence #474.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 1497; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human IKK-
CC   gamma substrate sequence.
XX
SQ   Sequence 17 BP; 0 A; 13 C; 2 G; 0 T; 2 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 93;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        193 CCCCCTGCCCCCCGCC 208
              |||| :||||||||||
Db          1 CCCCUUGCCCCCCGCC 16
```

```
RESULT 138
ACN73764
ID   ACN73764 standard; DNA; 17 BP.
XX
AC   ACN73764;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:10666.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 10666; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63103
XX
SQ   Sequence 17 BP; 5 A; 7 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 93;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 139
ACN73766
ID   ACN73766 standard; DNA; 17 BP.
XX
AC   ACN73766;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:10668.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 10668; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
```

```
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63103
XX
SQ   Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 93;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 140
AAZ48501
ID   AAZ48501 standard; DNA; 18 BP.
XX
AC   AAZ48501;
XX
DT   31-MAR-2000  (first entry)
XX
DE   Human TNFR1 mRNA inhibiting antisense oligo ISIS# 18894.
XX
KW   Tumour necrosis factor receptor type 1; TNFR1; antisense; infection;
KW   inflammation; tumour formation; TNFR1; anticancer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US6007995-A.
XX
PD   28-DEC-1999.
XX
PF   26-JUN-1998;   98US-00106038.
XX
PR   26-JUN-1998;   98US-00106038.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Baker BF,  Cowsert LM;
XX
DR   WPI; 2000-105333/09.
XX
PT   Antisense inhibition of tumor necrosis factor type 1 expression for
PT   diagnosis, treatment and prevention of disease, particularly tumors.
XX
PS   Example 10; Col 24; 34pp; English.
XX
CC   The invention provides antisense compounds targeted to human tumour
CC   necrosis factor receptor type 1 (TNFR1) RNA. These antisense compounds
CC   can be used in a method of inhibiting the expression of TNFR1 human cells
CC   or tissues. The antisense compounds specifically hybridize with one or
CC   more nucleic acids encoding TNFR1 modulating the function of nucleic acid
CC   molecules encoding TNFR1, ultimately modulating the amount of TNFR1
CC   produced. The antisense compounds and method are useful as research
CC   reagents and diagnostics, and in the treatment and prophylaxis of
CC   infection, inflammation or tumour formation. Sequences AAZ48482-565
CC   represent antisense oligos used for inhibition of the human TNFR1 mRNA
XX
SQ   Sequence 18 BP; 1 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 97;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || ||||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 141
AAZ71739/c
ID   AAZ71739 standard; DNA; 18 BP.
XX
AC   AAZ71739;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:6095.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 1530; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 18 BP; 9 A; 4 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 97;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGA 716
              |||||||||||| |||
Db         18 CTGTGTGTTCTTCTGA 3


RESULT 142
AAA87651
ID   AAA87651 standard; DNA; 18 BP.
XX
AC   AAA87651;
XX
```

```
DT   08-JAN-2001  (first entry)
XX
DE   Rat hepatocyte carcinogenesis biomarker nucleic acid SEQ ID NO:575.
XX
KW   Rat; phenobarbitol; carcinogenesis marker; carcinogenesis; detection;
KW   identification; carcinogenic; probe; primer; ds.
XX
OS   Rattus norvegicus.
XX
PN   WO200044902-A2.
XX
PD   03-AUG-2000.
XX
PF   28-JAN-2000; 2000WO-US000503.
XX
PR   29-JAN-1999;   99US-0118078P.
XX
PA   (SEAR ) SEARLE & CO G D.
XX
PI   Bunch RT,  Curtis SW,  Rodi CP,  Morris DL;
XX
DR   WPI; 2000-505977/45.
XX
PT   New nucleic acid encoding a carcinogenic biomarker, induced by
PT   phenobarbitol treatment of rat hepatocytes, useful for identifying
PT   carcinogenic compounds.
XX
PS   Claim 1; Page 239; 240pp; English.
XX
CC   AAA87080 to AAA87656 represent nucleic acid sequences (N1) encoding a
CC   carcinogenesis biomarkers. The carcinogenesis biomarkers are induced by
CC   treating rat hepatocytes with phenobarbitol. The nucleic acids are useful
CC   for identifying carcinogenic compounds. The nucleic acid molecules can be
CC   used to derive probes and/or primers for detecting or inducing
CC   carcinogenesis, respectively
XX
SQ   Sequence 18 BP; 7 A; 5 C; 6 G; 0 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 97;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        388 CGGCAAGCACGAGGAG 403
              ||||||||||||| |||
Db          3 CGGCAAGCACGAAGAG 18


RESULT 143
ABT04997
ID   ABT04997 standard; DNA; 18 BP.
XX
AC   ABT04997;
XX
DT   11-OCT-2002  (first entry)
XX
DE   TNFR1 expression modulation related antisense oligo SEQ ID No 27.
XX
KW   Antisense compound; tumour necrosis factor receptor 1; liver disease;
KW   TNFR1; hepatitis; liver injury; hyperproliferative disorder; cancer;
KW   human; ds.
XX
OS   Homo sapiens.
XX
PN   WO200248168-A1.
XX
PD   20-JUN-2002.
XX
PF   22-OCT-2001; 2001WO-US051224.
XX
PR   24-OCT-2000; 2000US-00695451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Baker BF,  Cowsert LM,  Zhang H,  Dean NM;
XX
DR   WPI; 2002-583481/62.
XX
PT   Novel antisense compound targeted to nucleic acid molecule encoding tumor
PT   necrosis factor receptor 1 (TNFR1), useful for treating humans having
PT   disease associated with TNFR1 e.g. hepatitis, liver injury, liver cancer.
XX
PS   Example 10; Page 44; 121pp; English.
XX
CC   The invention relates to an antisense compound 8 to 30 nucleotides in
CC   length targeted to nucleic acid molecule encoding tumour necrosis factor
CC   receptor 1 (TNFR1), where the antisense compound inhibits expression of
CC   TNFR1. The antisense compound is useful for inhibiting the expression of
CC   TNFR1 in cells or tissues. The antisense compound is also useful for
CC   treating an animal (preferably human) having a disease or condition
CC   associated with TNFR1, e.g. a liver disease (such as hepatitis, or liver
CC   injury) or a hyperproliferative disorder such as cancer, by inhibiting
CC   the expression of TNFR1. The antisense compound is useful for
CC   diagnostics, therapeutics, prophylaxis and as research reagents and kits.
CC   This polynucleotide sequence represents a human oligonucleotide relating
CC   to the TNFR1 of the invention
XX
SQ   Sequence 18 BP; 1 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 97;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || |||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 144
ADR06029
ID   ADR06029 standard; DNA; 18 BP.
XX
AC   ADR06029;
XX
DT   21-OCT-2004  (first entry)
XX
DE   Human TNFR1 antisense oligonucleotide seqid 27.
XX
KW   cytostatic; gene therapy; apoptosis inhibitor;
KW   radiation-induced apoptosis; tumour necrosis factor receptor 1; TNFR1;
KW   human; antisense oligonucleotide; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone"
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Optionally 2'-O-Methoxyethyl (2'-MOE)
FT                   nucleotides"
FT   modified_base   15. .18
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Optionally 2'-O-Methoxyethyl (2'-MOE)
FT                   nucleotides"
XX
PN   US2004147471-A1.
XX
PD   29-JUL-2004.
XX
PF   06-NOV-2003; 2003US-00702817.
XX
PR   26-JUN-1998;   98US-00106038.
```

```
PR   17-JUN-1999;   99WO-US013763.
PR   24-OCT-2000; 2000US-00695451.
XX
PA   (ZHAN/) ZHANG H.
XX
PI   Zhang H;
XX
DR   WPI; 2004-561407/54.
XX
PT   Inhibiting radiation-induced apoptosis in a cell or tissue comprises
PT   administering to the cell or tissue an antisense oligonucleotide targeted
PT   to a nucleic acid molecule encoding tumor necrosis factor receptor 1.
XX
PS   Example 10; SEQ ID NO 27; 24pp; English.
XX
CC   The invention describes a method of inhibiting radiation-induced
CC   apoptosis in a cell or tissue comprising administering to the cell or
CC   tissue an antisense oligonucleotide of 8-30 nucleotides in length
CC   targeted to a nucleic acid molecule encoding tumour necrosis factor
CC   receptor 1 (TNFR1). The method and antisense oligonucleotides are useful
CC   for inhibiting radiation-induced apoptosis in a cell or tissue, and for
CC   treating diseases associated with the expression of TNFR1. This sequence
CC   represents a human tumour necrosis factor receptor 1 (TNFR1) antisense
CC   oligonucleotide.
XX
SQ   Sequence 18 BP; 1 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 97;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || |||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 145
AAF46289
ID   AAF46289 standard; DNA; 15 BP.
XX
AC   AAF46289;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1128.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 41; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 11 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        194 CCCCTGCCCCCCGC 207
              ||||||||||||||
Db          2 CCCCTGCCCCCCGC 15


RESULT 146
AAF46291
ID   AAF46291 standard; DNA; 15 BP.
XX
AC   AAF46291;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1130.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 41; 201pp; English.
```

```
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 0 A; 12 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        195 CCCTGCCCCCCGCC 208
              ||||||||||||||
Db          1 CCCTGCCCCCCGCC 14


RESULT 147
ADF32131/c
ID   ADF32131 standard; DNA; 15 BP.
XX
AC   ADF32131;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Probe #55 used to illustrate chip detection techniques.
XX
KW   Chip detection; probe; Single Nucleotide Polymorphism; SNP; detection;
KW   ss.
XX
OS   Unidentified.
XX
PN   CN1381590-A.
XX
PD   27-NOV-2002.
XX
PF   13-APR-2001; 2001CN-00105980.
XX
PR   13-APR-2001; 2001CN-00105980.
XX
PA   (MIAO/) MIAO J.
XX
PI   Miao J;
XX
DR   WPI; 2003-249035/25.
XX
PT   Simple and fast technique for detecting single nucleotide polymorphism
PT   (SNP) by high-temp hybridized chip.
XX
PS   Example 1; Page 14; 19pp; Chinese.
XX
CC   The present invention related to an improvement to existing chip
CC   detection techniques. The invention uses DNA oligonucleotide probes
CC   (ADF32077-ADF32266) to detect Single Nucleotide Polymorphisms (SNP) in
CC   genomic DNA. Its advantages are simple process and short time (within 2
CC   hr).
XX
SQ   Sequence 15 BP; 1 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 92;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         14 AGCCACGCAGTCCA 1


RESULT 148
AAQ78888/c
ID   AAQ78888 standard; DNA; 17 BP.
XX
AC   AAQ78888;
XX
DT   25-MAR-2003  (revised)
DT   18-DEC-1995  (first entry)
XX
DE   Humicola grisea glucoamylase hybridization probe.
XX
KW   Glucoamylase; DNA probe; gene cloning; protein secretion; ss.
XX
OS   Synthetic.
XX
PN   EP625577-A1.
XX
PD   23-NOV-1994.
XX
PF   27-AUG-1986;   94EP-00201751.
XX
PR   29-AUG-1985;   85US-00771374.
PR   07-JUL-1986;   86US-00882224.
PR   27-AUG-1986;   86EP-00306624.
XX
PA   (GEMV ) GENENCOR INT INC.
XX
PI   Berka RM,  Cullen D,  Gray GL,  Hayenga KJ,  Lawlis VB;
XX
DR   WPI; 1994-359750/45.
XX
PT   Vectors and DNA for expressing polypeptide(s) in filamentous fungi -
PT   include secretory signal sequences that are native or foreign to
PT   heterologous polypeptide(s), such as chymosin or glucoamylase.
XX
PS   Example 9A3; Page 22; 50pp; English.
XX
CC   The DNA probe and corresponding probes covering the degenerate sites
CC   (AAQ78885-Q78891) correspond to amino acids 17-22 of the H. grisea
CC   glucoamylase peptide GA1 (AAR62933), and are used as hybridization probes
CC   to detect and isolate H. grisea glucoamylase DNA in a Southern blot.
CC   Resulting genomic DNA fragments are excised and cloned in plasmid pRSH1.
CC   This illustrates the main claims of the patent, i.e. a vector containing
CC   (i) DNA encoding a heterologous polypeptide (chymosin, prochymosin,
CC   preprochymosin, Aspergillus niger glucoamylase, H. grisea glucoamylase,
CC   or Mucor miehei carboxyl protease) and (ii) a secretory signal peptide,
CC   and a filamentous fungus (Aspergillus, Trichoderma, Neurospora,
CC   Podospora, Endothia, Mucor, Cochiobolus or Pyriclaria, especially A.
CC   nidulans, A. awamori or T. reesei) transformed with the vector for
CC   recombinant protein (enzyme) production. (Updated on 25-MAR-2003 to
CC   correct PF field.) (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ   Sequence 17 BP; 10 A; 2 C; 0 G; 4 T; 0 U; 1 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 1e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        713 TTGATACATTTATCTT 728
              |||||| ||||||:||
Db         17 TTGATATATTTATMTT 2


RESULT 149
ABK01791
ID   ABK01791 standard; RNA; 17 BP.
XX
```

```
AC   ABK01791;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Zinzyme #113.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 97; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a zinzyme molecule of the invention
XX
SQ   Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 1e+02;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        164 GGCGGCAGCAGCTG 177
              ||||||||||||:|
Db          2 GGCGGCAGCAGCUG 15


RESULT 150
ABK00765
ID   ABK00765 standard; RNA; 17 BP.
XX
AC   ABK00765;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Inozyme #35.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 78; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
```

```
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an inozyme of the invention
XX
SQ   Sequence 17 BP; 2 A; 6 C; 8 G; 0 T; 1 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 1e+02;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        164 GGCGGCAGCAGCTG 177
              ||||||||||||:|
Db          3 GGCGGCAGCAGCUG 16


RESULT 151
ABA81385
ID   ABA81385 standard; DNA; 17 BP.
XX
AC   ABA81385;
XX
DT   24-JAN-2002  (first entry)
XX
DE   PSEN1 mutation correcting oligonucleotide SEQ ID NO: 4231.
XX
KW   Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW   retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW   cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW   adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW   haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW   mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW   familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW   UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW   Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW   antilipemic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200173002-A2.
XX
PD   04-OCT-2001.
XX
PF   27-MAR-2001; 2001WO-US009761.
XX
PR   27-MAR-2000; 2000US-0192176P.
PR   27-MAR-2000; 2000US-0192179P.
PR   01-JUN-2000; 2000US-0208538P.
PR   30-OCT-2000; 2000US-0244989P.
XX
PA   (UYDE ) UNIV DELAWARE.
XX
PI   Kmiec EB,  Gamper HB,  Rice MC;
XX
DR   WPI; 2001-639230/73.
XX
PT   Oligonucleotide for targeted alterations of genetic sequences and for
PT   treating cystic fibrosis, comprises at least one mismatch and chemical
PT   modification.
XX
PS   Claim 7; Page 272; 294pp; English.
XX
CC   The present invention provides single-stranded oligonucleotides which can
CC   be used for the targeted alteration of genomic sequences, where the
CC   oligonucleotide has at least one mismatch compared with the genomic
CC   sequence to be altered. In particular, these sequences are directed at
CC   the following genes: adenosine deaminase, p53, beta-globin,
CC   retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC   (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC   1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC   apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC   (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC   presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC   such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC   haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC   Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC   various syndromes. The present sequence is one of the gene correcting
CC   oligonucleotides of the invention
XX
SQ   Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          3 AGCCACGCAGTCCA 16


RESULT 152
ABA81384/c
ID   ABA81384 standard; DNA; 17 BP.
XX
AC   ABA81384;
XX
DT   24-JAN-2002  (first entry)
XX
DE   PSEN1 mutation correcting oligonucleotide SEQ ID NO: 4230.
XX
KW   Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW   retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW   cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW   adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW   haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW   mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW   familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW   UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW   Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW   antilipemic; ss.
XX
OS   Homo sapiens.
XX
PN   WO200173002-A2.
XX
PD   04-OCT-2001.
XX
PF   27-MAR-2001; 2001WO-US009761.
XX
PR   27-MAR-2000; 2000US-0192176P.
PR   27-MAR-2000; 2000US-0192179P.
PR   01-JUN-2000; 2000US-0208538P.
```

```
PR   30-OCT-2000; 2000US-0244989P.
XX
PA   (UYDE ) UNIV DELAWARE.
XX
PI   Kmiec EB,  Gamper HB,  Rice MC;
XX
DR   WPI; 2001-639230/73.
XX
PT   Oligonucleotide for targeted alterations of genetic sequences and for
PT   treating cystic fibrosis, comprises at least one mismatch and chemical
PT   modification.
XX
PS   Claim 7; Page 271; 294pp; English.
XX
CC   The present invention provides single-stranded oligonucleotides which can
CC   be used for the targeted alteration of genomic sequences, where the
CC   oligonucleotide has at least one mismatch compared with the genomic
CC   sequence to be altered. In particular, these sequences are directed at
CC   the following genes: adenosine deaminase, p53, beta-globin,
CC   retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC   (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC   1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC   apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC   (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC   presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC   such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC   haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC   Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC   various syndromes. The present sequence is one of the gene correcting
CC   oligonucleotides of the invention
XX
SQ   Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         15 AGCCACGCAGTCCA 2


RESULT 153
ADF92264
ID   ADF92264 standard; DNA; 17 BP.
XX
AC   ADF92264;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human cytokeratin 19-derived F2 DNA - SEQ ID 352.
XX
KW   human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;
KW   tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;
KW   PCR; probe; F2.
XX
OS   Homo sapiens.
XX
PN   WO2003097878-A1.
XX
PD   27-NOV-2003.
XX
PF   20-MAY-2003; 2003WO-JP006256.
XX
PR   21-MAY-2002; 2002JP-00145689.
PR   17-JUN-2002; 2002JP-00175271.
PR   09-JUL-2002; 2002JP-00199759.
XX
PA   (SYSM-) SYSMEX CORP.
XX
PI   Tada S,  Akai Y,  Imura Y,  Abe S,  Minekawa H;
XX
DR   WPI; 2004-012543/01.
XX
PT   LAMP nucleic acid amplification primers for detection of cytokeratin
PT   expression as indicator in diagnosis of tumour metastasis.
XX
PS   Claim 19; SEQ ID NO 352; 266pp; Japanese.
XX
CC   The invention relates to novel nucleic acid amplification primers for the
CC   detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
CC   (loop mediated isothermal amplification) method. The primers of the
CC   invention may be useful for the detecting cytokeratin 18-20 expression as
CC   an indicator for the diagnosis of tumour metastasis, particularly
CC   prostate cancer and lymphoma. The amplification using the primers is
CC   highly efficient and allows very sensitive detection of tumour
CC   metastasis. The current sequence is that of the human CK19-derived DNA of
CC   the invention.
XX
SQ   Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         81 TCCGCGACTGGTAC 94
              ||||||||||||||
Db          4 TCCGCGACTGGTAC 17


RESULT 154
AAA17447
ID   AAA17447 standard; RNA; 17 BP.
XX
AC   AAA17447;
XX
DT   19-JUN-2000  (first entry)
XX
DE   Aryl hydrocarbon nuclear transport substrate sequence SEQ ID NO:673.
XX
KW   Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW   integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW   hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW   ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW   dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW   age related macular degeneration; inflammation; neovascular glaucoma;
KW   myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW   tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW   Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS   Homo sapiens.
XX
PN   WO9950403-A2.
XX
PD   07-OCT-1999.
XX
PF   24-MAR-1999;   99WO-US006507.
XX
PR   27-MAR-1998;   98US-0079678P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Pavco PA,  Roberts E,  Jarvis T,  Coeshott C,  Mcswiggen JA;
XX
DR   WPI; 1999-591315/50.
XX
PT   Novel ribozymes for modulating the synthesis, expression and/or stability
PT   of an mRNA encoding an angiogenic factors.
XX
PS   Claim 53; Page 80; 305pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   cleaving activity, which specifically cleave RNA encoded by an aryl
CC   hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC   gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC   AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
```

```
CC   and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC   corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC   AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC   and AAA19155 to AAA19222 represent their corresponding target sequences;
CC   AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC   sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC   AAA21596 to AAA21688 represent their corresponding target sequences;
CC   AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC   for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC   AAA23422 represent their corresponding target sequences. The ribozymes of
CC   the invention are used for modulating the synthesis, expression and/or
CC   stability of an mRNA encoding angiogenic factor, especially ARNT,
CC   integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC   especially used to treat cancer, diabetic retinopathy, age related
CC   macular degeneration (ARMD), inflammation, and arthritis, as well as
CC   neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC   angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC   syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC   and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC   integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ   Sequence 17 BP; 3 A; 9 C; 2 G; 0 T; 3 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1.1e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         64 CCCCAGCTGGGACCCCT 80
              ||||| |: |||||||:
Db          1 CCCCAACUUGGACCCCU 17


RESULT 155
AAV93490
ID   AAV93490 standard; RNA; 17 BP.
XX
AC   AAV93490;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Human B-raf substrate nucleotide position 1221.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T,  Matulic-Adamic J,  Reynolds M,  Kisich K,  Bellon L;
PI   Parry T,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Burgin A;
PI   Thompson J,  Workman CT,  Beaudry A,  Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 177; Page 168; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        363 CCAAGGATGGCGTGGTG 379
              |||||||:  ||:||:|
Db          1 CCAAGGAUUUCGUGGUG 17


RESULT 156
AAX01065/c
ID   AAX01065 standard; DNA; 17 BP.
XX
AC   AAX01065;
XX
DT   06-APR-1999  (first entry)
XX
DE   IPF1 gene exon 1 amplifying primer S17b.
XX
KW   Mature onset diabetes of the young; MODY; insulin promoter factor 1;
KW   IPF1; mutation; MODY4; pancreatic disorder; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9859078-A1.
XX
PD   30-DEC-1998.
XX
PF   24-JUN-1998;   98WO-US013467.
XX
PR   24-JUN-1997;   97US-00881450.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Habener JF,  Stoffers DA;
XX
DR   WPI; 1999-105636/09.
XX
PT   Detecting heterozygosity for insulin promoter factor 1 - useful to detect
PT   the presence of, or predisposition for, mature onset diabetes of the
PT   young.
XX
PS   Example 1; Page 9; 46pp; English.
```

```
XX
CC   The invention relates to a new method to screen for mature onset diabetes
CC   of the young (MODY). The method comprises detecting a mutation in the
CC   gene encoding insulin promoter factor 1 (IPF1), wherein heterozygosity
CC   for the mutation is indicative of MODY. The method may be used to
CC   determine if a patient with MODY symptoms has MODY4, to assess patients
CC   risk of developing MODY4, to assess the risk of a couple's progeny of
CC   inheriting MODY, and to assist in determining the genetic basis for other
CC   pancreatic disorders that might result from IPF-1 deficiency. Sequences
CC   AAX01063-66 represent primers used for amplifying the exon 1 of the IPF1
CC   gene using a nested PCR priming scheme
XX
SQ   Sequence 17 BP; 4 A; 3 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         38 CGCGTCCCCTTCTCGCT 54
              ||| |||||| ||||||
Db         17 CGCCTCCCCTGCTCGCT 1


RESULT 157
AAA36540/c
ID   AAA36540 standard; DNA; 17 BP.
XX
AC   AAA36540;
XX
DT   26-JUL-2000  (first entry)
XX
DE   Human genomic SNP allele specific oligonucleotide SEQ ID NO:605.
XX
KW   Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KW   allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KW   genomic classification; identification; DNA fingerprinting;
KW   tumour characterisation; hybridisation; ss.
XX
OS   Homo sapiens.
XX
PN   WO200018960-A2.
XX
PD   06-APR-2000.
XX
PF   24-SEP-1999;   99WO-US022283.
XX
PR   25-SEP-1998;   98US-0101757P.
XX
PA   (MASI ) MASSACHUSETTS INST TECHNOLOGY.
XX
PI   Landers JE,  Jordan B,  Housman DE,  Charest A;
XX
DR   WPI; 2000-293181/25.
XX
PT   Detection of single nucleotide polymorphisms in genomes by preparation
PT   and analysis of reduced complexity genomes, useful for genotyping,
PT   fingerprinting and determining allele frequency of SNPs.
XX
PS   Disclosure; Page 71; 111pp; English.
XX
CC   A method has been developed for detecting the presence or absence of a
CC   single nucleotide polymorphism (SNP) allele in a genomic sample. The
CC   method comprises preparing a reduced complexity genome (RCG) from the
CC   genomic sample and analysing the RCG for the presence or absence of a SNP
CC   allele. The method can be used to characterise a tumour, to generate a
CC   genomic pattern for an individual genome or to generate a genomic
CC   classification code for a genome. The method can be used to assess
CC   whether a subject is at risk for developing a disease or to identify a
CC   set of SNP alleles associated with a disease. The method can also be used
CC   to perform linkage analysis. AAA35944 to AAA35947 represent sequences
CC   used in the exemplification of the present invention. AAA35948 to
CC   AAA36632 represent nucleotide sequences containing SNPs
XX
SQ   Sequence 17 BP; 1 A; 2 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 AGTTCAAAGCAACCACC 762
              ||| |||||||| ||||
Db         17 AGTACAAAGCAAACACC 1


RESULT 158
ABK02414
ID   ABK02414 standard; RNA; 17 BP.
XX
AC   ABK02414;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Amberzyme #86.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 132; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
```

```
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an amberzyme molecule of the invention
XX
SQ   Sequence 17 BP; 1 A; 9 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1.1e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        462 CCGGTGTGGACCCCACC 478
              || |:|:||||||| ||
Db          1 CCCGUGUGGACCCCGCC 17


RESULT 159
AAH24028/c
ID   AAH24028 standard; DNA; 17 BP.
XX
AC   AAH24028;
XX
DT   29-AUG-2001  (first entry)
XX
DE   Yeast GAL3 gene upstream UASgal site, SEQ ID NO:11.
XX
KW   UASgal site; cis-acting transcription control element; Gal4; Gal3; Gal80;
KW   stoichiometrically balanced expression; yeast;
KW   galactose-inducible expression; expression construct; promoter; ds.
XX
OS   Saccharomyces cerevisiae.
XX
PN   US6221630-B1.
XX
PD   24-APR-2001.
XX
PF   24-MAR-1999;   99US-00275680.
XX
PR   24-MAR-1999;   99US-00275680.
XX
PA   (PENN-) PENN STATE RES FOUND.
XX
PI   Hopper JE;
XX
DR   WPI; 2001-307557/32.
XX
PT   Expression construct for inducing and sustaining high level recombinant
PT   polypeptide production in yeast, comprises nucleic acids encoding a trans
PT   -acting transcription factor, selectable marker and yeast origin of
PT   replication.
XX
PS   Disclosure; Col 15; 22pp; English.
XX
CC   The invention relates to high copy number expression constructs for high
CC   level polypeptide expression in yeast. The yeast expression constructs
CC   comprise a nucleic acid sequence encoding a set of trans- acting
CC   transcription factors, a nucleic acid encoding a yeast selectable marker
CC   providing an inefficiently or efficiently selected phenotype, a nucleic
CC   acid encoding a yeast or bacterial origin of replication (ori), and a
CC   unique restriction site downstream of a promoter containing a cis- acting
CC   transcription control element that is regulated by the transcription
CC   factors which are encoded by the expression construct. In a specific
CC   embodiment of the invention, the expression construct provides for
CC   galactose-inducible protein expression. Such constructs contain DNA
CC   encoding the transcription factors Gal3, Gal4 and Gal80, and a UASgal cis
CC   -acting control element within the promoter which drives expression of
CC   the inserted gene of interest. The vector-encoded transcription factors
CC   are expressed in stoichiometrically-balanced amounts, which is
CC   particularly important for a galactose-inducible system, as Gal4, when
CC   not balanced by stoichiometric levels of Gal3 and Gal80, becomes a
CC   constitutive transcription factor, and can become toxic to the cell. The
CC   constructs of the invention express the transcription factors at levels
CC   higher than those found in native yeast cells, thereby ensuring
CC   expression of the gene of interest. The expression constructs provide
CC   robust, high level expression of a gene of interest (which can encode an
CC   endogenous or heterologous polypeptide) in yeast. Sequences AAH24019-
CC   AAH24035 represent actual UASgal sites found within the promoters of
CC   various yeast galactose-inducible genes which may be used as the cis-
CC   acting control element in a galactose-inducible expression construct of
CC   the invention
XX
SQ   Sequence 17 BP; 1 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        290 CGGCACACTGCGGACCG 306
              ||||||||  | ||||||
Db         17 CGGCACACAGTGGACCG 1


RESULT 160
ABN02338/c
ID   ABN02338 standard; DNA; 17 BP.
XX
AC   ABN02338;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2330.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
```

```
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2330; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 161
ABN02339/c
ID   ABN02339 standard; DNA; 17 BP.
XX
AC   ABN02339;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2331.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2331; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              ||||| ||| |||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 162
ABN02337/c
ID   ABN02337 standard; DNA; 17 BP.
XX
AC   ABN02337;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2329.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
```

XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 2329; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 551 TCCAACGAGATCACCAT 567
|||| ||| ||||||||
Db 17 TCCAGCGACATCACCAT 1

RESULT 163
ABN10677
ID ABN10677 standard; DNA; 17 BP.
XX
AC ABN10677;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10669.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 10669; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;

```
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              ||| |||||||||||| |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 164
ABN10678
ID   ABN10678 standard; DNA; 17 BP.
XX
AC   ABN10678;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10670.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 10670; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 4 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||| ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 165
ABV78924/c
ID   ABV78924 standard; DNA; 17 BP.
XX
AC   ABV78924;
XX
DT   03-JAN-2003  (first entry)
XX
DE   Human HTPL scanning oligonucleotide SEQ ID 170.
XX
KW   Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW   human testis expressed Patched like protein; testis; adrenal; liver;
KW   male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW   prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   EP1229046-A2.
XX
PD   07-AUG-2002.
XX
PF   28-JAN-2002; 2002EP-00001167.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   23-MAY-2001; 2001US-00864761.
PR   09-OCT-2001; 2001US-0327898P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhan J;
XX
DR   WPI; 2002-676582/73.
XX
PT   Novel isolated human testis expressed Patched like protein (HTPL), useful
PT   for identifying agonist and antagonist and specific binding partners, and
PT   for treating subjects having defects in HTPL.
XX
PS   Example 2; Page 86; 718pp; English.
XX
CC   The present invention relates to human testis expressed Patched like
CC   protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC   has two isoforms, with a few single base pair differences between the
CC   two. One of the single base pair changes introduces a premature stop
CC   codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC   shares an overall structure organisation with the Patched protein. The
CC   shared structural features strongly imply that HTPL plays a role similar
CC   to that of Patched, and is a potential tumour suppressor. HTPL is
CC   important in regulating male germ cell development, and the HTPL gene was
CC   mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC   useful for diagnosing a disorder caused by mutation in HTPL, and in
```

CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potenial therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 2 A; 7 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 295 CACTGCGGACCGCTGGC 311
||||||||| ||| ||||
Db 17 CACTGCGGCCCGGTGGC 1

RESULT 166
ABV90510
ID ABV90510 standard; DNA; 17 BP.
XX
AC ABV90510;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1223.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
PT Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 1223; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 5 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 557 GAGATCACCATCCCAGT 573
||||||| || ||||||
Db 1 GAGATCAGCACCCCAGT 17

RESULT 167
ABK56935
ID ABK56935 standard; RNA; 17 BP.
XX
AC ABK56935;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #1306.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US024970.
XX
PR 09-AUG-2000; 2000US-0224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS Claim 4; Page 87; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition

```
CC   associated with the level of CLCA1, where the invention further comprises
CC   the use of one or more therapies under conditions suitable for the
CC   treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC   antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC   nucleic acids of the invention are also used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of CLCA1 RNA in a cell. This sequence represents an
CC   enzymatic nucleic acid molecule of the invention
XX
SQ   Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1.1e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        506 GGCACACTGACCGTGGA 522
              |||||| :|| ||:|||
Db          1 GGCACAGUGAUCGUGGA 17


RESULT 168
ABK57534/c
ID   ABK57534 standard; RNA; 17 BP.
XX
AC   ABK57534;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human CLCA1 gene enzymatic nucleic acid #1905.
XX
KW   Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW   antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW   chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW   oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW   acetylcysteine.
XX
OS   Homo sapiens.
XX
PN   WO200211674-A2.
XX
PD   14-FEB-2002.
XX
PF   09-AUG-2001; 2001WO-US024970.
XX
PR   09-AUG-2000; 2000US-0224383P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (SYNT ) SYNTEX USA LLC.
PA   (THOM/) THOMPSON J.
XX
PI   Thompson J,  Mcswiggen J,  Mckenzie T,  Ayers D,  Szymkowski DE;
PI   Grupe A;
XX
DR   WPI; 2002-217145/27.
XX
PT   Enzymatic polynucleotide that down regulates expression of chloride
PT   channel calcium activated gene, useful for treating Chronic obstructive
PT   pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS   Claim 4; Page 128; 152pp; English.
XX
CC   The invention relates to enzymatic nucleic acid molecules that down
CC   regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC   by cleaving RNA derived from the genes. The nucleic acid sequences are
CC   useful as pharmaceutical agents for treating conditions such as chronic
CC   obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC   fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC   that are related to or will respond to the levels of CLCA1 in a cell or
CC   tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC   hence, are useful for treatment of a patient having a condition
CC   associated with the level of CLCA1, where the invention further comprises
CC   the use of one or more therapies under conditions suitable for the
CC   treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC   antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC   nucleic acids of the invention are also used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of CLCA1 RNA in a cell. This sequence represents an
CC   enzymatic nucleic acid molecule of the invention
XX
SQ   Sequence 17 BP; 7 A; 2 C; 5 G; 0 T; 3 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        422 TACATCTCCCGGTGCTT 438
              |||||||||| ||| ||
Db         17 TACATCTCCCTGTGATT 1


RESULT 169
ABK57533/c
ID   ABK57533 standard; RNA; 17 BP.
XX
AC   ABK57533;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human CLCA1 gene enzymatic nucleic acid #1904.
XX
KW   Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW   antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW   chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW   oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW   acetylcysteine.
XX
OS   Homo sapiens.
XX
PN   WO200211674-A2.
XX
PD   14-FEB-2002.
XX
PF   09-AUG-2001; 2001WO-US024970.
XX
PR   09-AUG-2000; 2000US-0224383P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (SYNT ) SYNTEX USA LLC.
PA   (THOM/) THOMPSON J.
XX
PI   Thompson J,  Mcswiggen J,  Mckenzie T,  Ayers D,  Szymkowski DE;
PI   Grupe A;
XX
DR   WPI; 2002-217145/27.
XX
PT   Enzymatic polynucleotide that down regulates expression of chloride
PT   channel calcium activated gene, useful for treating Chronic obstructive
PT   pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS   Claim 4; Page 128; 152pp; English.
XX
CC   The invention relates to enzymatic nucleic acid molecules that down
CC   regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC   by cleaving RNA derived from the genes. The nucleic acid sequences are
CC   useful as pharmaceutical agents for treating conditions such as chronic
CC   obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC   fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC   that are related to or will respond to the levels of CLCA1 in a cell or
CC   tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC   hence, are useful for treatment of a patient having a condition
CC   associated with the level of CLCA1, where the invention further comprises
CC   the use of one or more therapies under conditions suitable for the
CC   treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC   antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC   nucleic acids of the invention are also used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
```

```
CC   the presence of CLCA1 RNA in a cell. This sequence represents an
CC   enzymatic nucleic acid molecule of the invention
XX
SQ   Sequence 17 BP; 6 A; 2 C; 6 G; 0 T; 3 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        423 ACATCTCCCGGTGCTTC 439
              |||||||||  ||| |||
Db         17 ACATCTCCCTGTGATTC 1


RESULT 170
ACN00114/c
ID   ACN00114 standard; RNA; 17 BP.
XX
AC   ACN00114;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Hammerhead Ribozyme substrate SEQ ID NO 104.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 104; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        728 TCTGTTTTTCTCAAATA 744
              |||||||||  ||||||
Db         17 TCTGTTTTTACCAAATA 1


RESULT 171
ACN09334
ID   ACN09334 standard; RNA; 17 BP.
XX
AC   ACN09334;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9337.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 9337; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 4 A; 3 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 1.1e+02;
  Matches    6;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        727 TTCTGTTTTTCTCAAAT 743
              ::|:|:::::  ||||:
Db          1 UUCUGUUUUUACCAAAU 17
```

```
RESULT 172
ACN09335
ID   ACN09335 standard; RNA; 17 BP.
XX
AC   ACN09335;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9338.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 9338; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 5 A; 3 C; 1 G; 0 T; 8 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 1.1e+02;
  Matches    7;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        728 TCTGTTTTTCTCAAATA 744
              :|:|:::::  ||||:|
Db          1 UCUGUUUUUACCAAAUA 17


RESULT 173
ACA07606/c
ID   ACA07606 standard; RNA; 17 BP.
XX
AC   ACA07606;
XX
DT   03-JUN-2003  (first entry)
XX
DE   NFKB sub-unit modulating zinzyme substrate #5.
XX
KW   Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW   G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW   lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW   oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW   cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW   lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW   chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW   cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW   gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW   rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW   gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW   transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW   allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS   Homo sapiens.
XX
PN   US2002177568-A1.
XX
PD   28-NOV-2002.
XX
PF   23-MAY-2001; 2001US-00864785.
XX
PR   07-DEC-1992;   92US-00987132.
PR   18-MAY-1994;   94US-00245466.
PR   15-AUG-1994;   94US-00291932.
PR   23-DEC-1996;   96US-00777916.
XX
PA   (STIN/) STINCHCOMB D T.
PA   (MCSW/) MCSWIGGEN J.
PA   (DRAP/) DRAPER K G.
XX
PI   Stinchcomb DT,  Mcswiggen J,  Draper KG;
XX
DR   WPI; 2003-340953/32.
XX
PT   Novel enzymatic nucleic acid molecules which down regulates expression of
PT   a sequence encoding a subunit of nuclear factor kappa B useful for
PT   treating cancer, inflammatory disorders and autoimmune diseases.
XX
PS   Claim 3; Page 37; 72pp; English.
XX
CC   The invention describes an enzymatic nucleic acid molecule (I) which down
CC   regulates expression of a sequence encoding a subunit of nuclear factor
CC   kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC   configuration. The enzymatic nucleic acid molecule is adapted to treat
CC   cancer and is useful for down-regulating REL-A activity in a cell, for
CC   treating a patient having a condition associated with the level of REL-A.
CC   (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC   the presence of a divalent cation, especially Mg^2^+. The enzymatic and
CC   antisense nucleic acid molecules are useful for treating breast, lung,
CC   prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC   cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC   multidrug resistant cancer. The method involves use of other drug
CC   therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC   chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC   cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
CC   gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC   acid molecules are also useful for treating inflammatory disease such as
CC   rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC   obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC   rejection, gene therapy applications, ischaemia/reperfusion injury
CC   (central nervous system (CNS) and myocardial), glomerulonephritis,
CC   sepsis, allergic airway inflammation, inflammatory bowel disease or
CC   infection. This sequence represents the substrate of a novel enzymatic
CC   nucleic acid molecule
XX
SQ   Sequence 17 BP; 1 A; 6 C; 8 G; 0 T; 2 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
```

```
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         62 GGCCCCAGCTGGGACCC 78
              || |||||||| |||||
Db         17 GGGCCCAGCTGCGACCC 1


RESULT 174
ABZ65193
ID   ABZ65193 standard; RNA; 17 BP.
XX
AC   ABZ65193;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human HER2 DNAzyme substrate #650.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 4; Page 145; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 0 A; 5 C; 8 G; 0 T; 4 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 175
ABZ60372
ID   ABZ60372 standard; RNA; 17 BP.
XX
AC   ABZ60372;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human K-Ras DNAzyme substrate #484.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 94; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 5 A; 2 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 1.1e+02;
  Matches    6;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 TTCTTTTGATACATTTA 724
              : |::::||:| |:::|
Db          1 UCCUUUUGAUAAAUUUA 17


RESULT 176
ACD65526
ID   ACD65526 standard; RNA; 17 BP.
XX
AC   ACD65526;
XX
DT   30-SEP-2003  (first entry)
XX
DE   HCV minus strand DNAzyme substrate sequence #2101.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
```

```
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 312; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 1 A; 9 C; 4 G; 0 T; 3 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        677 CACTGGCTGTGCCTCCC 693
              | |:||| |:|||:|||
Db          1 CCCUGGCAGUGCCUCCC 17


RESULT 177
ACC65874
ID   ACC65874 standard; DNA; 17 BP.
XX
AC   ACC65874;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 3121.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 395; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 7 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||  |||||||
Db          1 GATCACCAAACCAGTCA 17


RESULT 178
ACC65548/c
ID   ACC65548 standard; DNA; 17 BP.
XX
AC   ACC65548;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 2795.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
```

XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 357; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 273 GCGGGGTCTCGGAGATC 289
|| ||||||| ||||||
Db 17 GCTGGGTCTCAGAGATC 1

RESULT 179
ADC37976
ID ADC37976 standard; DNA; 17 BP.
XX
AC ADC37976;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:325.
XX
KW human; angiomotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1a; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
DR WPI; 2003-430501/40.
XX
PT New isolated nucleic acid molecule encoding a human angiomotin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
PS Example 2; SEQ ID NO 325; 172pp; English.
XX
CC The present invention describes the human angiomotin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
SQ Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 243 ACAGCCGCGCGCTCAGC 259
||| |||| ||||||||
Db 1 ACATCCGCTCGCTCAGC 17

RESULT 180
ADC24273/c
ID ADC24273 standard; DNA; 17 BP.
XX
AC ADC24273;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human NOV9 forward PCR primer SEQ ID NO:80.
XX
KW human; NOVX; cardiant; antiarteriosclerotic; hypotensive; vasotropic;
KW dermatological; anorectic; immunosuppressive; cytostatic;
KW antiinfertility; haemostatic; anti-HIV; antiasthmatic; antiinflammatory;
KW neuroprotective; anabolic; nootropic; antiparkinsonian; gene therapy;
KW cardiomyopathy; atherosclerosis; hypertension; congenital heart defect;
KW pulmonary stenosis; scleroderma; obesity; metabolic disturbance; obesity;
KW transplantation; adrenoleukodystrophy; congenital adrenal hyperplasia;
KW prostate cancer; diabetes; metabolic disorder; neoplasm; adenocarcinoma;
KW fertility; haemophilia; graft versus host disease; AIDS;
KW bronchial asthma; Crohn's disease; multiple sclerosis;
KW infectious disease; anorexia; neurodegenerative disorder;
KW Alzheimer's disease; Parkinson's disease; immune disorder;
KW haematopoietic disorder; dyslipidaemia; wasting disorder; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003076584-A2.
XX
PD 18-SEP-2003.
XX
PF 06-MAR-2003; 2003WO-US006951.
XX
PR 06-MAR-2002; 2002US-0361974P.
PR 19-MAR-2002; 2002US-0365477P.
PR 22-MAR-2002; 2002US-0366928P.
PR 06-AUG-2002; 2002US-0401661P.
PR 05-MAR-2003; 2003US-00401661.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Alsobrook JP, Burgess CE, Edinger SR, Gerlach VL, Ji W, Kekuda R;
PI Li L, Macdougall JR, Miller CE, Millet I, Patturajan M, Pena CEA;
PI Rieger DK, Sciore P, Shenoy SG, Smithson G, Spytek KA, Stone DJ;
PI Voss EZ, Zhong M;
XX
DR WPI; 2003-722330/68.
XX
PT New NOVX polypeptides and nucleic acids, useful for diagnosing or

```
PT   treating e.g. cardiomyopathy, atherosclerosis, hypertension, scleroderma,
PT   obesity, prostate cancer, AIDS, bronchial asthma, Crohn's disease, or
PT   multiple sclerosis.
XX
PS   Example C; SEQ ID NO 80; 229pp; English.
XX
CC   The present invention describes novel human proteins, designated NOVX
CC   proteins. The NOVX sequences have cardiant, antiarteriosclerotic,
CC   hypotensive, vasotropic, dermatological, anorectic, immunosuppressive,
CC   cytostatic, antiinfertility, haemostatic, anti-HIV, antiasthmatic,
CC   antiinflammatory, neuroprotective, anabolic, nootropic and
CC   antiparkinsonian activities, and can be used in gene therapy. The NOVX
CC   sequences can be used as a therapeutic in the manufacture of a medicament
CC   for treating a syndrome associated with a human disease, such as a
CC   pathology associated with NOVX. The NOVX proteins and nucleic acids
CC   encoding them are useful for diagnosing or treating pathologies, diseases
CC   or conditions associated with NOVX sequences, including cardiomyopathy,
CC   atherosclerosis, hypertension, congenital heart defects, pulmonary
CC   stenosis, scleroderma, obesity, metabolic disturbances associated with
CC   obesity, transplantation, adrenoleukodystrophy, congenital adrenal
CC   hyperplasia, prostate cancer, diabetes, metabolic disorders, neoplasm,
CC   adenocarcinoma, fertility, haemophilia, graft versus host disease, AIDS,
CC   bronchial asthma, Crohn's disease, multiple sclerosis, infectious
CC   disease, anorexia, neurodegenerative disorders (e.g. Alzheimer's disease,
CC   or Parkinson's disease), immune disorders, haematopoietic disorders,
CC   dyslipidaemias, and wasting disorders associated with chronic diseases.
CC   The proteins can also be used as immunogens to produce antibodies and as
CC   vaccines. The sequences may further be used in chromosome mapping,
CC   identifying individual from minute biological samples (tissue typing),
CC   and in forensic identification of a biological sample. The present
CC   sequence represents a PCR primer for a human NOVX sequence, which is used
CC   in an example from the present invention.
XX
SQ   Sequence 17 BP; 4 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        664 CCCCTGCTGCCGCCACT 680
              ||||| |||| ||||||
Db         17 CCCCTTCTGCAGCCACT 1


RESULT 181
ADF63855/c
ID   ADF63855 standard; DNA; 17 BP.
XX
AC   ADF63855;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1759.
XX
KW   chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW   prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW   human; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO2003050284-A1.
XX
PD   19-JUN-2003.
XX
PF   22-NOV-2002; 2002WO-US037506.
XX
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 1759; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 0 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        520 GGAGGCCCCCATGCCCA 536
              ||||| |||| |||||
Db         17 GGAGGCACCCAGGCCCA 1


RESULT 182
ADF63856/c
ID   ADF63856 standard; DNA; 17 BP.
XX
AC   ADF63856;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1760.
XX
KW   chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW   prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW   human; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO2003050284-A1.
XX
PD   19-JUN-2003.
XX
PF   22-NOV-2002; 2002WO-US037506.
XX
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 1760; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
```

```
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 1 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        519 TGGAGGCCCCCATGCCC 535
              ||||||| |||| ||||
Db         17 TGGAGGCACCCAGGCCC 1


RESULT 183
ADI49311
ID   ADI49311 standard; DNA; 17 BP.
XX
AC   ADI49311;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID1814.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 1814; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 7 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              ||||||||  |||||||
Db          1 GATCACCAAACCAGTCA 17


RESULT 184
ADI48838/c
ID   ADI48838 standard; DNA; 17 BP.
XX
AC   ADI48838;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID1341.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 1341; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 7 A; 1 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        734 TTTCTCAAATAAAGTTC 750
              ||||||||||||  | ||
Db         17 TTTCTCAAATAATGATC 1
```

```
RESULT 185
ABZ76956/c
ID   ABZ76956 standard; DNA; 17 BP.
XX
AC   ABZ76956;
XX
DT   07-MAY-2003  (first entry)
XX
DE   Bovine DGAT BAC-DNA sequencing primer #29.
XX
KW   Acyl CoA:diacylglycerol transferase; DGAT; enzyme; chromosome 14; bovine;
KW   milk; meat marbling; low fat; polymorphic; SNP;
KW   single nucleotide polymorphism; PCR primer; ss.
XX
OS   Bos taurus.
OS   Synthetic.
XX
PN   WO2003004630-A2.
XX
PD   16-JAN-2003.
XX
PF   05-JUL-2002; 2002WO-EP007520.
XX
PR   06-JUL-2001; 2001EP-00116412.
PR   13-MAY-2002; 2002US-0379412P.
XX
PA   (ARBE-) ARBEITSGEMEINSCHAFT DEUT RINDERZUECHTER.
XX
PI   Fries H,  Winter A;
XX
DR   WPI; 2003-239205/23.
XX
PT   New nucleic acid molecule comprising a sequence of an allele of a
PT   polymorphic bovine acyl CoA-diacylglycerol transferase gene useful for
PT   testing a mammal for its predisposition for fat content of milk and for
PT   meat marbling.
XX
PS   Example 1; Page 35; 91pp; English.
XX
CC   The present invention describes a nucleic acid molecule (NA) (I) encoding
CC   a bovine acyl CoA-diacylglycerol transferase (DGAT) contributing to or
CC   indicative for low fat content of milk and to low meat marbling
CC   (intramuscular fat content). Human DGAT is located to chromosome 8, and
CC   bovine DGAT is located to chromosome 14. (I) is useful for testing a
CC   mammal for its predisposition for fat content of milk and/or its
CC   predisposition for meat marbling. The method comprises analysing the gene
CC   encoding DGAT for nucleotide polymorphisms (e.g. single nucleotide
CC   polymorphisms (SNPs)) which are connected with the predisposition. The
CC   nucleotide polymorphisms are located in the coding region of the DGAT
CC   gene and result in substitution, deletion and/or addition of an amino
CC   acid sequence of the polypeptide which is encoded by the gene. The
CC   nucleic acid molecule has at the position 10433 and 10434 of the DGAT
CC   gene a guanine and a cytosine residue, at position 3343 a cytosine or
CC   guanine, 11030 a guanine, 11048 a cytosine or thymine and 11093 a
CC   thymine, which correlate with a predisposition for low fat content of
CC   milk and low meat marbling. The nucleic acid molecule has at the position
CC   corresponding to position 10433 and 10434 of the DGAT gene two adenine
CC   residues which correlate with a predisposition for high content of milk
CC   and high meat marbling. The nucleotide polymorphisms are located in a
CC   region which is responsible for the regulation of the expression of the
CC   product of the gene encoding DGAT. ABZ76924 to ABZ77045 and ABP96035 to
CC   ABP96046 represent sequences used in the exemplification of the present
CC   invention
XX
SQ   Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        467 GTGGACCCCACCCAAGT 483
              ||||||||||  ||| ||
Db         17 GTGGACCCCATCCAGGT 1
```

```
RESULT 186
ADL47965
ID   ADL47965 standard; RNA; 17 BP.
XX
AC   ADL47965;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human IKK-gamma substrate sequence #475.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 1498; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human IKK-
CC   gamma substrate sequence.
XX
SQ   Sequence 17 BP; 0 A; 13 C; 2 G; 0 T; 2 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 1.1e+02;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        194 CCCCTGCCCCCCGCCGC 210
              ||| :||||||||||  |
Db          1 CCCUUGCCCCCCGCCCC 17
```

```
RESULT 187
ADI87132
ID   ADI87132 standard; RNA; 17 BP.
XX
AC   ADI87132;
XX
DT   03-JUN-2004  (first entry)
XX
DE   HCV DNAzyme substrate sequence #4378.
XX
KW   ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW   HCV infection; type I interferon; DNAzyme.
XX
OS   Hepatitis C virus.
XX
PN   US2003125270-A1.
XX
PD   03-JUL-2003.
XX
PF   18-DEC-2000; 2000US-00740332.
XX
PR   18-DEC-2000; 2000US-00740332.
XX
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (ROBE/) ROBERTS E.
PA   (PAVC/) PAVCO P A.
PA   (MACE/) MACEJACK D.
XX
PI   Blatt L,  Mcswiggen J,  Roberts E,  Pavco PA,  Macejack D;
XX
DR   WPI; 2004-031273/03.
XX
PT   Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT   from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT   especially in combination with type I interferon therapy.
XX
PS   Claim 1; SEQ ID NO 4378; 198pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule which
CC   specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC   the binding arms of the enzymatic nucleic acid molecule comprises
CC   sequences complementary to any of the defined substrate sequences given
CC   in the specification. The nucleic acid molecule may be administered for
CC   the treatment of HCV infections, especially in combination with type I
CC   interferons. The present sequence represents a HCV DNAzyme substrate
CC   sequence.
XX
SQ   Sequence 17 BP; 1 A; 9 C; 4 G; 0 T; 3 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.1e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        677 CACTGGCTGTGCCTCCC 693
              | |:||| |:|||:|||
Db          1 CCCUGGCAGUGCCUCCC 17


RESULT 188
ACN65429/c
ID   ACN65429 standard; DNA; 17 BP.
XX
AC   ACN65429;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:2331.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 2331; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              |||||| ||| ||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 189
ACN73767
ID   ACN73767 standard; DNA; 17 BP.
XX
```

```
AC   ACN73767;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:10669.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 10669; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63103
XX
SQ   Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
               ||| |||||||||||  |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 190
ACN65427/c
ID   ACN65427 standard; DNA; 17 BP.
XX
AC   ACN65427;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:2329.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 2329; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
```

```
XX
SQ   Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
              |||| ||| ||||||||
Db         17 TCCAGCGACATCACCAT 1


RESULT 191
ACN73768
ID   ACN73768 standard; DNA; 17 BP.
XX
AC   ACN73768;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:10670.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 10670; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63103
XX
SQ   Sequence 17 BP; 4 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||| ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 192
ACN65428/c
ID   ACN65428 standard; DNA; 17 BP.
XX
AC   ACN65428;
XX
DT   02-DEC-2004  (first entry)
XX
DE   Human GDMLP-1 probe SEQ ID NO:2330.
XX
KW   Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW   hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW   skeletal muscle function.
XX
OS   Homo sapiens.
XX
PN   US2004137589-A1.
XX
PD   15-JUL-2004.
XX
PF   26-NOV-2003; 2003US-00723361.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
PR   25-MAY-2001; 2001US-00866108.
XX
PA   (GUYY/) GU Y.
PA   (JIYY/) JI Y.
PA   (PENN/) PENN S G.
PA   (HANZ/) HANZEL D K.
PA   (RANK/) RANK D.
PA   (CHEN/) CHEN W.
PA   (SHAN/) SHANNON M E.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank D,  Chen W,  Shannon ME;
XX
DR   WPI; 2004-533378/51.
XX
PT   Novel myosin-like protein-1, useful for treating or preventing disorder
PT   associated with decreased expression or activity of human genome-derived
```

```
PT   myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT   function.
XX
PS   Disclosure; SEQ ID NO 2330; 0pp; English.
XX
CC   The invention relates to a novel polypeptide (I) comprising a sequence
CC   (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC   defined in the specification, a fragment of at least 8 amino acids of
CC   (S1), 95% deviation from (S1) which are conservative substitutions, and
CC   65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC   antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC   pharmaceutical composition of the invention is useful for treating or
CC   preventing a disorder associated with decreased expression or activity of
CC   hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC   The present sequence represents a 17-mer nucleotide, used in the
CC   invention for scanning the sequence represented in ACN63102
XX
SQ   Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


Search completed: May 10, 2005, 07:16:07
Job time : 2 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: May 10, 2005, 07:17:21 ; Search time 0.001 Seconds
(without alignments)
1477.576 Million cell updates/sec

Title: US-10-605-498-91
Perfect score: 764
Sequence: 1 ggcacgaggagcagagtcag.....aagttcaaagcaaccacctg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 55 seqs, 967 residues

Total number of hits satisfying chosen parameters: 110

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 55 summaries

Database : rni91.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	25	3.3	25	1	US-08-859-998-1170	Sequence 1170, Ap
c	2	25	3.3	25	1	US-09-225-928-1170	Sequence 1170, Ap
c	3	25	3.3	25	1	US-09-225-201B-1170	Sequence 1170, Ap
	4	24	3.1	24	1	US-08-859-998-1169	Sequence 1169, Ap
	5	24	3.1	24	1	US-09-225-928-1169	Sequence 1169, Ap
	6	24	3.1	24	1	US-09-225-201B-1169	Sequence 1169, Ap
	7	20.8	2.7	25	1	US-09-396-196G-92419	Sequence 92419, A
	8	20.2	2.6	25	1	US-09-396-196G-92432	Sequence 92432, A
	9	15.8	2.1	19	1	US-09-990-613A-7	Sequence 7, Appli
	10	15.4	2.0	17	1	US-09-866-108A-10667	Sequence 10667, A
	11	15	2.0	15	1	US-09-081-646-605	Sequence 605, App
c	12	14.8	1.9	18	1	US-07-977-284A-13	Sequence 13, Appl
c	13	14.8	1.9	18	1	US-08-256-426B-13	Sequence 13, Appl
c	14	14.8	1.9	18	1	US-09-663-834A-37	Sequence 37, Appl
c	15	14.4	1.9	16	1	US-08-411-796-466	Sequence 466, App
c	16	14.4	1.9	16	1	US-08-471-039-466	Sequence 466, App
c	17	14.4	1.9	16	1	US-08-559-390-466	Sequence 466, App
c	18	14.4	1.9	16	1	PCT-US93-11198-466	Sequence 466, App
	19	14.4	1.9	17	1	US-09-866-108A-10666	Sequence 10666, A
	20	14.4	1.9	17	1	US-09-866-108A-10668	Sequence 10668, A
	21	14.4	1.9	18	1	US-09-106-038A-27	Sequence 27, Appl
	22	14.4	1.9	18	1	US-08-513-974B-249	Sequence 249, App
c	23	14.4	1.9	18	1	US-09-422-978-6095	Sequence 6095, Ap
	24	14	1.8	15	1	US-08-431-048F-150	Sequence 150, App
c	25	13.8	1.8	17	1	US-09-275-680-11	Sequence 11, Appl
c	26	13.8	1.8	17	1	US-08-881-450A-6	Sequence 6, Appli
	27	13.8	1.8	17	1	US-09-474-432B-773	Sequence 773, App
	28	13.8	1.8	17	1	US-09-476-387-772	Sequence 772, App
c	29	13.8	1.8	17	1	US-09-866-108A-2329	Sequence 2329, Ap
c	30	13.8	1.8	17	1	US-09-866-108A-2330	Sequence 2330, Ap
c	31	13.8	1.8	17	1	US-09-866-108A-2331	Sequence 2331, Ap
	32	13.8	1.8	17	1	US-09-866-108A-10669	Sequence 10669, A
	33	13.8	1.8	17	1	US-09-866-108A-10670	Sequence 10670, A
c	34	13.8	1.8	17	1	US-09-404-912-599	Sequence 599, App
	35	13.6	1.8	15	1	US-08-431-048F-151	Sequence 151, App
c	36	13.4	1.8	16	1	US-08-770-235A-24	Sequence 24, Appl
c	37	12.8	1.7	16	1	US-08-411-796-539	Sequence 539, App
c	38	12.8	1.7	16	1	US-08-471-039-539	Sequence 539, App
	39	12.8	1.7	16	1	US-08-464-582-16	Sequence 16, Appl
	40	12.8	1.7	16	1	US-08-462-513-16	Sequence 16, Appl
c	41	12.8	1.7	16	1	US-08-559-390-539	Sequence 539, App
	42	12.8	1.7	16	1	US-09-829-855-10	Sequence 10, Appl
	43	12.8	1.7	16	1	US-09-829-855-110	Sequence 110, App
	44	12.8	1.7	16	1	US-09-479-005A-187	Sequence 187, App
	45	12.8	1.7	16	1	US-08-031-801-17	Sequence 17, Appl
	46	12.8	1.7	16	1	US-08-031-801-29	Sequence 29, Appl
	47	12.8	1.7	16	1	US-09-696-791-4142	Sequence 4142, Ap
c	48	12.8	1.7	16	1	PCT-US93-11198-539	Sequence 539, App
	49	12.4	1.6	15	1	US-08-276-594A-8	Sequence 8, Appli
c	50	12.4	1.6	15	1	US-08-991-830A-9	Sequence 9, Appli
c	51	12.4	1.6	15	1	US-08-486-343A-6	Sequence 6, Appli
	52	12.4	1.6	15	1	US-09-081-646-654	Sequence 654, App
	53	12.4	1.6	15	1	US-09-625-634A-5	Sequence 5, Appli
c	54	12.4	1.6	15	1	US-09-716-320-9	Sequence 9, Appli
c	55	12.4	1.6	15	1	PCT-US95-07349-6	Sequence 6, Appli

ALIGNMENTS

RESULT 1
US-08-859-998-1170/c
; Sequence 1170, Application US/08859998
; Patent No. 5994076
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jokhadze, George
; APPLICANT: Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 1170:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer

```
US-08-859-998-1170

  Query Match             3.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 0.71;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 2
US-09-225-928-1170/c
; Sequence 1170, Application US/09225928
; Patent No. 6352829
;   GENERAL INFORMATION:
;        APPLICANT: Chenchik, Alex
;                   Jokhadze, George
;                   Bibilashvilli, Robert
;        TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                            EXPRESSION
;        NUMBER OF SEQUENCES: 1375
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Fish & Richardson, P.C.
;             STREET: 2200 Sand Hill Road, Suite 100
;             CITY: Menlo Park
;             STATE: CA
;             COUNTRY: US
;             ZIP: 94025
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: Windows95
;             SOFTWARE: FastSEQ for Windows Version 2.0
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/225,928
;             FILING DATE: 05-Jan-1999
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/859,998
;             FILING DATE: 21-MAY-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Field, Bret E.
;             REGISTRATION NUMBER: 37,620
;             REFERENCE/DOCKET NUMBER: 09096/002001
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-322-5070
;             TELEFAX: 415-854-0875
;   INFORMATION FOR SEQ ID NO: 1170:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 25 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             OTHER INFORMATION:  oligonucleotide primer
;        SEQUENCE DESCRIPTION: SEQ ID NO: 1170:
US-09-225-928-1170

  Query Match             3.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 0.71;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 3
US-09-225-201B-1170/c
; Sequence 1170, Application US/09225201B
; Patent No. 6489455
;   GENERAL INFORMATION:
;        APPLICANT: Chenchik, Alex
;                   Jokhadze, George
;                   Bibilashvilli, Robert
;        TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                            EXPRESSION
;        NUMBER OF SEQUENCES: 1375
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Fish & Richardson, P.C.
;             STREET: 2200 Sand Hill Road, Suite 100
;             CITY: Menlo Park
;             STATE: CA
;             COUNTRY: US
;             ZIP: 94025
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: Windows95
;             SOFTWARE: FastSEQ for Windows Version 2.0
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/225,201B
;             FILING DATE: 05-Jan-1999
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/859,998
;             FILING DATE: 21-MAY-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Field, Bret E.
;             REGISTRATION NUMBER: 37,620
;             REFERENCE/DOCKET NUMBER: 09096/002001
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-322-5070
;             TELEFAX: 415-854-0875
;   INFORMATION FOR SEQ ID NO: 1170:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 25 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        FEATURE:
;             OTHER INFORMATION:  oligonucleotide primer
;        SEQUENCE DESCRIPTION: SEQ ID NO: 1170:
US-09-225-201B-1170

  Query Match             3.3%;  Score 25;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 0.71;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAGCCCG 655
              |||||||||||||||||||||||||
Db         25 TGCCGCCAAGTAAAGCCTTAGCCCG 1


RESULT 4
US-08-859-998-1169
; Sequence 1169, Application US/08859998
; Patent No. 5994076
;  GENERAL INFORMATION:
;    APPLICANT:  Chenchik, Alex
;    APPLICANT:  Jokhadze, George
;    APPLICANT:  Bibilashvilli, Robert
;    TITLE OF INVENTION:  METHOD OF ASSAYING DIFFERENTIAL
;    TITLE OF INVENTION:  EXPRESSION
;    NUMBER OF SEQUENCES:  1375
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson, P.C.
;      STREET:  2200 Sand Hill Road, Suite 100
;      CITY:  Menlo Park
;      STATE:  CA
;      COUNTRY:  US
;      ZIP:  94025
;    COMPUTER READABLE FORM:
```

```
;       MEDIUM TYPE:  Diskette
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  Windows95
;       SOFTWARE:  FastSEQ for Windows Version 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/859,998
;       FILING DATE:  21-MAY-1997
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Field, Bret E.
;       REGISTRATION NUMBER:  37,620
;       REFERENCE/DOCKET NUMBER:  09096/002001
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  415-322-5070
;       TELEFAX:  415-854-0875
;   INFORMATION FOR SEQ ID NO:  1169:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  24 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
;     FEATURE:
;       OTHER INFORMATION:  oligonucleotide primer
US-08-859-998-1169

  Query Match             3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 0.99;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 5
US-09-225-928-1169
; Sequence 1169, Application US/09225928
; Patent No. 6352829
;   GENERAL INFORMATION:
;       APPLICANT: Chenchik, Alex
;                  Jokhadze, George
;                  Bibilashvilli, Robert
;       TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                           EXPRESSION
;       NUMBER OF SEQUENCES: 1375
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Fish & Richardson, P.C.
;            STREET: 2200 Sand Hill Road, Suite 100
;            CITY: Menlo Park
;            STATE: CA
;            COUNTRY: US
;            ZIP: 94025
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: Windows95
;            SOFTWARE: FastSEQ for Windows Version 2.0
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/225,928
;            FILING DATE: 05-Jan-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/859,998
;            FILING DATE: 21-MAY-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Field, Bret E.
;            REGISTRATION NUMBER: 37,620
;            REFERENCE/DOCKET NUMBER: 09096/002001
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 415-322-5070
;            TELEFAX: 415-854-0875
;   INFORMATION FOR SEQ ID NO: 1169:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 24 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            OTHER INFORMATION:  oligonucleotide primer
;       SEQUENCE DESCRIPTION: SEQ ID NO: 1169:
US-09-225-928-1169

  Query Match             3.1%;  Score 24;  DB 1;  Length 24;
  Best Local Similarity   100.0%;  Pred. No. 0.99;
  Matches   24;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24


RESULT 6
US-09-225-201B-1169
; Sequence 1169, Application US/09225201B
; Patent No. 6489455
;   GENERAL INFORMATION:
;       APPLICANT: Chenchik, Alex
;                  Jokhadze, George
;                  Bibilashvilli, Robert
;       TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
;                           EXPRESSION
;       NUMBER OF SEQUENCES: 1375
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Fish & Richardson, P.C.
;            STREET: 2200 Sand Hill Road, Suite 100
;            CITY: Menlo Park
;            STATE: CA
;            COUNTRY: US
;            ZIP: 94025
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: Windows95
;            SOFTWARE: FastSEQ for Windows Version 2.0
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/225,201B
;            FILING DATE: 05-Jan-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/08/859,998
;            FILING DATE: 21-MAY-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Field, Bret E.
;            REGISTRATION NUMBER: 37,620
;            REFERENCE/DOCKET NUMBER: 09096/002001
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 415-322-5070
;            TELEFAX: 415-854-0875
;   INFORMATION FOR SEQ ID NO: 1169:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 24 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       FEATURE:
;            OTHER INFORMATION:  oligonucleotide primer
;       SEQUENCE DESCRIPTION: SEQ ID NO: 1169:
US-09-225-201B-1169

  Query Match             3.1%;  Score 24;  DB 1;  Length 24;
```

Best Local Similarity 100.0%; Pred. No. 0.99;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        396 ACGAGGAGCGGCAGGACGAGCATG 419
              ||||||||||||||||||||||||
Db          1 ACGAGGAGCGGCAGGACGAGCATG 24
```

RESULT 7
US-09-396-196G-92419
; Sequence 92419, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 92419
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-92419

Query Match 2.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 2.4;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        499 CCCTGAGGGCACACTGACCGTGGA 522
              ||||||||||||||| |||||||
Db          2 CCCTGAGGGCACACTTTCCGTGGA 25
```

RESULT 8
US-09-396-196G-92432
; Sequence 92432, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 92432
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-92432

Query Match 2.6%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2.9;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy        375 TGGTGGAGATCACCGGCAAGCACGA 399
              | || |||||||| ||||||||||
Db          1 TTGTTGAGATCACTGGCAAGCACGA 25
```

RESULT 9
US-09-990-613A-7
; Sequence 7, Application US/09990613A
; Patent No. 6818446
; GENERAL INFORMATION:
; APPLICANT: Wu, Reen
; APPLICANT: Chen, Yin
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE
; TITLE OF INVENTION: ANALYSIS OF MUCIN GENE EXPRESSION AND IDENTIFICATION OF
; TITLE OF INVENTION: DRUGS HAVING THE ABILITY TO INHIBIT MUCIN GENE EXPRESSION
; FILE REFERENCE: 39754-0721A
; CURRENT APPLICATION NUMBER: US/09/990,613A
; CURRENT FILING DATE: 2001-11-21
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-990-613A-7

Query Match 2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 13;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        403 GCGGCAGGACGAGCATGGC 421
              |||||| ||||||||||
Db          1 GCGGCACCACGAGCATGGC 19
```

RESULT 10
US-09-866-108A-10667
; Sequence 10667, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108A-10667

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17
```

RESULT 11
US-09-081-646-605
; Sequence 605, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 605
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-605

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        529 CATGCCCAAGCTAGC 543
              |||||||||||||||
Db          1 CATGCCCAAGCTAGC 15
```

RESULT 12
US-07-977-284A-13/c
; Sequence 13, Application US/07977284A
; Patent No. 5558988
; GENERAL INFORMATION:
; APPLICANT: Prockop, Darwin J.
; APPLICANT: Ala-Kokko, Leena
; APPLICANT: Williams, Charlene J.
; APPLICANT: Ritvaniemi, Pertti
; APPLICANT: Baldwin, Clinton
; APPLICANT: Hopkinson, Ian
; APPLICANT: Ahmad, Nilofer Nina
; TITLE OF INVENTION: METHODS OF DETECTING A GENETIC
; TITLE OF INVENTION: PREDISPOSITION FOR OSTEOARTHRITIS
; NUMBER OF SEQUENCES: 261
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5558988ris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,284A
; FILING DATE: 13-NOV-1992
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLuca, Mark
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-0697
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: NUCLEIC ACID
; STRANDEDNESS: SINGLE
; TOPOLOGY: LINEAR
; ANTI-SENSE: NO
US-07-977-284A-13

Query Match 1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 19;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        129 TGCCCCGGCTGCCGGAGG 146
              ||||| |||||| |||||
Db         18 TGCCCTGGCTGCAGGAGG 1
```

RESULT 13
US-08-256-426B-13/c
; Sequence 13, Application US/08256426B
; Patent No. 5948611
; GENERAL INFORMATION:
; APPLICANT: Prockop, Darwin J.
; APPLICANT: Ala-Kokko, Leena
; APPLICANT: Williams, Charlene J.
; APPLICANT: Ritvaniemi, Pertti
; APPLICANT: Baldwin, Clinton
; APPLICANT: Hopkinson, Ian
; APPLICANT: Ahmad, Nilofer Nina
; TITLE OF INVENTION: Methods of Detecting A Genetic
; NUMBER OF SEQUENCES: 293
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5948611ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 3.1
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/256,426B
; FILING DATE: 03-FEB-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/10964
; FILING DATE: 12-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/977,284
; FILING DATE: 13-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Mark DeLuca
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-1082
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439

```
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  SINGLE
;      TOPOLOGY:  LINEAR
;    ANTI-SENSE:  NO
US-08-256-426B-13

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 19;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        129 TGCCCCGGCTGCCGGAGG 146
              ||||| |||||| |||||
Db         18 TGCCCTGGCTGCAGGAGG 1


RESULT 14
US-09-663-834A-37/c
; Sequence 37, Application US/09663834A
; Patent No. 6613567
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF HER-2 EXPRESSION
;  FILE REFERENCE: RTS-0033
;  CURRENT APPLICATION NUMBER: US/09/663,834A
;  CURRENT FILING DATE:  2000-09-15
;  NUMBER OF SEQ ID NOS: 48
; SEQ ID NO 37
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-663-834A-37

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 19;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTGC 140
              |||||||| | |||||||
Db         18 TCGGGCTGGCTCGGCTGC 1


RESULT 15
US-08-411-796-466/c
; Sequence 466, Application US/08411796
; Patent No. 5677149
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/411,796
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981044
;      FILING DATE:  24-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:  22-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  466:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
US-08-411-796-466

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| |||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 16
US-08-471-039-466/c
; Sequence 466, Application US/08471039
; Patent No. 6017523
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/471,039
```

```
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981,044
;      FILING DATE:  24-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:  22-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/5
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  466:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
US-08-471-039-466

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 17
US-08-559-390-466/c
; Sequence 466, Application US/08559390
; Patent No. 6479261
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/559,390
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/411,796
;      FILING DATE:
;      APPLICATION NUMBER:  US 07/981044
;      FILING DATE:  24-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:  22-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  466:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
US-08-559-390-466

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 18
PCT-US93-11198-466/c
; Sequence 466, Application PC/TUS9311198
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981044
;      FILING DATE:  24-NOV-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  466:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
PCT-US93-11198-466

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 23;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||||||
Db         16 CATTCCAGTCACCTTC 1


RESULT 19
US-09-866-108A-10666
; Sequence 10666, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10666
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10666

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 22;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 20
US-09-866-108A-10668
; Sequence 10668, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10668
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10668

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 22;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 21
US-09-106-038A-27
; Sequence 27, Application US/09106038A
; Patent No. 6007995
;  GENERAL INFORMATION:
;    APPLICANT:  Brenda F. Baker and Lex M. Cowsert
;    TITLE OF INVENTION:  ANTISENSE MODULATION OF TNFR1
;    TITLE OF INVENTION:  EXPRESSION
;    NUMBER OF SEQUENCES:  91
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Isis Pharmaceuticals, Inc.
;      STREET:  2292 Faraday Avenue
;      CITY:  Carlsbad
;      STATE:  CA
;      COUNTRY:  U.S.A.
;      ZIP:  92008
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch disk, 1.44 Mb
;      COMPUTER:  IBM PC compatible
```

```
;      OPERATING SYSTEM:  Windows NT
;      SOFTWARE:  Microsoft Word 97
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/106,038A
;      FILING DATE:  June 26, 1998
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Laurel Spear Bernstein
;      REGISTRATION NUMBER:  37,280
;      REFERENCE/DOCKET NUMBER:  RTS-0004
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (760) 931-9200
;      TELEFAX:  (760) 603-3820
;  INFORMATION FOR SEQ ID NO:  27:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-106-038A-27

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        487 CTCCTCCCTGTCCCCT 502
              || |||||||||||||
Db          2 CTTCTCCCTGTCCCCT 17


RESULT 22
US-08-513-974B-249
; Sequence 249, Application US/08513974B
; Patent No. 6114139
;  GENERAL INFORMATION:
;    APPLICANT:  Hinuma, Shuji
;    APPLICANT:  Hosoya, Masaki
;    APPLICANT:  Fujii, Ryo
;    APPLICANT:  Ohtaki, Tetsuya
;    APPLICANT:  Fukusumi, Shoji
;    APPLICANT:  Ohgi, Kazuhiro
;    TITLE OF INVENTION:  G PROTEIN COUPLED RECEPTOR PROTEIN,
;    TITLE OF INVENTION:  PRODUCTION, AND USE THEREOF
;    NUMBER OF SEQUENCES:  380
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
;      STREET:  130 Water Street
;      CITY:  Boston
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/513,974B
;      FILING DATE:  14-SEP-1995
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/JP95/01599
;      FILING DATE:  10-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 7-093989
;      FILING DATE:  19-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 7-057186
;      FILING DATE:  16-MAR-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 7-007177
;      FILING DATE:  20-JAN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-326611
;      FILING DATE:  28-DEC-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-270017
;      FILING DATE:  02-NOV-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-236357
;      FILING DATE:  30-SEP-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-236356
;      FILING DATE:  30-SEP-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-189274
;      FILING DATE:  11-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-189273
;      FILING DATE:  11-AUG-1945
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 6-189272
;      FILING DATE:  11-AUG-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Resnick, David S.
;      REGISTRATION NUMBER:  34,235
;      REFERENCE/DOCKET NUMBER:  45753
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-523-3400
;      TELEFAX:  617-523-6440
;  INFORMATION FOR SEQ ID NO:  249:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-513-974B-249

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        218 AGCCCCGCAGTGGCCG 233
              |||| ||||||||||||
Db          1 AGCCTCGCAGTGGCCG 16


RESULT 23
US-09-422-978-6095/c
; Sequence 6095, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6095
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-8894 for SEQ 2161,
US-09-422-978-6095
```

```
  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGA 716
              ||||||||||||| |||
Db         18 CTGTGTGTTCTTCTGA 3


RESULT 24
US-08-431-048F-150
; Sequence 150, Application US/08431048F
; Patent No. 6531586
;   GENERAL INFORMATION:
;        APPLICANT: ST. GEORGE-HYSLOP, PETER H
;                   ROMMENS, JOHANNA M
;                   FRASER, PAUL E
;        TITLE OF INVENTION: GENETIC SEQUENCES AND PROTEINS RELATED
;                            TO ALZHEIMER'S DISEASE
;        NUMBER OF SEQUENCES: 155
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: DARBY & DARBY P.C.
;             STREET: 805 THIRD AVENUE
;             CITY: NEW YORK
;             STATE: N.Y.
;             COUNTRY: U.S.A.
;             ZIP: 10022-7513
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/08/431,048F
;             FILING DATE: 28-Apr-1995
;             CLASSIFICATION: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: FEHLNER, PAUL F.
;             REGISTRATION NUMBER: 35135
;             REFERENCE/DOCKET NUMBER: 1034/0F808
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 212-527-7700
;             TELEFAX: 212-527-6237
;   INFORMATION FOR SEQ ID NO: 150:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 150:
US-08-431-048F-150

  Query Match             1.8%;  Score 14;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 28;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          2 AGCCACGCAGTCCA 15


RESULT 25
US-09-275-680-11/c
; Sequence 11, Application US/09275680
; Patent No. 6221630
; GENERAL INFORMATION:
;  APPLICANT: Hopper, James E
;  TITLE OF INVENTION: A High Copy Number Recombinant Expression Construct for
;  TITLE OF INVENTION: Regulated High-level Production of Polypeptides in
;  TITLE OF INVENTION: Yeast
;  FILE REFERENCE: 98428
;  CURRENT APPLICATION NUMBER: US/09/275,680
;  CURRENT FILING DATE: 1999-03-24
;  NUMBER OF SEQ ID NOS: 22
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 11
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Saccharomyces cerevisiae
US-09-275-680-11

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 26;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        290 CGGCACACTGCGGACCG 306
              ||||||||  | ||||||
Db         17 CGGCACACAGTGGACCG 1


RESULT 26
US-08-881-450A-6/c
; Sequence 6, Application US/08881450A
; Patent No. 6274310
;  GENERAL INFORMATION:
;    APPLICANT:  Habener, J.F. and Stoffers, D.A.
;    TITLE OF INVENTION:  COMPOSITIONS AND METHODS FOR DETECTING
;    TITLE OF INVENTION:  PANCREATIC DISEASE
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Banner & Witcoff, Inc.
;      STREET:  One Financial Center
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/881,450A
;      FILING DATE:  June 24, 1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kathleen M. Williams
;      REGISTRATION NUMBER:  34,380
;      REFERENCE/DOCKET NUMBER:  11275/7823
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-345-9100
;      TELEFAX:  617-345-9111
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;    FEATURE:
;      NAME/KEY:  primer S17b
US-08-881-450A-6

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 26;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         38 CGCGTCCCCTTCTCGCT 54
              ||| |||||| ||||||
Db         17 CGCCTCCCCTGCTCGCT 1
```

```
RESULT 27
US-09-474-432B-773
; Sequence 773, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 773
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-773

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 26;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 28
US-09-476-387-772
; Sequence 772, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 772
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-772

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 26;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 29
US-09-866-108A-2329/c
; Sequence 2329, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2329
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2329

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 26;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
              |||| ||| ||||||||
Db         17 TCCAGCGACATCACCAT 1


RESULT 30
US-09-866-108A-2330/c
; Sequence 2330, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```

```
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2330
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2330

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 26;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 31
US-09-866-108A-2331/c
; Sequence 2331, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2331
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2331

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 26;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              ||||||| ||| |||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 32
US-09-866-108A-10669
; Sequence 10669, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10669
```

```
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10669

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 26;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              ||| |||||||||||  |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 33
US-09-866-108A-10670
; Sequence 10670, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10670
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10670

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 26;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||||  ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 34
US-09-404-912-599/c
; Sequence 599, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 599
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-599

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 26;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        746 AGTTCAAAGCAACCACC 762
              ||| ||||||| ||||
Db         17 AGTACAAAGCAAACACC 1


RESULT 35
US-08-431-048F-151
; Sequence 151, Application US/08431048F
; Patent No. 6531586
;   GENERAL INFORMATION:
;        APPLICANT: ST. GEORGE-HYSLOP, PETER H
;                   ROMMENS, JOHANNA M
;                   FRASER, PAUL E
;        TITLE OF INVENTION: GENETIC SEQUENCES AND PROTEINS RELATED
;                            TO ALZHEIMER'S DISEASE
;        NUMBER OF SEQUENCES: 155
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: DARBY & DARBY P.C.
;             STREET: 805 THIRD AVENUE
;             CITY: NEW YORK
;             STATE: N.Y.
;             COUNTRY: U.S.A.
;             ZIP: 10022-7513
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/08/431,048F
;             FILING DATE: 28-Apr-1995
;             CLASSIFICATION: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: FEHLNER, PAUL F.
;             REGISTRATION NUMBER: 35135
;             REFERENCE/DOCKET NUMBER: 1034/0F808
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 212-527-7700
;             TELEFAX: 212-527-6237
;   INFORMATION FOR SEQ ID NO: 151:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 151:
```

```
US-08-431-048F-151

  Query Match             1.8%;  Score 13.6;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 31;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||:|||||||
Db          2 AGCCACKCAGTCCA 15


RESULT 36
US-08-770-235A-24/c
; Sequence 24, Application US/08770235A
; Patent No. 5939538
;  GENERAL INFORMATION:
;    APPLICANT:  Leavitt, Markley C.
;    APPLICANT:  Tritz, Richard
;    APPLICANT:  Feng, Yu
;    APPLICANT:  Barber, Jack
;    APPLICANT:  Yu, Mang
;    TITLE OF INVENTION:  Methods and Compositions for Inhibiting
;    TITLE OF INVENTION:  HIV Infection of Cells By Cleaving HIV Co-Receptor RNA
;    NUMBER OF SEQUENCES:  77
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, Eighth Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111-3834
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/770,235A
;      FILING DATE:  19-DEC-1996
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/027,875
;      FILING DATE:  25-OCT-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  QUINE, Jonathan A.
;      REGISTRATION NUMBER:  P-41,261
;      REFERENCE/DOCKET NUMBER:  016556-001610US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 576-0200
;      TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  RNA
US-08-770-235A-24

  Query Match             1.8%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 30;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        402 AGCGGCAGGACGAGC 416
              ||||||||||| |||
Db         16 AGCGGCAGGACCAGC 2


RESULT 37
US-08-411-796-539/c
; Sequence 539, Application US/08411796
; Patent No. 5677149
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/411,796
;      FILING DATE:
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981044
;      FILING DATE:  24-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:  22-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  539:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
US-08-411-796-539

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| |||||||||| ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 38
US-08-471-039-539/c
; Sequence 539, Application US/08471039
; Patent No. 6017523
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
```

```
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/471,039
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981,044
;      FILING DATE:  24-NOV-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:  22-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/5
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  539:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
US-08-471-039-539

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| |||||||||| ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 39
US-08-464-582-16
; Sequence 16, Application US/08464582
; Patent No. 6114598
; GENERAL INFORMATION:
;  APPLICANT: Kucherlapati, Raju
;  APPLICANT: Jakobovits, Aya
;  APPLICANT: Klapholz, Sue
;  APPLICANT: Brenner, Daniel G.
;  APPLICANT: Capon, Daniel J.
;  TITLE OF INVENTION: GENERATION OF XENOGENIC ANTIBODIES
;  FILE REFERENCE: CELL 4.10
;  CURRENT APPLICATION NUMBER: US/08/464,582
;  CURRENT FILING DATE: 1995-06-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: adapter
US-08-464-582-16

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 40
US-08-462-513-16
; Sequence 16, Application US/08462513
; Patent No. 6162963
; GENERAL INFORMATION:
;  APPLICANT: Kucherlapati, Raju
;  APPLICANT: Jakobovits, Aya
;  APPLICANT: Klapholz, Sue
;  APPLICANT: Brenner, Daniel G.
;  APPLICANT: Capon, Daniel J.
;  TITLE OF INVENTION: GENERATION OF XENOGENIC ANTIBODIES
;  FILE REFERENCE: CELL 4.16
;  CURRENT APPLICATION NUMBER: US/08/462,513
;  CURRENT FILING DATE: 1995-06-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: adapter
US-08-462-513-16

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 41
US-08-559-390-539/c
; Sequence 539, Application US/08559390
; Patent No. 6479261
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
```

```
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/559,390
;       FILING DATE:
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/411,796
;       FILING DATE:
;       APPLICATION NUMBER:  US 07/981044
;       FILING DATE:  24-NOV-1992
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US93/11198
;       FILING DATE:  22-NOV-1993
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Bennett, Dennis A.
;       REGISTRATION NUMBER:  34,547
;       REFERENCE/DOCKET NUMBER:  C2713/1
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (708)470-6501
;       TELEFAX:  (708)470-6881
;   INFORMATION FOR SEQ ID NO:  539:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (synthetic)
US-08-559-390-539

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||| ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 42
US-09-829-855-10
; Sequence 10, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
;  APPLICANT: Matthew, Ashby N.
;  TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;  FILE REFERENCE: ASHBY-1
;  CURRENT APPLICATION NUMBER: US/09/829,855
;  CURRENT FILING DATE:  2001-04-10
;  PRIOR APPLICATION NUMBER: US 60/196063
;  PRIOR FILING DATE: 2000-04-10
;  PRIOR APPLICATION NUMBER: US 60/196258
;  PRIOR FILING DATE: 2000-04-11
;  NUMBER OF SEQ ID NOS: 244
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: unknown
;   FEATURE:
;   OTHER INFORMATION: unidentified soil organism
US-09-829-855-10

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        525 CCCCCATGCCCAAGCT 540
              ||||| |||| |||||
Db          1 CCCCCGTGCCGAAGCT 16


RESULT 43
US-09-829-855-110
; Sequence 110, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
;  APPLICANT: Matthew, Ashby N.
;  TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;  FILE REFERENCE: ASHBY-1
;  CURRENT APPLICATION NUMBER: US/09/829,855
;  CURRENT FILING DATE:  2001-04-10
;  PRIOR APPLICATION NUMBER: US 60/196063
;  PRIOR FILING DATE: 2000-04-10
;  PRIOR APPLICATION NUMBER: US 60/196258
;  PRIOR FILING DATE: 2000-04-11
;  NUMBER OF SEQ ID NOS: 244
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 110
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: unknown
;   FEATURE:
;   OTHER INFORMATION: unidentified soil organism
US-09-829-855-110

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              |||||| ||| |||||
Db          1 CTGCGGTGCCGCAGCT 16


RESULT 44
US-09-479-005A-187
; Sequence 187, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 187
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-187

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   31.2%;  Pred. No. 35;
  Matches    5;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 TTCTTTTGATACATTT 723
              : |:::||:| |:::
Db          1 UCCUUUUGAUAAAUUU 16


RESULT 45
US-08-031-801-17
; Sequence 17, Application US/08031801
; Patent No. 6673986
; GENERAL INFORMATION:
```

```
;  APPLICANT: KUCHERLAPATI, RAJU
;  APPLICANT:  JAKOBOVITS, AYA
;  APPLICANT:  KLAPHOLZ, SUE
;  APPLICANT:  BRENNER, DANIEL G.
;  APPLICANT:  CAPON, DANIEL J.
;  TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
;  FILE REFERENCE: CELL 4.4 CPA RCE
;  CURRENT APPLICATION NUMBER: US/08/031,801
;  CURRENT FILING DATE:  2003-01-10
;  PRIOR APPLICATION NUMBER: 07/919,297
;  PRIOR FILING DATE: 1992-07-24
;  PRIOR APPLICATION NUMBER: PCT/US91/00245
;  PRIOR FILING DATE: 1991-01-11
;  PRIOR APPLICATION NUMBER: 07/610,515
;  PRIOR FILING DATE: 1990-11-08
;  PRIOR APPLICATION NUMBER: 07/466,008
;  PRIOR FILING DATE: 1990-01-12
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-08-031-801-17

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 46
US-08-031-801-29
; Sequence 29, Application US/08031801
; Patent No. 6673986
; GENERAL INFORMATION:
;  APPLICANT: KUCHERLAPATI, RAJU
;  APPLICANT:  JAKOBOVITS, AYA
;  APPLICANT:  KLAPHOLZ, SUE
;  APPLICANT:  BRENNER, DANIEL G.
;  APPLICANT:  CAPON, DANIEL J.
;  TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
;  FILE REFERENCE: CELL 4.4 CPA RCE
;  CURRENT APPLICATION NUMBER: US/08/031,801
;  CURRENT FILING DATE:  2003-01-10
;  PRIOR APPLICATION NUMBER: 07/919,297
;  PRIOR FILING DATE: 1992-07-24
;  PRIOR APPLICATION NUMBER: PCT/US91/00245
;  PRIOR FILING DATE: 1991-01-11
;  PRIOR APPLICATION NUMBER: 07/610,515
;  PRIOR FILING DATE: 1990-11-08
;  PRIOR APPLICATION NUMBER: 07/466,008
;  PRIOR FILING DATE: 1990-01-12
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: polylinker
US-08-031-801-29

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         68 AGCTGGGACCCCTTCC 83
              |||||| ||||||| |
Db          1 AGCTGGAACCCCTTGC 16


RESULT 47
US-09-696-791-4142
; Sequence 4142, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4142
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Hairpin ribozyme recognition site for cyclin B1
US-09-696-791-4142

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        351 TGACGGTCAAGACCAA 366
              |||| ||||||| |||
Db          1 TGACTGTCAAGAACAA 16


RESULT 48
PCT-US93-11198-539/c
; Sequence 539, Application PC/TUS9311198
;  GENERAL INFORMATION:
;    APPLICANT:  Abrams, Mark A.
;    APPLICANT:  Bauer, S. C.
;    APPLICANT:  Braford-Goldberg, Sarah R.
;    APPLICANT:  Caparon, Maire H.
;    APPLICANT:  Easton, Alan M.
;    APPLICANT:  Klein, Barbara K.
;    APPLICANT:  McKearn, John P.
;    APPLICANT:  Olins, Peter O.
;    APPLICANT:  Paik, Kumnan
;    APPLICANT:  Polazzi, Joseph O.
;    APPLICANT:  Thomas, John W.
;    TITLE OF INVENTION:  Interleukin-3 (IL-3) Mutant Polypeptides
;    NUMBER OF SEQUENCES:  549
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dennis A. Bennett, G.D. Searle & Co.,
;      ADDRESSEE:  Corporate Patent Dept.
;      STREET:  P. O. Box 5110
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60680
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11198
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/981044
```

```
;      FILING DATE:  24-NOV-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bennett, Dennis A.
;      REGISTRATION NUMBER:  34,547
;      REFERENCE/DOCKET NUMBER:  C2713/1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (708)470-6501
;      TELEFAX:  (708)470-6881
;  INFORMATION FOR SEQ ID NO:  539:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (synthetic)
PCT-US93-11198-539

  Query Match             1.7%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 35;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        565 CATCCCAGTCACCTTC 580
              ||| ||||||||| ||
Db         16 CATTCCAGTCACCGTC 1


RESULT 49
US-08-276-594A-8
; Sequence 8, Application US/08276594A
; Patent No. 5693499
;  GENERAL INFORMATION:
;    APPLICANT:  YONEMURA, Hiroshi
;    APPLICANT:  TAJIMA, Yoshitaka
;    APPLICANT:  SUGAWARA, Keishin
;    APPLICANT:  MASUDA, Kenichi
;    TITLE OF INVENTION:  PROCESS FOR PREPARING HUMAN COAGULATION
;    TITLE OF INVENTION:  FACTOR VIII PROTEIN COMPLEX
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Foley & Lardner
;      STREET:  3000 K Street, N.W., Suite 500
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20007-5109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/276,594A
;      FILING DATE:  18-JUL-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/950,191
;      FILING DATE:  24-SEP-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 243262/1991
;      FILING DATE:  24-SEP-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  WEGNER, Harold C.
;      REGISTRATION NUMBER:  25,258
;      REFERENCE/DOCKET NUMBER:  74129/195/AOPA
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)672-5300
;      TELEFAX:  (202)672-5399
;      TELEX:  904136
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-276-594A-8

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        594 AGCTTGGGGGCCCA 607
              ||||| ||||||||
Db          1 AGCTTTGGGGCCCA 14


RESULT 50
US-08-991-830A-9/c
; Sequence 9, Application US/08991830A
; Patent No. 6027892
;  GENERAL INFORMATION:
;    APPLICANT:  Chang, Esther H.
;    APPLICANT:  Pirollo, Kathleen F.
;    TITLE OF INVENTION:  Compositions and Methods for Reducing Radiation and Drug Resis
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sana A. Pratt
;      STREET:  10821 Hillbrooke Lane
;      CITY:  Potomac
;      STATE:  MARYLAND
;      COUNTRY:  USA
;      ZIP:  20854
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh 7.5
;      SOFTWARE:  Microsoft Word 6.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/991,830A
;      FILING DATE:  16 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/034,160
;      FILING DATE:  30 December 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sana A. Pratt
;      REGISTRATION NUMBER:  39,441
;      REFERENCE/DOCKET NUMBER:
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (301) 294-9171
;      TELEFAX:  (301) 294-7357
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  Nucleic acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    MOLECULE TYPE:  DNA
US-08-991-830A-9

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        410 GACGAGCATGGCTA 423
              ||| ||||||||||
Db         15 GACAAGCATGGCTA 2


RESULT 51
US-08-486-343A-6/c
; Sequence 6, Application US/08486343A
; Patent No. 6071695
;  GENERAL INFORMATION:
;    APPLICANT:  OZKAYNAK, ENGIN
;    APPLICANT:  OPPERMANN, HERMANN
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR MODULATING
```

```
;    TITLE OF INVENTION:  MORPHOGENIC PROTEIN EXPRESSION
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
;      ADDRESSEE:  INC.
;      STREET:  45 SOUTH STREET
;      CITY:  HOPKINTON
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  07148
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,343A
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  PITCHER, Edmund R
;      REGISTRATION NUMBER:  27,829
;      REFERENCE/DOCKET NUMBER:  CRP-091CP
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617)-248-7000
;      TELEFAX:  (617)-248-7100
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  1..15
;      OTHER INFORMATION:  /note= "WT1/EGR MOUSE TCC BINDING
;      OTHER INFORMATION:  SITE"
US-08-486-343A-6

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        398 GAGGAGCGGCAGGA 411
              ||||||||| ||||
Db         14 GAGGAGCGGGAGGA 1


RESULT 52
US-09-081-646-654
; Sequence 654, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 654
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-654

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        369 ATGGCGTGGTGGAG 382
              |||||| |||||||
Db          2 ATGGCGGGGTGGAG 15


RESULT 53
US-09-625-634A-5
; Sequence 5, Application US/09625634A
; Patent No. 6653448
; GENERAL INFORMATION:
;  APPLICANT: Vernet, Corine
;  APPLICANT:  Rastelli, Luca
;  APPLICANT:  Herrmann, John
;  TITLE OF INVENTION: WNT-7B-LIKE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING
;  TITLE OF INVENTION:  SAME
;  FILE REFERENCE: Cura-244 (15966-744) US
;  CURRENT APPLICATION NUMBER: US/09/625,634A
;  CURRENT FILING DATE:  2000-07-26
;  PRIOR APPLICATION NUMBER: USSN 60/194,256
;  PRIOR FILING DATE: 2000-04-03
;  PRIOR APPLICATION NUMBER: USSN 60/192,838
;  PRIOR FILING DATE: 2000-03-29
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  SYNTHETIC PCR
;   OTHER INFORMATION: PRIMER
US-09-625-634A-5

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        426 TCTCCCGGTGCTTC 439
              |||||||| |||||
Db          1 TCTCCCGGCGCTTC 14


RESULT 54
US-09-716-320-9/c
; Sequence 9, Application US/09716320
; Patent No. 6803360
; GENERAL INFORMATION:
;  APPLICANT: Chang, Esther H
;  APPLICANT:  Pirollo, Kathleen F
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR REDUCING RADIATION AND DRUG RESISTAN
;  FILE REFERENCE: 2444-109
;  CURRENT APPLICATION NUMBER: US/09/716,320
;  CURRENT FILING DATE:  2000-11-21
;  PRIOR APPLICATION NUMBER: US 09/480,143
;  PRIOR FILING DATE: 2000-01-10
;  PRIOR APPLICATION NUMBER: US 08/991,830
;  PRIOR FILING DATE: 1997-12-16
;  PRIOR APPLICATION NUMBER: US 60/034,160
;  PRIOR FILING DATE: 1996-12-30
;  PRIOR APPLICATION NUMBER: US 09/601,444
;  PRIOR FILING DATE: 2001-01-04
;  PRIOR APPLICATION NUMBER: PCT/US98/24657
;  PRIOR FILING DATE: 1998-11-19
;  PRIOR APPLICATION NUMBER: US 60/066,188
;  PRIOR FILING DATE: 1997-11-19
;  PRIOR APPLICATION NUMBER: US 60/083,175
;  PRIOR FILING DATE: 1998-04-27
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.1
```

```
; SEQ ID NO 9
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: HER-2 control oligonucleotide scrambled 2
US-09-716-320-9

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        410 GACGAGCATGGCTA 423
              ||| ||||||||||
Db         15 GACAAGCATGGCTA 2


RESULT 55
PCT-US95-07349-6/c
; Sequence 6, Application PC/TUS9507349
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR MODULATING
;    TITLE OF INVENTION:  MORPHOGEN EXPRESSION
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
;      ADDRESSEE:  INC.
;      STREET:  45 SOUTH STREET
;      CITY:  HOPKINTON
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  07148
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/07349
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/938,021
;      FILING DATE:  28-AUG-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  KELLEY, ROBIN D
;      REGISTRATION NUMBER:  34,637
;      REFERENCE/DOCKET NUMBER:  CRP-091PC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (508)-435-9001
;      TELEFAX:  (508)-435-0992
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  1..15
;      OTHER INFORMATION:  /note= "WT1 MOUSE TCC BINDING SITE"
PCT-US95-07349-6

  Query Match             1.6%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 42;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        398 GAGGAGCGGCAGGA 411
              ||||||||| ||||
Db         14 GAGGAGCGGGAGGA 1
```

```
Search completed: May 10, 2005, 07:17:21
Job time : 0.001 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: May 10, 2005, 07:19:34 ; Search time 1 Seconds
(without alignments)
6.386 Million cell updates/sec

Title: US-10-605-498-91
Perfect score: 764
Sequence: 1 ggcacgaggagcagagtcag.....aagttcaaagcaaccacctg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 198 seqs, 4179 residues

Total number of hits satisfying chosen parameters: 396

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 199 summaries

Database : rnpb91.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	52.2	6.8	65	1	US-09-908-975-2665	Sequence 2665, Ap
	2	50	6.5	50	1	US-10-131-827-3859	Sequence 3859, Ap
	3	49	6.4	60	1	US-10-764-420-95	Sequence 95, Appl
	4	23.4	3.1	25	1	US-10-719-900-265359	Sequence 265359,
c	5	23.4	3.1	25	1	US-10-719-900-475563	Sequence 475563,
	6	23.4	3.1	25	1	US-10-719-900-618137	Sequence 618137,
c	7	23.4	3.1	25	1	US-10-719-900-657749	Sequence 657749,
c	8	23.4	3.1	25	1	US-10-719-900-858223	Sequence 858223,
c	9	23	3.0	23	1	US-10-840-038-4	Sequence 4, Appli
c	10	22.4	2.9	25	1	US-10-719-900-152005	Sequence 152005,
	11	22.4	2.9	25	1	US-10-719-900-653170	Sequence 653170,
	12	22.4	2.9	25	1	US-10-719-900-653171	Sequence 653171,
	13	22.4	2.9	25	1	US-10-719-900-855205	Sequence 855205,
	14	22.4	2.9	25	1	US-10-719-900-855206	Sequence 855206,
	15	22	2.9	22	1	US-10-840-038-5	Sequence 5, Appli
c	16	21.8	2.9	25	1	US-10-719-900-51105	Sequence 51105, A
	17	21.8	2.9	25	1	US-10-719-900-248862	Sequence 248862,
	18	21.8	2.9	25	1	US-10-719-900-265360	Sequence 265360,
	19	21.8	2.9	25	1	US-10-719-900-376560	Sequence 376560,
	20	21.8	2.9	25	1	US-10-719-900-415441	Sequence 415441,
c	21	21.8	2.9	25	1	US-10-719-900-472172	Sequence 472172,
c	22	21.8	2.9	25	1	US-10-719-900-475562	Sequence 475562,
	23	21.8	2.9	25	1	US-10-719-900-592386	Sequence 592386,
	24	21.8	2.9	25	1	US-10-719-900-618136	Sequence 618136,
c	25	21.8	2.9	25	1	US-10-719-900-657748	Sequence 657748,
	26	21.8	2.9	25	1	US-10-719-900-830334	Sequence 830334,
c	27	21.8	2.9	25	1	US-10-719-900-858224	Sequence 858224,
	28	21.4	2.8	23	1	US-09-911-904-63	Sequence 63, Appl
c	29	21	2.7	21	1	US-10-605-498-1	Sequence 1, Appli
c	30	21	2.7	21	1	US-10-605-498-2	Sequence 2, Appli
c	31	21	2.7	21	1	US-10-605-498-3	Sequence 3, Appli
c	32	21	2.7	21	1	US-10-605-498-4	Sequence 4, Appli
c	33	21	2.7	21	1	US-10-605-498-5	Sequence 5, Appli
c	34	21	2.7	21	1	US-10-605-498-6	Sequence 6, Appli
c	35	21	2.7	21	1	US-10-605-498-7	Sequence 7, Appli
c	36	21	2.7	21	1	US-10-605-498-8	Sequence 8, Appli
c	37	21	2.7	21	1	US-10-605-498-9	Sequence 9, Appli
c	38	21	2.7	21	1	US-10-605-498-10	Sequence 10, Appl
c	39	21	2.7	21	1	US-10-605-498-11	Sequence 11, Appl
c	40	21	2.7	21	1	US-10-605-498-12	Sequence 12, Appl
c	41	21	2.7	21	1	US-10-605-498-13	Sequence 13, Appl
c	42	21	2.7	21	1	US-10-605-498-14	Sequence 14, Appl
c	43	21	2.7	21	1	US-10-605-498-15	Sequence 15, Appl
c	44	21	2.7	21	1	US-10-605-498-16	Sequence 16, Appl
c	45	21	2.7	21	1	US-10-605-498-17	Sequence 17, Appl
c	46	21	2.7	21	1	US-10-605-498-18	Sequence 18, Appl
c	47	21	2.7	21	1	US-10-605-498-19	Sequence 19, Appl
c	48	21	2.7	21	1	US-10-605-498-20	Sequence 20, Appl
c	49	21	2.7	21	1	US-10-605-498-21	Sequence 21, Appl
c	50	21	2.7	21	1	US-10-605-498-22	Sequence 22, Appl
c	51	21	2.7	21	1	US-10-605-498-23	Sequence 23, Appl
c	52	21	2.7	21	1	US-10-605-498-24	Sequence 24, Appl
c	53	21	2.7	21	1	US-10-605-498-25	Sequence 25, Appl
c	54	21	2.7	21	1	US-10-605-498-26	Sequence 26, Appl
c	55	21	2.7	21	1	US-10-605-498-27	Sequence 27, Appl
c	56	21	2.7	21	1	US-10-605-498-28	Sequence 28, Appl
c	57	21	2.7	21	1	US-10-605-498-29	Sequence 29, Appl
c	58	21	2.7	21	1	US-10-605-498-30	Sequence 30, Appl
c	59	21	2.7	21	1	US-10-605-498-31	Sequence 31, Appl
c	60	21	2.7	21	1	US-10-605-498-32	Sequence 32, Appl
c	61	21	2.7	21	1	US-10-605-498-33	Sequence 33, Appl
c	62	21	2.7	21	1	US-10-605-498-34	Sequence 34, Appl
c	63	21	2.7	21	1	US-10-605-498-35	Sequence 35, Appl
c	64	21	2.7	21	1	US-10-605-498-36	Sequence 36, Appl
c	65	21	2.7	21	1	US-10-605-498-37	Sequence 37, Appl
c	66	21	2.7	21	1	US-10-605-498-38	Sequence 38, Appl
c	67	21	2.7	21	1	US-10-605-498-39	Sequence 39, Appl
c	68	21	2.7	21	1	US-10-605-498-40	Sequence 40, Appl
c	69	21	2.7	21	1	US-10-605-498-41	Sequence 41, Appl
c	70	21	2.7	21	1	US-10-605-498-42	Sequence 42, Appl
c	71	21	2.7	21	1	US-10-605-498-43	Sequence 43, Appl
c	72	21	2.7	21	1	US-10-605-498-44	Sequence 44, Appl
c	73	21	2.7	21	1	US-10-605-498-45	Sequence 45, Appl
c	74	21	2.7	21	1	US-10-605-498-46	Sequence 46, Appl
c	75	21	2.7	21	1	US-10-605-498-47	Sequence 47, Appl
c	76	21	2.7	21	1	US-10-605-498-48	Sequence 48, Appl
c	77	21	2.7	21	1	US-10-605-498-49	Sequence 49, Appl
c	78	21	2.7	21	1	US-10-605-498-50	Sequence 50, Appl
c	79	21	2.7	21	1	US-10-605-498-51	Sequence 51, Appl
c	80	21	2.7	21	1	US-10-605-498-52	Sequence 52, Appl
c	81	21	2.7	21	1	US-10-605-498-53	Sequence 53, Appl
c	82	21	2.7	21	1	US-10-605-498-54	Sequence 54, Appl
c	83	21	2.7	21	1	US-10-605-498-55	Sequence 55, Appl
c	84	21	2.7	21	1	US-10-605-498-56	Sequence 56, Appl
c	85	21	2.7	21	1	US-10-605-498-57	Sequence 57, Appl
c	86	21	2.7	21	1	US-10-605-498-58	Sequence 58, Appl
c	87	21	2.7	21	1	US-10-605-498-59	Sequence 59, Appl
c	88	21	2.7	21	1	US-10-605-498-60	Sequence 60, Appl
c	89	21	2.7	21	1	US-10-605-498-61	Sequence 61, Appl
c	90	21	2.7	21	1	US-10-605-498-62	Sequence 62, Appl
c	91	21	2.7	21	1	US-10-605-498-63	Sequence 63, Appl
c	92	21	2.7	21	1	US-10-605-498-64	Sequence 64, Appl
c	93	21	2.7	21	1	US-10-605-498-65	Sequence 65, Appl
c	94	21	2.7	21	1	US-10-605-498-66	Sequence 66, Appl
c	95	21	2.7	21	1	US-10-605-498-67	Sequence 67, Appl
c	96	21	2.7	21	1	US-10-605-498-68	Sequence 68, Appl
c	97	21	2.7	21	1	US-10-605-498-69	Sequence 69, Appl
c	98	21	2.7	21	1	US-10-605-498-70	Sequence 70, Appl
c	99	21	2.7	21	1	US-10-605-498-71	Sequence 71, Appl
c	100	21	2.7	21	1	US-10-605-498-72	Sequence 72, Appl
c	101	21	2.7	21	1	US-10-605-498-73	Sequence 73, Appl
c	102	21	2.7	21	1	US-10-605-498-74	Sequence 74, Appl
c	103	21	2.7	21	1	US-10-605-498-75	Sequence 75, Appl
c	104	21	2.7	21	1	US-10-605-498-76	Sequence 76, Appl
c	105	21	2.7	21	1	US-10-605-498-78	Sequence 78, Appl
c	106	21	2.7	21	1	US-10-605-498-79	Sequence 79, Appl

c 107	21	2.7	21	1	US-10-605-498-80	Sequence 80, Appl
c 108	21	2.7	21	1	US-10-605-498-81	Sequence 81, Appl
c 109	20.8	2.7	25	1	US-10-719-900-152006	Sequence 152006,
110	20.8	2.7	25	1	US-10-809-189-92419	Sequence 92419, A
c 111	20.2	2.6	25	1	US-10-719-900-51106	Sequence 51106, A
112	20.2	2.6	25	1	US-10-719-900-72371	Sequence 72371, A
c 113	20.2	2.6	25	1	US-10-719-900-147040	Sequence 147040,
114	20.2	2.6	25	1	US-10-719-900-248861	Sequence 248861,
115	20.2	2.6	25	1	US-10-719-900-347106	Sequence 347106,
116	20.2	2.6	25	1	US-10-719-900-376561	Sequence 376561,
117	20.2	2.6	25	1	US-10-719-900-415444	Sequence 415444,
c 118	20.2	2.6	25	1	US-10-719-900-472173	Sequence 472173,
119	20.2	2.6	25	1	US-10-719-900-581985	Sequence 581985,
120	20.2	2.6	25	1	US-10-719-900-592387	Sequence 592387,
121	20.2	2.6	25	1	US-10-719-900-611646	Sequence 611646,
c 122	20.2	2.6	25	1	US-10-719-900-685015	Sequence 685015,
c 123	20.2	2.6	25	1	US-10-719-900-685016	Sequence 685016,
c 124	20.2	2.6	25	1	US-10-719-900-819345	Sequence 819345,
125	20.2	2.6	25	1	US-10-719-900-830335	Sequence 830335,
126	20.2	2.6	25	1	US-10-809-189-92432	Sequence 92432, A
c 127	20	2.6	20	1	US-10-605-498-82	Sequence 82, Appl
128	20	2.6	20	1	US-10-713-808-13	Sequence 13, Appl
129	19	2.5	19	1	US-10-605-498-87	Sequence 87, Appl
130	19	2.5	19	1	US-10-605-498-90	Sequence 90, Appl
131	18.4	2.4	21	1	US-10-472-779-1	Sequence 1, Appli
c 132	18	2.4	18	1	US-10-605-498-77	Sequence 77, Appl
133	17.8	2.3	21	1	US-10-605-498-89	Sequence 89, Appl
c 134	17.8	2.3	22	1	US-10-472-779-2	Sequence 2, Appli
135	17	2.2	17	1	US-10-339-793-168	Sequence 168, App
136	16.8	2.2	21	1	US-10-751-736-34691	Sequence 34691, A
137	15.8	2.1	19	1	US-09-990-613-0	Sequence 0, Appli
138	15.8	2.1	19	1	US-10-605-498-83	Sequence 83, Appl
139	15.8	2.1	21	1	US-10-605-498-7	Sequence 7, Appli
140	15.4	2.0	17	1	US-09-866-108-10667	Sequence 10667, A
c 141	15.4	2.0	17	1	US-10-211-689-82	Sequence 82, Appl
142	15.4	2.0	17	1	US-10-723-361-10667	Sequence 10667, A
c 143	14.8	1.9	18	1	US-10-450-472-50	Sequence 50, Appl
c 144	14.4	1.9	16	1	US-10-179-940-466	Sequence 466, App
145	14.4	1.9	17	1	US-09-866-108-10666	Sequence 10666, A
146	14.4	1.9	17	1	US-09-866-108-10668	Sequence 10668, A
c 147	14.4	1.9	17	1	US-10-060-830-218	Sequence 218, App
c 148	14.4	1.9	17	1	US-10-060-830-219	Sequence 219, App
149	14.4	1.9	17	1	US-10-156-306-5028	Sequence 5028, Ap
c 150	14.4	1.9	17	1	US-10-238-700-2848	Sequence 2848, Ap
151	14.4	1.9	17	1	US-10-723-361-10666	Sequence 10666, A
152	14.4	1.9	17	1	US-10-723-361-10668	Sequence 10668, A
153	14.4	1.9	17	1	US-10-498-462-2203	Sequence 2203, Ap
154	14.4	1.9	17	1	US-10-498-462-2204	Sequence 2204, Ap
c 155	14.4	1.9	17	1	US-10-724-270-1527	Sequence 1527, Ap
c 156	14.4	1.9	18	1	US-10-349-143-6095	Sequence 6095, Ap
c 157	14	1.8	17	1	US-09-818-875-4230	Sequence 4230, Ap
158	14	1.8	17	1	US-09-818-875-4231	Sequence 4231, Ap
159	14	1.8	17	1	US-09-780-533A-765	Sequence 765, App
160	14	1.8	17	1	US-09-780-533A-1791	Sequence 1791, Ap
c 161	14	1.8	17	1	US-10-209-787-4230	Sequence 4230, Ap
162	14	1.8	17	1	US-10-209-787-4231	Sequence 4231, Ap
c 163	14	1.8	17	1	US-10-261-185-4230	Sequence 4230, Ap
164	14	1.8	17	1	US-10-261-185-4231	Sequence 4231, Ap
c 165	14	1.8	17	1	US-10-681-074-4230	Sequence 4230, Ap
166	14	1.8	17	1	US-10-681-074-4231	Sequence 4231, Ap
c 167	13.8	1.8	17	1	US-09-866-108-2329	Sequence 2329, Ap
c 168	13.8	1.8	17	1	US-09-866-108-2330	Sequence 2330, Ap
c 169	13.8	1.8	17	1	US-09-866-108-2331	Sequence 2331, Ap
170	13.8	1.8	17	1	US-09-866-108-10669	Sequence 10669, A
171	13.8	1.8	17	1	US-09-866-108-10670	Sequence 10670, A
c 172	13.8	1.8	17	1	US-09-864-785-1425	Sequence 1425, Ap
173	13.8	1.8	17	1	US-09-825-805-772	Sequence 772, App
174	13.8	1.8	17	1	US-09-780-533A-2414	Sequence 2414, Ap
175	13.8	1.8	17	1	US-09-927-046-1306	Sequence 1306, Ap
c 176	13.8	1.8	17	1	US-09-927-046-1904	Sequence 1904, Ap
c 177	13.8	1.8	17	1	US-09-927-046-1905	Sequence 1905, Ap
178	13.8	1.8	17	1	US-09-740-332-4378	Sequence 4378, Ap
179	13.8	1.8	17	1	US-09-817-879-4378	Sequence 4378, Ap
c 180	13.8	1.8	17	1	US-10-060-756A-170	Sequence 170, App
181	13.8	1.8	17	1	US-10-163-552-650	Sequence 650, App
182	13.8	1.8	17	1	US-10-156-306-5029	Sequence 5029, Ap
183	13.8	1.8	17	1	US-10-238-700-484	Sequence 484, App
184	13.8	1.8	17	1	US-10-061-201-1223	Sequence 1223, Ap
c 185	13.8	1.8	17	1	US-10-382-248-80	Sequence 80, Appl
c 186	13.8	1.8	17	1	US-10-676-154-599	Sequence 599, App
c 187	13.8	1.8	17	1	US-10-712-672-332	Sequence 332, App
188	13.8	1.8	17	1	US-10-669-841-6971	Sequence 6971, Ap
c 189	13.8	1.8	17	1	US-10-723-361-2329	Sequence 2329, Ap
c 190	13.8	1.8	17	1	US-10-723-361-2330	Sequence 2330, Ap
c 191	13.8	1.8	17	1	US-10-723-361-2331	Sequence 2331, Ap
192	13.8	1.8	17	1	US-10-723-361-10669	Sequence 10669, A
193	13.8	1.8	17	1	US-10-723-361-10670	Sequence 10670, A
194	13.8	1.8	17	1	US-10-494-343-325	Sequence 325, App
c 195	13.8	1.8	17	1	US-10-498-462-1759	Sequence 1759, Ap
c 196	13.8	1.8	17	1	US-10-498-462-1760	Sequence 1760, Ap
197	13.8	1.8	17	1	US-10-724-270-484	Sequence 484, App
198	13.8	1.8	17	1	US-10-724-270-5305	Sequence 5305, Ap
199	13.4	1.8	16	1	US-10-712-672-1489	Sequence 1489, Ap

ALIGNMENTS

```
RESULT 1
US-09-908-975-2665
; Sequence 2665, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
;  APPLICANT: SHOSHAN, Avi
;  APPLICANT:  WASSERMAN, Alon
;  APPLICANT:  MINTZ, Eli
;  APPLICANT:  MINTZ, Liat
;  APPLICANT:  FAIGLER, Simchon
;  TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
;  TITLE OF INVENTION:  THAT POPULATE A TRANSCRIPTOME
;  FILE REFERENCE: 36688-0005
;  CURRENT APPLICATION NUMBER: US/09/908,975
;  CURRENT FILING DATE:  2001-07-20
;  PRIOR APPLICATION NUMBER: US 60/287,724
;  PRIOR FILING DATE: 2001-05-02
;  PRIOR APPLICATION NUMBER: US 60/221,607
;  PRIOR FILING DATE: 2000-07-28
;  NUMBER OF SEQ ID NOS: 32337
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2665
;   LENGTH: 65
;   TYPE: DNA
;   ORGANISM: Rattus norvegicus
US-09-908-975-2665

  Query Match             6.8%;  Score 52.2;  DB 1;  Length 65;
  Best Local Similarity   87.7%;  Pred. No. 0.15;
  Matches   57;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy        314 GTGTCCCTGGATGTCAACCACTTCGCCCCGGACGAGCTGACGGTCAAGACCAAGGATGGC 373
              |||||||||||| ||||||||||||||| || || ||||| || || |||||||||||| |||
Db          1 GTGTCCCTGGACGTCAACCACTTCGCTCCTGAGGAGCTCACAGTTAAGACCAAGGAAGGC 60

Qy        374 GTGGT 378
              |||||
Db         61 GTGGT 65


RESULT 2
US-10-131-827-3859
; Sequence 3859, Application US/10131827
; Publication No. US20040009479A1
; GENERAL INFORMATION:
;  APPLICANT: Wohlgemuth, Jay
;  APPLICANT:  Fry, Kirk
;  APPLICANT:  Woodward, Robert
```

```
;  APPLICANT:  Ly, Ngoc
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
;  TITLE OF INVENTION:  CHRONIC INFLAMMATORY DISEASES
;  FILE REFERENCE: 506612000120
;  CURRENT APPLICATION NUMBER: US/10/131,827
;  CURRENT FILING DATE:  2002-09-06
;  PRIOR APPLICATION NUMBER: US 10/006,290
;  PRIOR FILING DATE: 2001-10-22
;  PRIOR APPLICATION NUMBER: US 60/296,764
;  PRIOR FILING DATE: 2001-06-08
;  NUMBER OF SEQ ID NOS: 9090
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3859
;   LENGTH: 50
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-131-827-3859

  Query Match             6.5%;  Score 50;  DB 1;  Length 50;
  Best Local Similarity   100.0%;  Pred. No. 0.18;
  Matches   50;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        683 CTGTGCCTCCCCCGCCACCTGTGTGTTCTTTTGATACATTTATCTTCTGT 732
              ||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CTGTGCCTCCCCCGCCACCTGTGTGTTCTTTTGATACATTTATCTTCTGT 50


RESULT 3
US-10-764-420-95
; Sequence 95, Application US/10764420
; Publication No. US20050084872A1
; GENERAL INFORMATION:
;  APPLICANT: Lum, Pek Yee
;  APPLICANT:  Tan, Yejun
;  APPLICANT:  Dai, Hongyue
;  TITLE OF INVENTION: Methods For Determining Whether An Agent
;  TITLE OF INVENTION:  Possesses A Defined Biological Activity
;  FILE REFERENCE: ROSA122057
;  CURRENT APPLICATION NUMBER: US/10/764,420
;  CURRENT FILING DATE:  2004-01-23
;  PRIOR APPLICATION NUMBER: US 60/442,797
;  PRIOR FILING DATE: 2003-01-24
;  PRIOR APPLICATION NUMBER: US 60/474,413
;  PRIOR FILING DATE: 2003-05-30
;  NUMBER OF SEQ ID NOS: 3683
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 95
;   LENGTH: 60
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide probe
US-10-764-420-95

  Query Match             6.4%;  Score 49;  DB 1;  Length 60;
  Best Local Similarity   91.2%;  Pred. No. 0.27;
  Matches   52;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy        405 GGCAGGACGAGCATGGCTACATCTCCCGGTGCTTCACGCGGAAATACACGCTGCCCC 461
              |||||||||| |||||||||||||| |||||||||| |||||||||||||| || |
Db          4 GGCAGGACGAACATGGCTACATCTCTCGGTGCTTCACCCGGAAATACACGCTCCCTC 60


RESULT 4
US-10-719-900-265359
; Sequence 265359, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 265359
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-265359

  Query Match             3.1%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 27;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        417 ATGGCTACATCTCCCGGTGCTTCAC 441
              ||||||||||||| ||||||||||
Db          1 ATGGCTACATCTCTCGGTGCTTCAC 25


RESULT 5
US-10-719-900-475563/c
; Sequence 475563, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 475563
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-475563

  Query Match             3.1%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 27;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        405 GGCAGGACGAGCATGGCTACATCTC 429
              |||||||||| ||||||||||||||
Db         25 GGCAGGACGAACATGGCTACATCTC 1


RESULT 6
US-10-719-900-618137
; Sequence 618137, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 618137
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-618137

  Query Match             3.1%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 27;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        309 GGCGCGTGTCCCTGGATGTCAACCA 333
```

```
                  ||||||||||||||||| ||||||||
Db          1 GGCGCGTGTCCCTGGACGTCAACCA 25


RESULT 7
US-10-719-900-657749/c
; Sequence 657749, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 657749
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-657749

  Query Match             3.1%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 27;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        308 TGGCGCGTGTCCCTGGATGTCAACC 332
                  ||||||||||||||||| |||||||
Db         25 TGGCGCGTGTCCCTGGACGTCAACC 1


RESULT 8
US-10-719-900-858223/c
; Sequence 858223, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 858223
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-858223

  Query Match             3.1%;  Score 23.4;  DB 1;  Length 25;
  Best Local Similarity   96.0%;  Pred. No. 27;
  Matches   24;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        362 ACCAAGGATGGCGTGGTGGAGATCA 386
                  |||||||| |||||||||||||||||
Db         25 ACCAAGGAAGGCGTGGTGGAGATCA 1


RESULT 9
US-10-840-038-4/c
; Sequence 4, Application US/10840038
; Publication No. US20050009137A1
; GENERAL INFORMATION:
;  APPLICANT: Adams, John
;  APPLICANT:  Chen, Hong
;  TITLE OF INVENTION: An Intracellular Estradiol Binding Protein, a Polynucleotide
;  TITLE OF INVENTION:  Encoding the Same and Cell Lines Overexpressing the Same
;  FILE REFERENCE: 81476-302961
;  CURRENT APPLICATION NUMBER: US/10/840,038
;  CURRENT FILING DATE:  2004-05-06
;  PRIOR APPLICATION NUMBER: US 60/468,717
;  PRIOR FILING DATE: 2003-05-07
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer
US-10-840-038-4

  Query Match             3.0%;  Score 23;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 27;
  Matches   23;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         38 CGCGTCCCCTTCTCGCTCCTGCG 60
                  |||||||||||||||||||||||
Db         23 CGCGTCCCCTTCTCGCTCCTGCG 1


RESULT 10
US-10-719-900-152005/c
; Sequence 152005, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 152005
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-152005

  Query Match             2.9%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   95.8%;  Pred. No. 33;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        406 GCAGGACGAGCATGGCTACATCTC 429
                  |||||||| |||||||||||||||
Db         25 GCAGGACGAACATGGCTACATCTC 2


RESULT 11
US-10-719-900-653170
; Sequence 653170, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 653170
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-653170

  Query Match             2.9%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   95.8%;  Pred. No. 33;
```

```
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        376 GGTGGAGATCACCGGCAAGCACGA 399
              ||||||||||||  ||||||||||
Db          1 GGTGGAGATCACAGGCAAGCACGA 24


RESULT 12
US-10-719-900-653171
; Sequence 653171, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 653171
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-653171

  Query Match             2.9%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   95.8%;  Pred. No. 33;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        376 GGTGGAGATCACCGGCAAGCACGA 399
              ||||||||||||  ||||||||||
Db          1 GGTGGAGATCACTGGCAAGCACGA 24


RESULT 13
US-10-719-900-855205
; Sequence 855205, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 855205
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-855205

  Query Match             2.9%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   95.8%;  Pred. No. 33;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        502 TGAGGGCACACTGACCGTGGAGGC 525
              ||||||||||||  ||||||||||
Db          1 TGAGGGCACACTAACCGTGGAGGC 24


RESULT 14
US-10-719-900-855206
; Sequence 855206, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 855206
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-855206

  Query Match             2.9%;  Score 22.4;  DB 1;  Length 25;
  Best Local Similarity   95.8%;  Pred. No. 33;
  Matches   23;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        502 TGAGGGCACACTGACCGTGGAGGC 525
              ||||||||||||  ||||||||||
Db          1 TGAGGGCACACTTACCGTGGAGGC 24


RESULT 15
US-10-840-038-5
; Sequence 5, Application US/10840038
; Publication No. US20050009137A1
; GENERAL INFORMATION:
;  APPLICANT: Adams, John
;  APPLICANT:  Chen, Hong
;  TITLE OF INVENTION: An Intracellular Estradiol Binding Protein, a Polynucleotide
;  TITLE OF INVENTION:  Encoding the Same and Cell Lines Overexpressing the Same
;  FILE REFERENCE: 81476-302961
;  CURRENT APPLICATION NUMBER: US/10/840,038
;  CURRENT FILING DATE:  2004-05-06
;  PRIOR APPLICATION NUMBER: US 60/468,717
;  PRIOR FILING DATE: 2003-05-07
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA.
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer
US-10-840-038-5

  Query Match             2.9%;  Score 22;  DB 1;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches   22;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         38 CGCGTCCCCTTCTCGCTCCTGC 59
              ||||||||||||||||||||||
Db          1 CGCGTCCCCTTCTCGCTCCTGC 22


RESULT 16
US-10-719-900-51105/c
; Sequence 51105, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 51105
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-51105
```

```
  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 38;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        414 AGCATGGCTACATCTCCCGGTGCTT 438
              | ||||||||||||||| ||||||||
Db         25 AACATGGCTACATCTCTCGGTGCTT 1


RESULT 17
US-10-719-900-248862
; Sequence 248862, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 248862
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-248862

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 38;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        425 ATCTCCCGGTGCTTCACGCGGAAAT 449
              ||||| |||||||||||| |||||||
Db          1 ATCTCTCGGTGCTTCACCCGGAAAT 25


RESULT 18
US-10-719-900-265360
; Sequence 265360, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 265360
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-265360

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 38;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        417 ATGGCTACATCTCCCGGTGCTTCAC 441
              |||||||||||  ||||||||||
Db          1 ATGGCTACATCTGTCGGTGCTTCAC 25


RESULT 19
US-10-719-900-376560
; Sequence 376560, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 376560
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-376560

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 38;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        429 CCCGGTGCTTCACGCGGAAATACAC 453
              | ||||||||||| ||||||||||
Db          1 CTCGGTGCTTCACCCGGAAATACAC 25


RESULT 20
US-10-719-900-415441
; Sequence 415441, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 415441
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-415441

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 38;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        413 GAGCATGGCTACATCTCCCGGTGCT 437
              || |||||||||||||| |||||||
Db          1 GAACATGGCTACATCTCTCGGTGCT 25


RESULT 21
US-10-719-900-472172/c
; Sequence 472172, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 472172
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-472172
```

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 38;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        407 CAGGACGAGCATGGCTACATCTCCC 431
              ||||||| ||||||||||||||| |
Db         25 CAGGACGAACATGGCTACATCTCTC 1
```

RESULT 22
US-10-719-900-475562/c
; Sequence 475562, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 475562
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-475562

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 38;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        405 GGCAGGACGAGCATGGCTACATCTC 429
              |||||||||| | ||||||||||||
Db         25 GGCAGGACGAACTTGGCTACATCTC 1
```

RESULT 23
US-10-719-900-592386
; Sequence 592386, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 592386
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-592386

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 38;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        409 GGACGAGCATGGCTACATCTCCCGG 433
              |||||| ||||||||||||||| |||
Db          1 GGACGAACATGGCTACATCTCTCGG 25
```

RESULT 24
US-10-719-900-618136
; Sequence 618136, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 618136
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-618136

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 38;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        309 GGCGCGTGTCCCTGGATGTCAACCA 333
              |||||||||||| ||| ||||||||
Db          1 GGCGCGTGTCCCAGGACGTCAACCA 25
```

RESULT 25
US-10-719-900-657748/c
; Sequence 657748, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 657748
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-657748

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 38;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        308 TGGCGCGTGTCCCTGGATGTCAACC 332
              |||||||||||| |||| |||||||
Db         25 TGGCGCGTGTCCGTGGACGTCAACC 1
```

RESULT 26
US-10-719-900-830334
; Sequence 830334, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 830334
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-830334

Query Match 2.9%; Score 21.8; DB 1; Length 25;

```
  Best Local Similarity   92.0%;  Pred. No. 38;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        428 TCCCGGTGCTTCACGCGGAAATACA 452
              || |||||||||| ||||||||||
Db          1 TCTCGGTGCTTCACCCGGAAATACA 25


RESULT 27
US-10-719-900-858224/c
; Sequence 858224, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 858224
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-858224

  Query Match             2.9%;  Score 21.8;  DB 1;  Length 25;
  Best Local Similarity   92.0%;  Pred. No. 38;
  Matches   23;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        362 ACCAAGGATGGCGTGGTGGAGATCA 386
              |||||||| ||| ||||||||||||
Db         25 ACCAAGGAAGGCCTGGTGGAGATCA 1


RESULT 28
US-09-911-904-63
; Sequence 63, Application US/09911904
; Publication No. US20030096234A1
; GENERAL INFORMATION:
;  APPLICANT: Farr, Spencer B.
;  APPLICANT:  Pickett, Gavin G.
;  APPLICANT:  Neft, Robin Eileen
;  APPLICANT:  Dunn, II, Robert Thomas
;  TITLE OF INVENTION: CANINE TOXICITY GENES
;  FILE REFERENCE: 400742000200
;  CURRENT APPLICATION NUMBER: US/09/911,904
;  CURRENT FILING DATE:  2002-04-09
;  PRIOR APPLICATION NUMBER: US 60/220,057
;  PRIOR FILING DATE: 2000-07-21
;  NUMBER OF SEQ ID NOS: 386
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 63
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Canis familiaris
US-09-911-904-63

  Query Match             2.8%;  Score 21.4;  DB 1;  Length 23;
  Best Local Similarity   95.7%;  Pred. No. 38;
  Matches   22;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         73 GGACCCCTTCCGCGACTGGTACC 95
              |||||| ||||||||||||||||
Db          1 GGACCCTTTCCGCGACTGGTACC 23


RESULT 29
US-10-605-498-1/c
; Sequence 1, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-1

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 GGCACGAGGAGCAGAGTCAGC 21
              |||||||||||||||||||||
Db         21 GGCACGAGGAGCAGAGTCAGC 1


RESULT 30
US-10-605-498-2/c
; Sequence 2, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-2

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         11 GCAGAGTCAGCCAGCATGACC 31
              |||||||||||||||||||||
Db         21 GCAGAGTCAGCCAGCATGACC 1


RESULT 31
US-10-605-498-3/c
; Sequence 3, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
```

```
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-3

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         21 CCAGCATGACCGAGCGCCGCG 41
              |||||||||||||||||||||
Db         21 CCAGCATGACCGAGCGCCGCG 1


RESULT 32
US-10-605-498-4/c
; Sequence 4, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-4

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         31 CGAGCGCCGCGTCCCCTTCTC 51
              |||||||||||||||||||||
Db         21 CGAGCGCCGCGTCCCCTTCTC 1


RESULT 33
US-10-605-498-5/c
; Sequence 5, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-5

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         41 GTCCCCTTCTCGCTCCTGCGG 61
              |||||||||||||||||||||
Db         21 GTCCCCTTCTCGCTCCTGCGG 1


RESULT 34
US-10-605-498-6/c
; Sequence 6, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-6

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 CGCTCCTGCGGGGCCCCAGCT 71
              |||||||||||||||||||||
Db         21 CGCTCCTGCGGGGCCCCAGCT 1


RESULT 35
US-10-605-498-7/c
; Sequence 7, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
```

; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-7

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 61 GGGCCCCAGCTGGGACCCCTT 81
||||||||||||||||||||
Db 21 GGGCCCCAGCTGGGACCCCTT 1

RESULT 36
US-10-605-498-8/c
; Sequence 8, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-8

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 71 TGGGACCCCTTCCGCGACTGG 91
||||||||||||||||||||
Db 21 TGGGACCCCTTCCGCGACTGG 1

RESULT 37
US-10-605-498-9/c
; Sequence 9, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-9

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 81 TCCGCGACTGGTACCCGCATA 101
||||||||||||||||||||
Db 21 TCCGCGACTGGTACCCGCATA 1

RESULT 38
US-10-605-498-10/c
; Sequence 10, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-10

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 91 GTACCCGCATAGCCGCCTCTT 111
||||||||||||||||||||
Db 21 GTACCCGCATAGCCGCCTCTT 1

RESULT 39
US-10-605-498-11/c
; Sequence 11, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-11

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        101 AGCCGCCTCTTCGACCAGGCC 121
              |||||||||||||||||||||
Db         21 AGCCGCCTCTTCGACCAGGCC 1


RESULT 40
US-10-605-498-12/c
; Sequence 12, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-12

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        111 TCGACCAGGCCTTCGGGCTGC 131
              |||||||||||||||||||||
Db         21 TCGACCAGGCCTTCGGGCTGC 1


RESULT 41
US-10-605-498-13/c
; Sequence 13, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-13

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        121 CTTCGGGCTGCCCCGGCTGCC 141
              |||||||||||||||||||||
Db         21 CTTCGGGCTGCCCCGGCTGCC 1


RESULT 42
US-10-605-498-14/c
; Sequence 14, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-14

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        131 CCCCGGCTGCCGGAGGAGTGG 151
              |||||||||||||||||||||
Db         21 CCCCGGCTGCCGGAGGAGTGG 1


RESULT 43
US-10-605-498-15/c
; Sequence 15, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-15

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        141 CGGAGGAGTGGTCGCAGTGGT 161
              |||||||||||||||||||||
Db         21 CGGAGGAGTGGTCGCAGTGGT 1


RESULT 44
US-10-605-498-16/c
; Sequence 16, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-16

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        151 GTCGCAGTGGTTAGGCGGCAG 171
              |||||||||||||||||||||
Db         21 GTCGCAGTGGTTAGGCGGCAG 1


RESULT 45
US-10-605-498-17/c
; Sequence 17, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-17

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        161 TTAGGCGGCAGCAGCTGGCCA 181
              |||||||||||||||||||||
Db         21 TTAGGCGGCAGCAGCTGGCCA 1


RESULT 46
US-10-605-498-18/c
; Sequence 18, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-18

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        171 GCAGCTGGCCAGGCTACGTGC 191
              |||||||||||||||||||||
Db         21 GCAGCTGGCCAGGCTACGTGC 1


RESULT 47
US-10-605-498-19/c
; Sequence 19, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-19

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        181 AGGCTACGTGCGCCCCCTGCC 201
              |||||||||||||||||||||
Db         21 AGGCTACGTGCGCCCCCTGCC 1


RESULT 48
US-10-605-498-20/c
; Sequence 20, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
```

```
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-605-498-20

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        191 CGCCCCCTGCCCCCCGCCGCC 211
              |||||||||||||||||||||
Db         21 CGCCCCCTGCCCCCCGCCGCC 1


RESULT 49
US-10-605-498-21/c
; Sequence 21, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 21
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-605-498-21

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        201 CCCCCGCCGCCATCGAGAGCC 221
              |||||||||||||||||||||
Db         21 CCCCCGCCGCCATCGAGAGCC 1


RESULT 50
US-10-605-498-22/c
; Sequence 22, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 22
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-605-498-22

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        211 CATCGAGAGCCCCGCAGTGGC 231
              |||||||||||||||||||||
Db         21 CATCGAGAGCCCCGCAGTGGC 1


RESULT 51
US-10-605-498-23/c
; Sequence 23, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-605-498-23

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        221 CCCGCAGTGGCCGCGCCCGCC 241
              |||||||||||||||||||||
Db         21 CCCGCAGTGGCCGCGCCCGCC 1


RESULT 52
US-10-605-498-24/c
; Sequence 24, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24
;    LENGTH: 21
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-605-498-24
```

```
  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        231 CCGCGCCCGCCTACAGCCGCG 251
              |||||||||||||||||||||
Db         21 CCGCGCCCGCCTACAGCCGCG 1


RESULT 53
US-10-605-498-25/c
; Sequence 25, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-25

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        241 CTACAGCCGCGCGCTCAGCCG 261
              |||||||||||||||||||||
Db         21 CTACAGCCGCGCGCTCAGCCG 1


RESULT 54
US-10-605-498-26/c
; Sequence 26, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-26

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        251 GCGCTCAGCCGGCAACTCAGC 271
              |||||||||||||||||||||
Db         21 GCGCTCAGCCGGCAACTCAGC 1


RESULT 55
US-10-605-498-27/c
; Sequence 27, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 27
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-27

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        261 GGCAACTCAGCAGCGGGGTCT 281
              |||||||||||||||||||||
Db         21 GGCAACTCAGCAGCGGGGTCT 1


RESULT 56
US-10-605-498-28/c
; Sequence 28, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-28

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        271 CAGCGGGGTCTCGGAGATCCG 291
              |||||||||||||||||||||
Db         21 CAGCGGGGTCTCGGAGATCCG 1


RESULT 57
```

```
US-10-605-498-29/c
; Sequence 29, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-29

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        281 TCGGAGATCCGGCACACTGCG 301
              |||||||||||||||||||||
Db         21 TCGGAGATCCGGCACACTGCG 1


RESULT 58
US-10-605-498-30/c
; Sequence 30, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 30
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-30

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        291 GGCACACTGCGGACCGCTGGC 311
              |||||||||||||||||||||
Db         21 GGCACACTGCGGACCGCTGGC 1


RESULT 59
US-10-605-498-31/c
; Sequence 31, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-31

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        301 GGACCGCTGGCGCGTGTCCCT 321
              |||||||||||||||||||||
Db         21 GGACCGCTGGCGCGTGTCCCT 1


RESULT 60
US-10-605-498-32/c
; Sequence 32, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-32

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        311 CGCGTGTCCCTGGATGTCAAC 331
              |||||||||||||||||||||
Db         21 CGCGTGTCCCTGGATGTCAAC 1


RESULT 61
US-10-605-498-33/c
; Sequence 33, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
```

```
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-33

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        321 TGGATGTCAACCACTTCGCCC 341
              |||||||||||||||||||||
Db         21 TGGATGTCAACCACTTCGCCC 1


RESULT 62
US-10-605-498-34/c
; Sequence 34, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-34

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        331 CCACTTCGCCCCGGACGAGCT 351
              |||||||||||||||||||||
Db         21 CCACTTCGCCCCGGACGAGCT 1


RESULT 63
US-10-605-498-35/c
; Sequence 35, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 35
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-35

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        341 CCGGACGAGCTGACGGTCAAG 361
              |||||||||||||||||||||
Db         21 CCGGACGAGCTGACGGTCAAG 1


RESULT 64
US-10-605-498-36/c
; Sequence 36, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-36

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        351 TGACGGTCAAGACCAAGGATG 371
              |||||||||||||||||||||
Db         21 TGACGGTCAAGACCAAGGATG 1


RESULT 65
US-10-605-498-37/c
; Sequence 37, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37
;   LENGTH: 21
```

```
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-37

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        361 GACCAAGGATGGCGTGGTGGA 381
              |||||||||||||||||||||
Db         21 GACCAAGGATGGCGTGGTGGA 1


RESULT 66
US-10-605-498-38/c
; Sequence 38, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-38

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        371 GGCGTGGTGGAGATCACCGGC 391
              |||||||||||||||||||||
Db         21 GGCGTGGTGGAGATCACCGGC 1


RESULT 67
US-10-605-498-39/c
; Sequence 39, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-39

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        381 AGATCACCGGCAAGCACGAGG 401
              |||||||||||||||||||||
Db         21 AGATCACCGGCAAGCACGAGG 1


RESULT 68
US-10-605-498-40/c
; Sequence 40, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-40

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        391 CAAGCACGAGGAGCGGCAGGA 411
              |||||||||||||||||||||
Db         21 CAAGCACGAGGAGCGGCAGGA 1


RESULT 69
US-10-605-498-41/c
; Sequence 41, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 41
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-41

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        401 GAGCGGCAGGACGAGCATGGC 421
              |||||||||||||||||||||
```

```
Db         21 GAGCGGCAGGACGAGCATGGC 1


RESULT 70
US-10-605-498-42/c
; Sequence 42, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-42

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        411 ACGAGCATGGCTACATCTCCC 431
              |||||||||||||||||||||
Db         21 ACGAGCATGGCTACATCTCCC 1


RESULT 71
US-10-605-498-43/c
; Sequence 43, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-43

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        421 CTACATCTCCCGGTGCTTCAC 441
              |||||||||||||||||||||
Db         21 CTACATCTCCCGGTGCTTCAC 1


RESULT 72
US-10-605-498-44/c
; Sequence 44, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-44

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        431 CGGTGCTTCACGCGGAAATAC 451
              |||||||||||||||||||||
Db         21 CGGTGCTTCACGCGGAAATAC 1


RESULT 73
US-10-605-498-45/c
; Sequence 45, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-45

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        441 CGCGGAAATACACGCTGCCCC 461
              |||||||||||||||||||||
Db         21 CGCGGAAATACACGCTGCCCC 1


RESULT 74
US-10-605-498-46/c
; Sequence 46, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
```

```
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 46
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-46

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity  100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        451 CACGCTGCCCCCCGGTGTGGA 471
              |||||||||||||||||||||
Db         21 CACGCTGCCCCCCGGTGTGGA 1


RESULT 75
US-10-605-498-47/c
; Sequence 47, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 47
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-47

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity  100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        461 CCCGGTGTGGACCCCACCCAA 481
              |||||||||||||||||||||
Db         21 CCCGGTGTGGACCCCACCCAA 1


RESULT 76
US-10-605-498-48/c
; Sequence 48, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 48
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-48

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity  100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        471 ACCCCACCCAAGTTTCCTCCT 491
              |||||||||||||||||||||
Db         21 ACCCCACCCAAGTTTCCTCCT 1


RESULT 77
US-10-605-498-49/c
; Sequence 49, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-49

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity  100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        481 AGTTTCCTCCTCCCTGTCCCC 501
              |||||||||||||||||||||
Db         21 AGTTTCCTCCTCCCTGTCCCC 1


RESULT 78
US-10-605-498-50/c
; Sequence 50, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
```

```
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-50

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        491 TCCCTGTCCCCTGAGGGCACA 511
              |||||||||||||||||||||
Db         21 TCCCTGTCCCCTGAGGGCACA 1


RESULT 79
US-10-605-498-51/c
; Sequence 51, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 51
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-51

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        501 CTGAGGGCACACTGACCGTGG 521
              |||||||||||||||||||||
Db         21 CTGAGGGCACACTGACCGTGG 1


RESULT 80
US-10-605-498-52/c
; Sequence 52, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 52
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-52

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        511 ACTGACCGTGGAGGCCCCCAT 531
              |||||||||||||||||||||
Db         21 ACTGACCGTGGAGGCCCCCAT 1


RESULT 81
US-10-605-498-53/c
; Sequence 53, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 53
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-53

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        521 GAGGCCCCCATGCCCAAGCTA 541
              |||||||||||||||||||||
Db         21 GAGGCCCCCATGCCCAAGCTA 1


RESULT 82
US-10-605-498-54/c
; Sequence 54, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 54
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-54

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
```

```
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        531 TGCCCAAGCTAGCCACGCAGT 551
              |||||||||||||||||||||
Db         21 TGCCCAAGCTAGCCACGCAGT 1


RESULT 83
US-10-605-498-55/c
; Sequence 55, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 55
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-55

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCAACGAGAT 561
              |||||||||||||||||||||
Db         21 AGCCACGCAGTCCAACGAGAT 1


RESULT 84
US-10-605-498-56/c
; Sequence 56, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-56

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCATCCCA 571
              |||||||||||||||||||||
Db         21 TCCAACGAGATCACCATCCCA 1


RESULT 85
US-10-605-498-57/c
; Sequence 57, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 57
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-57

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        561 TCACCATCCCAGTCACCTTCG 581
              |||||||||||||||||||||
Db         21 TCACCATCCCAGTCACCTTCG 1


RESULT 86
US-10-605-498-58/c
; Sequence 58, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 58
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-58

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        571 AGTCACCTTCGAGTCGCGGGC 591
              |||||||||||||||||||||
Db         21 AGTCACCTTCGAGTCGCGGGC 1


RESULT 87
US-10-605-498-59/c
; Sequence 59, Application US/10605498
```

; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 59
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-59

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 581 GAGTCGCGGGCCCAGCTTGGG 601
||||||||||||||||||||
Db 21 GAGTCGCGGGCCCAGCTTGGG 1

RESULT 88
US-10-605-498-60/c
; Sequence 60, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 60
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-60

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 591 CCCAGCTTGGGGGCCCAGAAG 611
||||||||||||||||||||
Db 21 CCCAGCTTGGGGGCCCAGAAG 1

RESULT 89
US-10-605-498-61/c
; Sequence 61, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 61
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-61

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 601 GGGCCCAGAAGCTGCAAAATC 621
||||||||||||||||||||
Db 21 GGGCCCAGAAGCTGCAAAATC 1

RESULT 90
US-10-605-498-62/c
; Sequence 62, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 62
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-62

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 611 GCTGCAAAATCCGATGAGACT 631
||||||||||||||||||||
Db 21 GCTGCAAAATCCGATGAGACT 1

RESULT 91
US-10-605-498-63/c
; Sequence 63, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02

```
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 63
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-63

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        621 CCGATGAGACTGCCGCCAAGT 641
              |||||||||||||||||||||
Db         21 CCGATGAGACTGCCGCCAAGT 1


RESULT 92
US-10-605-498-64/c
; Sequence 64, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 64
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-64

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        631 TGCCGCCAAGTAAAGCCTTAG 651
              |||||||||||||||||||||
Db         21 TGCCGCCAAGTAAAGCCTTAG 1


RESULT 93
US-10-605-498-65/c
; Sequence 65, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 65
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-65

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        641 TAAAGCCTTAGCCCGGATGCC 661
              |||||||||||||||||||||
Db         21 TAAAGCCTTAGCCCGGATGCC 1


RESULT 94
US-10-605-498-66/c
; Sequence 66, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 66
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-66

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        651 GCCCGGATGCCCACCCCTGCT 671
              |||||||||||||||||||||
Db         21 GCCCGGATGCCCACCCCTGCT 1


RESULT 95
US-10-605-498-67/c
; Sequence 67, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 67
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
```

```
US-10-605-498-67

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        661 CCACCCCTGCTGCCGCCACTG 681
              |||||||||||||||||||||
Db         21 CCACCCCTGCTGCCGCCACTG 1


RESULT 96
US-10-605-498-68/c
; Sequence 68, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 68
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-68

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        671 TGCCGCCACTGGCTGTGCCTC 691
              |||||||||||||||||||||
Db         21 TGCCGCCACTGGCTGTGCCTC 1


RESULT 97
US-10-605-498-69/c
; Sequence 69, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-69

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        681 GGCTGTGCCTCCCCCGCCACC 701
              |||||||||||||||||||||
Db         21 GGCTGTGCCTCCCCCGCCACC 1


RESULT 98
US-10-605-498-70/c
; Sequence 70, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 70
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-70

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        691 CCCCCGCCACCTGTGTGTTCT 711
              |||||||||||||||||||||
Db         21 CCCCCGCCACCTGTGTGTTCT 1


RESULT 99
US-10-605-498-71/c
; Sequence 71, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 71
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-71

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGATACAT 721
              |||||||||||||||||||||
Db         21 CTGTGTGTTCTTTTGATACAT 1
```

```
RESULT 100
US-10-605-498-72/c
; Sequence 72, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 72
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-72

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        711 TTTTGATACATTTATCTTCTG 731
              |||||||||||||||||||||
Db         21 TTTTGATACATTTATCTTCTG 1


RESULT 101
US-10-605-498-73/c
; Sequence 73, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-73

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        721 TTTATCTTCTGTTTTTCTCAA 741
              |||||||||||||||||||||
Db         21 TTTATCTTCTGTTTTTCTCAA 1


RESULT 102
US-10-605-498-74/c
; Sequence 74, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 74
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-74

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        731 GTTTTTCTCAAATAAAGTTCA 751
              |||||||||||||||||||||
Db         21 GTTTTTCTCAAATAAAGTTCA 1


RESULT 103
US-10-605-498-75/c
; Sequence 75, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 75
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-75

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        741 AATAAAGTTCAAAGCAACCAC 761
              |||||||||||||||||||||
Db         21 AATAAAGTTCAAAGCAACCAC 1


RESULT 104
US-10-605-498-76/c
; Sequence 76, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
```

```
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 76
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-76

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        744 AAAGTTCAAAGCAACCACCTG 764
              |||||||||||||||||||||
Db         21 AAAGTTCAAAGCAACCACCTG 1


RESULT 105
US-10-605-498-78/c
; Sequence 78, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 78
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-78

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        365 AAGGATGGCGTGGTGGAGATC 385
              |||||||||||||||||||||
Db         21 AAGGATGGCGTGGTGGAGATC 1


RESULT 106
US-10-605-498-79/c
; Sequence 79, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 79
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-79

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        265 ACTCAGCAGCGGGGTCTCGGA 285
              |||||||||||||||||||||
Db         21 ACTCAGCAGCGGGGTCTCGGA 1


RESULT 107
US-10-605-498-80/c
; Sequence 80, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 80
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-80

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        264 AACTCAGCAGCGGGGTCTCGG 284
              |||||||||||||||||||||
Db         21 AACTCAGCAGCGGGGTCTCGG 1


RESULT 108
US-10-605-498-81/c
; Sequence 81, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 81
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-81

  Query Match             2.7%;  Score 21;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 37;
  Matches   21;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCCCC 46
              |||||||||||||||||||||
Db         21 ATGACCGAGCGCCGCGTCCCC 1


RESULT 109
US-10-719-900-152006/c
; Sequence 152006, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 152006
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-152006

  Query Match             2.7%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 47;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        406 GCAGGACGAGCATGGCTACATCTC 429
              ||||||||| || ||||||||||
Db         25 GCAGGACGAACAAGGCTACATCTC 2


RESULT 110
US-10-809-189-92419
; Sequence 92419, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 92419
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-92419

  Query Match             2.7%;  Score 20.8;  DB 1;  Length 25;
  Best Local Similarity   91.7%;  Pred. No. 47;
  Matches   22;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        499 CCCTGAGGGCACACTGACCGTGGA 522
              |||||||||||||||  |||||||
Db          2 CCCTGAGGGCACACTTTCCGTGGA 25


RESULT 111
US-10-719-900-51106/c
; Sequence 51106, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 51106
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-51106

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        414 AGCATGGCTACATCTCCCGGTGCTT 438
              | |||||||||| ||| ||||||||
Db         25 AACATGGCTACAACTCTCGGTGCTT 1


RESULT 112
US-10-719-900-72371
; Sequence 72371, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 72371
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-72371

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        447 AATACACGCTGCCCCCCGGTGTGGA 471
              |||||||||| || || ||||||||
Db          1 AATACACGCTCCCTCCAGGTGTGGA 25


RESULT 113
US-10-719-900-147040/c
; Sequence 147040, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
```

```
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 147040
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-147040

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        257 AGCCGGCAACTCAGCAGCGGGGTCT 281
              | ||| || ||||||||||||||||
Db         25 AACCGACAGCTCAGCAGCGGGGTCT 1


RESULT 114
US-10-719-900-248861
; Sequence 248861, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 248861
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-248861

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        425 ATCTCCCGGTGCTTCACGCGGAAAT 449
              ||||| |||||| |||| |||||||
Db          1 ATCTCTCGGTGCATCACCCGGAAAT 25


RESULT 115
US-10-719-900-347106
; Sequence 347106, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 347106
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-347106

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        132 CCCGGCTGCCGGAGGAGTGGTCGCA 156
              ||||| |||| || ||||||||||||
Db          1 CCCGGTTGCCCGATGAGTGGTCGCA 25


RESULT 116
US-10-719-900-376561
; Sequence 376561, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 376561
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-376561

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        429 CCCGGTGCTTCACGCGGAAATACAC 453
              | ||||||||||  ||||||||||
Db          1 CTCGGTGCTTCAGCCGGAAATACAC 25


RESULT 117
US-10-719-900-415444
; Sequence 415444, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 415444
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-415444

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        413 GAGCATGGCTACATCTCCCGGTGCT 437
              || |||||||||| |||| |||||||
Db          1 GAACATGGCTACTTCTCTCGGTGCT 25


RESULT 118
US-10-719-900-472173/c
; Sequence 472173, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
```

```
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 472173
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-472173

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       407 CAGGACGAGCATGGCTACATCTCCC 431
             ||||||||  ||| ||||||||||  |
Db        25 CAGGACGAACATCGCTACATCTCTC 1


RESULT 119
US-10-719-900-581985
; Sequence 581985, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 581985
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-581985

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       444 GGAAATACACGCTGCCCCCCGGTGT 468
             |||||||||||||  || ||  |||||
Db         1 GGAAATACACGCTCCCTCCAGGTGT 25


RESULT 120
US-10-719-900-592387
; Sequence 592387, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 592387
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-592387

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       409 GGACGAGCATGGCTACATCTCCCGG 433
             ||||||  |||||  ||||||||  |||
Db         1 GGACGAACATGGGTACATCTCTCGG 25


RESULT 121
US-10-719-900-611646
; Sequence 611646, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 611646
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-611646

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       405 GGCAGGACGAGCATGGCTACATCTC 429
             |||||||  ||  ||||||||||  ||
Db         1 GGCAGGATGACCATGGCTACATTTC 25


RESULT 122
US-10-719-900-685015/c
; Sequence 685015, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 685015
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-685015

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       448 ATACACGCTGCCCCCCGGTGTGGAC 472
             |||||||||  ||  ||  |||||||||
Db        25 ATACACGCTCCCTCCAGGTGTGGAC 1


RESULT 123
US-10-719-900-685016/c
; Sequence 685016, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
```

```
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 685016
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-685016

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        448 ATACACGCTGCCCCCCGGTGTGGAC 472
              ||||||||| || || |||||||||
Db         25 ATACACGCTCCCACCAGGTGTGGAC 1


RESULT 124
US-10-719-900-819345/c
; Sequence 819345, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 819345
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-819345

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        324 ATGTCAACCACTTCGCCCCGGACGA 348
              | ||||||||||||||| ||||| ||
Db         25 ACGTCAACCACTTCGCTCCGGAGGA 1


RESULT 125
US-10-719-900-830335
; Sequence 830335, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
;  APPLICANT: Xue Mei Zhou
;  TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
;  FILE REFERENCE: 3528.1
;  CURRENT APPLICATION NUMBER: US/10/719,900
;  CURRENT FILING DATE:  2003-11-20
;  PRIOR APPLICATION NUMBER: 60/427,808
;  PRIOR FILING DATE: 2002 11 20
;  NUMBER OF SEQ ID NOS: 982914
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 830335
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-10-719-900-830335

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        428 TCCCGGTGCTTCACGCGGAAATACA 452
              || |||||||||  | ||||||||||
Db          1 TCTCGGTGCTTCTCCCGGAAATACA 25


RESULT 126
US-10-809-189-92432
; Sequence 92432, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
;  APPLICANT: Michael Mittmann
;  APPLICANT:  David Mack
;  APPLICANT:  David Lockhart
;  APPLICANT:  Affymetrix, Inc.
;  TITLE OF INVENTION: Methods of Genetic Analysis
;  FILE REFERENCE: 3101.1
;  CURRENT APPLICATION NUMBER: US/10/809,189
;  CURRENT FILING DATE:  2004-03-25
;  PRIOR APPLICATION NUMBER: US/09/396,196
;  PRIOR FILING DATE: 1999-09-15
;  PRIOR APPLICATION NUMBER: 60/100,678
;  PRIOR FILING DATE: 1998-09-17
;  NUMBER OF SEQ ID NOS: 127806
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 92432
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: mus musculus
US-10-809-189-92432

  Query Match             2.6%;  Score 20.2;  DB 1;  Length 25;
  Best Local Similarity   88.0%;  Pred. No. 53;
  Matches   22;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        375 TGGTGGAGATCACCGGCAAGCACGA 399
              | || |||||||| ||||||||||
Db          1 TTGTTGAGATCACTGGCAAGCACGA 25


RESULT 127
US-10-605-498-82/c
; Sequence 82, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 82
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-82

  Query Match             2.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 44;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCCC 45
              ||||||||||||||||||||
Db         20 ATGACCGAGCGCCGCGTCCC 1


RESULT 128
US-10-713-808-13
; Sequence 13, Application US/10713808
```

```
; Publication No. US20040265845A1
; GENERAL INFORMATION:
;  APPLICANT: University of Southern California
;  APPLICANT:  Hoon, Dave S. B.
;  APPLICANT:  Takeuchi, Hiroya
;  TITLE OF INVENTION: Detection of Micro Metastasis of Melanoma and Breast Cancer in
;  TITLE OF INVENTION:  Paraffin-Embedded Tumor Draining Lymph Nodes by Multimarker
;  TITLE OF INVENTION:  Quantitative RT-PCR
;  FILE REFERENCE: 89212.0014
;  CURRENT APPLICATION NUMBER: US/10/713,808
;  CURRENT FILING DATE:  2003-11-14
;  PRIOR APPLICATION NUMBER: US 60/426,216
;  PRIOR FILING DATE: 2002-11-14
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
US-10-713-808-13

  Query Match             2.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 44;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        399 AGGAGCGGCAGGACGAGCAT 418
              ||||||||||||||||||||
Db          1 AGGAGCGGCAGGACGAGCAT 20


RESULT 129
US-10-605-498-87
; Sequence 87, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 87
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-605-498-87

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 51;
  Matches   16;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        556 CGAGATCACCATCCCAGTC 574
              |||||:|||||:|||||:|
Db          1 CGAGAUCACCAUCCCAGUC 19


RESULT 130
US-10-605-498-90
; Sequence 90, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 90
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-605-498-90

  Query Match             2.5%;  Score 19;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 51;
  Matches   17;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         26 ATGACCGAGCGCCGCGTCC 44
              |:|||||||||||||:||
Db          1 AUGACCGAGCGCCGCGUCC 19


RESULT 131
US-10-472-779-1
; Sequence 1, Application US/10472779
; Publication No. US20040097539A1
; GENERAL INFORMATION:
;  APPLICANT: TERASHITA, Zen-ichi
;  APPLICANT:  NARUO, Ken-ichi
;  APPLICANT:  UCHIKAWA, Osamu
;  APPLICANT:  NAKANISHI, Atsushi
;  TITLE OF INVENTION: HSP inducing agent
;  FILE REFERENCE: 2890 US0P
;  CURRENT APPLICATION NUMBER: US/10/472,779
;  CURRENT FILING DATE:  2003-09-24
;  PRIOR APPLICATION NUMBER: PCT/JP02/02946
;  PRIOR FILING DATE: 2002-03-27
;  PRIOR APPLICATION NUMBER: JP 2001-92704
;  PRIOR FILING DATE: 2001-03-28
;  NUMBER OF SEQ ID NOS: 3
; SEQ ID NO 1
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer for amplifying HSP27 gene
US-10-472-779-1

  Query Match             2.4%;  Score 18.4;  DB 1;  Length 21;
  Best Local Similarity   95.0%;  Pred. No. 64;
  Matches   19;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        359 AAGACCAAGGATGGCGTGGT 378
              |||||||||| ||||||||
Db          2 AAGACCAAGGAAGGCGTGGT 21


RESULT 132
US-10-605-498-77/c
; Sequence 77, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
```

```
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 77
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-77

  Query Match             2.4%;  Score 18;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 59;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        226 AGTGGCCGCGCCCGCCTA 243
              ||||||||||||||||||
Db         18 AGTGGCCGCGCCCGCCTA 1


RESULT 133
US-10-605-498-89
; Sequence 89, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 89
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-605-498-89

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 21;
  Best Local Similarity   76.2%;  Pred. No. 72;
  Matches   16;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        576 CCTTCGAGTCGCGGGCCCAGC 596
              ||::|| |:|||||||| ||
Db          1 CCUUCGUGUCGCGGGCCCUGC 21


RESULT 134
US-10-472-779-2/c
; Sequence 2, Application US/10472779
; Publication No. US20040097539A1
; GENERAL INFORMATION:
;  APPLICANT: TERASHITA, Zen-ichi
;  APPLICANT:  NARUO, Ken-ichi
;  APPLICANT:  UCHIKAWA, Osamu
;  APPLICANT:  NAKANISHI, Atsushi
;  TITLE OF INVENTION: HSP inducing agent
;  FILE REFERENCE: 2890 US0P
;  CURRENT APPLICATION NUMBER: US/10/472,779
;  CURRENT FILING DATE:  2003-09-24
;  PRIOR APPLICATION NUMBER: PCT/JP02/02946
;  PRIOR FILING DATE: 2002-03-27
;  PRIOR APPLICATION NUMBER: JP 2001-92704
;  PRIOR FILING DATE: 2001-03-28
;  NUMBER OF SEQ ID NOS: 3
; SEQ ID NO 2
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer for amplifying HSP27 gene
US-10-472-779-2

  Query Match             2.3%;  Score 17.8;  DB 1;  Length 22;
  Best Local Similarity   90.5%;  Pred. No. 75;
  Matches   19;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        413 GAGCATGGCTACATCTCCCGG 433
              || |||||||||||||| |||
Db         21 GAACATGGCTACATCTCTCGG 1


RESULT 135
US-10-339-793-168
; Sequence 168, Application US/10339793
; Publication No. US20030180764A1
; GENERAL INFORMATION:
;  APPLICANT: Lynx Therapeutics, Inc.
;  APPLICANT:  Shang, Jin
;  APPLICANT:  Bowen, Benjamin
;  TITLE OF INVENTION: GENES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
;  FILE REFERENCE: 37-000310US
;  CURRENT APPLICATION NUMBER: US/10/339,793
;  CURRENT FILING DATE:  2003-01-08
;  NUMBER OF SEQ ID NOS: 443
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 168
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-339-793-168

  Query Match             2.2%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 69;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        559 GATCACCATCCCAGTCA 575
              |||||||||||||||||
Db          1 GATCACCATCCCAGTCA 17


RESULT 136
US-10-751-736-34691
; Sequence 34691, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34691
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-34691

  Query Match             2.2%;  Score 16.8;  DB 1;  Length 21;
```

```
  Best Local Similarity   75.0%;  Pred. No. 88;
  Matches   15;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        170 AGCAGCTGGCCAGGCTACGT 189
              || |||:||||||||:|| :
Db          2 AGGAGCUGGCCAGGCUACUU 21


RESULT 137
US-09-990-613-0
; Sequence 0, Application US/09990613
; Publication No. US20030096219A1
; GENERAL INFORMATION:
;  APPLICANT: Wu, Reen
;  APPLICANT:  Chen, Yin
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE
;  TITLE OF INVENTION:  ANALYSIS OF MUCIN GENE EXPRESSION AND IDENTIFICATION OF
;  TITLE OF INVENTION:  DRUGS HAVING THE ABILITY TO INHIBIT MUCIN GENE EXPRESSION
;  FILE REFERENCE: UC072.001A
;  CURRENT APPLICATION NUMBER: US/09/990,613
;  CURRENT FILING DATE:  2001-11-21
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-990-613-0

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 97;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        403 GCGGCAGGACGAGCATGGC 421
              ||||||  ||||||||||
Db          1 GCGGCACCACGAGCATGGC 19


RESULT 138
US-10-605-498-83
; Sequence 83, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 83
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-605-498-83

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 97;
  Matches   14;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        266 CTCAGCAGCGGGGTCTCGG 284
              |:| || ||||||:|:|||
Db          1 CUCUGCUGCGGGGUCUCGG 19


RESULT 139
US-10-605-498-7
; Sequence 7, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
;  APPLICANT: Gleave, Martin
;  APPLICANT:  Rocchi, Palma
;  APPLICANT:  Signaevsky, Maxim
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
;  TITLE OF INVENTION:  Cancers
;  FILE REFERENCE: UBC.P-031
;  CURRENT APPLICATION NUMBER: US/10/605,498
;  CURRENT FILING DATE:  2003-10-02
;  PRIOR APPLICATION NUMBER: US 60/415,859
;  PRIOR FILING DATE: 2002-10-02
;  PRIOR APPLICATION NUMBER: US 60/463,952
;  PRIOR FILING DATE: 2003-04-18
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-605-498-7

  Query Match             2.1%;  Score 15.8;  DB 1;  Length 21;
  Best Local Similarity   89.5%;  Pred. No. 1.1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         60 GGGGCCCCAGCTGGGACCC 78
              |||| |||||||||| |||
Db          3 GGGGTCCCAGCTGGGGCCC 21


RESULT 140
US-09-866-108-10667
; Sequence 10667, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10667
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-10667

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 95;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17


RESULT 141
US-10-211-689-82/c
; Sequence 82, Application US/10211689
; Publication No. US20030232347A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, John II
;  APPLICANT:  Anderson, David W.
;  APPLICANT:  Boldog, Ferenc L.
;  APPLICANT:  Burgess, Catherine E.
;  APPLICANT:  Casman, Stacie J.
;  APPLICANT:  Edinger, Shlomit R.
;  APPLICANT:  Gangolli, Esha A.
;  APPLICANT:  Gorman, Linda
;  APPLICANT:  Guo, Xiaojia (Sasha)
;  APPLICANT:  Khramstov, Nikolai V.
;  APPLICANT:  Lepley, Denise M.
;  APPLICANT:  MacDougall, John R.
;  APPLICANT:  Pena, Carol A.
;  APPLICANT:  Peyman, John A.
;  APPLICANT:  Patturajan, Meera
;  APPLICANT:  Rieger, Daniel K.
;  APPLICANT:  Shimkets, Richard A.
;  APPLICANT:  Smithson, Glennda
;  APPLICANT:  Spytek, Kimberly A.
;  APPLICANT:  Vernet, Corine A. M.
;  APPLICANT:  Voss, Edward Z.
;  APPLICANT:  Zhong, Mei
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
;  FILE REFERENCE: 21402-416B
;  CURRENT APPLICATION NUMBER: US/10/211,689
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: 60/311751
;  PRIOR FILING DATE: 2001-08-10
;  PRIOR APPLICATION NUMBER: 60/310,802
;  PRIOR FILING DATE: 2001-08-08
;  PRIOR APPLICATION NUMBER: 60/310,795
;  PRIOR FILING DATE: 2001-08-08
;  PRIOR APPLICATION NUMBER: 60/311,292
;  PRIOR FILING DATE: 2001-08-09
;  PRIOR APPLICATION NUMBER: 60/361,159
;  PRIOR FILING DATE: 2002-02-28
;  PRIOR APPLICATION NUMBER: 60/373,050
;  PRIOR FILING DATE: 2002-04-16
;  PRIOR APPLICATION NUMBER: 60/380,970
;  PRIOR FILING DATE: 2002-05-15
;  PRIOR APPLICATION NUMBER: 60/311,979
;  PRIOR FILING DATE: 2001-08-13
;  PRIOR APPLICATION NUMBER: 60/381,030
;  PRIOR FILING DATE: 2002-05-16
;  PRIOR APPLICATION NUMBER: 60/323,944
;  PRIOR FILING DATE: 2001-09-21
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 132
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 82
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artifical Sequence:  Primer/Probe
US-10-211-689-82

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 95;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        399 AGGAGCGGCAGGACGAG 415
              |||||| ||||||||||
Db         17 AGGAGCAGCAGGACGAG 1


RESULT 142
US-10-723-361-10667
; Sequence 10667, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10667
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-10667

  Query Match             2.0%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 95;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCATG 28
              ||||| ||||||||||
Db          1 CAGAGCCAGCCAGCATG 17
```

```
RESULT 143
US-10-450-472-50/c
; Sequence 50, Application US/10450472
; Publication No. US20040132094A1
; GENERAL INFORMATION:
;  APPLICANT: Borean Pharma A/S
;  TITLE OF INVENTION: Combinatorial libraries of proteins having the scaffold structure
;  TITLE OF INVENTION:  of C-type lectin-like domains
;  FILE REFERENCE: BOR00003/WO
;  CURRENT APPLICATION NUMBER: US/10/450,472
;  CURRENT FILING DATE:  2003-12-08
;  NUMBER OF SEQ ID NOS: 91
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-10-450-472-50

  Query Match             1.9%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          86 GACTGGTACCCGCATAGC 103
               ||| |||||||||||  ||
Db          18 GACCGGTACCCGCATCGC 1


RESULT 144
US-10-179-940-466/c
; Sequence 466, Application US/10179940
; Publication No. US20040018618A1
;   GENERAL INFORMATION:
;        APPLICANT: Abrams, Mark A.
;                   Bauer, S. C.
;                   Braford-Goldberg, Sarah R.
;                   Caparon, Maire H.
;                   Easton, Alan M.
;                   Klein, Barbara K.
;                   McKearn, John P.
;                   Olins, Peter O.
;                   Paik, Kumnan
;                   Polazzi, Joseph O.
;        TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
;        NUMBER OF SEQUENCES: 549
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Carol M. Nielsen, Gardere Wynne Sewell LLP,
;             STREET: 1601 Elm Street, Suite 3000
;             CITY: Dallas
;             STATE: Texas
;             COUNTRY: USA
;             ZIP: 75201-4761
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/179,940
;             FILING DATE: 19-Jun-2002
;             CLASSIFICATION: Unknown
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 07/981044
;             FILING DATE: 24-NOV-1992
;             APPLICATION NUMBER: PCT/US93/11198
;             FILING DATE: 22-NOV-1993
;             APPLICATION NUMBER: US 08/411796
;             FILING DATE: 09-APR-1995
;             APPLICATION NUMBER: US 08/559390
;             FILING DATE: 15-NOV-1995
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Carol M. Nielsen
;             REGISTRATION NUMBER: 37,676
;             REFERENCE/DOCKET NUMBER: 126181-1056 (C2713/1)
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (713)276-5383
;             TELEFAX: (713)276-5555
;   INFORMATION FOR SEQ ID NO: 466:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (synthetic)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 466:
US-10-179-940-466

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         565 CATCCCAGTCACCTTC 580
               ||| ||||||||||||
Db          16 CATTCCAGTCACCTTC 1


RESULT 145
US-09-866-108-10666
; Sequence 10666, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
```

```
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10666
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108-10666

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 146
US-09-866-108-10668
; Sequence 10668, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10668
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108-10668

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 147
US-10-060-830-218/c
; Sequence 218, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
;  FILE REFERENCE: PB0169
;  CURRENT APPLICATION NUMBER: US/10/060,830
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/325,062
;  PRIOR FILING DATE: 2001-09-25
;  NUMBER OF SEQ ID NOS: 1123
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 218
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-060-830-218

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         11 GCAGAGTCAGCCAGCA 26
              |||||||||||| |||
Db         17 GCAGAGTCAGCCTGCA 2


RESULT 148
US-10-060-830-219/c
; Sequence 219, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
;  FILE REFERENCE: PB0169
;  CURRENT APPLICATION NUMBER: US/10/060,830
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/325,062
;  PRIOR FILING DATE: 2001-09-25
;  NUMBER OF SEQ ID NOS: 1123
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 219
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-830-219

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         11 GCAGAGTCAGCCAGCA 26
              ||||||||||||| |||
Db         16 GCAGAGTCAGCCTGCA 1


RESULT 149
US-10-156-306-5028
; Sequence 5028, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5028
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-5028

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        193 CCCCCTGCCCCCCGCC 208
              |||| :||||||||||
Db          1 CCCCUUGCCCCCCGCC 16


RESULT 150
US-10-238-700-2848/c
; Sequence 2848, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2848
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-2848

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        227 GTGGCCGCGCCCGCCT 242
              ||||||||| ||||||
Db         16 GTGGCCGCGGCCGCCT 1


RESULT 151
US-10-723-361-10666
; Sequence 10666, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10666
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-10666

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         12 CAGAGTCAGCCAGCAT 27
              ||||| ||||||||||
Db          2 CAGAGCCAGCCAGCAT 17


RESULT 152
US-10-723-361-10668
; Sequence 10668, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
```

```
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10668
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-10668

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         13 AGAGTCAGCCAGCATG 28
              |||| ||||||||||||
Db          1 AGAGCCAGCCAGCATG 16


RESULT 153
US-10-498-462-2203
; Sequence 2203, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
;  APPLICANT: Guo, Jinjiao
;  TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
;  FILE REFERENCE: PB01102
;  CURRENT APPLICATION NUMBER: US/10/498,462
;  CURRENT FILING DATE:  2004-06-10
;  PRIOR APPLICATION NUMBER: US 60/339,764
;  PRIOR FILING DATE: 2001-12-10
;  PRIOR APPLICATION NUMBER: PCT/US02/37506
;  PRIOR FILING DATE: 2002-11-22
;  NUMBER OF SEQ ID NOS: 3320
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2203
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-498-462-2203

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              ||| ||||||||||||
Db          2 CTGAGGGGCCCCAGCT 17


RESULT 154
US-10-498-462-2204
; Sequence 2204, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
;  APPLICANT: Guo, Jinjiao
;  TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
;  FILE REFERENCE: PB01102
;  CURRENT APPLICATION NUMBER: US/10/498,462
;  CURRENT FILING DATE:  2004-06-10
;  PRIOR APPLICATION NUMBER: US 60/339,764
;  PRIOR FILING DATE: 2001-12-10
;  PRIOR APPLICATION NUMBER: PCT/US02/37506
;  PRIOR FILING DATE: 2002-11-22
;  NUMBER OF SEQ ID NOS: 3320
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2204
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-498-462-2204

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         56 CTGCGGGGCCCCAGCT 71
              ||| ||||||||||||
Db          1 CTGAGGGGCCCCAGCT 16


RESULT 155
US-10-724-270-1527/c
; Sequence 1527, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  TITLE OF INVENTION:  RAS, HER2 and HIV
;  FILE REFERENCE: 400/046-US  (MBHB02-326-A)
;  CURRENT APPLICATION NUMBER: US/10/724,270
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: PCT/US02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 10/238,700
;  PRIOR FILING DATE: 2002-09-10
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2002-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 6810
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1527
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
```

```
US-10-724-270-1527

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        227 GTGGCCGCGCCCGCCT 242
              ||||||||| ||||||
Db         16 GTGGCCGCGGCCGCCT 1


RESULT 156
US-10-349-143-6095/c
; Sequence 6095, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6095
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-8894 for SEQ 2161,
US-10-349-143-6095

  Query Match             1.9%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        701 CTGTGTGTTCTTTTGA 716
              ||||||||||||| |||
Db         18 CTGTGTGTTCTTCTGA 3


RESULT 157
US-09-818-875-4230/c
; Sequence 4230, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4230
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-4230

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         15 AGCCACGCAGTCCA 2


RESULT 158
US-09-818-875-4231
; Sequence 4231, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4231
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-4231

  Query Match             1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          3 AGCCACGCAGTCCA 16


RESULT 159
US-09-780-533A-765
; Sequence 765, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 765
```

```
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-765

  Query Match          1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        164 GGCGGCAGCAGCTG 177
              ||||||||||||:|
Db          3 GGCGGCAGCAGCUG 16


RESULT 160
US-09-780-533A-1791
; Sequence 1791, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1791
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1791

  Query Match          1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        164 GGCGGCAGCAGCTG 177
              ||||||||||||:|
Db          2 GGCGGCAGCAGCUG 15


RESULT 161
US-10-209-787-4230/c
; Sequence 4230, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4230
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-209-787-4230

  Query Match          1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity  100.0%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db         15 AGCCACGCAGTCCA 2


RESULT 162
US-10-209-787-4231
; Sequence 4231, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4231
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-209-787-4231

  Query Match          1.8%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity  100.0%;  Pred. No. 1.2e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        541 AGCCACGCAGTCCA 554
              ||||||||||||||
Db          3 AGCCACGCAGTCCA 16


RESULT 163
US-10-261-185-4230/c
; Sequence 4230, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
```

; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4230
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-4230

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCAGTCCA 554
||||||||||||||
Db 15 AGCCACGCAGTCCA 2

RESULT 164
US-10-261-185-4231
; Sequence 4231, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: NaPro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4231
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-4231

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCAGTCCA 554
||||||||||||||
Db 3 AGCCACGCAGTCCA 16

RESULT 165
US-10-681-074-4230/c
; Sequence 4230, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMIEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4230
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-4230

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCAGTCCA 554
||||||||||||||
Db 15 AGCCACGCAGTCCA 2

RESULT 166
US-10-681-074-4231
; Sequence 4231, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMIEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4231
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-4231

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCAGTCCA 554
||||||||||||||
Db 3 AGCCACGCAGTCCA 16

RESULT 167
US-09-866-108-2329/c
; Sequence 2329, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6

```
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2329
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108-2329

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
              |||| ||| ||||||||
Db         17 TCCAGCGACATCACCAT 1


RESULT 168
US-09-866-108-2330/c
; Sequence 2330, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2330
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108-2330

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 169
US-09-866-108-2331/c
; Sequence 2331, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2331
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-2331

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              ||||||  |||  ||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 170
US-09-866-108-10669
; Sequence 10669, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10669
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-10669

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              |||  |||||||||| |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 171
US-09-866-108-10670
; Sequence 10670, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10670
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-10670

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
```

```
              || |||||||||||| ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 172
US-09-864-785-1425/c
; Sequence 1425, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Draper, Ken
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of NF-Kappa B
;  FILE REFERENCE: 400/022 (MBHB00-812-D)
;  CURRENT APPLICATION NUMBER: US/09/864,785
;  CURRENT FILING DATE:  2001-05-23
;  NUMBER OF SEQ ID NOS: 3929
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1425
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-864-785-1425

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         62 GGCCCCAGCTGGGACCC 78
              || |||||||| |||||
Db         17 GGGCCCAGCTGCGACCC 1


RESULT 173
US-09-825-805-772
; Sequence 772, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-F (400/009)
;  CURRENT APPLICATION NUMBER: US/09/825,805
;  CURRENT FILING DATE:  2001-09-27
;  PRIOR APPLICATION NUMBER: 09/578,223
;  PRIOR FILING DATE: 2000-05-23
;  PRIOR APPLICATION NUMBER: 09/476,387
;  PRIOR FILING DATE: 1999-12-30
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1558
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 772
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-825-805-772

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 174
US-09-780-533A-2414
; Sequence 2414, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2414
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2414

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        462 CCGGTGTGGACCCCACC 478
              || |:|:||||||| ||
Db          1 CCCGUGUGGACCCCGCC 17


RESULT 175
US-09-927-046-1306
; Sequence 1306, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1306
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1306

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 1.3e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy        506 GGCACACTGACCGTGGA 522
              |||||| :|| ||:|||
Db          1 GGCACAGUGAUCGUGGA 17


RESULT 176
US-09-927-046-1904/c
; Sequence 1904, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1904
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1904

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        423 ACATCTCCCGGTGCTTC 439
              ||||||||| ||| |||
Db         17 ACATCTCCCTGTGATTC 1


RESULT 177
US-09-927-046-1905/c
; Sequence 1905, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1905
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1905

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        422 TACATCTCCCGGTGCTT 438
              |||||||||| ||| ||
Db         17 TACATCTCCCTGTGATT 1


RESULT 178
US-09-740-332-4378
; Sequence 4378, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4378
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4378

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        677 CACTGGCTGTGCCTCCC 693
              | |:||| |:|||:|||
Db          1 CCCUGGCAGUGCCUCCC 17


RESULT 179
US-09-817-879-4378
; Sequence 4378, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4378
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-4378

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        677 CACTGGCTGTGCCTCCC 693
              | |:||| |:|||:|||
Db          1 CCCUGGCAGUGCCUCCC 17


RESULT 180
US-10-060-756A-170/c
; Sequence 170, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
```

```
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 170
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-170

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        295 CACTGCGGACCGCTGGC 311
              ||||||||  |||  ||||
Db         17 CACTGCGGCCCGGTGGC 1


RESULT 181
US-10-163-552-650
; Sequence 650, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
;  TITLE OF INVENTION:  HER2
;  FILE REFERENCE: MBHB01-1653-A (400/014)
;  CURRENT APPLICATION NUMBER: US/10/163,552
;  CURRENT FILING DATE:  2002-06-06
;  NUMBER OF SEQ ID NOS: 1997
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 650
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-163-552-650

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 182
US-10-156-306-5029
; Sequence 5029, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5029
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-5029

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        194 CCCCTGCCCCCCGCCGC 210
              ||| :|||||||||| |
Db          1 CCCUUGCCCCCCGCCCC 17


RESULT 183
US-10-238-700-484
; Sequence 484, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 484
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-484

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 1.3e+02;
  Matches    6;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 TTCTTTTGATACATTTA 724
              : |::::||:| |:::|
Db          1 UCCUUUUGAUAAAUUUA 17


RESULT 184
US-10-061-201-1223
; Sequence 1223, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
```

; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1223
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1223

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 557 GAGATCACCATCCCAGT 573
||||||| || ||||||
Db 1 GAGATCAGCACCCCAGT 17

RESULT 185
US-10-382-248-80/c
; Sequence 80, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-568C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 80
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artifical Sequence: Primer/Probe
US-10-382-248-80

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 664 CCCCTGCTGCCGCCACT 680
||||| |||| ||||||
Db 17 CCCCTTCTGCAGCCACT 1

RESULT 186
US-10-676-154-599/c
; Sequence 599, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; TITLE OF INVENTION: Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/676,154
; CURRENT FILING DATE: 2003-09-29
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 599
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-10-676-154-599

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 746 AGTTCAAAGCAACCACC 762
||| |||||||| ||||
Db 17 AGTACAAAGCAAACACC 1

RESULT 187
US-10-712-672-332/c
; Sequence 332, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 332
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-332

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 254 CTCAGCCGGCAACTCAG 270
||||||||| ||||||
Db 17 CTCAGCCGGACACTCAG 1

RESULT 188
US-10-669-841-6971
; Sequence 6971, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper

```
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6971
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6971

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        677 CACTGGCTGTGCCTCCC 693
              | |:||| |:|||:|||
Db          1 CCCUGGCAGUGCCUCCC 17


RESULT 189
US-10-723-361-2329/c
; Sequence 2329, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2329
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-2329

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        551 TCCAACGAGATCACCAT 567
              |||| ||| ||||||||
Db         17 TCCAGCGACATCACCAT 1


RESULT 190
US-10-723-361-2330/c
; Sequence 2330, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2330
;   LENGTH: 17
;   TYPE: DNA
```

```
;   ORGANISM: Homo sapiens
US-10-723-361-2330

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        550 GTCCAACGAGATCACCA 566
              ||||| ||| |||||||
Db         17 GTCCAGCGACATCACCA 1


RESULT 191
US-10-723-361-2331/c
; Sequence 2331, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2331
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-2331

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        549 AGTCCAACGAGATCACC 565
              ||||||  ||| ||||||
Db         17 AGTCCAGCGACATCACC 1


RESULT 192
US-10-723-361-10669
; Sequence 10669, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10669
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-10669

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         14 GAGTCAGCCAGCATGAC 30
              |||  |||||||||||  |
Db          1 GAGCCAGCCAGCATGGC 17


RESULT 193
US-10-723-361-10670
; Sequence 10670, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10670
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-10670

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         15 AGTCAGCCAGCATGACC 31
              || |||||||||||| ||
Db          1 AGCCAGCCAGCATGGCC 17


RESULT 194
US-10-494-343-325
; Sequence 325, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  APPLICANT:  Phan, Thuymy
;  TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
;  FILE REFERENCE: PB0184
;  CURRENT APPLICATION NUMBER: US/10/494,343
;  CURRENT FILING DATE:  2004-04-30
;  PRIOR APPLICATION NUMBER: US to be assigned
;  PRIOR FILING DATE: to be assigned
;  PRIOR APPLICATION NUMBER: PCT/US2002/035129
;  PRIOR FILING DATE: 2002-11-01
;  PRIOR APPLICATION NUMBER: US 60/334,773
;  PRIOR FILING DATE: 2001-11-01
;  NUMBER OF SEQ ID NOS: 870
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 325
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-494-343-325

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        243 ACAGCCGCGCGCTCAGC 259
              ||| |||| ||||||||
Db          1 ACATCCGCTCGCTCAGC 17


RESULT 195
US-10-498-462-1759/c
; Sequence 1759, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
;  APPLICANT: Guo, Jinjiao
;  TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
;  FILE REFERENCE: PB01102
;  CURRENT APPLICATION NUMBER: US/10/498,462
;  CURRENT FILING DATE:  2004-06-10
;  PRIOR APPLICATION NUMBER: US 60/339,764
;  PRIOR FILING DATE: 2001-12-10
;  PRIOR APPLICATION NUMBER: PCT/US02/37506
;  PRIOR FILING DATE: 2002-11-22
;  NUMBER OF SEQ ID NOS: 3320
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1759
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-498-462-1759

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        520 GGAGGCCCCCATGCCCA 536
              |||||| |||| |||||
Db         17 GGAGGCACCCAGGCCCA 1


RESULT 196
US-10-498-462-1760/c
; Sequence 1760, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
;  APPLICANT: Guo, Jinjiao
;  TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
;  FILE REFERENCE: PB01102
;  CURRENT APPLICATION NUMBER: US/10/498,462
;  CURRENT FILING DATE:  2004-06-10
;  PRIOR APPLICATION NUMBER: US 60/339,764
;  PRIOR FILING DATE: 2001-12-10
;  PRIOR APPLICATION NUMBER: PCT/US02/37506
;  PRIOR FILING DATE: 2002-11-22
;  NUMBER OF SEQ ID NOS: 3320
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1760
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-498-462-1760

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        519 TGGAGGCCCCCATGCCC 535
              ||||||| |||| ||||
Db         17 TGGAGGCACCCAGGCCC 1


RESULT 197
US-10-724-270-484
; Sequence 484, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  TITLE OF INVENTION:  RAS, HER2 and HIV
;  FILE REFERENCE: 400/046-US  (MBHB02-326-A)
;  CURRENT APPLICATION NUMBER: US/10/724,270
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: PCT/US02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 10/238,700
;  PRIOR FILING DATE: 2002-09-10
```

```
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2002-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 6810
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 484
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-724-270-484

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 1.3e+02;
  Matches    6;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        708 TTCTTTTGATACATTTA 724
              : |:::::||:| |:::|
Db          1 UCCUUUUGAUAAAUUUA 17


RESULT 198
US-10-724-270-5305
; Sequence 5305, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  TITLE OF INVENTION:  RAS, HER2 and HIV
;  FILE REFERENCE: 400/046-US  (MBHB02-326-A)
;  CURRENT APPLICATION NUMBER: US/10/724,270
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: PCT/US02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 10/238,700
;  PRIOR FILING DATE: 2002-09-10
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/693,059
;  PRIOR FILING DATE: 2002-10-23
;  PRIOR APPLICATION NUMBER: US 10/444,853
;  PRIOR FILING DATE: 2003-05-23
;  PRIOR APPLICATION NUMBER: US 10/417,012
;  PRIOR FILING DATE: 2003-04-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 6810
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5305
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-724-270-5305

  Query Match             1.8%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 1.3e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        123 TCGGGCTGCCCCGGCTG 139
              :|||||:| | ||||:|
Db          1 UCGGGCUGGCUCGGCUG 17


RESULT 199
US-10-712-672-1489
; Sequence 1489, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1489
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-1489

  Query Match             1.8%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy        197 CTGCCCCCCGCCGCC 211
              | ||||||||||||
Db          2 CCGCCCCCCGCCGCC 16


Search completed: May 10, 2005, 07:19:36
Job time : 2 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: May 10, 2005, 07:20:54 ; Search time 1 Seconds
(without alignments)
2.228 Million cell updates/sec

Title: US-10-605-498-91
Perfect score: 764
Sequence: 1 ggcacgaggagcagagtcag.....aagttcaaagcaaccacctg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 22 seqs, 1458 residues

Total number of hits satisfying chosen parameters: 44

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 22 summaries

Database : rst91.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	76	9.9	76	1	BF724453	ACCESSION:BF724453
c	2	76	9.9	79	1	R54840	ACCESSION:R54840
c	3	75	9.8	77	1	N69052	ACCESSION:N69052
c	4	71	9.3	79	1	H83878	ACCESSION:H83878
	5	68.8	9.0	72	1	H43744	ACCESSION:H43744
c	6	68.2	8.9	73	1	AA687680	ACCESSION:AA687680
c	7	67	8.8	74	1	BG314925	ACCESSION:BG314925
c	8	66.6	8.7	78	1	H39198	ACCESSION:H39198
	9	66.4	8.7	78	1	H95446	ACCESSION:H95446
	10	64.4	8.4	67	1	R63765	ACCESSION:R63765
	11	62.8	8.2	72	1	R11127	ACCESSION:R11127
	12	58.2	7.6	66	1	H57322	ACCESSION:H57322
	13	58	7.6	59	1	H19710	ACCESSION:H19710
	14	57.6	7.5	68	1	T78695	ACCESSION:T78695
	15	57	7.5	62	1	R24645	ACCESSION:R24645
	16	56.4	7.4	60	1	R63589	ACCESSION:R63589
	17	55.2	7.2	64	1	R69493	ACCESSION:R69493
	18	51.2	6.7	62	1	H45605	ACCESSION:H45605
c	19	49.4	6.5	53	1	T51563	ACCESSION:T51563
c	20	49.4	6.5	59	1	AI567984	ACCESSION:AI567984
c	21	35.8	4.7	39	1	AA757804	ACCESSION:AA757804
	22	34.8	4.6	41	1	T98725	ACCESSION:T98725

ALIGNMENTS

RESULT 1
BF724453
LOCUS BF724453 76 bp mRNA linear EST 05-JAN-2001
DEFINITION bx05a12.y1 Human Iris cDNA (Un-normalized, unamplified): BX Homo sapiens cDNA clone bx05a12 5', mRNA sequence.
ACCESSION BF724453
VERSION BF724453.1 GI:12040362
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 76)
AUTHORS Wistow,G.J., Bernstein,S., Behal,A. and Smith,D.
TITLE NEIBANK: EST analysis and bioinformatics for ocular genomics
JOURNAL Invest. Ophthalmol. Vis. Sci. 41 (2000) In press
COMMENT Contact: Wistow G
Section on Molecular Structure and Function
National Eye Institute
6/331, NIH, Bethesda, MD 20892-2740, USA
Tel: 301 402 3452
Fax: 301 496 0078
Email: graeme@helix.nih.gov
Plate: 05 row: a column: 12
Seq primer: M13RP1 reverse primer (ABI).
FEATURES Location/Qualifiers
source 1. .76
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="bx05a12"
/tissue_type="Iris"
/dev_stage="Adult"
/lab_host="EMDH10B"
/clone_lib="Human Iris cDNA (Un-normalized, unamplified): BX"
/note="Organ: Eye; Vector: pCMVSPORT6; Post-mortem iris tissue was pooled from 10 individuals ranging in age from 4-80 years and RNA was extracted. From this pooled sample an aliquot of 60ug of total RNA yielded 2.17ug of mRNA. A directionally cloned cDNA library in the pCMVSPORT6 vector was constructed at Life Technologies, essentially following the protocols of the SuperScript Plasmid System full details of which are contained in the manufacturer's Instruction manual (http://www.lifetech.com/). First strand synthesis was carried out using a Not I primer-adapter [5'-pGACTAGTTCTAGATCGCGAGCGGCCGCCC(T)15-3']. Not I/blunt end inserts were cloned into the Not I/EcoR V sites in the vector. EST analysis was performed on the unamplified library at the NIH Intramural Sequencing Center (NISC)."

Query Match 9.9%; Score 76; DB 1; Length 76;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 76; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        122 TTCGGGCTGCCCCGGCTGCCGGAGGAGTGGTCGCAGTGGTTAGGCGGCAGCAGCTGGCCA 181
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 TTCGGGCTGCCCCGGCTGCCGGAGGAGTGGTCGCAGTGGTTAGGCGGCAGCAGCTGGCCA 60

Qy        182 GGCTACGTGCGCCCCC 197
              ||||||||||||||||
Db         61 GGCTACGTGCGCCCCC 76
```

RESULT 2
R54840/c
LOCUS R54840 79 bp mRNA linear EST 22-MAY-1995
DEFINITION yj74b05.s1 Soares breast 2NbHBst Homo sapiens cDNA clone IMAGE:154449 3' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN (HUMAN);, mRNA sequence.
ACCESSION R54840
VERSION R54840.1 GI:818962
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 79)

```
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Insert Size: 826
            High quality sequence starts: 1 High quality sequence stops: 1
            Source: IMAGE Consortium, LLNL This clone is available royalty-free
            through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov)
            for further information. Trace considered overall poor quality
            Insert Length: 826   Std Error: 0.00
            Seq primer: Promega -21m13
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .79
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:566881"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:154449"
                     /sex="Female"
                     /dev_stage="adult"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares breast 2NbHBst"
                     /note="Organ: breast; Vector: pT7T3D (Pharmacia) with a
                     modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
                     strand cDNA was primed with a Not I - oligo(dT) primer [5'
                     TGTTACCAATCTGAAGTGGGAGCGGCCGCCCTTTTTTTTTTTTTTTTTT 3'],
                     double-stranded cDNA was ligated to Eco RI adaptors
                     (Pharmacia), digested with Not I and cloned into the Not I
                     and Eco RI sites of a modified pT7T3 vector (Pharmacia).
                     Library went through one round of normalization to a Cot =
                     230. Library constructed by Bento Soares and M.Fatima
                     Bonaldo."

  Query Match             9.9%;  Score 76;  DB 1;  Length 79;
  Best Local Similarity   96.2%;  Pred. No. 3.1;
  Matches   76;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        584 TCGCGGGCCCAGCTTGGGGGCCCAGAAGCTGCAAAATCCGATGAGACTGCCGCCAAGTAA 643
              ||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||
Db         79 TCGCGGGCCCAGCTTGGGGGCCCAGAAGCTGCNAAATCCGATGAGACTGCCGCCAAGTAA 20

Qy        644 AGCCTTAGCCCGGATGCCC 662
              | |||| ||||||||||||
Db         19 ANCCTTNGCCCGGATGCCC 1


RESULT 3
N69052/c
LOCUS       N69052                    77 bp    mRNA    linear   EST 13-MAR-1996
DEFINITION  za72f09.s1 Soares_fetal_lung_NbHL19W Homo sapiens cDNA clone
            IMAGE:298121 3' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);, mRNA sequence.
ACCESSION   N69052
VERSION     N69052.1  GI:1225213
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 77)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Seq primer: m13 -40 forward
            High quality sequence stop: 29.
FEATURES             Location/Qualifiers
     source          1. .77
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:1243043"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:298121"
                     /dev_stage="19 weeks"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares_fetal_lung_NbHL19W"
                     /note="Organ: lung; Vector: pT7T3D (Pharmacia) with a
                     modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
                     strand cDNA was primed with a Not I - oligo(dT) primer
                     [5'-TGTTACCAATCTGAAGTGGGAGCGGCCGCAATTTTTTTTTTTTTTTTT-3'],
                     double-stranded cDNA was size selected, ligated to Eco RI
                     adapters (Pharmacia), digested with Not I and cloned into
                     the Not I and Eco RI sites of a modified pT7T3 vector
                     (Pharmacia). Library went through one round of
                     normalization to a Cot = 5. Library constructed by Bento
                     Soares and M.Fatima Bonaldo. This library was constructed
                     from the same fetus as the fetal heart library, Soares
                     fetal heart NbHH19W."

  Query Match             9.8%;  Score 75;  DB 1;  Length 77;
  Best Local Similarity   97.4%;  Pred. No. 3.2;
  Matches   75;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        682 GCTGTGCCTCCCCCGCCACCTGTGTGTTCTTTTGATACATTTATCTTCTGTTTTTCTCAA 741
              |||||||||||||||||| || ||||||||||||||||||||||||||||||||||||||
Db         77 GCTGTGCCTCCCCCGCCANCTNTGTGTTCTTTTGATACATTTATCTTCTGTTTTTCTCAA 18

Qy        742 ATAAAGTTCAAAGCAAC 758
              |||||||||||||||||
Db         17 ATAAAGTTCAAAGCAAC 1


RESULT 4
H83878/c
LOCUS       H83878                    79 bp    mRNA    linear   EST 13-NOV-1995
DEFINITION  yv84c01.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone
            IMAGE:249408 3' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);contains PTR5 repetitive element ;, mRNA sequence.
ACCESSION   H83878
VERSION     H83878.1  GI:1062549
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 79)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
```

```
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            High quality sequence starts: 1
            High quality sequence stops: 1
            Source: IMAGE Consortium, LLNL
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Trace considered overall poor quality
            Seq primer: Promega -21m13
            High quality sequence stop: 1.
FEATURES              Location/Qualifiers
     source           1. .79
                      /organism="Homo sapiens"
                      /mol_type="mRNA"
                      /db_xref="GDB:3867114"
                      /db_xref="taxon:9606"
                      /clone="IMAGE:249408"
                      /sex="Male"
                      /tissue_type="melanocyte"
                      /lab_host="DH10B (ampicillin resistant)"
                      /clone_lib="Soares melanocyte 2NbHM"
                      /note="Vector: pT7T3D (Pharmacia) with a modified
                      polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
                      was primed with a Not I - oligo(dT) primer [5'
                      TGTTACCAATCTGAAGTGGGAGCGGCCGCAGTTTTTTTTTTTTTTTTTT 3'],
                      double-stranded cDNA was size selected, ligated to Eco RI
                      adapters (Pharmacia), digested with Not I and cloned into
                      the Not I and Eco RI sites of a modified pT7T3 vector
                      (Pharmacia). Library constructed by Bento Soares and
                      M.Fatima Bonaldo. RNA from normal foreskin melanocytes
                      (FS374) was kindly provided by Dr. Anthony P. Albino."

  Query Match             9.3%;  Score 71;  DB 1;  Length 79;
  Best Local Similarity   89.9%;  Pred. No. 4;
  Matches   71;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy        587 CGGGCCCAGCTTGGGGGCCCAGAAGCTGCAAAATCCGATGAGACTGCCGCCAAGTAAAGC 646
              ||||||||||||||||||| ||||||||| | |||| || ||||||||||||||| ||||
Db         79 CGGGCCCAGCTTGGGGGCCCNGAAGCTGCANANTCCGNTGNGACTGCCGCCAAGTNAAGC 20

Qy        647 CTTAGCCCGGATGCCCACC 665
              ||| |||||| ||||||||
Db         19 CTTNGCCCGGNTGCCCACC 1


RESULT 5
H43744
LOCUS       H43744                   72 bp    mRNA    linear   EST 31-JUL-1995
DEFINITION  yp21d08.r1 Soares breast 3NbHBst Homo sapiens cDNA clone
            IMAGE:188079 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);, mRNA sequence.
ACCESSION   H43744
VERSION     H43744.1  GI:919796
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 72)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            High quality sequence starts: 1
            High quality sequence stops: 1
            Source: IMAGE Consortium, LLNL
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Seq primer: M13RP1
            High quality sequence stop: 1.
FEATURES              Location/Qualifiers
     source           1. .72
                      /organism="Homo sapiens"
                      /mol_type="mRNA"
                      /db_xref="GDB:3818976"
                      /db_xref="taxon:9606"
                      /clone="IMAGE:188079"
                      /sex="Female"
                      /dev_stage="adult"
                      /lab_host="DH10B (ampicillin resistant)"
                      /clone_lib="Soares breast 3NbHBst"
                      /note="Organ: breast; Vector: pT7T3D (Pharmacia) with a
                      modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
                      strand cDNA was primed with a Not I - oligo(dT) primer [5'
                      TGTTACCAATCTGAAGTGGGAGCGGCCGCCCTTTTTTTTTTTTTTTTT 3'],
                      double-stranded cDNA was ligated to Eco RI adaptors
                      (Pharmacia), digested with Not I and cloned into the Not I
                      and Eco RI sites of a modified pT7T3 vector (Pharmacia).
                      Library went through one round of normalization to a Cot =
                      20. Library constructed by Bento Soares and M.Fatima
                      Bonaldo."

  Query Match             9.0%;  Score 68.8;  DB 1;  Length 72;
  Best Local Similarity   97.2%;  Pred. No. 4.2;
  Matches   70;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         63 GCCCCAGCTGGGACCCCTTCCGCGACTGGTACCCGCATAGCCGCCTCTTCGACCAGGCCT 122
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||
Db          1 GCCCCAGCTGGGACCCCTTCCGCGACTGGTACCCGCATAGCCGCCTCTTCGACCAGGGCT 60

Qy        123 TCGGGCTGCCCC 134
              |||||||| |||
Db         61 TCGGGCTGGCCC 72


RESULT 6
AA687680/c
LOCUS       AA687680                 73 bp    mRNA    linear   EST 24-DEC-1997
DEFINITION  nv11f04.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:1219903 3'
            similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN (HUMAN);, mRNA
            sequence.
ACCESSION   AA687680
VERSION     AA687680.1  GI:2674586
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 73)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Michael J. Brownstein, M.D., Ph.D., Michael R.
            Emmert-Buck, M.D., Ph.D.
             cDNA Library Preparation: M. Bento Soares, Ph.D.
             cDNA Library Arrayed by: Greg Lennon, Ph.D.
             DNA Sequencing by: Washington University Genome Sequencing Center
             Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            www-bio.llnl.gov/bbrp/image/image.html
            Insert Length: 267   Std Error: 0.00
            Seq primer: -40m13 fwd. ET from Amersham.
```

```
FEATURES             Location/Qualifiers
     source          1. .73
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:1219903"
                     /sex="male"
                     /tissue_type="normal prostate"
                     /lab_host="DH10B"
                     /clone_lib="NCI_CGAP_Pr22"
                     /note="Organ: prostate; Vector: pT7T3D-Pac (Pharmacia)
                     with a modified polylinker; 1st strand cDNA was prepared
                     from normal prostate bulk tissue, and was then primed with
                     a Not I - oligo(dT) primer. Double-stranded cDNA was
                     ligated to Eco RI adaptors (Pharmacia), digested with Not
                     I and cloned into the Not I  and Eco RI sites of the
                     modified pT7T3 vector.  Library is normalized, and was
                     constructed by Bento Soares and M. Fatima Bonaldo. "

  Query Match             8.9%;  Score 68.2;  DB 1;  Length 73;
  Best Local Similarity   95.9%;  Pred. No. 4.4;
  Matches   70;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        587 CGGGCCCAGCTTGGGGGCCCAGAAGCTGCAAAATCCGATGAGACTGCCGCCAAGTAAAGC 646
              ||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||
Db         73 CGGGCCCAGCTTGGGGGCCCAGAAGCTGCAAAATCCGATGAGACAGCCGCCAAGTAAAGC 14

Qy        647 CTTAGCCCGGATG 659
              | |||| ||||||
Db         13 CATAGCACGGATG 1


RESULT 7
BG314925/c
LOCUS       BG314925                 74 bp    mRNA    linear   EST 14-MAR-2002
DEFINITION  OP2.0.235 Human THP1 cell line library Homo sapiens cDNA, mRNA
            sequence.
ACCESSION   BG314925
VERSION     BG314925.1  GI:18997787
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 74)
  AUTHORS   Andersson,T., Borang,S., Larsson,M., Thelin,A.,
            Ekstrand-Hammarsrom,B., Wirta,V., Wenborg,A., Lundeberg,J. and
            Odeberg,J.
  TITLE     Identification of candidate genes in atherosclerosis - Virtual chip
            analysis in RDA based transcript profiling of monocyte/macrophage
            response to oxidised LDL
  JOURNAL   Unpublished (2001)
COMMENT     Contact: Andersson Tove
            Department of Biotechnology
            KTH
            Teknikringen 34, plan 6, 100 44 Stockholm, Sweden
            Tel: +46 8 790 71 29
            Fax: +46 8 245452
            Email: tove@biochem.kth.se
            POLYA=No.
FEATURES             Location/Qualifiers
     source          1. .74
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /cell_line="THP1"
                     /clone_lib="Human THP1 cell line library"
                     /note="Vector: pRIT28; Site_1: BamHI; Site_2: BamHI;
                     Shotgun cloning of RDA difference products. Macrophage and
                     foamcell  libraries were submitted to successive rounds of
                     subtractive  hybridisations generating populations of gene
                     fragments that are  differentially expressed in macrophage
                     to foam cell formation."

  Query Match             8.8%;  Score 67;  DB 1;  Length 74;
  Best Local Similarity   100.0%;  Pred. No. 4.7;
  Matches   67;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        474 CCACCCAAGTTTCCTCCTCCCTGTCCCCTGAGGGCACACTGACCGTGGAGGCCCCCATGC 533
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         74 CCACCCAAGTTTCCTCCTCCCTGTCCCCTGAGGGCACACTGACCGTGGAGGCCCCCATGC 15

Qy        534 CCAAGCT 540
              |||||||
Db         14 CCAAGCT 8


RESULT 8
H39198/c
LOCUS       H39198                   78 bp    mRNA    linear   EST 25-JUL-1995
DEFINITION  yn84e12.s1 Soares adult brain N2b5HB55Y Homo sapiens cDNA clone
            IMAGE:175150 3' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);, mRNA sequence.
ACCESSION   H39198
VERSION     H39198.1  GI:908697
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 78)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Insert Size: 645
            High quality sequence starts: 1
            High quality sequence stops: 1
            Source: IMAGE Consortium, LLNL
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Trace considered overall poor quality
            Insert Length: 645   Std Error: 0.00
            Seq primer: Promega -21m13
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .78
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:3837185"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:175150"
                     /sex="Male"
                     /dev_stage="55-year old"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares adult brain N2b5HB55Y"
                     /note="Organ: brain; Vector: pT7T3D (Pharmacia) with a
                     modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
                     strand cDNA was primed with a Not I - oligo(dT) primer [5'
                     TGTTACCAATCTGAAGTGGGAGCGGCCGCGCTTTTTTTTTTTTTTTTTT 3'],
                     double-stranded cDNA was size selected, ligated to Eco RI
                     adapters (Pharmacia), digested with Not I and cloned into
                     the Not I and Eco RI sites of a modified pT7T3 vector
                     (Pharmacia). Library went through one round of
                     normalization to a Cot = 53. Library constructed by Bento
                     Soares and M.Fatima Bonaldo. The adult brain RNA was
                     provided by Dr. Donald H. Gilden. Tissue was acquired
```

17-18 hours after death which occurred in consequence of a ruptured aortic aneurysm. RNA was prepared from a pool of tissues representing the following areas of the brain: frontal, parietal, temporal and occipital cortex from the left and right hemispheres, subcortical white matter, basal ganglia, thalamus, cerebellum, midbrain, pons and medulla."

```
  Query Match             8.7%;  Score 66.6;  DB 1;  Length 78;
  Best Local Similarity   88.5%;  Pred. No. 4.9;
  Matches   69;  Conservative    0;  Mismatches    9;  Indels    0;  Gaps    0;

Qy        589 GGCCCAGCTTGGGGGCCCAGAAGCTGCAAAATCCGATGAGACTGCCGCCAAGTAAAGCCT 648
              |||||| |||||  |||||  || || ||||||||||||||||||||||||| |||| |||
Db         78 GGCCCAACTTGGNNGCCCAAAANCTNCAAAATCCGATGAGACTGCCGCCAAATAAAACCT 19

Qy        649 TAGCCCGGATGCCCACCC 666
              |||||||||||||| ||||
Db         18 TAGCCCGGATGCCNACCC 1
```

```
RESULT 9
H95446
LOCUS       H95446                 78 bp    mRNA    linear   EST 25-NOV-1996
DEFINITION  yw60d12.r1 Soares_placenta_8to9weeks_2NbHP8to9W Homo sapiens cDNA
            clone IMAGE:256631 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);, mRNA sequence.
ACCESSION   H95446
VERSION     H95446.1  GI:1103079
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 78)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            High quality sequence starts: 1
            High quality sequence stops: 1
            Source: IMAGE Consortium, LLNL
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Trace considered overall poor quality
            Insert Length: 1192   Std Error: 0.00
            Seq primer: M13RP1.
FEATURES             Location/Qualifiers
     source          1. .78
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:3886241"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:256631"
                     /dev_stage="two placentae: one from 8 weeks and another
                     from 9 weeks post conception"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares_placenta_8to9weeks_2NbHP8to9W"
                     /note="Organ: placenta; Vector: pT7T3D (Pharmacia) with a
                     modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
                     strand cDNA was primed with a Not I - oligo(dT) primer [5'
                     TGTTACCAATCTGAAGTGGGAGCGGCCGCGATTTTTTTTTTTTTTTTT 3'],
                     double-stranded cDNA was size selected, ligated to Eco RI
                     adapters (Pharmacia), digested with Not I and cloned into
                     the Not I and Eco RI sites of a modified pT7T3 vector
                     (Pharmacia). Library constructed by Bento Soares and
                     M.Fatima Bonaldo."
```

```
  Query Match             8.7%;  Score 66.4;  DB 1;  Length 78;
  Best Local Similarity   85.9%;  Pred. No. 5;
  Matches   67;  Conservative    0;  Mismatches   11;  Indels    0;  Gaps    0;

Qy         50 TCGCTCCTGCGGGGCCCCAGCTGGGACCCCTTCCGCGACTGGTACCCGCATAGCCGCCTC 109
              | |||||||||||||||||||||||||||||| |||  ||| ||||| ||| |||||||  ||
Db          1 TNGCTCCTGCGGGGCCCCAGCTGGGACCCNTTCNNCGANTGGTANCCGTATAGCCGNNTC 60

Qy        110 TTCGACCAGGCCTTCGGG 127
              |||||||||||||| | ||
Db         61 TTCGACCAGGCCTNCNGG 78
```

```
RESULT 10
R63765
LOCUS       R63765                 67 bp    mRNA    linear   EST 26-MAY-1995
DEFINITION  yi15d02.r1 Soares placenta Nb2HP Homo sapiens cDNA clone
            IMAGE:139299 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);, mRNA sequence.
ACCESSION   R63765
VERSION     R63765.1  GI:835644
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 67)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Insert Size: 856
            High qality sequence starts: 1
            High qality sequence stops: 1
            Source: IMAGE Consortium, LLNL
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Trace considered overall poor quality
            Insert Length: 856   Std Error: 0.00
            Seq primer: M13RP1
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .67
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:545869"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:139299"
                     /sex="Female"
                     /dev_stage="placenta obtained at birth (full term)"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares placenta Nb2HP"
                     /note="Organ: placenta; Vector: pT7T3D (Pharmacia) with a
                     modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
                     strand cDNA was primed with a Not I - oligo(dT) primer [5'
                     AACTGGAAGAATTCGCGGCCGCAGGAATTTTTTTTTTTTTTTTT 3'],
                     double-stranded cDNA was ligated to Eco RI adaptors
                     (Pharmacia), digested with Not I and cloned into the Not I
                     and Eco RI sites of the modified pT7T3 vector. Library
                     went through one round of normalization. Library
```

constructed by Bento Soares and M.Fatima Bonaldo. "

Query Match 8.4%; Score 64.4; DB 1; Length 67;
Best Local Similarity 97.0%; Pred. No. 5;
Matches 65; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy         83 CGCGACTGGTACCCGCATAGCCGCCTCTTCGACCAGGCCTTCGGGCTGCCCCCGGCTGCCG 142
              ||||||||||||||||||||||||||||||||||||||||||| | ||||||||||||||
Db          1 CGCGACTGGTACCCGCATAGCCGCCTCTTCGACCAGGCCTTCGTGNTGCCCCGGCTGCCG 60

Qy        143 GAGGAGT 149
              |||||||
Db         61 GAGGAGT 67
```

RESULT 11
R11127
LOCUS R11127 72 bp mRNA linear EST 11-APR-1995
DEFINITION yf39h04.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:129271 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN (HUMAN);, mRNA sequence.
ACCESSION R11127
VERSION R11127.1 GI:763862
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 72)
AUTHORS Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M., Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M., Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F., Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and Wilson,R.
TITLE The WashU-Merck EST Project
JOURNAL Unpublished (1995)
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 941
High quality sequence starts: 1 High quality sequence stops: 1
Source: IMAGE Consortium, LLNL This clone is available royalty-free through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information. Trace considered overall poor quality
Insert Length: 941 Std Error: 0.00
Seq primer: M13RP1
High quality sequence stop: 1.

FEATURES Location/Qualifiers
source 1. .72
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:481432"
/db_xref="taxon:9606"
/clone="IMAGE:129271"
/sex="male"
/dev_stage="20 week-post conception fetus"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares fetal liver spleen 1NFLS"
/note="Organ: Liver and Spleen; Vector: pT7T3D (Pharmacia) with a modified polylinker; Site_1: Pac I; Site_2: Eco RI; 1st strand cDNA was primed with a Pac I - oligo(dT) primer [5' AACTGGAAGAATTAATTAAAGATCTTTTTTTTTTTTTTTTTT 3'], double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Pac I and cloned into the Pac I and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization. Library constructed by Bento Soares and M.Fatima Bonaldo."

Query Match 8.2%; Score 62.8; DB 1; Length 72;
Best Local Similarity 88.9%; Pred. No. 5.7;
Matches 64; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

```
Qy          63 GCCCCAGCTGGGACCCCTTCCGCGACTGGTACCCGCATAGCCGCCTCTTCGACCAGGCCT 122
               |||||||||||||||| |||||| |||||||||| | ||||||| ||||| ||||||| ||
Db           1 GCCCCAGCTGGGACCNCTTCCGTGACTGGTACCNGNATAGCCGNCTCTTNGACCAGGNCT 60

Qy         123 TCGGGCTGCCCC 134
               |||||||| |||
Db          61 TCGGGCTGACCC 72
```

RESULT 12
H57322
LOCUS H57322 66 bp mRNA linear EST 05-OCT-1995
DEFINITION yr10d12.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:204887 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN (HUMAN);, mRNA sequence.
ACCESSION H57322
VERSION H57322.1 GI:1010154
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 66)
AUTHORS Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M., Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M., Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F., Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and Wilson,R.
TITLE The WashU-Merck EST Project
JOURNAL Unpublished (1995)
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 944
High quality sequence starts: 1
High quality sequence stops: 1
Source: IMAGE Consortium, LLNL
This clone is available royalty-free through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
Trace considered overall poor quality
Insert Length: 944 Std Error: 0.00
Seq primer: M13RP1
High quality sequence stop: 1.

FEATURES Location/Qualifiers
source 1. .66
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:3779695"
/db_xref="taxon:9606"
/clone="IMAGE:204887"
/sex="male"
/dev_stage="20 week-post conception fetus"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares fetal liver spleen 1NFLS"
/note="Organ: Liver and Spleen; Vector: pT7T3D (Pharmacia) with a modified polylinker; Site_1: Pac I; Site_2: Eco RI; 1st strand cDNA was primed with a Pac I - oligo(dT) primer [5' AACTGGAAGAATTAATTAAAGATCTTTTTTTTTTTTTTTTTT 3'], double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Pac I and cloned into the Pac I and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization. Library constructed by Bento Soares and M.Fatima Bonaldo."

Query Match 7.6%; Score 58.2; DB 1; Length 66;
Best Local Similarity 90.9%; Pred. No. 6.8;
Matches 60; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

```
Qy          14 GAGTCAGCCAGCATGACCGAGCGCCGCGTCCCCTTCTCGCTCCTGCGGGGCCCCAGCTGG 73
               ||||||||||||||||||| |||| |||||||||||||||||| ||   |||||||||
Db           1 GAGTCAGCCAGCATGACCGAACGCCNCGTCCCCTTCTCGCTCCTGNGGNTGCCCAGCTGG 60

Qy          74 GACCCC 79
               ||||||
Db          61 GACCCC 66
```

```
RESULT 13
H19710
LOCUS       H19710                   59 bp    mRNA    linear   EST 03-JUL-1995
DEFINITION  yn60b06.r1 Soares adult brain N2b5HB55Y Homo sapiens cDNA clone
            IMAGE:172787 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);, mRNA sequence.
ACCESSION   H19710
VERSION     H19710.1  GI:888405
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 59)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Insert Size: 1585
            High quality sequence starts: 1
            High quality sequence stops: 1
            Source: IMAGE Consortium, LLNL
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Trace considered overall poor quality
            Insert Length: 1585   Std Error: 0.00
            Seq primer: M13RP1
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .59
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:3834822"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:172787"
                     /sex="Male"
                     /dev_stage="55-year old"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares adult brain N2b5HB55Y"
                     /note="Organ: brain; Vector: pT7T3D (Pharmacia) with a
                     modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
                     strand cDNA was primed with a Not I - oligo(dT) primer [5'
                     TGTTACCAATCTGAAGTGGGAGCGGCCGCGCTTTTTTTTTTTTTTTTTT 3'],
                     double-stranded cDNA was size selected, ligated to Eco RI
                     adapters (Pharmacia), digested with Not I and cloned into
                     the Not I and Eco RI sites of a modified pT7T3 vector
                     (Pharmacia). Library went through one round of
                     normalization to a Cot = 53. Library constructed by Bento
                     Soares and M.Fatima Bonaldo. The adult brain RNA was
                     provided by Dr. Donald H. Gilden. Tissue was acquired
                     17-18 hours after death which occurred in consequence of a
                     ruptured aortic aneurysm. RNA was prepared from a pool of
                     tissues representing the following areas of the brain:
                     frontal, parietal, temporal and occipital cortex from the
                     left and right hemispheres, subcortical white matter,
                     basal ganglia, thalamus, cerebellum, midbrain, pons and
                     medulla."
```

```
  Query Match             7.6%;  Score 58;  DB 1;  Length 59;
  Best Local Similarity   100.0%;  Pred. No. 6.5;
  Matches   58;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         392 AAGCACGAGGAGCGGCAGGACGAGCATGGCTACATCTCCCGGTGCTTCACGCGGAAAT 449
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           2 AAGCACGAGGAGCGGCAGGACGAGCATGGCTACATCTCCCGGTGCTTCACGCGGAAAT 59
```

```
RESULT 14
T78695
LOCUS       T78695                   68 bp    mRNA    linear   EST 07-MAR-1995
DEFINITION  yd01d11.r1 Soares infant brain 1NIB Homo sapiens cDNA clone
            IMAGE:24384 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);, mRNA sequence.
ACCESSION   T78695
VERSION     T78695.1  GI:697204
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 68)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Insert Size: 905
            High quality sequence starts: 1 High quality sequence stops: 1
            Source: IMAGE Consortium, LLNL This clone is available royalty-free
            through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov)
            for further information. Trace considered overall poor quality
            Insert Length: 905   Std Error: 0.00
            Seq primer: M13RP1
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .68
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:396731"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:24384"
                     /sex="female"
                     /dev_stage="73 days post natal"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares infant brain 1NIB"
                     /note="Organ: whole brain; Vector: Lafmid BA; Site_1: Not
                     I; Site_2: Hind III; 1st strand cDNA was primed with a Not
                     I - oligo(dT) primer [5'
                     AACTGGAAGAATTCGCGGCCGCAGGAATTTTTTTTTTTTTTTTT 3'];
                     double-stranded cDNA was ligated to Hind III adaptors
                     (Pharmacia), digested with Not I and directionally cloned
                     into the Not I and Hind III sites of the Lafmid BA vector.
                     Library went through one round of normalization. Library
                     constructed by Bento Soares and M.Fatima Bonaldo."
```

```
  Query Match             7.5%;  Score 57.6;  DB 1;  Length 68;
  Best Local Similarity   88.2%;  Pred. No. 7.1;
  Matches   60;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy          14 GAGTCAGCCAGCATGACCGAGCGCCGCGTCCCCTTCTCGCTCCTGCGGGGCCCCAGCTGG 73
```

```
                 |||||| ||||||| ||| |||||| |||||||||||| ||| || |||||||||||||  |
Db          1 GAGTCAACCAGCATNACCCAGCGCCNCGTCCCCTTCTTGCTNCTTCGGGGCCCCAGCTNG 60

Qy         74 GACCCCTT 81
              ||||||||
Db         61 GACCCCTT 68
```

RESULT 15
R24645
LOCUS R24645 62 bp mRNA linear EST 20-APR-1995
DEFINITION yh36g07.r1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:131868 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN (HUMAN);, mRNA sequence.
ACCESSION R24645
VERSION R24645.1 GI:779533
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 62)
AUTHORS Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M., Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M., Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F., Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and Wilson,R.
TITLE The WashU-Merck EST Project
JOURNAL Unpublished (1995)
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 651
High quality sequence starts: 1
High quality sequence stops: 1
Source: IMAGE Consortium, LLNL
This clone is available royalty-free through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
Trace considered overall poor quality
Insert Length: 651 Std Error: 0.00
Seq primer: M13RP1
High quality sequence stop: 1.

FEATURES Location/Qualifiers
source 1. .62
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:537408"
/db_xref="taxon:9606"
/clone="IMAGE:131868"
/sex="Female"
/dev_stage="placenta obtained at birth (full term)"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares placenta Nb2HP"
/note="Organ: placenta; Vector: pT7T3D (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5' AACTGGAAGAATTCGCGGCCGCAGGAATTTTTTTTTTTTTTTTT 3'], double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization. Library constructed by Bento Soares and M.Fatima Bonaldo. "

```
  Query Match             7.5%;  Score 57;  DB 1;  Length 62;
  Best Local Similarity   91.9%;  Pred. No. 7;
  Matches   57;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy        177 GGCCAGGCTACGTGCGCCCCCTGCCCCCCGCCGCCATCGAGAGCCCCGCAGTGGCCGCGC 236
              |||||||||||||||||||| |||||| |||||||||||| ||||||| ||||||||
Db          1 GGCCAGGCTACGTGCGCCCCCTNCCCCCCNCCGCCATCGAGANCCCCGCANTGGCCGCGN 60

Qy        237 CC 238
              ||
Db         61 CC 62
```

RESULT 16
R63589
LOCUS R63589 60 bp mRNA linear EST 26-MAY-1995
DEFINITION yi09g04.r1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:138774 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN (HUMAN);, mRNA sequence.
ACCESSION R63589
VERSION R63589.1 GI:835468
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 60)
AUTHORS Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M., Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M., Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F., Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and Wilson,R.
TITLE The WashU-Merck EST Project
JOURNAL Unpublished (1995)
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 844
High qality sequence starts: 1
High qality sequence stops: 1
Source: IMAGE Consortium, LLNL
This clone is available royalty-free through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
Trace considered overall poor quality
Insert Length: 844 Std Error: 0.00
Seq primer: M13RP1
High quality sequence stop: 1.

FEATURES Location/Qualifiers
source 1. .60
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:545210"
/db_xref="taxon:9606"
/clone="IMAGE:138774"
/sex="Female"
/dev_stage="placenta obtained at birth (full term)"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares placenta Nb2HP"
/note="Organ: placenta; Vector: pT7T3D (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5' AACTGGAAGAATTCGCGGCCGCAGGAATTTTTTTTTTTTTTTTT 3'], double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization. Library constructed by Bento Soares and M.Fatima Bonaldo. "

```
  Query Match             7.4%;  Score 56.4;  DB 1;  Length 60;
  Best Local Similarity   95.0%;  Pred. No. 7;
  Matches   57;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy         67 CAGCTGGGACCCCTTCCGCGACTGGTACCCGCATAGCCGCCTCTTCGACCAGGCCTTCGG 126
              |||||||||||||||||||||| |||||||||||||| |||||||||||||||| ||
Db          1 CAGCTGGGACCCCTTCCGCGACTNGTACCCGCATAGCCGTCTCTTCGACCAGGCCTTNGG 60
```

```
RESULT 17
R69493
LOCUS       R69493                  64 bp    mRNA    linear   EST 01-JUN-1995
DEFINITION  yj83e01.r1 Soares breast 2NbHBst Homo sapiens cDNA clone
            IMAGE:155352 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);, mRNA sequence.
ACCESSION   R69493
VERSION     R69493.1  GI:843010
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 64)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Insert Size: 665
            High quality sequence starts: 1
            High quality sequence stops: 1
            Source: IMAGE Consortium, LLNL
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Trace considered overall poor quality
            Insert Length: 665   Std Error: 0.00
            Seq primer: M13RP1
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .64
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:572309"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:155352"
                     /sex="Female"
                     /dev_stage="adult"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares breast 2NbHBst"
                     /note="Organ: breast; Vector: pT7T3D (Pharmacia) with a
                     modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
                     strand cDNA was primed with a Not I - oligo(dT) primer [5'
                     TGTTACCAATCTGAAGTGGGAGCGGCCGCCCTTTTTTTTTTTTTTTTT 3'],
                     double-stranded cDNA was ligated to Eco RI adaptors
                     (Pharmacia), digested with Not I and cloned into the Not I
                     and Eco RI sites of a modified pT7T3 vector (Pharmacia).
                     Library went through one round of normalization to a Cot =
                     230. Library constructed by Bento Soares and M.Fatima
                     Bonaldo."

  Query Match             7.2%;  Score 55.2;  DB 1;  Length 64;
  Best Local Similarity   89.1%;  Pred. No. 7.7;
  Matches   57;  Conservative    0;  Mismatches    7;  Indels    0;  Gaps    0;

Qy         63 GCCCCAGCTGGGACCCCTTCCGCGACTGGTACCCGCATAGCCGCCTCTTCGACCAGGCCT 122
              || ||| |||||||||||| ||||||| ||||||| ||||||| |||||||| |||||||
Db          1 GCTCCAACTGGGACCCCTTTCGCGACTNGTACCCGNATAGCCGNCTCTTCGANCAGGCCT 60

Qy        123 TCGG 126
              ||||
Db         61 TCGG 64


RESULT 18
```

```
H45605
LOCUS       H45605                  62 bp    mRNA    linear   EST 31-JUL-1995
DEFINITION  yn97g04.r1 Soares adult brain N2b5HB55Y Homo sapiens cDNA clone
            IMAGE:176406 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);, mRNA sequence.
ACCESSION   H45605
VERSION     H45605.1  GI:921657
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 62)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Insert Size: 648
            High quality sequence starts: 1
            High quality sequence stops: 1
            Source: IMAGE Consortium, LLNL
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Trace considered overall poor quality
            Insert Length: 648   Std Error: 0.00
            Seq primer: M13RP1
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .62
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:3838602"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:176406"
                     /sex="Male"
                     /dev_stage="55-year old"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares adult brain N2b5HB55Y"
                     /note="Organ: brain; Vector: pT7T3D (Pharmacia) with a
                     modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
                     strand cDNA was primed with a Not I - oligo(dT) primer [5'
                     TGTTACCAATCTGAAGTGGGAGCGGCCGCGCTTTTTTTTTTTTTTTTT 3'],
                     double-stranded cDNA was size selected, ligated to Eco RI
                     adapters (Pharmacia), digested with Not I and cloned into
                     the Not I and Eco RI sites of a modified pT7T3 vector
                     (Pharmacia). Library went through one round of
                     normalization to a Cot = 53. Library constructed by Bento
                     Soares and M.Fatima Bonaldo. The adult brain RNA was
                     provided by Dr. Donald H. Gilden. Tissue was acquired
                     17-18 hours after death which occurred in consequence of a
                     ruptured aortic aneurysm. RNA was prepared from a pool of
                     tissues representing the following areas of the brain:
                     frontal, parietal, temporal and occipital cortex from the
                     left and right hemispheres, subcortical white matter,
                     basal ganglia, thalamus, cerebellum, midbrain, pons and
                     medulla."

  Query Match             6.7%;  Score 51.2;  DB 1;  Length 62;
  Best Local Similarity   85.5%;  Pred. No. 9.2;
  Matches   53;  Conservative    0;  Mismatches    9;  Indels    0;  Gaps    0;

Qy        407 CAGGACGAGCATGGCTACATCTCCCGGTGCTTCACGCGGAAATACACGCTGCCCCCCGGT 466
              || |||||||||| ||||||| ||||||||| | | ||||||||| | | |||||||||
Db          1 CANGACGAGCATGGNTACATCTTCCGGTGCTTNANGGGGAAATACANGGTNCCCCCCGGT 60
```

```
Qy        467 GT 468
              ||
Db         61 GT 62


RESULT 19
T51563/c
LOCUS       T51563                    53 bp    mRNA    linear   EST 06-FEB-1995
DEFINITION  yb25f09.s1 Stratagene fetal spleen (#937205) Homo sapiens cDNA
            clone IMAGE:72233 3' similar to similar to gb:Z23090 HEAT SHOCK 27
            KD PROTEIN (HUMAN), mRNA sequence.
ACCESSION   T51563
VERSION     T51563.1  GI:653423
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 53)
  AUTHORS   Hillier,L., Lennon,G., Becker,M., Bonaldo,M.F., Chiapelli,B.,
            Chissoe,S., Dietrich,N., DuBuque,T., Favello,A., Gish,W.,
            Hawkins,M., Hultman,M., Kucaba,T., Lacy,M., Le,M., Le,N.,
            Mardis,E., Moore,B., Morris,M., Parsons,J., Prange,C., Rifkin,L.,
            Rohlfing,T., Schellenberg,K., Soares,M.B., Tan,F., Thierry-Meg,J.,
            Trevaskis,E., Underwood,K., Wohldmann,P., Waterston,R., Wilson,R.
            and Marra,M.
  TITLE     Generation and analysis of 280,000 human expressed sequence tags
  JOURNAL   Genome Res. 6 (9), 807-828 (1996)
  MEDLINE   97044478
   PUBMED   8889549
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Insert Size: 620
            High qality sequence starts: 1 High qality sequence stops: 1
            Source: IMAGE Consortium, LLNL This clone is available royalty-free
            through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov)
            for further information. Trace considered overall poor quality
            Insert Length: 620   Std Error: 0.00
            Seq primer: -21m13
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .53
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:493898"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:72233"
                     /tissue_type="fetal spleen"
                     /dev_stage="fetal"
                     /lab_host="SOLR cells (kanamycin resistant)"
                     /clone_lib="Stratagene fetal spleen (#937205)"
                     /note="Organ: spleen; Vector: pBluescript SK-; Site_1:
                     EcoRI; Site_2: XhoI; Cloned unidirectionally.  Primer:
                     Oligo dT. Pooled spleens. Average insert size: 1.0 kb;
                     Uni-ZAP XR Vector; -5' adaptor sequence: 5' GAATTCGGCACGAG
                     3' -3' adaptor sequence: 5' CTCGAGTTTTTTTTTTTTTTTTT 3'"

  Query Match             6.5%;  Score 49.4;  DB 1;  Length 53;
  Best Local Similarity   94.3%;  Pred. No. 9.3;
  Matches   50;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        682 GCTGTGCCTCCCCCGCCACCTGTGTGTTCTTTTGATACATTTATCTTCTGTTT 734
              |||||||||  |||||  |||||||||||||||||||||||||||||||||||
Db         53 GCTGTGCCTNACCCGCNACCTGTGTGTTCTTTTGATACATTTATCTTCTGTTT 1


RESULT 20
AI567984/c
```

```
LOCUS       AI567984                  59 bp    mRNA    linear   EST 14-MAY-1999
DEFINITION  tq86g04.x1 NCI_CGAP_Ov23 Homo sapiens cDNA clone IMAGE:2215734 3'
            similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN (HUMAN);contains
            TAR1.t2 MSR1 repetitive element ;, mRNA sequence.
ACCESSION   AI567984
VERSION     AI567984.1  GI:4526436
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 59)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
            Emmert-Buck, M.D., Ph.D.
             cDNA Library Preparation: Life Technologies, Inc.
             cDNA Library Arrayed by: Greg Lennon, Ph.D.
             DNA Sequencing by: Washington University Genome Sequencing Center
             Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            www-bio.llnl.gov/bbrp/image/image.html

            Trace considered overall poor quality
            Insert Length: 1066   Std Error: 0.00
            Seq primer: -40UP from Gibco
            High quality sequence stop: 1
            POLYA=No.
FEATURES             Location/Qualifiers
     source          1. .59
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:2215734"
                     /tissue_type="tumor, 5 pooled (see description)"
                     /lab_host="DH10B"
                     /clone_lib="NCI_CGAP_Ov23"
                     /note="Organ: ovary; Vector: pCMV-SPORT6; Site_1: SalI;
                     Site_2: NotI; Cloned unidirectionally.  Primer: Oligo dT.
                     Average insert size 1.35 kb. Tumor types include: mixed
                     Mullerian tumor, papillary serous, clear cell, spindle
                     cell.  All are primary tumors, metastasis positive. Life
                     Technologies catalog #: 11534-013"

  Query Match             6.5%;  Score 49.4;  DB 1;  Length 59;
  Best Local Similarity   89.8%;  Pred. No. 9.8;
  Matches   53;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy        695 CGCCACCTGTGTGTTCTTTTGATACATTTATCTTCTGTTTTTCTCAAATAAAGTTCAAA 753
              | || ||  ||| |||||||||| ||||||||||||||||||||||||||||||||||||
Db         59 CCCCCCCCTTGTTTTCTTTTGATCCATTTATCTTCTGTTTTTCTCAAATAAAGTTCAAA 1


RESULT 21
AA757804/c
LOCUS       AA757804                  39 bp    mRNA    linear   EST 23-JAN-1998
DEFINITION  zg44a08.s1 Soares_pineal_gland_N3HPG Homo sapiens cDNA clone
            IMAGE:396182 3' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);, mRNA sequence.
ACCESSION   AA757804
VERSION     AA757804.1  GI:2805667
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 39)
  AUTHORS   Hillier,L., Allen,M., Bowles,L., Dubuque,T., Geisel,G., Jost,S.,
            Krizman,D., Kucaba,T., Lacy,M., Le,N., Lennon,G., Marra,M.,
```

```
            Martin,J., Moore,B., Schellenberg,K., Steptoe,M., Tan,F.,
            Theising,B., White,Y., Wylie,T., Waterston,R. and Wilson,R.
  TITLE     WashU-NCI human EST Project
  JOURNAL   Unpublished (1997)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Trace considered overall poor quality
            Seq primer: -40m13 fwd. ET from Amersham
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .39
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:1302084"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:396182"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares_pineal_gland_N3HPG"
                     /note="Organ: pineal gland; Vector: pT7T3D (Pharmacia)
                     with a modified polylinker; Site_1: Not I; Site_2: Eco RI;
                     1st strand cDNA was primed with a Not I - oligo(dT) primer
                     [5' TGTTACCAATCTGAAGTGGGAGCGGCCGCCGTTTTTTTTTTTTTTTTTT
                     3'], double-stranded cDNA was size selected, ligated to
                     Eco RI adapters (Pharmacia), digested with Not I and
                     cloned into the Not I and Eco RI sites of a modified pT7T3
                     vector (Pharmacia). Library constructed by Bento Soares
                     and M.Fatima Bonaldo. "

  Query Match             4.7%;  Score 35.8;  DB 1;  Length 39;
  Best Local Similarity   94.9%;  Pred. No. 15;
  Matches   37;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy        723 TATCTTCTGTTTTTCTCAAATAAAGTTCAAAGCAACCAC 761
              ||||||||||||||||| ||||||||||||||| |||||
Db         39 TATCTTCTGTTTTTCTCCAATAAAGTTCAAAGCTACCAC 1


RESULT 22
T98725
LOCUS       T98725                   41 bp    mRNA    linear   EST 31-MAR-1995
DEFINITION  ye61g03.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone
            IMAGE:122260 5' similar to gb:Z23090 HEAT SHOCK 27 KD PROTEIN
            (HUMAN);, mRNA sequence.
ACCESSION   T98725
VERSION     T98725.1  GI:748462
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 41)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,
            Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,
            Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F.,
            Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and
            Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished (1995)
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Insert Size: 885
            High qality sequence starts: 1 High qality sequence stops: 1
            Source: IMAGE Consortium, LLNL This clone is available royalty-free
            through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov)
            for further information. Trace considered overall poor quality
            Insert Length: 885   Std Error: 0.00
            Seq primer: M13RP1
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .41
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:474805"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:122260"
                     /sex="male"
                     /dev_stage="20 week-post conception fetus"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares fetal liver spleen 1NFLS"
                     /note="Organ: Liver and Spleen; Vector: pT7T3D (Pharmacia)
                     with a modified polylinker; Site_1: Pac I; Site_2: Eco RI;
                     1st strand cDNA was primed with a Pac I - oligo(dT) primer
                     [5' AACTGGAAGAATTAATTAAAGATCTTTTTTTTTTTTTTTTTT 3'],
                     double-stranded cDNA was ligated to Eco RI adaptors
                     (Pharmacia), digested with Pac I and cloned into the Pac I
                     and Eco RI sites of the modified pT7T3 vector.  Library
                     went through one round of normalization. Library
                     constructed by Bento Soares and M.Fatima Bonaldo."

  Query Match             4.6%;  Score 34.8;  DB 1;  Length 41;
  Best Local Similarity   87.8%;  Pred. No. 16;
  Matches   36;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy         84 GCGACTGGTACCCGCATAGCCGCCTCTTCGACCAGGCCTTC 124
              |||||| |||||| |||||||  || ||||||||||||||
Db          1 GCGACTNGTACCCNCATAGCCNACTATTCGACCAGGCCTTC 41


Search completed: May 10, 2005, 07:20:55
Job time : 1 secs
```

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.